frontiers | Research Topics

Molecular regulation of tumor cells migration and metastatic growth

Edited by
Michelle L. Matter and Vasiliki Gkretsi

Published in
Frontiers in Oncology
Frontiers in Frontiers in Cell and Developmental Biology



ISSN 1664-8714
ISBN 978-2-8325-4043-5
DOI 10.3389/978-2-8325-4043-5

About Frontiers

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals.

Frontiers journal series

The Frontiers journal series is a multi-tier and interdisciplinary set of open-access, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the *Frontiers journal series* operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too.

Dedication to quality

Each Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public - and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation.

What are Frontiers Research Topics?

Frontiers Research Topics are very popular trademarks of the *Frontiers journals series*: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers editorial office: frontiersin.org/about/contact

Molecular regulation of tumor cells migration and metastatic growth

Topic editors

Michelle L. Matter — Tulane University, United States

Vasiliki Gkretsi — European University Cyprus, Cyprus

Citation

Matter, M. L., Gkretsi, V., eds. (2023). *Molecular regulation of tumor cells migration and metastatic growth*. Lausanne: Frontiers Media SA.

doi: 10.3389/978-2-8325-4043-5

Table of contents

frontiers | Frontiers in Oncology

TYPE Editorial
PUBLISHED 17 November 2023
DOI 10.3389/fonc.2023.1329053

OPEN ACCESS

EDITED AND REVIEWED BY
Tao Liu,
University of New South Wales, Australia

*CORRESPONDENCE
Michelle L. Matter
mmatter@tulane.edu
Vasiliki Gkretsi
v.gkretsi@euc.ac.cy

RECEIVED 27 October 2023
ACCEPTED 09 November 2023
PUBLISHED 17 November 2023

CITATION
Matter ML and Gkretsi V (2023) Editorial: Molecular regulation of tumor cells migration and metastatic growth.
Front. Oncol. 13:1329053.
doi: 10.3389/fonc.2023.1329053

Editorial: Molecular regulation of tumor cells migration and metastatic growth

Michelle L. Matter[1,2]* and Vasiliki Gkretsi[3,4]*

[1]School of Medicine, University of Tulane, New Orleans, LA, United States, [2]Louisiana Cancer Research Center, New Orleans, LA, United States, [3]Biomedical Sciences Program, Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus, [4]Cancer Metastasis and Adhesion Group, Basic and Translational Cancer Research Center (BTCRC), European University Cyprus, Nicosia, Cyprus

KEYWORDS

migration, invasion, metastasis, miRNAs, EMT, uPA, cytoskeleton

Editorial on the Research Topic
Molecular regulation of tumor cells migration and metastatic growth

Migration and metastasis in cancer

The migratory and invasive capacity of cells is the key differentiating factor between benign and malignant tumors that affects patient prognosis and survival, as more than 90% of cancer deaths is due to metastasis. Hence, metastasis is a complex multistep process involving gene and signaling pathway changes that lead to cancer cell migration, invasion, and ultimately establishment of a new metastatic tumor. The collection of articles in this *Frontiers Research Topic* presents recent advances and reviews current knowledge in the molecular regulation of malignant transformation driving tumor cell migration and metastatic growth.

Cell adhesion and migration are essential for malignant transformation, cancer progression and the development of chemoresistance. Cancer cells hijack various molecular pathways to evade cell regulatory constraints. For example, cancer cells utilize multiple migration and invasion methods during metastasis. The switch between migration/invasion modes is called invasion plasticity and is the topic of the review by Legatova et al. Rapid modulation in cell morphology due to changes in microtubules and cross talk with cytoskeletal networks are critical components in metastasis and tumor cell plasticity. Remodeling of the actin cytoskeleton is another way tumor cells transition to the malignant phenotype. Wang et al. review how actin cytoskeleton remodeling is regulated by actin-binding proteins with a focus on the LIM domain and acting-binding protein ($LIMA_1$). They discuss how $LIMA_1$ dysregulation contributes to changes in cytoskeletal dynamics promoting cancer cell migration and invasion. Indeed, changes at the leading edge of tumor cells alters migration and cytoskeletal dynamics. Original research by Asano et al. identifies that lamellipodia formation in migrating cells is controlled by conversion of inositol phospholipid $PI(4,5)P_2$ into $PI(3,4,5)P_3$. In particular, these authors demonstrate cancer cell migration is regulated by VIPR2, a vasoactive receptor for vasoactive intestinal peptide (VIP), which controls actin nucleation and lamellipodium formation via $PI(3,4,5)P_3$. Another cytoskeletal interacting protein cytoplasmic Sirtuin 1 (SIRT1) interacts with

cortactin to promote cancer cell migration and metastasis. This member of the Sirtuins family is a histone deacetylase enzyme, which requires the nicotinamide adenine dinucleotide (NAD^+) co-factor to function. Nuclear SITR1 deacetylates several oncogenes and transcription factors to control their function. Ahmad et al. review SITR1 function and its role as a novel target for CD44 signaling in breast cancer.

Apart from specific genes and signaling pathways that are dysregulated in cancer metastasis, non-coding RNAs, and microRNAs (miRs) in particular, play a pivotal role since they can be exploited therapeutically as they can be chemically synthesized and prepared as lentiviral particles or loaded into liposomes for anti-cancer therapeutic interventions (1). Original research by Ran et al. investigated the involvement of miR-23 in multiple myeloma, as it was predicted by the online tool miRDB as a candidate miR targeting urokinase plasminogen activator (uPA), a fundamental protease in cancer cell invasion. UPA expression was found to be significantly upregulated in multiple myeloma with increasing disease severity. Also, overexpression of miR-23 in cell lines and patient-derived cells inhibits uPA expression and cancer cell invasion both *in vitro* and *in vivo* in a nude mouse model. Notably, Luo et al. reveal an interesting role for another miR in regulating cancer cell metastasis. Specifically, they assessed miRNA-145-5p expression in bone metastatic prostate cancer cells, non-metastatic cells, as well as patient tissue samples and found miRNA-145-5p levels were downregulated in prostate cancer bone metastasis. MiRNA-145-5p was also shown to inhibit cell proliferation, and epithelial to mesenchymal transition (EMT) as well as the expression of basic growth factors in bone metastatic prostate cells while Transforming Growth Factor-β2 was predicted to be its target gene. Along the same line, Alves and Geraldo identified MiR-495-3p from an *in silico* target prediction and gene enrichment analysis as one of the miRs belonging to the DLK1-DIO3 region, found on the long arm of chromosome 14 and known to host the largest miR cluster in the human genome, which was previously shown to be downregulated in papillary thyroid carcinoma. In this study, miR-495-3p expression was assessed in a cell-line panel showing reduced expression in correlation to the degree of differentiation while its loss during papillary thyroid carcinoma development plays an important role in its progression.

Another approach was employed by Li et al. that uses single-cell RNA sequencing for transcriptome profiling of individual cancer cells addressing heterogeneity at the single-cell level. They found a cluster of malignant epithelial cells with EMT and identified a hyperproliferative gene signature, which includes a family with sequence similarity 83 member D (FAM83D) malignant epithelial cells that were strongly associated with cancer-related pathways. FAM83D was shown to promote ovarian cancer progression as its downregulation in ovarian cancer cells reduced proliferation, migration, and invasion and increased cisplatin sensitivity. Moreover, binding analysis experiments revealed that FAM83D can be targeted by miR-138-5p, which can significantly reverse ovarian cancer cell migration, invasion, and EMT. Bao et al. aimed to develop a mutation-based gene-signature-established on the clinical score system to improve clinical prognosis. To that end, tissues from 144 patients with colorectal liver metastases were analyzed with next-generation sequencing and genomic alterations identified. They also tested the predicting efficiency and found it better than other scoring systems in identifying high-risk colorectal liver metastases patients who may benefit from personalized treatment.

Emerging therapies against metastasis is the focus of the review by Du et al. These authors discuss cancer progression and metastasis in osteosarcoma and review available treatments and clinical trials. They outline cell wide changes that contribute to tumor progression and metastasis describing the complex molecular and genetic alterations driving osteosarcoma metastasis.

In summary, we provide reviews and original research to describe key components involved in driving cancer metastasis that we anticipate will contribute to the overall understanding of cancer progression with the goal to better understand and target the metastatic phenotype.

Author contributions

MM: Conceptualization, Writing – original draft, Writing – review & editing. VG: Conceptualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

Reference

1. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Front Endocrinol (Lausanne)* (2018) 9:40. doi: 10.3389/fendo.2018.00402

frontiers | Frontiers in Oncology

ORIGINAL RESEARCH
published: 30 May 2022
doi: 10.3389/fonc.2022.835299

Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells *via* the Aberrant Expression of uPA

Qijie Ran[1]*, *Dehong Xu*[1], *Qi Wang*[1] and *Dongsheng Wang*[2,3]*

[1] Department of Hematology, General Hospital of Central Theater Command, Wuhan, China, [2] Department of Neurosurgery, The Fifth People's Hospital of Dalian, Dalian, China, [3] Department of Neurosurgery, The Second Affiliated Hospital of Dalian Medical University, Dalian City, China

OPEN ACCESS

Edited by:
Ana Cristina Gonçalves, University of Coimbra, Portugal

Reviewed by:
Maria Tsagiopoulou, Center for Genomic Regulation (CRG), Spain
Nashwa El-Khazragy, Ain Shams University, Egypt

***Correspondence:**
Qijie Ran
ranqijie2021@163.com
Dongsheng Wang
15541178350@126.com

Specialty section:
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

Received: *15 December 2021*
Accepted: *02 May 2022*
Published: *30 May 2022*

Citation:
Ran Q, Xu D, Wang Q and Wang D (2022) Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA. Front. Oncol. 12:835299. doi: 10.3389/fonc.2022.835299

Multiple myeloma has a long course, with no obvious symptoms in the early stages. However, advanced stages are characterized by injury to the bone system and represent a severe threat to human health. The results of the present work indicate that the hypermethylation of miR-23 promoter mediates the aberrant expression of uPA/PLAU (urokinase plasminogen activator, uPA) in multiple myeloma cells. miR-23, a microRNA that potentially targets uPA's 3'UTR, was predicted by the online tool miRDB. The endogenous expressions of uPA and miR-23 are related to disease severity in human patients, and the expression of miR-23 is negatively related to uPA expression. The hypermethylation of the promoter region of miR-23 is a promising mechanism to explain the low level of miR-23 or aberrant uPA expression associated with disease severity. Overexpression of miR-23 inhibited the expression of uPA by targeting the 3'UTR of uPA, not only in MM cell lines, but also in patient-derived cell lines. Overexpression of miR-23 also inhibited *in vitro* and *in vivo* invasion of MM cells in a nude mouse model. The results therefore extend our knowledge about uPA in MM and may assist in the development of more effective therapeutic strategies for MM treatment.

Keywords: multiple myeloma, uPA, miR-23, hypermethylation, patient-derived cell lines

INTRODUCTION

Multiple myeloma (MM) is a clonal malignant plasma cell disease that accumulates in bone marrow, leading to bone destruction and marrow failure as well as out-bone injury for the whole body at advanced stages (1–3). Increasing data have been indicated that the MM is often accompanied by the multiple osteolytic lesions, hypercalcemia, or kidney damage (1–5). Although therapeutic approaches to MM have been rapidly evolving, and MM is typically sensitive to a variety of cytotoxic chemotherapies, the prognosis of patients with distal metastasis (the extra-bone MM, at an advanced stage of the disease) is still poor (4–6). Bone destruction is among the most debilitating manifestations of MM and results from the interaction between

myeloma cells and the bone marrow microenvironment (7, 8). During the malignant transformation of MM, the aggregation and clustering of MM cells increases, which not only breaks through the bone marrow and enters the bone but also eventually forms masses and solid tumor tissues (9–11). This feature is not only closely related to the progression of MM disease but also affects patient prognosis (9–11). Therefore, it is of value to explore the molecular metastasis of MM as it induces bone injury or distal metastasis.

The interactions between cancerous cells, extracellular matrix (ECM) or tumor microenvironment are of importance to the invasion and metastasis of human malignancies (12–14). Increasing evidence confirms that a key step in the metastasis and invasion of malignant tumor cells is the dissolution and destruction of the basal membrane, which is mainly constructed by the ECM (15–17). After this membrane is destroyed by cancerous cells, the cells can metastasize from the original site to other sites or the organs (15–17). The uPA, a serine protease involved in ECM degradation, degrades the ECM by cleaving the precursor proteins of MMPs to activate them (18–21). There are many reports on the functions and regulatory mechanisms of uPA in HCC and other solid tumor tissues (21) but not in hematological malignancies/neoplasms such as MM, a blood cancer of monoclonal plasma cells. There are only a few reports on the influence of uPA in other cells of the bone marrow/bone tissue (such as osteoclasts) on the microenvironment of bone tissue and MM cells (22–26). At the same time, the interaction between MM cells and tumor microenvironment is of great important (22–26). Therefore, it is important to explore the function and regulation mechanisms of uPA in regulating MM cells.

Here, we report for the first time and clarify the expression of uPA in MM tissues. In MM cells, miR-23 downregulates the expression level of uPA by acting on its 3'UTR. The hypermethylation of the promoter region of miR-23 leads to low expression of miR-23 and high expression of uPA. In MM cells, the overexpression of miR-23 can inhibit the tumorigenesis of MM cells in nude mice by downregulating the expression of uPA. At the same time, this study creatively uses image analysis and other quantitative methods to determine whether the morphology of the tumor tissue formed by MM cells is regular, and finally, it simulates and detects the aggregation and clustering features of MM cells.

MATERIALS AND METHODS

Clinical Specimens, Cell Lines and Vectors

The human related materials were included MM cells and tumor tissues. The clinical specimens used in this study were (1) 35 samples of intra-marrow MM (separated from intraosseous samples); (2) 42 samples of intra-blood MM (separated from blood samples); (3) 38 samples of MM with bone-tumor tissues in the form of masses or lumps, where the MM cells form solid tumor tissue or mass in bone (bone tumor samples); and (4) 21 MM samples with long-distance metastasis, or extra-bone masses or lumps forming a solid tumor tissue or mass in other organs, developed through long distance metastasis (extra-bone tumor samples). The sample size for the four groups' MM used has adequate power to detect a pre-specified effect size (the 1-β: 0.8; α/2: 0.025; $P<0.05$): the original hypothesis was that the expression level of uPA or miR-23 was not significantly different between groups; whereas the alternative hypothesis was that the expression level of uPA or miR-23 was significantly different between groups. For the bone marrow aspirate, the CD38 is used as the marker for sorting, and the CD38 positive components are retained; for the peripheral blood, the peripheral blood lymphocytes are directly separated, and then the CD38 is used as the marker for sorting, and the CD38 positive components are retained; For tumor tissue outside the bone or bone, only the tumor tissue can be collected for detection.

The enrolled patients' inclusion and exclusion criteria: (1) Bone tumor or extra-none tumor/extraosseous (the solitary plasmacytoma), Biopsy-proven solitary lesion of bone or soft tissue consisting of clonal plasma cells; Normal random bone marrow biopsy with no evidence of clonal plasma cells; Normal skeletal survey and MRI or CT (except for the primary solitary lesion); Absence of end-organ damage, such as hypercalcaemia, renal insufficiency, anaemia, and bone lesions (CRAB) attributable to a plasma cell proliferative disorder. (2) intraosseous/intra-marrow MM (the plasma cell myeloma), Clonal bone marrow plasma cell percentage ≥ 10% or biopsy-proven plasmacytoma and ≥ 1 of the following myeloma-defining events (End-organ damage attributable to the plasma cell proliferative disorder; Hypercalcaemia: serum calcium > 0.25 mmol/L [> 1 mg/dL] higher than the upper limit of normal or > 2.75 mmol/L [> 11 mg/dL]; Renal insufficiency:creatinine clearance < 40 mL/minute or serum creatinine > 177 μmol/L [> 2 mg/dL]; Anaemia: a haemoglobin value of > 20 g/L below the lower limit of normal or a haemoglobin value < 100 g/L; Bone lesions: ≥ 1 osteolytic lesion on skeletal radiography, CT, or PET/CT≥ 1 of the following biomarkers of malignancy; Clonal bone marrow plasma cell percentage ≥ 60%; An involved-to-uninvolved serum free light chain ratio ≥100; > 1 focal lesion on MRI); (3) blood/intra-blood MM (the plasma cell leukemia), at least 20% circulating plasma cells and a total plasma cell count in peripheral blood of at least 2×10^9/L.

Among the patient-derived cell (PDC) lines, PDC-1 and PDC-2 were directly separated, cultured, and stored. The MM clinical specimens of solid tumor tissues from PDC-3 to PDC-8 were ground in a sterile 200-mesh steel sieve with 20% FBS DMEM, and the ground cell suspension was washed with 20% FBS DMEM to obtain PDCs (27). MM cell lines used in the present work were U266 and RPMI-8226, purchased from the Cell Resource Center, Institute of Basic Medicine, Chinese Academy of Medical Sciences, Beijing, China, from the National Infrastructure of Cell Line Resources of Chinese Government. Eight PDC lines of MM cells were generated and used in the present work: (1) clonal plasma cells progressively expanded and separated within the bone marrow, PDC-1 and PDC-2; (2) cells separated from the blood/extra-bone marrow) PDC-3 and PDC-4; (3) MM cells separated from bone tumor

tissues, PDC-5 and PDC-6; (4) MM cells separated from extra-bone tumor tissues, PDC-7 and PDC-8. For PDC-1–4, the cell suspension was directly cultured and frozen in liquid nitrogen tanks. For PDC-5–8, the surgically resected tumor tissue was preserved with DMEM, containing 20% FBS (27). At the same time, 20 lines of primary B cells were used as control compared with MM.

Specific preparation methods for cell lines: (1) for the MM in the bone, the bone marrow aspirate is directly sorting by CD38, and a stable MM cell line is finally obtained; (2) for the peripheral blood MM, the peripheral blood lymphocytes are directly sorting by CD38 and cultured for a long time; (3) for bone tumors, through surgical resection or bone puncture specimens, the tumor tissue was microdissected using a pre-sterilized 200-mesh steel sieve containing 20% The DMEM of FBS was ground to obtain a single-cell suspension; the single-cell suspension was washed and then cultured to obtain a patient-derived MM cell line; (4) for peripheral organ tumors, surgically resected specimens were microdissected. Then, the tumor tissue was ground with pre-sterilized 200-mesh steel sieve DMEM containing 20% FBS to obtain a single-cell suspension; the single-cell suspension was washed and then cultured to finally obtain a patient-derived MM cell line. The PDC lines were generated using the samples for one patient only. For primary B cells, healthy human peripheral blood lymphocytes (that is, peripheral blood lymphocytes obtained from the remaining part of the whole blood provided by the blood transfusion department except plasma and red blood cells) were used and primary B cells obtained by flow sorting ($CD45^+/CD19^+$).

Full-length sequences of has-pre-miR-23c (miR-23c), PLAUs with wild-type miR-23c targeting sites located in the 3'UTR, and PLAUs with mutated miR-23c targeting sites located in the 3'UTR were prepared as lentivirus particles (Vigene Coporation, Jinan City, Shandong Province, China). The MM cells were cultured and transfected with the lentivirus according to the instruction from the manufacture. MM cells were cultured and counted, and approximately 10^9 pfu of lentivirus was inoculated per 5 x 10^6 cells, followed by screening for stable transfection. Among them, uPA was screened by G418, and miR-23 was screened by puromycin.

qPCR and BSP-NGS

The expression level of uPA or miR-23 in MM samples was measured using qPCR following the methods described in previous publications and instructions from the manufactures (28–30). Briefly, RNA samples of MM cells or tumor tissues were extracted using a PARISTM Kit (Thermo Fisher Scientific, Waltham, MA, USA). Next, these RNA samples were reverse transcribed with Multiscribe™ Reverse Transcriptase (Thermo Fisher Scientific) into the cDNA samples. Then the expression level of uPA and miR-23 in MM was determined using quantitative PCR (qPCR), which was performed following the methods described in previous studies (31, 32). The level of β-actin mRNA was measured as a loading control. The primers used in qPCR experiments were as follows: uPA/PLAU: forward sequence, 5'-TTGCTCACCACAACGACATT-3'; reverse sequence, 5'-ATTTTCAGCTGCTCCGGATA-3'. β-actin (the loading control) forward sequence, 5'-CACCATTGGCA ATGAGCGGTTC-3'; reverse sequence, 5'-AGGTCTTTGCG GATGTCCACGT-3.'

The methylation rates of miR-23 in MM samples or cultured cells were examined by BSP-NGS following previous publications (33, 34). Briefly, the genomic DNA of clinical tissues and cell lines was extracted and isolated by using the DNeasy Blood & Tissue Kit (Cat No. 69504; QIAGEN, Hilden, Germany). For the Bisulfite (BSP) assays, the DNA samples were treated with the EpiTect Bisulfite Kit (Cat No. 59104; QIAGEN). Next, the polymerase chain reaction (PCR) assays were performed by using the Platinum II Hot-Start PCR Master Mix (Cat No. 14000012; Thermo Fisher Scientific) to amplify of the selected promoter region of miR-23 and the PCR products were directly sequenced by using Ion Torrent PGM methods (Ion PGM HI-Q View Sequencing 200 kits, Cat. No.4462921; Thermo Fisher Scientific; analytic software: Torrent Suite 5.6 and Ion Reporter 5.6, Life-technology, Thermo Fisher Scientific, Waltham, MA, USA). The The Methyl-Primer Express v1.0 software (Thermo Fisher Scientific, USA) was used to predict the CpG sites and the information of miR-23's promoter region were: Position: hg38 chr9 (95,083,208- 95,085,207), Size: 97, and Strand: +strand. The primers used in the present work were as follows: forward sequence 5'-AGGAATTATGTGTGT TAGGAAAG-3'; reverse sequence 5'-ACAAAAATTCCCC ATAAAAAA-3'. Results are given as the methylation rate (mean ± SD). During judging the results, if the miR-23s' promoter region after BSP treatment is C, the results indicated that the CpG site was methylated; whereas if the sequence o after BSP treatment was T, the results indicated that the CpG site was not methylated. The methylation rate of miR-23's promoter regions was calculated as the number of methylated CpG sites divided by the total number of CpG sites in the selected regions.

Taking the correlation analysis, the association between uPA expression with mir-23 expression as an example, the expression level of uPA and mir-23 can be measured in each tissue specimen. At this time, taking the expression level of uPA as the abscissa and the expression of mir-23 as the ordinate, each specimen can correspond to a data point. A group of specimens can correspond to a group of data points, which can be fitted and linearly regressed to obtain a regression equation and P value.

Western Blotting Assays

The expression levels of PLAU in MM cell lines were measured using Western blotting assays. MM cells were transfected with the vectors (control miRNA, miR-23, miR-23 + uPA^{Mut} or miR-23 + inhibitor) and harvested for Western blotting. The expression levels of uPA in MM cells were evaluated based on the presence of antibody (Cat. No.: ab169754, Abcam, Cambridge, UK). The loading control used in the western blot section as GAPDH. The images of western blot was quantitatively analyzed by using the Image J software [National Institutes of Health (NIH), Bethesda, Maryland, USA].

Subcutaneous Tumor Model in Nude Mice

The animal experiments were performed in a nude mice model (35). Mice 4–5 weeks old were used. MM cells were cultured in DMEM with 10% FBS and transfected with plasmids and

subcutaneously injected into the mice to form tumor tissues. After 6–8 weeks of growth, the MM cells formed subcutaneous tumor tissues. The tumors were harvested and analyzed. To determine tumor volumes, tumor width and length were determined using Vernier calipers. Tumor volumes were calculated as tumor width × tumor width × length divided by 2. Tumor weights were examined using a precision-balance.

For the detection and discrimination of the morphological regularity of the tumor tissues, we first determined the magnitude of the long axis of each tumor tissue (tumor length). We used the image analysis software Image J to calculate the circumference of the perimeter of the tumor tissue, its diameter, and its area (36, 37). The total number of pixels in the area designated in the software is the total area of the selected area. Then the tumor tissue is subtracted out of this area, and this difference is divided by the total area selected to obtain an F value, which is evaluated to determine whether the morphology of the tumor tissue is close to that of a circle. The greater the F value, the larger the difference between the total area of the tumor tissue and the selected area, and less regular the shape of the tumor tissue. **Figure 1** is a schematic diagram of this method, and **Figure 2** shows the calculation formula. For experimental animals, each group is 8-10 animals (Each animal corresponds to a subcutaneous tumor tissue), each animal is inoculated with about 5×10^6 cells, and the animal feeding cycle is 6 weeks.

In Vivo Invasion of MM Cells in the Nude Mice Model

Invasion of MM cells was assessed following the methods of a previous study (21). The cells were mixed with medical hydrogels to form hydrogel drops. The drops were adhered to the surface of liver organs *via* open surgery. After 3–4 weeks of rearing, the mice were harvested, and the intrahepatic lesions/nodules formed by the MM cells were examined by pathological staining (Masson staining). Staining was quantitatively examined using the Image J software. The total depth of the liver and the invaded depth of MM cells (the depth of the intrahepatic lesions/nodules) were revealed by pixel analyses.

$$F = \frac{S2\text{-}S1}{S2}$$

D: Diameter of circumscribed circle /long axis of tumor tissue
S1: Total area of tumor tissue
S2: Total area of circumscribed circle
F: Non-circular difference ratio

FIGURE 2 | Formula for calculating the detection method of tumor tissue morphology regularity.

The relative invasion of MM cells was calculated as the depth of invasion of MM cells divided by the total depth of the liver.

Small Inhibitor of uPA Used in the Present Work

Small inhibitor of uPA, UK-371804 (Cat. No.: HY-101214), was purchased from the MedChemExpress Corporation (China Branch), Pudong New Area, Shanghai, China. UK-371804 occurs as light yellow or white powder, and was received with a purity of ≥98.0%. Organic solvents, including dimethyl sulfoxide, polyethylene glycol 400, and Tween 80 were used to resolve the pure drug powder. The UK-371804 organic solvent solution was diluted with sterilized saline. During this period, ultrasound, stirring, and vortexing were used to avoid drug precipitation (38–41). Finally, an oral liquid for oral administration to nude mice was prepared. The final concentration of UK-371804 in the oral liquid was about 1 mg/mL. Then, the anti-tumor activity of UK-371804 on MM cell tumor formation in nude mice was tested. The MM cells were injected subcutaneously to form tumor tissues. The mice were orally administered UK-371804 (1 mg/kg, 5 mg/kg, or 10 mg/kg dose) once for 3 days (38–41). The tumor volumes and weights were measured using the methods outlined above.



FIGURE 1 | Schematic diagram of the detection method of tumor tissue morphological regularity.

Statistical Analysis

The results in the present study are given as means ± SDs from three or more biological repetitions. Significance-related analyses were examined using SPSS (Cat. No.: 9.0, IBM Corporation, Armonk, NY, USA) with the Bonferroni correction and two-way ANOVA for paired groups or the paired-sample t-test with two-ways (SPSS 16.0 statistical software; SPSS Inc., Chicago, IL, USA). The parametric linear regression the used for the co-relation analysis.

RESULTS

Association Between uPA and Disease Stages/Types

The expression of uPA in MM clinical specimens was examined by qPCR. As shown in **Figure 3A**, expression was significantly lower in intraosseous samples than in the other three MM specimens, and highest in extra-bone tumor samples. Expression was almost the same in blood and bone tumor samples.

To clarify the possible mechanisms of the gradual increase in uPA expression in MM specimens of different degrees of malignancy, we used the online prediction tool miRDB to predict the miRNA molecules that may act on uPA. As shown in **Figure 3B**, Among the 7 miRNA molecules (miR-23, miR-193a, miR-5692a, miR-3606-5p, miR-645, miR-4363 or miR-3190-59) with the highest scores selected in the prediction results, miR-23 was clearly expressed in MM specimens, and the expression of the other 6 miRNA molecules was negative or significantly lower than that of miR-23. Therefore, we focused on the expression and mechanism of miR-23 in MM.

Next, the effects of miR-23 on uPA were assessed using assays. The results showed that miR-23, a microRNA molecule that may



FIGURE 3 | Expression of miR-23 and uPA in MM. **(A)** The expression level of uPA in MM specimensat different stages or primary B cells. **(B)** The expression level of 7 miRNA molecules (miR-23, miR-193a, miR-5692a, miR-3606-5p, miR-645, miR-4363 or miR-3190-59) potentially targeting to the 3'UTR of uPA was examined in the MM clinical specimens. **(C)** The expression level of miR-23 in MM specimens at different stages or primary B cells. **(D)** The targeting site of miR-23 at 3'UTR of uPA or mutated sequences. **(E)** The expression of uPA, miR-23, or the promoter region of miR-23 in MM cells. **(F, G)** The effects of miR-23 on uPA protein level in PDC-7 and PDC-8. **(H–K)** The association between miR-23 and uPA in MM specimens at different stages. *P<0.05.

act on the 3'UTR of uPA, had an opposite expression trend in MM specimens from that in uPA: it was highest intraosseous specimens and lowest in extra-bone tumor samples (**Figure 3C**). The targeting sites of miR-23 in the uPA's 3'UTR was shown as pattern diagram (**Figure 3D**). The expression level of uPA and miR-23 was also examined in MM cell lines (**Figure 3E**). Moreover, as shown in **Figures 3F** and **G**, overexpression of miR-23 in MM PDC-7 (**Figure 3F**) and PDC-8 (**Figure 3G**) led to the highest endogenous uPA level among the cell lines (**Figure 3**) and reduced the expression of uPA. The transfection of uPA with mutated miR-23 targeting sites or the antisense sequence inhibitor of miR-23 almost blocked the effects of miR-23 on the expression of uPA (**Figures 3F, G**).

The results in **Figures 3F, G** preliminarily show the effect of miR-23 on uPA expression. To further confirm the effects of miR-23 on uPA, we assessed the association between the expression levels of miR-23 and uPA in MM specimens. The results indicated that the expression level of miR-23 was negatively related with the the expression of uPA in MM specimens at different stages, and the results were shown as the scatter plot, regression equation and P values (**Figures 3H–K** and **Table 3**).

On this basis, taking primary B cells as the control, the expression levels of uPA and miR-23 in primary B cells were detected (**Figures 3A, C**). The results showed that the expression level of uPA in B cells was significantly lower than that in MM specimens (**Figure 3A**), while the expression level of miR-23 in B cells was significantly higher than that in MM specimens (**Figure 3C**). These results further confirmed the relationship between uPA and miR-23 in MM.

Severity of Disease Stage of MM PDCs Is Associated With Aggregation and Agglomeration of Tumor Cells

Because hematological malignant cells rarely form regular solid tumors subcutaneously and because aggregation/agglomeration is often associated with the severity of MM, a subcutaneous growth model was developed for these cells (**Figure 4**). As shown in **Figure 4**, injection of a cell suspensions of MM cells (the PDC-1 [the Intraosseous MM], PDC-3 [the MM cells separated from patients' blood], PDC-5 [the MM cells separated from the tumor tissues in bone], PDC-7 [the Extra-bone tumor]) in nude mice resulted in the formation of subcutaneous tumor tissues (the solid tumor tissues). Among the four cell lines, the tumor tissues formed by PDC-1 were uneven (Inoculated PDC-1 subcutaneously in 10 animals, and finally form tumor tissue in 7 animals) and irregularly shaped; those of PDC-3, PDC-5, and PDC-7 all formed tumor tissues that were more even and homogenous (**Figure 4A** and **Table 1**). However, those formed by PDC-7 had the greatest uniformity of traits compared with ODC-3 or PDC-5 (**Figure 4** and **Table 1**).

At the same time, the MM cells of different origins and at different disease stages had different proliferation rates (**Figure 4**). Inoculated with the same number of PDCs, the volumes and weights of the tumor tissues formed by PDC-3, PDC-5, and PDC-7 were found to be significantly larger than the tumor



FIGURE 4 | *In vivo* growth of MM cells in nude mice. PDCs (1, 3, 5, or 7) of MM were injected subcutaneously into nude mice to form tumor tissues. The results are shown as images of tumor tissues **(A)**, tumor volumes **(B)**, or tumor weights **(C)**. *P < 0.05.

TABLE 1 | The shape-regularity (F-values) of tumor tissues mentioned in the **Figure 4**.

Tumor No.	PDC-1	PDC-3	PDC-5	PDC-7
	F values			
1	0.232	0.174	0.113	0.023
2	0.338	0.216	0.185	0.028
3	N.A.	0.133	0.103	0.079
4	0.102	0.152	0.223	0.012
5	N.A.	0.266	0.121	0.015
6	0.244	0.166	0.176	0.016
7	0.376	0.098	0.122	0.018
8	0.285	0.122	0.121	0.125
9	0.223	0.128	0.095	0.116
10	0.196	0.186	0.106	0.177

N.A., none-application/not available.

tissues formed by PDC-1. The volume and weight of tumor tissues formed by PDC-7 were the greatest. These results indicate that the method established in this study intuitively reflects and simulates MM cells, which gradually increase their aggregation, clustering, and proliferation capabilities as the disease progresses.

uPA Enhances Aggregation and Agglomeration

Next, the effects of uPA on MM were examined. As shown in **Figure 5**, it was difficult for the cells (the MM cell lines U266 and PDC-1 with low levels of uPA) to form solid tumor tissues. The injection of these two cells subcutaneously into nude mice resulted in the formation of irregularly shaped and uneven tumorous tissues. The outcomes were also partial: among the



FIGURE 5 | The effect of uPA overexpression on MM cells' subcutaneous growth. The PDC-1 or U266 cells were transfected with control or uPA and injected into the subcutaneous position of nude mice to form the subcutaneous tumors. The results are shown as images of tumor tissues **(A)**, tumor volumes **(B)**, or tumor weights **(C)**. The expression level of uPA or miR-23 in the tumor tissues were examined by qPCR and shown as histogram by mean ± SD **(D, E)**. *P < 0.05.

H226 cells, eight animals grew five tumors; for PDC-1, eight animals grew six tumors. Overexpression of uPA in H226 or PDC-1 cells significantly upregulated the subcutaneous growth of these two cells (**Figure 5** and **Table 2**); nude mice inoculated with these two kinds of cells formed tumor tissues with significantly improved uniformity (**Figure 5** and **Table 2**). The results were shown as images of tumor tissues (**Figure 5A**), tumor volumes (**Figure 5B**) or tumor weights (**Figure 5C**). The expression level of uPA and miR-23 in the subcutaneous tumor tissues formed by transfected cells were shown as **Figures 5D** and **E**. Therefore, uPA can significantly improve the *in vivo* proliferative ability of MM cells.

TABLE 2 | The shape-regularity (F-values) of tumor tissues mentioned in the **Figure 5**.

Tumor No.	PDC-1		U266	
	Control	uPA	Control	uPA
	F values			
1	N.A.	0.206	0.146	0.142
2	0.157	0.068	0.426	0.126
3	0.242	0.088	N.A.	0.089
4	0.386	0.103	0.286	0.044
5	0.256	0.062	0.313	0.046
6	0.313	0.036	0.266	0.213
7	N.A.	0.126	N.A.	0.168
8	0.042	0.077	N.A.	0.097

N.A., none-application/not available.

Hypermethylation of miR-23 Promoter Is Associated With Low miR-23 Levels and High uPA Levels in MM

The above results indicate that as the stage of MM disease (its degree of malignancy) increases, the expression level of miR-23 significantly decreases. For this reason, possible mechanisms for the loss of miR-23 expression were explored. As shown in **Figure 6**, hypermethylation of miR-23 was identified in MM specimens. In the selected (-2000 to -1) miR-23 promoter region, there are three CpG islands, and each has multiple methylation sites (**Figure 6A**). The trend for the methylation rate in the promoter region of miR-23 is exactly the opposite of that for miR-23 expression: among the four MM specimens, the methylation rate of the uPA promoter region was significantly lower in intraosseous samples than in the other three MM specimens; that of extra-bone tumor samples was the highest (**Figure 6B**). The methylation rates of uPA's promoter region in Blood (MM with blood distribution) and MM with Bone-tumor tissues is almost the same (**Figure 6B**).



FIGURE 6 | The methylation rates of miR-23's promoter in MM. **(A)** the selected promoter region of miR-23 and island in the selected regions were shown. **(B)** the methylation rates of miR-23's promoter region in MM clinical specimens or the primary B cells. **(C–F)** the co-relationship between miR-23 with the methylation rates of miR-23's promoter region in different MM specimens. **(G–J)** the co-relationship between uPA/PLAU with the methylation rates of miR-23's promoter region in different MM specimens. *P < 0.05.

To further confirm the effects of miR-23 promoter hypermethylation, we assessed the association between methylation rates and the expression levels of miR-23 and uPA in MM specimens. We found that methylation rates were negatively related to the expression of miR-23 and positively associated with the expression of uPA in MM specimens at different stages, and the results were shown as the scatter plot, regression equation and P values (**Figure 6** and **Table 3**). As an important control, the methylation rate of the miR-23 promoter region in primary B cells was also detected. As shown in **Figure 6B**, the methylation rate of the miR-23 promoter region in B cells was significantly lower than The methylation rate in MM, this result further corroborates the related results. Therefore, hypermethylation in the promoter region of miR-23 may be a mechanism for the loss of miR-23 expression in MM and the high expression of uPA.

Overexpression of miR-23 Represses the Proliferation of MM Cells in a Nude Mouse Model by Targeting uPA

To further elucidate the roles of miR-23/uPA in MM, each was overexpressed in MM cells. As shown in **Figure 7**, PDC-5 of MM cells formed subcutaneous tumor tissues in nude mice. Overexpression of uPA significantly promoted the subcutaneous growth of MM PDC-5. Moreover, the overexpression of miR-23 in PDC-5 not only inhibited the expression of uPA but also inhibited the subcutaneous growth of PDC-5. Co-transfection of uPA^{mut} (the uPA vector with a mutated miR-23 targeting site) almost completely blocked the inhibitory effects of miR-23 on uPA and PDC-5 (**Figures 7A–D**). Overexpression of miR-23 or uPA did not affect the methylation of miR-23 promoter in PDC-5. Therefore, miR-23 represses the proliferation of MM cells in nude mice by targeting uPA.

TABLE 3 | The co-relation analysis of **Figure 3** and **Figure 6**.

The association		uPA with miR-23	miR-23 with methylation	uPA with methylation
Intraosseous tumor	P values	0.0026	<0.0001	<0.0001
	Equation	Y = -0.3209*X + 1.332	Y = -2.315*X + 6.758	Y = 0.1224*X + 0.4664
Blood	P values	<0.0001	<0.0001	0.0116
	Equation	Y = -1.399*X + 3.119	Y = -10.39*X + 12.61	Y = 0.05848*X + 1.879
Bone-tumor	P values	0.0027	<0.0001	0.0008
	Equation	Y = -0.8661*X + 1.208	Y = -15.18*X + 13.51	Y = 0.04807*X + 0.5024
Extraosseous Tumor	P values	0.0026	0.0332	0.0027
	Equation	Y = -8.516*X + 5.186	Y = -49.70*X + 21.43	Y = 0.07975*X + 2.919

The "methylation" referring to "the methylation rates of miR-23's promoter region".
**P<0.05.*



FIGURE 7 | Effect of overexpression of miR-23 on uPA and in vivo proliferation in nude mice. PDC-5 of MM was transfected with vectors (control, uPA, miR-23, miR-23 + uPA^{Mut}) and injected subcutaneously into nude mice. The results are shown as images of tumors **(A)**, tumor volumes **(B)**, or tumor weights **(C)**. The level of uPA expression, miR-23 expression or the methylation rates of miR-23's promoter was shown as histogram **(D)**. #P<0.05 compared with control group; *P<0.05 compared with control group.

Overexpression of miR-23 Represses the *In Vivo* Invasion of MM Cells in Nude Mice

Next, we tested an *in vivo* invasion model (**Figure 8**). MM cell suspension was mixed with medical gel to form droplets, and then the droplets were adhered to the surfaces of the livers of nude mice. MM cells can destroy the liver capsule and gradually invade the liver to form tumor microlesions. For PDC-1 cells, the overexpression of uPA promoted intrahepatic invasion of PDC-1. At the same time, the co-transfection of miR-23 + uPA and miR-23 inhibited the expression of uPA and inhibited the invasion induced by uPA. However, in the co-transfection of the miR-23 + uPA^{Mut} group, miR-23 did not inhibit the expression of uPA^{Mut} and the invasion induced by uPA overexpression.

Next, the effects of miR-23/uPA on MM cells were also examined in PDC-5. Although the endogenous expression of PDC-5 uPA was greater than that of PDC-1, the overexpression of uPA still significantly promoted the intrahepatic invasion of PDC-5. On this basis, because the background expression of uPA in PDC-5 is higher than that of PDC-1, miR-23+uPA was not co-transfected, but miR-23 was directly overexpressed to downregulate uPA in PDC-5. The results showed that compared to the control group, miR-23 inhibited the intrahepatic invasion of PDC-5. After this, with the overexpression of miR-23, uPAMut was co-transfected, and miR-23 no longer had an inhibitory effect on PDC-5 intrahepatic invasion. These results confirm that miR-23 inhibits the invasion of MM cells by targeting 3'UTR of uPA.

Treatment of uPA Inhibitor Suppresses the Subcutaneous Growth of MM Cells

The above results indicate that uPA is an ideal intervention target for MM treatment. To this end, we tested whether targeting uPA can inhibit the proliferation of MM cells. After inoculating MM PDC-9 cells subcutaneously into nude mice, oral gavage treatment was administered, after which tumor tissues were collected to determine tumor volume and tumor weight (**Figure 9**). The oral uPA inhibitor UK-371804 inhibited the tumorigenic effects of PDC-7 in nude mice in a dose-dependent manner. This indicates that uPA is an ideal intervention target for MM, and small-molecule inhibitors targeting uPA show clear anti-tumor activity against MM.

DISCUSSION

Current MM staging standards can be divided into three stages, based on the Durie and Salmon staging standards (1975), ISS



FIGURE 8 | Effect of overexpression of miR-23 on uPA and *in vivo* invasion in nude mice's liver organs. PDC-1 **(A, C)** or PDC-5 **(B, D)** of MM was transfected with vectors (control, uPA, miR-23 + uPA, miR-23 + uPA^{Mut} for PDC-1 or control, uPA, miR-23, miR-23 + uPA^{Mut} for PDC-5) mixed with hydrogel to form drops. The hydrogel drops were adhered to the surface of nude mice's liver organs, and the intrahepatic invasion of MM cells were measured using Masson staining **(A, B)** and the quantitative results of A and B **(C, D)**. The magnification power is 400×. *P < 0.05.



FIGURE 9 | Antitumor effects of uPA small molecular inhibitor on the *in vivo* proliferation of MM cells. PDC-7 of MM was injected subcutaneously into nude mice. The mice received 1 mg/kg, 3 mg/kg, or 10 mg/kg UK-371804 *via* oral administration. The results are shown as images of tumors **(A)**, tumor volumes **(B)**, or tumor weights **(C)**. *P < 0.05.

international prognostic staging standards (2005), and revised R-ISS international prognostic staging standards (2015) (42–46). These staging systems are mainly based on some biochemical indicators (serum β2 microglobulin ≥ 5.5 mg/L, hypercalcemia, and so forth), bone damage (progressive osteolytic lesions, and so forth), and iFISH detection. This study was conducted to supplement this, beginning with the clinical symptoms, to detect the role of miR-23/uPA in MM. Our results differentiated patients according to the location and symptoms of MM, and also linked to differences in traditional staging classification. The hyper-methylation of the promoter region of miR-23 can lead to the down-regulation or deletion of uPA expression in MM, which in turn leads to the up-regulation of uPA expression. The results show that the expression trend of uPA in MM cells in blood is similar to that in bone tumor tissues. This indicates that the destruction of bone tissue by MM is a key step in its malignant transformation, and whether it migrates to the blood or forms solid tumor tissue in the bone may be affected by specific conditions represented by the miR-23/uPA axis.

The progress of human malignancies represented by the MM complex is often affected by the ECM or microenvironment (1–6). One sign of malignant transformation of these malignant tumor cells is metastasis and invasion, in which cells destroy the ECM/basal membrane of the primary site through MMPs and achieve invasive growth and migration to other tissues and organs (21). MMPs are vital to the destruction of local tissues, but they are inactive precursors and must be cleaved by uPA to be activated (21). The results of this study show that the expression level of uPA is closely related to the disease progression of MM. The overexpression of uPA in MM cells can promote the invasion of MM cells *in vitro* and *in vivo*. Although uPA-related research is of great importance, there have been very few reports on uPA in MM similar to that shown in this study, and the current publications mainly focus on the interaction between MM cells and intraosseous cells (such as osteoclasts) and the bone marrow microenvironment (22–26). There are no reports on the expression of uPA in MM cells, the effects of uPA on MM cells, or related molecular mechanisms. To explore the possible mechanisms of the high expression of uPA in MM specimens, we found that miR-23 can act on uPA and downregulate the expression level of uPA. The expression trend of miR-23 in MM specimens is opposite to that of uPA. Overexpression of miR-23 in MM cells can inhibit the proliferation and invasion of MM cells by targeting the 3'UTR of uPA. This study reports the function and mechanism of miR-23/uPA in MM cells for the first time. Reports of uPA-related miR mainly focus on miR-193a, mainly the influence of miR-193a on uPA in various malignant tumors (47–51). This research not only expands our understanding of uPA-related miR, but also indicates more options for MM response.

MicroRNA is a type of non-coding RNA molecule transcribed by RNA Pol II (52–54). In mammalian cells, miRNA is an important target for epigenetic research and an important regulator of many important physiological functions, such as cell

proliferation, cell differentiation, survival, and cancer (55–57). Additionally, use of miRs is also an important and effective aspect of anti-tumor gene therapy: the full sequence of miRs is chemically synthesized and prepared as lentiviral particles or coated by various liposomes, which can have anti-tumor effects (58, 59). In this way, the lack or deficiency of expression of miRs functioning as tumor suppressors is also among the important mechanisms of cell canceration. DNA methylation is also an important mechanism for the epigenetic regulation of mammalian cells (60–62). Hypermethylation in the promoter region of tumor suppressor genes can lead to the loss of their expression. For example, Ma *et al.* reported that methylation of the miR-34a promoter region in pancreatic cancer cells can lead to the loss of miR-34a expression in pancreatic cancer cells and clinical specimens (21). In this study, the expression levels of uPA and miR-23 were detected, as was the methylation rate of the promoter region of miR-23. Further, a correlation analysis was conducted, which found that the methylation rate of the promoter region of miR-23 is negatively correlated with the expression level of miR-23 and is positively correlated with the expression level of uPA. The data detected in these clinical specimens further confirms the effects of miR-23 on uPA. Nevertheless, we must still elaborate on the causal relationship between the methylation of the miR-23 promoter region and the expression of uPA in the future. Wang et al. found that DNA methyltransferase 1 can mediate the methylation of the miR-338-5p promoter region, cause the loss of miR-338-5p expression, and ultimately cause a high level of ETS-1 in gliomas (63). For this reason, in the future, our research group will investigate (1) DNMT-1 expression detection in MM; (2) the effects of DNMT-1 overexpression or knockdown on the expression of miR-23, and on the miR-23 promoter's methylation; and (3) the recruitment of DNMT-1 to the CpG islands in the promoter region of miR-23.

In addition, this study featured a novel methodology. First, for the detection of methylation rate, we used the BSP-NGS method to detect the methylation level of the promoter region of miR-23 in MM cells. In the use of this technology, the sequencing chip for second-generation sequencing can be used directly to detect dozens of samples at the same time. In addition, after the BSP step is completed, the methylation site can be sequenced as an SNP-like site, and the accurate methylation rate of any specific site in a specimen can be directly obtained. In addition, for the study of blood tumor cells such as MM, the main research method adopted is to culture cells for proliferation experiments such as MTT or cell counting. Because it is not easy for blood tumor cells to form subcutaneous neutral tissues, it is difficult for researchers to inoculate such cells under the skin of nude mice to form solid tumor tissues for quantitative analyses. In this study, solid tumor tissues were formed by subcutaneously inoculating MM cells of different sources and stages into nude mice. This is consistent with the characteristics of MM itself: as the disease progresses and the degree of malignant transformation increases, MM cells have greater agglomeration and aggregation, eventually forming solid tumors. Only some MM cells with a relatively low degree of malignancy can form solid tumor tissues after inoculation into nude mice. At the same time, the solid tumor tissue that forms is irregular in shape. The transfection of uPA into MM cells or their inoculation with a higher degree of malignant transformation into nude mice can form more uniform tumor tissues, and at the same time, their ability to form tumors is stronger (after inoculation with the same number of cells, the tumor tissues have larger volumes weights). We used image analysis software to identify the shapes of the tumor tissue. Finally, not only did we clarify the functions of uPA in MM, but we also used small-molecule inhibitors of uPA to produce the anti-tumor activity of MM cells. Moreover, the study's limitations are also acknowledged here: (1) In this study, we found that miR-23 was expressed in MM, while other miRNAs potentially targeting on uPA were expressed at very low or no levels in MM. To this end, we mainly focused on miR-23, while failing to uncover and explore the possible mechanisms for the deficency of expression of other miRNAs in MM; (2) Our results also showed that the methylation of the miR-23 promoter region may be a possible mechanism for the downregulation of miR-23 expression and the upregulation of uPA expression, but we failed to elucidate the possible mechanism of the methylation of the miR-23 promoter region, such as the relationship between DNA methylation transferase (41, 64–66) with miR-23; (3) The promoter methylation of tumor suppressor genes represented by some miRNAs is an important mechanism for the occurrence and progression of malignant tumors (53, 67–69). Small-molecular inhibitors such as DNA methyltransferase can not only upregulate the expression of some tumor suppressor genes, but also interact with the tumor suppressor genes (53, 67–69). Molecular targeted drugs and other anti-tumor drugs are used in combination. This study failed to detect the effect of DNA methyltransferase inhibitors on MM cells, which will be further explored in the future. Despite many advances, the options for MM anti-tumor drug treatment remain limited. It is worth mentioning that in addition to the action of uPA on MMPs, it can also form a complex with uPAP (the uPA-uPAR axis) and invoke non-proteolytic receptor-related pathways participating in the migration/invasion, adhesion, differentiation, tumor progression, or angiogenesis of cancer cells (70). In the future, we will explore the role of uPA/uPAR in MM in depth. Moreover, our future researches will also refer to or include the publicly available data for RNAseq and DNA methylation (71). We also systematically summarize all previous findings from other studies in pubmed that uPA is closely related to the disease progression of MM, and is also an important regulator of the interaction between MM and the tumor microenvironment (22–26, 72–79). This also confirms the results of this study from one side.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of the General Hospital of Central Theater Command. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

QR and DW: concept, design, statistics, data collection, manuscript writing, final approval. CH: design, statistics, data collection. DX concept, data collection. QW: statistics, manuscript writing. QR: statistics, data collection. QW and DW: statistics, data collection. DW and QR: concept, design, statistics, data collection, manuscript writing, final approval. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank Prof. and Dr. Ling Wei in Beijing Centre for Physical and Chemical Analysis, Beijing 100089, PR China for the experimental materials and technical guidance. We also thank Dr. Yan Ma in Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China and Dr. Qiyu Jiang in Research Center for Clinical and Transitional Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China for launching Help and technical guidance provided in methylation related research.

REFERENCES

1. Uckun FM. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. *Front Oncol* (2021) 11:760382. doi: 10.3389/fonc.2021.760382
2. Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D, Silva GN. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. *Front Oncol* (2021) 11:740796. doi: 10.3389/fonc.2021.740796
3. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple Myeloma. *Lancet* (2021) 397(10272):410–27. doi: 10.1016/S0140-6736(21)00135-5
4. Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Baljevic M, Lentzsch S, et al. Once Weekly Selinexor, Carfilzomib and Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients. *Br J Cancer* (2021) 20:1–8. doi: 10.1038/s41416-021-01608-2
5. Ciftciler R, Ciftciler AE. The Importance of Microbiota in Hematology. *Transfus Apher Sci* (2021) 17:103320. doi: 10.1016/j.transci.2021.103320
6. Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM, Yu BT, et al. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. *Front Immunol* (2021) 12:782775. doi: 10.3389/fimmu.2021.782775
7. Sabol HM, Delgado-Calle J. The Multifunctional Role of Notch Signaling in Multiple Myeloma. *J Cancer Metastasis Treat* (2021) 7:20. doi: 10.20517/2394-4722.2021.35
8. Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, et al. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction Without Gut Toxicity. *Cancer Res* (2021) 81(19):5102–14. doi: 10.1158/0008-5472.CAN-21-0524
9. Hofbauer D, Mougiakakos D, Broggini L, Zaiss M, Büttner-Herold M, Bach C, et al. Beta(2)-Microglobulin Triggers NLRP3 Inflammasome Activation in Tumor-Associated Macrophages to Promote Multiple Myeloma Progression. *Immunity* (2021) 54(8):1772–87.e9. doi: 10.1016/j.immuni.2021.07.002
10. Liu H, Wang Z, He J, Li Z, Gao JY, Liu R, et al. Promotion of Bone Lesions Through the Myeloma Integrin Alpha6-Mediated Osteolytic Signaling. *Front Oncol* (2021) 11:692190. doi: 10.3389/fonc.2021.692190
11. Lo CH, Shay G, McGuire JJ, Li T, Shain KH, Choi JY, et al. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. *Cancer Res* (2021) 81(9):2415–28. doi: 10.1158/0008-5472.CAN-20-2705
12. Ma H, Yao Y, Wang C, Zhang L, Cheng L, Wang Y, et al. Transcription Factor Activity of Estrogen Receptor α Activation Upon Nonylphenol or Bisphenol A Treatment Enhances the *In Vitro* Proliferation, Invasion, and Migration of Neuroblastoma Cells. *Onco Targets Ther* (2016) 9:3451–63. doi: 10.2147/OTT.S105745
13. Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Integrins as Attractive Targets for Cancer Therapeutics. *Acta Pharm Sin B* (2021) 11(9):2726–37. doi: 10.1016/j.apsb.2021.01.004
14. Niu FY, Jin C, Ma L, Shi YX, Li XS, Jiang P, et al. Urokinase Plasminogen Activator Predicts Poor Prognosis in Hepatocellular Carcinoma. *J Gastrointest Oncol* (2021) 12(4):1851–9. doi: 10.21037/jgo-21-343
15. Iozzo RV, Theocharis AD, Neill T, Karamanos NK. Complexity of Matrix Phenotypes. *Matrix Biol Plus* (2020) 6-7:100038. doi: 10.1016/j.mbplus.2020.100038
16. Gonias SL, Zampieri C. Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development. *Curr Drug Targets* (2020) 21(7):647–56. doi: 10.2174/1389450120666191122101658
17. Hatoum A, Mohammed R, Zakieh O. The Unique Invasiveness of Glioblastoma and Possible Drug Targets on Extracellular Matrix. *Cancer Manag Res* (2019) 11:1843–55. doi: 10.2147/CMAR.S186142
18. Meng D, Lei M, Han Y, Zhao D, Zhang X, Yang Y, et al. MicroRNA-645 Targets Urokinase Plasminogen Activator and Decreases the Invasive Growth of MDA-MB-231 Triple-Negative Breast Cancer Cells. *Onco Targets Ther* (2018) 11:7733–43. doi: 10.2147/OTT.S187221
19. Dede E, Liapis D, Davos C, Katsimpoulas M, Varela A, Mpotis I, et al. The Effects of Exercise Training on Cardiac Matrix Metalloproteinases Activity and Cardiac Function in Mice With Diabetic Cardiomyopathy. *Biochem Biophys Res Commun* (2021) 586:8–13. doi: 10.1016/j.bbrc.2021.11.013
20. Nonino CB, Noronha NY, de Araújo Ferreira-Julio M, Moriguchi Watanabe L, Cassia KF, Ferreira Nicoletti C, et al. Differential Expression of MMP2 and TIMP2 in Peripheral Blood Mononuclear Cells After Roux-En-Y Gastric Bypass. *Front Nutr* (2021) 8:628759. doi: 10.3389/fnut.2021.628759
21. Ling W, Yongzhi L, Xiaoping Z, Shang H, Lijuan G, Yan L, et al. Novel Urokinase-Plasminogen Activator Inhibitor SPINK13 Inhibits Growth and Metastasis of Hepatocellular Carcinoma *In Vivo*. *Pharmacol Res* (2019) 143:73–85. doi: 10.1016/j.phrs.2019.03.009
22. Shen J, Wang Q, Wang J, Su GH, Wang J, Guo SH, et al. Analysis of Soluble Urokinase Plasminogen Activator Receptor in Multiple Myeloma for Predicting Prognosis. *Oncol Lett* (2015) 10(4):2403–9. doi: 10.3892/ol.2015.3613
23. Ciavarella S, Laurenzana A, De Summa S, Pilato B, Chillà A, Lacalamita R, et al. U-PAR Expression in Cancer Associated Fibroblast: New Acquisitions in Multiple Myeloma Progression. *BMC Cancer* (2017) 17(1):215. doi: 10.1186/s12885-017-3183-y
24. Khan R, Gupta N, Kumar R, Sharma M, Kumar L, Sharma A. Augmented Expression of Urokinase Plasminogen Activator and Extracellular Matrix Proteins Associates With Multiple Myeloma Progression. *Clin Exp Metastasis* (2014) 31(5):585–93. doi: 10.1007/s10585-014-9652-7
25. Albayrak M, Şahin Balçık Ö, Dağdaş S, Yılmaz M, Ceran F, Yokuş O, et al. Role of Flow Cytometry in Multiple Myeloma and the Prognostic Significance of CD87 (uPAR) Expression. *Turk J Haematol* (2010) 27(3):182–9. doi: 10.5152/tjh.2010.26
26. Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O. Interactions of Myeloma Cells With Osteoclasts Promote Tumour Expansion and Bone Degradation

Through Activation of a Complex Signalling Network and Upregulation of Cathepsin K, Matrix Metalloproteinases (MMPs) and Urokinase Plasminogen Activator (uPA). *Exp Cell Res* (2008) 314(5):1082–93. doi: 10.1016/j.yexcr.2007.10.021
27. Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, et al. Novel ADAM-17 Inhibitor ZLDI-8 Enhances the *In Vitro* and *In Vivo* Chemotherapeutic Effects of Sorafenib on Hepatocellular Carcinoma Cells. *Cell Death Dis* (2018) 9(7):743. doi: 10.1038/s41419-018-0804-6
28. Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q, et al. A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. *Front Oncol* (2021) 11:783194. doi: 10.3389/fonc.2021.783194
29. He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, et al. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting Cyp3a4. *Front Oncol* (2021) 11:735447. doi: 10.3389/fonc.2021.735447
30. Zhu Y, Feng F, Yu J, Song B, Hu M, Gao X, et al. L1-ORF1p, a Smad4 Interaction Protein, Promotes Proliferation of HepG2 Cells and Tumorigenesis in Mice. *DNA Cell Biol* (2013) 32(9):531–40. doi: 10.1089/dna.2013.2097
31. Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma Cells *via* Decelerating Its Intracellular Clearance. *Onco Targets Ther* (2019) 12:1629–40. doi: 10.2147/OTT.S196713
32. Ji Q, Xu X, Kang L, Xu Y, Xiao J, Goodman SB, et al. Hematopoietic PBX-Interacting Protein Mediates Cartilage Degeneration During the Pathogenesis of Osteoarthritis. *Nat Commun* (2019) 10(1):313. doi: 10.1038/s41467-018-08277-5
33. Ma Y, Chai N, Jiang Q, Chang Z, Chai Y, Li X, et al. DNA Methyltransferase Mediates the Hypermethylation of the microRNA 34a Promoter and Enhances the Resistance of Patient-Derived Pancreatic Cancer Cells to Molecular Targeting Agents. *Pharmacol Res* (2020) 160:105071. doi: 10.1016/j.phrs.2020.105071
34. He W, Gong S, Wang X, Dong X, Cheng H. DNA Methylation Integratedly Modulates the Expression of Pit-Oct-Unt Transcription Factors in Esophageal Squamous Cell Carcinoma. *J Cancer* (2021) 12(6):1634–43. doi: 10.7150/jca.49231
35. Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma HD, et al. Rhamnetin Induces Sensitization of Hepatocellular Carcinoma Cells to a Small Molecular Kinase Inhibitor or Chemotherapeutic Agents. *Biochim Biophys Acta* (2016) 1860(7):1417–30. doi: 10.1016/j.bbagen.2016.04.007
36. Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, et al. ETS-1 Induces Sorafenib-Resistance in Hepatocellular Carcinoma Cells *via* Regulating Transcription Factor Activity of PXR. *Pharmacol Res* (2018) 135:188–200. doi: 10.1016/j.phrs.2018.08.003
37. Sun H, Feng F, Xie H, Li X, Jiang Q, Chai Y, et al. Quantitative Examination of the Inhibitory Activation of Molecular Targeting Agents in Hepatocellular Carcinoma Patient-Derived Cell Invasion *via* a Novel *In Vivo* Tumor Model. *Anim Model Exp Med* (2019) 2(4):259–68. doi: 10.1002/ame2.12085
38. Feng YQ, Li BA, Feng F, Chen YS, Ren YX, Zhang H, et al. Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. *Onco Targets Ther* (2020) 13:7165–76. doi: 10.2147/OTT.S244474
39. Yue W, Shuo L, Qin C, Yixin R, Zhongxiang L, Shuang C. Novel Small Molecular Inhibitor of Pit-Oct-Unc Transcription Factor 1 Suppresses Hepatocellular Carcinoma Cell Proliferation. *Life Sci* (2021) 277:119521. doi: 10.1016/j.lfs.2021.119521
40. Zou X-Z, Zhou X-H, Feng Y-Q, Hao J-F, Liang B, Jia M-W. Novel Inhibitor of OCT1 Enhances the Sensitivity of Human Esophageal Squamous Cell Carcinoma Cells to Antitumor Agents. *Eur J Pharmacol* (2021) 907:174222. doi: 10.1016/j.ejphar.2021.174222
41. Wang JH, Zeng Z, Sun J, Chen Y, Gao X. A Novel Small-Molecule Antagonist Enhances the Sensitivity of Osteosarcoma to Cabozantinib *In Vitro* and *In Vivo* by Targeting DNMT-1 Correlated With Disease Severity in Human Patients. *Pharmacol Res* (2021) 173:105869. doi: 10.1016/j.phrs.2021.105869
42. Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, et al. Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage. *Blood Cancer J* (2021) 11(12):192. doi: 10.1038/s41408-021-00587-0
43. Visram A, Vachon C, Baughn LB, Larson D, Smadbeck J, Dispenzieri A, et al. Family History of Plasma Cell Disorders Is Associated With Improved Survival in MGUS, Multiple Myeloma, and Systemic AL Amyloidosis. *Leukemia* (2021) 36(4):1058–65. doi: 10.1038/s41375-021-01454-4
44. Negroni D, Cassarà A, Trisoglio A, Soligo E, Berardo S, Carriero A, et al. Learning Curves in Radiological Reporting of Whole-Body MRI in Plasma Cell Disease: A Retrospective Study. *Radiol Med* (2021) 126(11):1451–9. doi: 10.1007/s11547-021-01391-3
45. Galieni P, Travaglini F, Vagnoni D, Ruggieri M, Caraffa P, Bigazzi C, et al. The Detection of Circulating Plasma Cells may Improve the Revised International Staging System (R-ISS) Risk Stratification of Patients With Newly Diagnosed Multiple Myeloma. *Br J Haematol* (2021) 193(3):542–50. doi: 10.1111/bjh.17118
46. Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, et al. Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated With Novel Agents as a Primary Therapy. *Am J Hematol* (2017) 92(12):1280–6. doi: 10.1002/ajh.24891
47. Lin M, Zhang Z, Gao M, Yu H, Sheng H, Huang J. MicroRNA-193a-3p Suppresses the Colorectal Cancer Cell Proliferation and Progression Through Downregulating the PLAU Expression. *Cancer Manag Res* (2019) 11:5353–63. doi: 10.2147/CMAR.S208233
48. Tsai KW, Leung CM, Lo YH, Chen TW, Chan WC, Yu SY, et al. Arm Selection Preference of MicroRNA-193a Varies in Breast Cancer. *Sci Rep* (2016) 6:28176. doi: 10.1038/srep28176
49. Lv L, Li Y, Deng H, Zhang C, Pu Y, Qian L, et al. MiR-193a-3p Promotes the Multi-Chemoresistance of Bladder Cancer by Targeting the HOXC9 Gene. *Cancer Lett* (2015) 357(1):105–13. doi: 10.1016/j.canlet.2014.11.002
50. Lv L, Deng H, Li Y, Zhang C, Liu X, Liu Q, et al. The DNA Methylation-Regulated miR-193a-3p Dictates the Multi-Chemoresistance of Bladder Cancer *via* Repression of SRSF2/PLAU/HIC2 Expression. *Cell Death Dis* (2014) 5(9):e1402. doi: 10.1038/cddis.2014.367
51. Iliopoulos D, Rotem A, Struhl K. Inhibition of miR-193a Expression by Max and RXRalpha Activates K-Ras and PLAU to Mediate Distinct Aspects of Cellular Transformation. *Cancer Res* (2011) 71(15):5144–53. doi: 10.1158/0008-5472.CAN-11-0425
52. Li B, Feng F, Jia H, Jiang Q, Cao S, Wei L, et al. Rhamnetin Decelerates the Elimination and Enhances the Antitumor Effect of the Molecular-Targeting Agent Sorafenib in Hepatocellular Carcinoma Cells *via* the miR-148a/PXR Axis. *Food Funct* (2021) 12(6):2404–17. doi: 10.1039/d0fo02270e
53. Peng Z, Zhang Y, Shi D, Jia Y, Shi H, Liu H. miR-497-5p/SALL4 Axis Promotes Stemness Phenotype of Choriocarcinoma and Forms a Feedback Loop With DNMT-Mediated Epigenetic Regulation. *Cell Death Dis* (2021) 12(11):1046. doi: 10.1038/s41419-021-04315-1
54. Wang Y, Dong L, Wan F, Chen F, Liu D, Chen D, et al. MiR-9-3p Regulates the Biological Functions and Drug Resistance of Gemcitabine-Treated Breast Cancer Cells and Affects Tumor Growth Through Targeting MTDH. *Cell Death Dis* (2021) 12(10):861. doi: 10.1038/s41419-021-04145-1
55. Wang C, Ding S, Sun B, Shen L, Xiao L, Han Z, et al. Hsa-miR-4271 Downregulates the Expression of Constitutive Androstane Receptor and Enhances *In Vivo* the Sensitivity of Non-Small Cell Lung Cancer to Gefitinib. *Pharmacol Res* (2020) 161:105110. doi: 10.1016/j.phrs.2020.105110
56. Yang H, Ren L, Wang Y, Bi X, Li X, Wen M, et al. FBI-1 Enhanced the Resistance of Triple-Negative Breast Cancer Cells to Chemotherapeutic Agents *via* the miR-30c/PXR Axis. *Cell Death Dis* (2020) 11(10):851. doi: 10.1038/s41419-020-03053-0
57. Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, et al. MicroRNA-3163 Targets ADAM-17 and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. *Cell Death Dis* (2019) 10(10):784. doi: 10.1038/s41419-019-2023-1
58. Shao QP, Wei C, Yang J, Zhang WZ. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway. *Onco Targets Ther* (2020) 13:7213–27. doi: 10.2147/OTT.S246471
59. Wang T, Gao L, Quan D. Multivesicular Liposome (MVL) Sustained Delivery of a Novel Synthetic Cationic GnRH Antagonist for Prostate Cancer

Treatment. *J Pharm Pharmacol* (2011) 63(7):904–10. doi: 10.1111/j.2042-7158.2011.01295.x
60. Xue T, Qiu X, Liu H, Gan C, Tan Z, Xie Y, et al. Epigenetic Regulation in Fibrosis Progress. *Pharmacol Res* (2021) 173:105910. doi: 10.1016/j.phrs.2021.105910
61. Lu J, Huang Y, Zhang X, Xu Y, Nie S. Noncoding RNAs Involved in DNA Methylation and Histone Methylation, and Acetylation in Diabetic Vascular Complications. *Pharmacol Res* (2021) 170:105520. doi: 10.1016/j.phrs.2021.105520
62. Yi L, Huang P, Zou X, Guo L, Gu Y, Wen C, et al. Integrative Stemness Characteristics Associated With Prognosis and the Immune Microenvironment in Esophageal Cancer. *Pharmacol Res* (2020) 161:105144. doi: 10.1016/j.phrs.2020.105144
63. Wang J, Huo C, Yin J, Tian L, Ma L, Wang D. Hypermethylation of the Promoter of miR-338-5p Mediates Aberrant Expression of ETS-1 and Is Correlated With Disease Severity Of Astrocytoma Patients. *Front Oncol* (2021) 11:773644. doi: 10.3389/fonc.2021.773644
64. Liu YY, Ding CZ, Chen JL, Wang ZS, Yang B, Wu XM. A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells. *Front Pharmacol* (2022) 13:863339. doi: 10.3389/fphar.2022.863339
65. Li XF, Wu S, Yan Q, Wu YY, Chen H, Yin SQ, et al. And Activation of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis. *Front Pharmacol* (2021) 12:700373. doi: 10.3389/fphar.2021.700373
66. Hong Q, Xu W, Lin Z, Liu J, Chen W, Zhu H, et al. Role of GABRD Gene Methylation in the Nucleus Accumbens in Heroin-Seeking Behavior in Rats. *Front Pharmacol* (2021) 11:612200. doi: 10.3389/fphar.2020.612200
67. Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. Targeting Cancer Epigenetic Pathways With Small-Molecule Compounds: Therapeutic Efficacy and Combination Therapies. *Pharmacol Res* (2021) 173:105702. doi: 10.1016/j.phrs.2021.105702
68. Zhang X, Zhao S, Yuan Q, Zhu L, Li F, Wang H, et al. TXNIP, a Novel Key Factor to Cause Schwann Cell Dysfunction in Diabetic Peripheral Neuropathy, Under the Regulation of PI3K/Akt Pathway Inhibition-Induced DNMT1 and DNMT3a Overexpression. *Cell Death Dis* (2021) 12 (7):642. doi: 10.1038/s41419-021-03930-2
69. Li X, Lyu C, Luo ZC, Zhao J, Wang Z, Yang C, et al. The Roles of IGF2 and DNMT Methylation and Elongase6 Related Fatty Acids in Metabolic Syndrome. *Food Funct* (2021) 12(20):10253–62. doi: 10.1039/d1fo00502b
70. Endo-Munoz L, Cai N, Cumming A, Macklin R, Merida de Long L, Topkas E, et al. Progression of Osteosarcoma From a Non-Metastatic to a Metastatic Phenotype Is Causally Associated With Activation of an Autocrine and Paracrine uPA Axis. *PloS One* (2015) 10(8):e0133592. doi: 10.1371/journal.pone.0133592.
71. Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, et al. Whole-Epigenome Analysis in Multiple Myeloma Reveals DNA Hypermethylation of B Cell-Specific Enhancers. *Genome Res* (2015) 25(4):478–87. doi: 10.1101/gr.180240.114
72. Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Myeloma Cells (5TMM) and Their Interactions With the Marrow Microenvironment. *Blood Cells Mol Dis* (2004) 33(2):111–9. doi: 10.1016/j.bcmd.2004.04.012
73. Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, et al. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) as an Independent Factor Predicting Worse Prognosis and Extra-Bone Marrow Involvement in Multiple Myeloma Patients. *Br J Haematol* (2003) 120(6):953–9. doi: 10.1046/j.1365-2141.2003.04176.x
74. Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O. Osteoblasts Promote Migration and Invasion of Myeloma Cells Through Upregulation of Matrix Metalloproteinases, Urokinase Plasminogen Activator, Hepatocyte Growth Factor and Activation of P38 MAPK. *Br J Haematol* (2007) 138 (4):446–58. doi: 10.1111/j.1365-2141.2007.06665.x
75. Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, et al. Expression of Urokinase Plasminogen Activator and the Urokinase Plasminogen Activator Receptor in Myeloma Cells. *Br J Haematol* (2000) 109 (4):815–22. doi: 10.1046/j.1365-2141.2000.02089.x
76. Mazar AP, Ahn RW, O'Halloran TV. Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic. *Curr Pharm Des* (2011) 17(19):1970–8. doi: 10.2174/138161211796718152
77. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma. *J Biol Chem* (2008) 283(47):32628–36. doi: 10.1074/jbc.M806266200
78. Uchiba M, Imamura T, Hata H, Tatetsu H, Yonemura Y, Ueda M, et al. Excessive Fibrinolysis in AL-Amyloidosis Is Induced by Urokinae-Type Plasminogen Activator From Bone Marrow Plasma Cells. *Amyloid* (2009) 16(2):89–93. doi: 10.1080/13506120902879269
79. Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, et al. Mechanisms Involved in the Differential Bone Marrow Homing of CD45 Subsets in 5T Murine Models of Myeloma. *Clin Exp Metastasis* (2002) 19(7):583–91. doi: 10.1023/a:1020987830132

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

frontiers | Frontiers in Cell and Developmental Biology

ORIGINAL RESEARCH
published: 04 July 2022
doi: 10.3389/fcell.2021.760618

Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value

Xuanwen Bao[1†], Kun Wang[2†], Ming Liu[2], Bin Li[1], Hongwei Wang[2], Kemin Jin[2], Xiaoluan Yan[2], Hangyu Zhang[1], Quan Bao[2], Da Xu[2], Lijun Wang[2], Wei Liu[2], Yanyan Wang[2], Juan Li[2], Lijuan Liu[2], Weijia Fang[1] and Baocai Xing[2]**

[1]Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, China, [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital and Institute, Beijing, China

OPEN ACCESS

Edited by:
Rui Manuel Reis,
Barretos Cancer Hospital, Brazil

Reviewed by:
Adriane Feijo Evangelista,
Barretos Cancer Hospital, Brazil
Ana Preto,
University of Minho, Portugal
Gabriel Macedo,
Clinical Hospital of Porto Alegre, Brazil

***Correspondence:**
Weijia Fang
weijiafang@zju.edu.cn
Baocai Xing
xingbaocai88@sina.com

[†]These authors have contributed equally to this work

Specialty section:
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Cell and Developmental Biology

Received: 18 August 2021
Accepted: 23 December 2021
Published: 04 July 2022

Citation:
Bao X, Wang K, Liu M, Li B, Wang H, Jin K, Yan X, Zhang H, Bao Q, Xu D, Wang L, Liu W, Wang Y, Li J, Liu L, Fang W and Xing B (2022) Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value. Front. Cell Dev. Biol. 9:760618. doi: 10.3389/fcell.2021.760618

Colorectal liver metastases (CRLMs) are clinically heterogeneous lesions with poor prognosis. Genetic alterations play a crucial role in their progression. The traditional Fong clinical risk score (Fong-CRS) is commonly used for risk stratification and prognosis prediction. By identifying the genomic alterations of CRLMs, we aimed to develop a mutation-based gene-signature-based clinical score (mut-CS) system to improve clinical prognostication. Tumour tissues from 144 patients with CRLMs were analysed with next-generation sequencing (NGS). A mut-CS scoring system considering the unique mutation-based gene signature, primary site, and Fong-CRS was developed and could identify CRLM patients with poor prognosis. The mean time-dependent receiver operating characteristic curve AUC value of the mut-CS system was greater than that of previously established scoring measures (the Fong-CRS, the e-clinical score, the presence of concomitant RAS and TP53 mutations, and other clinical traits). Taking together, we identified a mutant signature that exhibits a strong prognostic effect for CRLMs. Traditional clinical scoring system characteristics were incorporated into the new mut-CS scoring system to help determine the appropriate treatment for CRLMs.

Keywords: colorectal liver metastases, genomic landscape, prognostics, overall survival, mutation signature

INTRODUCTION

Colorectal cancer (CRC) is one of the most common cancers worldwide (Siegel et al., 2020). Metastases are the main cause of mortality in CRC patients (Ansa et al., 2018). Approximately 22% of CRCs are metastatic at initial diagnosis, and approximately 70% of patients will eventually develop metastatic relapse (Ansa et al., 2018). The liver is the most common location for distant metastasis of colorectal cancer due to its close proximity to the colorectum, with less frequent metastasis to the lung, bone, and nervous system (Manfredi et al., 2006; Engstrand et al., 2018; Wang et al., 2020). Vermaat et al. showed a significant difference in mutations in genes known to be involved in cancer

Abbreviations: CRC, colorectal cancer; CRLMs, colorectal liver metastases; Fong-CRS, Fong clinical risk score; NGS, next-generation sequencing; e-CS, extended clinical score; mut-CS, mutation-based gene signature-based clinical score; GATK, Genome Analysis Toolkit; MAF, mutant allele frequency; LASSO, least absolute shrinkage and selection operator; GEO, Gene Expression Omnibus.

pathways between primary CRC and matched liver metastases. They found significant genetic differences, with numerous losses and gains across the genome (Vermaat et al., 2012). Furthermore, colorectal liver metastases (CRLMs) are clinically heterogeneous lesions with poor prognosis (Manfredi et al., 2006; Turtoi et al., 2014). Hepatic resection improves the 5-years survival up to 50% (Abdalla et al., 2004; Rees et al., 2008). However, the varied prognoses and responses to therapy in CRLM require the stratification of patients according to risk for appropriate individualized treatments. Several clinical scores, which are commonly based on the preoperative carcinoembryonic antigen (CEA) value, resection margin, primary tumour site, tumour TNM stage (T: the size of the origin and whether it has invaded nearby tissue; N: nearby lymph nodes that are involved; M: distant metastasis), lymph node metastasis, and tumour size, are designed to evaluate the status and predict the prognosis of patients with CRLM (Nordlinger et al., 1996; Fong et al., 1999; Kattan et al., 2008). Among these, the Fong clinical risk score (Fong-CRS) is one of the most famous scoring systems (Fong et al., 1999). Some recent studies also raised several other scoring systems for better clinical decisions for CRLM patients. Kim et al. developed a scoring system based on synchronosity, CA19-9 level, number of liver metastases, largest size of liver metastases, resection margin of hepatic lesions, neutrophil-to-lymphocyte ratio, and prognostic nutritional index. They demonstrated that the novel scoring system would improve the sensitivity for the prediction of disease recurrence in CRLM patients (Kim et al., 2020). Liu et al. identified five independent risk factors for CRLM patients: tumour larger than 5 cm, more than one tumour, RAS mutation, primary lymph node metastasis, and primary tumour located on the right side (Liu et al., 2021). With the five identified risk factors, they constructed a nomogram to predict the progression-free survival of CRLM patients. Chen et al. established a modified tumour burden score (mTBS) by a mathematical equation with parameters including CRLM size, CRLM number, and unilobar or bilobar metastasis, which showed superior discriminatory capacity for stratifying CRLM patients with poor prognosis (Chen et al., 2020a). Nevertheless, most of the previous established scoring systems were constructed with the clinicopathological features of patients with CRLM. Considering the tumor heterogeneity and genomic difference between different patients, integrating genomic information may improve the predicting efficiency and provide new insight into the understanding the link between genome alteration, tumor progression and prognosis of CRLM patients. Next-generation sequencing (NGS) allows a comprehensive depiction of the genomic alterations (Chen et al., 2021; Wang et al., 2021), which helps determine molecular pathway alterations involved in CRLM and their relevance to prognosis. Recently, one study assessed the effect of 720 genes on the oncological outcome after resection of CRLMs and revealed that alterations of the SMAD family, as well as the RAS/RAF pathway, affected the prognosis of CRLM (Lang et al., 2019). A novel extended clinical score (e-CS) including RAS/RAF pathway and SMAD family alterations was developed to predict the overall survival of CRLM patients (Lang et al., 2019), which showed improved prediction efficiency compared with the traditional Fong-CRS system.

In this study, through the application of NGS, we identified genomic alterations in CRLM. Furthermore, associations between the primary sites of CRLM and gene mutations were identified in CRLM patients. To improve the prediction efficiency of mutation-based scoring system, we developed a novel mutation-based gene-signature-based clinical score (mut-CS).

With several machine learning concepts (e.g., regression, training and testing), we confirmed the robustness of the mut-CS system, which also showed better predicting efficiency than several previous established scoring systems. This study may provide helpful therapeutic information and improve the stratification of patients with CRLM.

MATERIALS AND METHODS

Sample Collection

This study was approved by the Ethics Committee of Peking University Cancer Hospital and Institute in compliance with the ethical guidelines of the 1975 Declaration of Helsinki. The collection period is 8 years and all participants provided written informed consent to take part in the study. A total number of 146 patients were included and the mean age is 57.62 tumors were originated from left side of colon and 84 tumors were originated from right side of colon. The detailed patient information is provided in **Supplementary Table S1**.

Next-Generation Sequencing

NGS analyses were performed in a centralized clinical testing centre according to protocols reviewed and approved by the Ethics Committee of Beijing Cancer Hospital. DNA was extracted from FFPE tumour tissues using a DNA Extraction Kit (QIAamp DNA FFPE Tissue Kit) according to the manufacturer's protocols. Then, the DNA was sheared into 150–200 bp fragments with a BioruptorRPico Instrument (Diagenode, Seraing, Belgium). For each sample, 200–500 ng of FFPE DNA was then used for library preparation and quantification. Fragmented DNA libraries were constructed by the KAPA Hyper Prep Kit (KAPA Biosystems, Wilmington, Massachusetts, United States) following the manufacturer's instructions. The final library was more than 600 ng, and fragment lengths were within the range of 250–400 base pairs (bp). DNA libraries were captured with a designed panel of 620 key cancer-related genes (GloriousMed, Shanghai, China). The list of 620 genes are shown in **Supplementary Table S2**. The captured samples were subjected to Illumina HiSeq X-Ten sequencing with a minimum depth of 500 ×.

Mutation Calls

Illumina bcl2fastq (v2.19) software was used to demultiplex the sequencing data, followed by analysis with Trimmomatic (Bolger et al., 2014) to remove low-quality (quality<15) or N bases. Then, alignment of the data to the hg19 reference human genome was performed with the Burrows-Wheeler Aligner (bwa-mem) (Li, 2013), followed by processing using the Picard suite (available at

https://broadinstitute.github.io/picard/) and the Genome Analysis Toolkit (GATK) with the default parameters (DePristo et al., 2011). Here, the Picard software can deduplicate the sequence. GATK-HaplotypeCaller was used to call germline SNPs, and GATK-Mutect2 was used to call somatic SNVs and indels. The Variant Allele Frequency (VAF) cut-off was set as 0.5%. Then, authenticity was confirmed in IGV (IGV Win 2.4.16). Known germline alternations in dbSNP were filtered out by comparison to the patient's whole blood controls from each patient. Visualization of the genomic alterations was performed with maftools (Mayakonda et al., 2018). VEP software was used to annotate the mutation information, including the c-point and p-point information of the mutation under the HGVS rule, and the effect of the mutation on the protein function was also provided. ANNOVAR was further used to enrich the annotation results of mutations, including annotating the region where the mutation site is located, the type of SNV or Indel mutation in the exon region, the allele frequency of the mutation base at the mutation site in 1,000 Genomes, the mutation ID in dbSNP and so on. The information for annotated variants is in **Supplementary Table S3**. TP53- and KRAS-driven mutations were identified through the IntOGen-mutations platform (http://www.intogen.org/mutations/), which analysed 4,623 exomes from 13 cancer sites.

Mutation-Based Gene Signature Construction

The least absolute shrinkage and selection operator (LASSO) algorithm was applied to establish the mutation-based gene signature. The L1-norm was applied to penalize the weight of the coefficients (Tibshirani, 1996). The cv.glmnet function from the glmnet package was used to build the model with the default parameters. Ten cross-validations were performed when constructing the scoring system. The key features were then selected while other features were penalized. The coefficient of the model was then identified with the coef function. A mut-CS formula was established by including individual mutation status (mutation: 1; wild-type: 0) weighted by the LASSO Cox coefficients and other clinical traits: size of metastases (1 point for >5 cm) + lymph node status (1 point for > positive) + primary site (1 point for right) + metastasis number (1 point for >1) + CEA value (1 point for >200) + metastasis status (1 point for synchronous) + $\sum coef\,ficient\,(gene\ mutation_i)\,(from\ Figure\ 4C) \times mutation\ status$.

Public Data Processing

NGS clinical data of the MSKCC cohort were downloaded from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/).

Statistics

Overall survival was calculated from the day of diagnosis or liver resection until the death of the patient. All statistical analyses were performed with R software and Python software. Survival analysis was performed with the "survival" package (Therneau and Lumley, 2014). The HR was determined with univariate or multivariate Cox regression analysis. The time-dependent receiver operating characteristic (tROC) curve quantifies the discriminative ability of a marker at each time point under consideration and was used to evaluate the AUC value during the follow-up period with the "survivalROC" package (Heagerty et al., 2013). Clinicopathological features with a significant effect in the univariate analysis were used to build a multivariate Cox model. p values < 0.05 were considered statistically significant.

RESULTS

Genomic Alterations of Colorectal Liver Metastases

We analysed a total of 144 colorectal liver metastases. The detailed genomic alterations are shown in **Figure 1A,B**. *TP53* (83%), *APC* (69%), *KRAS* (43%) and *SMAD4* (17%) were the most frequent mutations in CRLMs. The major mutation type for *TP53* and *KRAS* was missense mutation, while the major mutation type of *APC* was frame-shift insertion. Furthermore, we extracted the data from patients with CRLMs from the MSKCC cohort (Yaeger et al., 2018) and reanalysed the genomic alterations of the samples. In the MSKCC cohort, *TP53* (82%), *APC* (80%), *KRAS* (38%) and *PIK3CA* (18%) were the genes most frequently mutated in patients with CRLMs (**Supplementary Figure S1A,B**).

Considering the synergistic contribution of RAS activation and the loss of p53 function in the malignant transformation of colorectal cancer cells, we also explored the effect of concomitant RAS and TP53 mutations on CRLM prognosis. In our results, the driver KRAS mutation was a predictive marker for overall survival in patients with CRLM (p = 0.007, HR = 1.87, 95% CI: 1.18–2.94 for OS from diagnosis of CRLM and p = 0.015, HR = 1.75, 95% CI: 1.11–2.76 for OS from hepatic resection) (**Supplementary Figure S1A,B**), while TP53 mutation showed an insignificant association with overall survival (p = 0.33, HR = 1.39, 95% CI: 0.71–2.72 for OS from diagnosis of CRLM; and p = 0.313, HR = 1.41, 95% CI: 0.72–2.75 for OS from hepatic resection) (**Supplementary Figure S1C,D**). Furthermore, dual mutations in RAS and TP53 were not an independent predictor of worse survival in CRLM patients (Figure S1E).

Next, oncogenic signalling pathways were also examined. RTK-RAS was the most affected oncogenic pathway and had the most gene mutations in the in-house CRLM cohort (**Figure 2A**, **Supplementary Table S4**). Of the genes in the RTK-RAS pathway with alterations, most were oncogenes in the CRLM cohort (**Figure 2B**). The patients with RAS-RAF pathway alterations had an unfavourable overall survival outcome compared with patients without RAS-RAF pathway alterations (p = 0.003, HR = 2.03, 95% CI: 1.27–3.24 for OS from diagnosis of CRLM; and p = 0.005, HR = 1.97, 95% CI: 1.23–3.15 for OS from hepatic resection) (**Supplementary Figure S2A,B**). We also analysed SMAD family gene mutations and the combined effect of SMAD pathway and RAS-RAF pathway alterations in our in-house cohort (**Supplementary Table S4**). Nevertheless, SMAD pathway alterations did not have a significant



FIGURE 1 | Distribution of commonly altered genes in the in-house CRLM **(A)** and SMKCC CRLM **(B)** cohorts and the frequencies of the mutations. CRLM: Colorectal liver metastases.

effect on the overall survival of patients with CRLM (**Supplementary Figure S2C,D**). Patients with alterations in both the SMAD pathway and the RTK-RAS pathway had a significantly different prognosis from patients without mutations in both pathways (pairwise comparison $p = 0.03$) (**Supplementary Figure S2E**).

Genomic Difference by Primary Tumour Site

The total gene mutation burden and the frequent mutation sites were analysed for left- and right-side colorectal liver metastases. The TMB values of CRLM and tumours from the TCGA cohort were compared. Greater tumour mutational burden (TMB) values were found in colorectal liver metastases originating from the right side than in those originating from the right side (**Figure 3A**). Of the 10 most significantly mutated genes in CRLM, *TCF7L2* showed a significantly higher alteration frequency in right side (29.2%) than in left side (9.2%) tumours ($p = 0.013$) (**Figure 3B**). *FBXW7* mutation frequency was marginally significantly different between CRLMs originating from the left (14.2%) and CRLMs originating from the right (0%) side ($p = 0.07$) (**Figure 3B**). Then, we compared the 50 most significantly mutated genes in CRLMs originating from the left and right sides. A total of 75 genes were included (**Supplementary Table S5**). Among the 75 genes, *KRAS, AMER1, NSD1, EPPK1, PIK3R1, ACVR2A, EPHB1, HNF1A, EZH1* and *CD1D* mutations were enriched in CRLMs originating from the right side (p value from chi-square tests) (**Figure 3C**, **Supplementary Table S6**).

Establishment of a Mutation-Based Gene Signature for Overall Survival in CRLM Patients

The association between gene mutations and overall survival was analysed with univariate Cox analysis. The genes mutated in more



FIGURE 2 | Oncogenic pathway changes and specific gene alterations in the RTK-RAS pathway **(A)** Oncogenic pathway changes in CRLMs **(B)** Specific gene alterations in the RTK-RAS pathway in CRLMs. CRLM: Colorectal liver metastases.

than 3% of samples in the whole in-house cohort were filtered and then subjected to univariate Cox regression. In total, eight gene mutations showed unfavourable overall survival outcomes in patients with CRLM (**Figure 4A**). LASSO Cox regression was performed, and a mutation-based gene signature was built with six genes (**Figures 4B,C**). The patients from the in-house CRLM cohort were stratified into high-risk (at least one gene mutation) and low-risk groups (none of the six genes mutated). Kaplan–Meier plots and univariate Cox regression revealed that patients without the six gene mutations had favourable overall survival outcomes compared with patients with at least one gene mutation ($p < 0.001$, HR = 2.82) (**Figure 4D**). The detailed mutation types of the six genes are shown in **Figure 5E**. Missense mutation was the most frequent mutation type in *BRCA2, KRAS, TSC2 and PIK3CA*, while nonsense mutation was the most frequent in *PIK3R1* and *LATS2*. With the mutation-based gene signature, the patients could be stratified into high- and low-risk groups regarding the overall survival from hepatic resection in our in-house colorectal liver metastasis cohort ($p < 0.001$, HR = 2.68) (**Figure 4F**). To further validate the mutation-based gene signature, we applied it to an external cohort. The patients classified as high risk (at least one gene mutation) in the MSKCC colorectal liver metastasis cohort had unfavourable overall survival outcomes compared with the patients classified as low risk (no mutation) ($p = 0.03$, HR = 1.57) (**Figure 4G**).

Combination of the Mutation-Based Gene Signature and Clinical Variables to Establish a Mut-CS Scoring System to Improve Risk Assessment and Stratification

Kaplan–Meier plots and univariate Cox regression revealed that Fong-CRS and primary site stratified patient survival in our in-house CRLM cohort (**Figures 5A,B**). In our in-house CRLM cohort, patients with left primary tumour sites had favourable survival outcomes compared with patients with right primary tumour sites ($p < 0.001$, HR = 2.89). In addition, patients with a higher Fong-CRS (>2) had marginally unfavourable survival compared with patients with a lower Fong-CRS (≤2) ($p = 0.095$, HR = 1.49).

The Fong-CRS is a useful tool in clinical practice. Recently, a study presented the concept of an extended clinical score (e-CS) considering the size of metastases, lymph node status and alterations in the RAS/RAF pathway, as well as the SMAD family (Lang et al., 2019). We established a novel mut-CS scoring system: size of metastases (1 point for >5 cm) + lymph node status (1 point for > positive) + primary site (1 point for right) + metastasis number (1 point for >1) + CEA value (1 point for >200) + metastasis status (1 point for synchronous) + $\sum coefficient\,(gene\ mutation_i)\,(from\ Figure\ 4C) \times mutation\ status$ and compared the predictive power of the Fong-CRS score, the e-CS, primary site, concomitant *RAS* and *TP53* mutations and the mut-CS scoring system (**Figure 5C**). The average predictive power of the mut-CS system was greater than that of the Fong-CRS, e-CS, concomitant *RAS* and *TP53* mutations and other clinical traits (mean time-dependent ROC value of mut-CS = 0.75, cut off-value for mut-CS is 1.7, 1.1, 1.1, 1.1, and 1.0 for 1–5 years, respectively). Kaplan–Meier and univariate Cox regression analyses revealed that patients with a high mut-CS (>3) had poor prognosis ($p < 0.01$, HR = 3.81) (**Figure 5D**).

DISCUSSION

With the application of liver surgery and the resection of liver metastases, the majority of tumours can be removed (R0



FIGURE 3 | Genomic alterations by primary site **(A)** Comparison of the TMB values in CRLMs originating from the left and right sides of the colon with those in other tumour types. Data source: TCGA database **(B)** Genomic alteration frequency analysis by primary tumour site **(C)** Oncoplot of gene alterations with different frequencies in tumours originating from the left and right sides of the colon. TMB: tumour mutation burden; TCGA: The Cancer Genome Atlas.

resection). Traditionally, the criteria for patient selection and operation are clinically relevant, such as the Fong-CRS score, the response to preoperative chemotherapy and CEA levels and changes following chemotherapy. Among such prognostic factors, the Fong-CRS has been one of the most famous scoring systems since it was proposed in 1999. The Fong-CRS is constructed by several clinicopathological features, which are easily measured and assessed during clinical practice, which made the Fong-score as one of the commonly used tools. Due to the development of NGS, some studies have focused on improving the stratification and predictive capacity of the Fong-CRS system. Nevertheless, the Fong-CRS is still the top tool for determining risk and CRLM patient status. Brudvik et al. refined the Fong-CRS by including the lymph node status of the primary tumour, the size of the largest metastasis and the RAS mutation status (Brudvik et al., 2019). An e-CS that included size of metastases (1 point for >5 cm), lymph node status (1 point for lymph node positivity) and alterations in the RTK-RAS pathway (1 point for alteration), as well as the SMAD family (1 point for alteration), was raised by Lang et al. and exhibited accurate stratification capacity in patients with CRLMs (Lang et al., 2019). In this study, we identified a mutation-based gene signature including six gene mutations. Mutation-based gene-signature-based mut-CS stratified patients with CRLMs into high- and low-risk groups. The mut-CS system was developed based on the mutation-based gene signature identified in this study and the Fong-CRS. It is a new simple way to help clinicians make clinical decisions. With a calculation method similar to that of the traditional Fong-CRS (the sum of risk points for mutation status and clinical traits), each patient with CRLMs can obtain a risk score for prognosis prediction, which can help them receive individualized treatment. We also compared mut-CS with existing stratification methods based on concomitant *RAS* and *TP53* mutations, e-CS and the traditional CRS scoring system. The time-dependent ROC analysis suggested that mut-CS had higher predictive efficacy than e-CS, concomitant *RAS* and *TP53* mutations, primary site or



FIGURE 4 | Mutation-based gene-signature construction **(A)** Selection of prognostic gene alterations **(B)** LASSO Cox regression feature selection **(C)** Distribution of the coefficients of the established gene signature **(D)** Patients with at least one gene mutation exhibited worse OS from the time of diagnosis of CRLM than those with no gene mutations in the in-house CRLM cohort **(E)** Oncoplot showing mutation types in the in-house CRLM cohort **(F)** Patients with at least one gene mutation exhibited worse OS after hepatic resection than those with no gene mutations in the in-house CRLM cohort **(G)** The external MSKCC-CRLM cohort validated the efficacy of the mutation-based gene signature. LASSO: least absolute shrinkage and selection operator; OS: overall survival; CRLM: colorectal liver metastases.



FIGURE 5 | Combination of the mutation-based gene signature and clinical variables to establish the mut-CS scoring system to improve risk assessment and stratification **(A)** The association between Fong-CRS and OS from the time of diagnosis of CRLM **(B)** The association between the primary site of CRLM and OS from the time of diagnosis of CRLM **(C)** The association between mut-CS and OS from the time of diagnosis of CRLM **(D)** Time-dependent ROC analysis was performed to evaluate the predictive power of the mut-CS scoring system for OS in CRLM patients. OS: overall survival, CRLM: colorectal liver metastases.

Fong-CRS. Thus, mut-CS represents an improved version of the already established Fong-CRS system and may lead to further stratification of the treatment of CRLMs.

The mutation-based signature was constructed with *BRCA2, LATS2, TSC2, KRAS, PIK3R1* and *PIK3CA*. *BRCA2* is one of the crucial proteins involved in homologous recombination, which is the most accurate method of double-stranded DNA break repair. Germline mutations in *BRCA2* are highly penetrant for breast cancer and ovarian cancer (Antoniou et al., 2003), but the mechanism of *BRCA2* mutation in CRC is still not clear. One recent study shows *BRCA2* deletion triggers *TERRA* hyperexpression and alternative lengthening mechanisms (ALT) in colon cancer in presence of telomerase activity, which opens the question if patients bearing *BRCA2* mutation suitable for anti-telomerase therapies (Pompili et al., 2019). The continuous activation of Wnt signaling is one important mechanism for CRC initiation. *LATS2* suppresses oncogenic Wnt signaling by disrupting β-Catenin/BCL9 interaction (Li et al., 2013). *TSC2* inhibits cell growth by acting as a GTPase-activating protein toward Rheb, thereby inhibiting mTOR. The mutation in the *TSC2* tumor suppressor causes aberrant cell growth and therefore may contribute the tumor progression and metastasis of CRC (Inoki et al., 2006). *PIK3R1* which acting as the regulatory subunit of PI3K, stabilizes and inhibits the PI3K p110 catalytic subunit. PIK3R1 mutations are commonly occurred in CRC, therefore leading to CRC tumorgenesis (Philp et al., 2001). *PIK3CA* mutation is associated with poor prognosis among CRC patients and predicts response of colon cancer cells to the cetuximab (Jhawer et al., 2008; Ogino et al., 2009).

TP53, APC, KRAS, SMAD, CHEK2 and *TCF7L2* were the most significantly altered genes in our CRLM cohort. The introduction of mutations in *APC, KRAS, PIK3CA, SMAD4* and *TP53*, four or five major driver genes for colorectal cancer, induces epithelial cell transformation, resulting in the development of transplantable tumours *in vivo* (Drost et al., 2015). The p53 mutation is found in approximately 60% of colorectal cancers, and a majority of mutations are missense-type at "hot spots", suggesting an oncogenic role of mutant *p53* (Giannakis et al., 2016). *KRAS* mutation occurs early in CRC carcinogenesis and was observed in 27–43% of patients with CRC. *KRAS* mutation is considered a marker of resistance to EGFR inhibitor therapy (Lou et al., 2017). Among patients treated with cetuximab, the objective response rate for WT *KRAS* patients was 12.8%, compared with a 1.2% response rate for patients in the *KRAS* mutant group (Amado et al., 2008). Additional *KRAS* mutation

activation induces more malignant phenotypes, such as EMT and metastasis (Bakir et al., 2020; Chen et al., 2020b). In our analysis, *KRAS* mutation was a prognostic indicator for overall survival, while *TP53* mutation showed no significant value for predicting overall survival in CRLM patients. One recent study also revealed that RAS mutation is a negative prognostic factor for OS, while *TP53* gene mutations do not seem to affect long-term outcomes, which is consistent with our results (Tsilimigras et al., 2018). Cooperation between mutated *TP53* and RAS activation plays a crucial role in the malignant progression of colorectal cancer cells (Parada et al., 1984; McMurray et al., 2008). The multiple steps of malignant transformation in colorectal cancer cells depend upon genes controlled synergistically by RAS activation and the loss of p53 function (McMurray et al., 2008). Recently, one study also confirmed that dual mutation of RAS/TP53 is an indicator of poor survival in patients with CRLMs (Chun et al., 2019). Thus, we analysed the association of overall survival and dual mutation of *TP53* and *KRAS* to evaluate the prognostic value of *TP53* and *KRAS* dual mutation. Nevertheless, the results showed that dual mutation of *KRAS* and *TP53* was not a predictive factor in our CRLM cohort. Furthermore, one study indicated that the most predictive parameters for poor survival were alterations in the SMAD family and RAS-RAF pathway in a colorectal liver metastasis cohort (Lang et al., 2019). In that study, combined consideration of alterations of the SMAD family, as well as the RTK-RAS pathway, could identify patients with poor survival (Lang et al., 2019). Nevertheless, we did not find that SMAD pathway alterations had a significant effect on the overall survival of patients with CRLM. This discrepant result may come from the criteria we used for patient selection, differences in chemotherapy response and/or ethnic differences, which warrants confirmation in larger patient cohorts.

The molecular differences between CRLMs originating from right-side and left-side primary colon cancer were evaluated. TMB values of CRLMSs from right-side were greater than that of CRLMs from left-side, which is in consistent with the previous studies (Kim et al., 2019; Bao et al., 2020). Of the 10 most commonly mutated genes in CRLMs, *TCF7L2* showed a significantly higher frequency in CRLMs originating from right-side colon cancer than in CRLMs originating from left-side colon cancer, while the *FBXW7* mutation frequency was marginally significantly different between tumours of these two origins. *TCF7L2* mutations included missense mutations (most frequent), splice site alterations, translation start site alterations, frame-shift insertions, nonsense mutations and frame-shift deletions in our in-house cohort. *TCF7L2* interacts with translocated β-catenin in the nucleus, thus leading to the conversion of *TCF7L2* into a transcription factor activator (Nelson and Nusse, 2004). The active form of *TCF7L2* induces the expression of c-MYC and other target genes, playing a crucial role in CRC carcinogenesis (Nelson and Nusse, 2004). However, the loss of TCF7L2 promotes migration and the invasion of human CRC by suppressing the expression of pro-oncogenic transcription factor RUNX2 and cell adhesion molecules, supporting tumour-suppressive functions (Wenzel et al., 2020). This paradox implies the complex roles of *TCF7L2* in CRC carcinogenesis. Alternative splicing creates *TCF7L2* isoforms with short or long C-terminal ends (Duval et al., 2000). The isoform with a long C-terminal end mediates transcriptional repression in CRC (Duval et al., 2000). Frameshift mutation leads to selective loss of TCF-4 isoforms with CtBP binding abilities (Cuilliere-Dartigues et al., 2006). One study revealed that, in MSI-H CRC that harbours a frameshift mutation of *TCF7L2*, CtBP is not able to repress *TCF7L2*-mediated transcription (Cuilliere-Dartigues et al., 2006). A higher frequency of *TCF7L2* mutations was found in CRLMs originating from the right side of the colon than in CRLMs originating from the left side of the colon. The higher frequency of *TCF7L2* alterations in CRLMs originating from the right side of the colon may also affect the WNT signalling pathway. *FBXW7* is a tumour repressor gene. *FBXW7* is the substrate recognition subunit for a ubiquitin ligase complex that can negatively regulate cell growth and metabolism by regulating the expression of c-Myc, cyclin E, Notch, TGIF and KLF5 (Welcker and Clurman, 2008). As *FBXW7* regulates a range of substrates, it may be a promising candidate for targeted therapeutics. A larger cohort may be required to explore the difference in *FBXW7* between CRLMs originating from the left and right sides of the colon as well as alteration-induced pathway changes. We also identified that the mutation burden was significantly higher in CRLMs originating from the right side of the colon than in CRLMs originating from the left side of the colon, which is consistent with data from primary colorectal cancer (Yaeger et al., 2018).

There are still some limitations to our study. In this study, we took blood as self-control. The existence of circulating tumour cells in blood may have reduced the reliability of our conclusion. Additionally, we proposed our scoring system of CRLM for clinical decision-making and validated it in an external cohort to further prove this system. However, the cohort size was still relatively small. Last, the number of CRLMs originating from the left site and right site of the colon was imbalanced.

In summary, we revealed the genomic alterations of CRLMs, which provided a potential biological explanation for clinical differences seen in metastases with different primary tumour sites and enabled the identification of prognostic factors. The mut-CS scoring system, which incorporates the Fong-CRS, primary site and mutation-based gene signature (*BRCA2, KRAS, TSC2, PIK3CA, PIK3R1* and *LATS2*), showed improved risk assessment for individual patients compared with the existing Fong-CRS. We hope that the mutation-based gene signature and mut-CS scoring system described in this report can be useful tools for identifying high-risk CRLM patients who may benefit from adjuvant therapies and contribute to the personalized management of CRLMs.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the CNSA repository (https://db.cngb.org/cnsa/), accession number CNP0003154.

ETHICS STATEMENT

This study was approved by the Ethics Committee of Peking University Cancer Hospital and Institute. All participants provided written informed consent to take part in the study.

AUTHOR CONTRIBUTIONS

BX and WF supervised the project. XB and KW designed the workflow and performed the bioinformatic analysis. BX, KW and WF led the study. KJ, XY, HZ, QB, DX, LW, WL, YW, JL and LL performed material preparation and data collection. XB and KW wrote the first draft. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

FUNDING

This study was supported by grants (No. 81874143, No. 31971192, No. 82101830) from the National Nature Science Foundation of China and the Beijing Natural Science Foundation (No. 7192035).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.760618/full#supplementary-material

REFERENCES

Abdalla, E. K., Vauthey, J.-N., Ellis, L. M., Ellis, V., Pollock, R., Broglio, K. R., et al. (2004). Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/ablation for Colorectal Liver Metastases. *Ann. Surg.* 239 (6), 818–827. doi:10.1097/01.sla.0000128305.90650.71

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., et al. (2008). Wild-type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer. *J. Clin. Oncol.* 26 (10), 1626–1634.

Ansa, B., Coughlin, S., Alema-Mensah, E., and Smith, S. (2018). Evaluation of Colorectal Cancer Incidence Trends in the United States (2000-2014). *Jcm* 7 (2), 22. doi:10.3390/jcm7020022

Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: a Combined Analysis of 22 Studies. *Am. J. Hum. Genet.* 72 (5), 1117–1130. doi:10.1086/375033

Bakir, B., Chiarella, A. M., Pitarresi, J. R., and Rustgi, A. K. (2020). EMT, MET, Plasticity, and Tumor Metastasis. *Trends Cell Biology* 30, 764. doi:10.1016/j.tcb.2020.07.003

Bao, X., Zhang, H., Wu, W., Cheng, S., Dai, X., Zhu, X., et al. (2020). Analysis of the Molecular Nature Associated with Microsatellite Status in colon Cancer Identifies Clinical Implications for Immunotherapy. *J. Immunother. Cancer* 8 (2), e001437. doi:10.1136/jitc-2020-001437

Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a Flexible Trimmer for Illumina Sequence Data. *Bioinformatics* 30 (15), 2114–2120. doi:10.1093/bioinformatics/btu170

Brudvik, K. W., Jones, R. P., Giuliante, F., Shindoh, J., Passot, G., Chung, M. H., et al. (2019). RAS Mutation Clinical Risk Score to Predict Survival after Resection of Colorectal Liver Metastases. *Ann. Surg.* 269 (1), 120–126. doi:10.1097/sla.0000000000002319

Chen, D., Bao, X., Zhang, R., Ding, Y., Zhang, M., Li, B., et al. (2021). Depiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma. *Br. J. Cancer* 125, 1–9. doi:10.1038/s41416-021-01501-y

Chen, P., Li, X., Zhang, R., Liu, S., Xiang, Y., Zhang, M., et al. (2020). Combinative Treatment of β-elemene and Cetuximab Is Sensitive to KRAS Mutant Colorectal Cancer Cells by Inducing Ferroptosis and Inhibiting Epithelial-Mesenchymal Transformation. *Theranostics* 10 (11), 5107–5119. doi:10.7150/thno.44705

Chen, Y., Chang, W., Ren, L., Chen, J., Tang, W., Liu, T., et al. (2020). Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation. *The oncologist* 25 (7), e1031–e1041. doi:10.1634/theoncologist.2019-0797

Chun, Y. S., Passot, G., Yamashita, S., Nusrat, M., Katsonis, P., Loree, J. M., et al. (2019). Deleterious Effect of RAS and Evolutionary High-Risk TP53 Double Mutation in Colorectal Liver Metastases. *Ann. Surg.* 269 (5), 917–923. doi:10.1097/sla.0000000000002450

Cuilliere-Dartigues, P., El-Bchiri, J., Krimi, A., Buhard, O., Fontanges, P., Fléjou, J. F., et al. (2006). TCF-4 Isoforms Absent in TCF-4 Mutated MSI-H Colorectal Cancer Cells Colocalize with Nuclear CtBP and Repress TCF-4-Mediated Transcription. *Oncogene* 25 (32), 4441–4448. doi:10.1038/sj.onc.1209471

DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., et al. (2011). A Framework for Variation Discovery and Genotyping Using Next-Generation DNA Sequencing Data. *Nat. Genet.* 43 (5), 491–498. doi:10.1038/ng.806

Drost, J., Van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., Van Boxtel, R., Buijs, A., et al. (2015). Sequential Cancer Mutations in Cultured Human Intestinal Stem Cells. *Nature* 521 (7550), 43–47. doi:10.1038/nature14415

Duval, A., Rolland, S., Tubacher, E., Bui, H., Thomas, G., and Hamelin, R. (2000). The Human T-Cell Transcription Factor-4 Gene: Structure, Extensive Characterization of Alternative Splicings, and Mutational Analysis in Colorectal Cancer Cell Lines. *Cancer Res.* 60 (14), 3872–3879.

Engstrand, J., Nilsson, H., Strömberg, C., Jonas, E., and Freedman, J. (2018). Colorectal Cancer Liver Metastases - a Population-Based Study on Incidence, Management and Survival. *BMC cancer* 18 (1), 78–11. doi:10.1186/s12885-017-3925-x

Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., and Blumgart, L. H. (1999). Clinical Score for Predicting Recurrence after Hepatic Resection for Metastatic Colorectal Cancer. *Ann. Surg.* 230 (3), 309. doi:10.1097/00000658-199909000-00004

Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., et al. (2016). Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. *Cel Rep.* 15 (4), 857–865. doi:10.1016/j.celrep.2016.03.075

Heagerty, P., Saha, P., and P, S. (2013). *survivalROC: Time-dependent ROC Curve Estimation from Censored Survival Data R Package Version 1.0*. San Francisco.

Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., et al. (2006). TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth. *Cell* 126 (5), 955–968. doi:10.1016/j.cell.2006.06.055

Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., et al. (2008). PIK3CA Mutation/PTEN Expression Status Predicts Response of colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab. *Cancer Res.* 68 (6), 1953–1961. doi:10.1158/0008-5472.can-07-5659

Kattan, M. W., Gönen, M., Jarnagin, W. R., DeMatteo, R., D'Angelica, M., Weiser, M., et al. (2008). A Nomogram for Predicting Disease-specific Survival after Hepatic Resection for Metastatic Colorectal Cancer. *Ann. Surg.* 247 (2), 282–287. doi:10.1097/sla.0b013e31815ed67b

Kim, J. E., Chun, S.-M., Hong, Y. S., Kim, K.-p., Kim, S. Y., Kim, J., et al. (2019). Mutation burden and I index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. *J. Mol. Diagn.* 21 (2), 241–250. doi:10.1016/j.jmoldx.2018.09.005

Kim, W.-J., Lim, T.-W., Kang, S.-H., Park, P.-J., Choi, S.-B., Lee, S.-i., et al. (2020). Development and Validation of Novel Scoring System for the Prediction of

Disease Recurrence Following Resection of Colorectal Liver Metastasis. *Asian J. Surg.* 43 (2), 438–446. doi:10.1016/j.asjsur.2019.06.001

Lang, H., Baumgart, J., Heinrich, S., Tripke, V., Passalaqua, M., Maderer, A., et al. (2019). Extended Molecular Profiling Improves Stratification and Prediction of Survival after Resection of Colorectal Liver Metastases. *Ann. Surg.* 270 (5), 799–805. doi:10.1097/sla.0000000000003527

Li, H. (2013). *Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM*. [Preprint]. Cambridge, MA.

Li, J., Chen, X., Ding, X., Cheng, Y., Zhao, B., Lai, Z.-c., et al. (2013). LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction. *Cel Rep.* 5 (6), 1650–1663. doi:10.1016/j.celrep.2013.11.037

Liu, W., Zhang, W., Xu, Y., Li, Y-H., and Xing, B-C. (2021). A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in This Modern Era. *Ann. Surg. Oncol.* 28, 1–10. doi:10.1245/s10434-021-10143-6

Lou, E., D'Souza, D., and Nelson, A. C. (2017). Therapeutic Response of Metastatic Colorectal Cancer Harboring aKRASMissense Mutation after Combination Chemotherapy with the EGFR Inhibitor Panitumumab. *J. Natl. Compr. Canc Netw.* 15 (4), 427–432. doi:10.6004/jnccn.2017.0043

Manfredi, S., Lepage, C. m., Hatem, C., Coatmeur, O., Faivre, J., and Bouvier, A.-M. (2006). Epidemiology and Management of Liver Metastases from Colorectal Cancer. *Ann. Surg.* 244 (2), 254–259. doi:10.1097/01.sla.0000217629.94941.cf

Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., and Koeffler, H. P. (2018). Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer. *Genome Res.* 28 (11), 1747–1756. doi:10.1101/gr.239244.118

McMurray, H. R., Sampson, E. R., Compitello, G., Kinsey, C., Newman, L., Smith, B., et al. (2008). Synergistic Response to Oncogenic Mutations Defines Gene Class Critical to Cancer Phenotype. *Nature* 453 (7198), 1112–1116. doi:10.1038/nature06973

Nelson, W. J., and Nusse, R. (2004). Convergence of Wnt, SS-Catenin, and Cadherin Pathways. *Science* 303 (5663), 1483–1487. doi:10.1126/science.1094291

Nordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjema, K., Bachellier, P., et al. (1996). Surgical Resection of Colorectal Carcinoma Metastases to the Liver: a Prognostic Scoring System to Improve Case Selection, Based on 1568 Patients. *Cancer* 77 (7), 1254–1262. doi:10.1002/(sici)1097-0142(19960401)77:7<1254:aid-cncr5>3.0.co;2-i

Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., et al. (2009). PIK3CA Mutation Is Associated with Poor Prognosis Among Patients with Curatively Resected colon Cancer. *Jco* 27 (9), 1477–1484. doi:10.1200/jco.2008.18.6544

Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., and Rotter, V. (1984). Cooperation between Gene Encoding P53 Tumour Antigen and Ras in Cellular Transformation. *Nature* 312 (5995), 649–651. doi:10.1038/312649a0

Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., et al. (2001). The Phosphatidylinositol 3'-kinase P85alpha Gene Is an Oncogene in Human Ovarian and colon Tumors. *Cancer Res.* 61 (20), 7426–7429.

Pompili, L., Maresca, C., Dello Stritto, A., Biroccio, A., and Salvati, E. (2019). BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive colon Cancer Cells. *Genes* 10 (9), 697. doi:10.3390/genes10090697

Rees, M., Tekkis, P. P., Welsh, F. K. S., O'Rourke, T., and John, T. G. (2008). Evaluation of Long-Term Survival after Hepatic Resection for Metastatic Colorectal Cancer. *Ann. Surg.* 247 (1), 125–135. doi:10.1097/sla.0b013e31815aa2c2

Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., et al. (2020). *Colorectal Cancer Statistics*. CA Cancer J Clin.

Therneau, T. M., and Lumley, T. (2014). *Package 'survival'. Survival Analysis Published on CRAN*. [Preprint]. Rochester, MN, 3.

Tibshirani, R. (1996). Regression Shrinkage and Selection via the Lasso. *J. R. Stat. Soc. Ser. B (Methodological)* 58 (1), 267–288. doi:10.1111/j.2517-6161.1996.tb02080.x

Tsilimigras, D. I., Ntanasis-Stathopoulos, I., Bagante, F., Moris, D., Cloyd, J., Spartalis, E., et al. (2018). Clinical Significance and Prognostic Relevance of KRAS, BRAF, PI3K and TP53 Genetic Mutation Analysis for Resectable and Unresectable Colorectal Liver Metastases: A Systematic Review of the Current Evidence. *Surg. Oncol.* 27 (2), 280–288. doi:10.1016/j.suronc.2018.05.012

Turtoi, A., Blomme, A., Debois, D., Somja, J., Delvaux, D., Patsos, G., et al. (2014). Organized Proteomic Heterogeneity in Colorectal Cancer Liver Metastases and Implications for Therapies. *Hepatology* 59 (3), 924–934. doi:10.1002/hep.26608

Vermaat, J. S., Nijman, I. J., Koudijs, M. J., Gerritse, F. L., Scherer, S. J., Mokry, M., et al. (2012). Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment. *Clin. Cancer Res.* 18 (3), 688–699. doi:10.1158/1078-0432.ccr-11-1965

Wang, H., Ding, Y., Chen, Y., Jiang, J., Chen, Y., Lu, J., et al. (2021). A Novel Genomic Classification System of Gastric Cancer via Integrating Multidimensional Genomic Characteristics. *Gastric Cancer* 24, 1227–1241. doi:10.1007/s10120-021-01201-9

Wang, J., Li, S., Liu, Y., Zhang, C., Li, H., and Lai, B. (2020). Metastatic Patterns and Survival Outcomes in Patients with Stage IV colon Cancer: A Population-based Analysis. *Cancer Med.* 9 (1), 361–373. doi:10.1002/cam4.2673

Welcker, M., and Clurman, B. E. (2008). FBW7 Ubiquitin Ligase: a Tumour Suppressor at the Crossroads of Cell Division, Growth and Differentiation. *Nat. Rev. Cancer* 8 (2), 83–93. doi:10.1038/nrc2290

Wenzel, J., Rose, K., Haghighi, E. B., Lamprecht, C., Rauen, G., Freihen, V., et al. (2020). Loss of the Nuclear Wnt Pathway Effector TCF7L2 Promotes Migration and Invasion of Human Colorectal Cancer Cells. *Oncogene* 39 (19), 3893–3909. doi:10.1038/s41388-020-1259-7

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., et al. (2018). Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. *Cancer cell* 33 (1), 125–136. doi:10.1016/j.ccell.2017.12.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 06 September 2022
DOI 10.3389/fonc.2022.988794

OPEN ACCESS

EDITED BY
Vasiliki Gkretsi,
European University Cyprus, Cyprus

REVIEWED BY
Cecilia Battistelli,
Sapienza University of Rome, Italy
Yen-Nien Liu,
Taipei Medical University, Taiwan

*CORRESPONDENCE
Guan-Ming Kuang
kuanggm@hku-szh.org

†These authors have contributed equally to this work

SPECIALTY SECTION
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

RECEIVED 07 July 2022
ACCEPTED 03 August 2022
PUBLISHED 06 September 2022

CITATION
Luo B, Yuan Y, Zhu Y, Liang S, Dong R, Hou J, Li P, Xing Y, Lu Z, Lo R and Kuang GM (2022) microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition. *Front. Oncol.* 12:988794. doi: 10.3389/fonc.2022.988794

microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition

Bingfeng Luo[1†], Yuan Yuan[1†], Yifei Zhu[1], Songwu Liang[1], Runan Dong[1], Jian Hou[1], Ping Li[2], Yaping Xing[1], Zhenquan Lu[1], Richard Lo[1] and Guan-Ming Kuang[3*]

[1]Division of Urology, Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China, [2]Department of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China, [3]Department of Orthopedics and Traumatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

Objective: To investigate the effects of miRNA-145-5p on the tumor development and progression of prostate cancer (Pca) bone metastasis.

Methods: Levels of miRNA-145-5p were assessed by real-time quantitative PCR in PC3 (bone metastatic Pca cells), 22RV1 (non-metastatic Pca cells), RWPE-1 (non-cancerous prostate epithelial cells) and Pca tissues collected from patients with and without bone metastases. The impact of miRNA-145-5p on cell proliferation was tested by CCK8 assay, colony formation assay and flow cytometric cell cycle analysis. Effects on invasion and migration of PC3 cells were determined by Transwell and wound healing assays. Western blotting, enzyme-linked immunosorbent assay, and flow cytometry apoptosis analyses were also performed to assess roles in metastasis.

Results: Levels of miRNA-145-5p were decreased in Pca bone metastases and miRNA-145-5p inhibited cell proliferation, migration and invasion. miRNA-145-5p inhibited the expression of basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF) and transforming growth factor-β (TGF-β) in PC3 cells. miR-145-5p increased the expression of the epithelial marker E-cadherin and reduced the expression of matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). It was found that miRNA-145-5p mediated the epithelial-mesenchymal transition (EMT) and induced apoptosis.

Conclusions: miRNA-145-5p negatively regulated the EMT, inhibited Pca bone metastasis and promoted apoptosis in Pca bone metastasis. Mimicry of miRNA-145-5p action raises the possibility of a novel target for treating Pca with bone metastases.

KEYWORDS

miRNA-145-5p, prostate cancer bone metastasis, apoptosis, epithelial-mesenchymal transition, non-coding RNA

Introduction

Prostate cancer (Pca) represents a supreme challenge to human health with 1.3 million global cases diagnosed annually and 400000 deaths from metastatic Pca (1). Bone is the most common site of Pca metastasis, rendering patients predisposed to adverse skeletal events, including bone pain, spinal cord compression, pathological fractures and poor prognosis (1, 2). Stephen Page was the first to address the complexity of bone and proposed in 1889 that cancer cells tend to migrate to organs where they may be "sown" into advantageous "soil" leading to the development of metastatic lesions. Clear distinctions among the "soils" of potential metastatic sites have become apparent, with metastases being common in pelvic bones, ribs, vertebrae and the termini of long bones (2, 3). Therefore, there is a pressing need to identify the genes responsible for Pca bone metastasis in order to facilitate treatment advances. Previous reports have demonstrated the involvement of osteonectin, vascular endothelial growth factor (VEGF), TGF-β and C-X-C motif chemokine ligand 12 (CXCL12) in the extravasation and direction of Pca cells to bone (3). Besides, cadherin 11 mediates the interaction between Pca cells and osteoblasts (4) and urokinase (N-terminal fragment) stimulates Pca proliferation (5). Tumor microenvironmental factors, such as IGF, bFGF and TGF-β regulate Pca cell survival and growth (6). The regulator of TGF-β signal transduction, prostate transmembrane protein androgen-induced 1 (PMEPA1), has an inhibitory effect on Pca bone metastasis (6). However, further exploration of potential clinical applications of these genes is required to assess implications for the treatment of Pca bone metastasis.

MicroRNAs (miRNAs) are defined as small noncoding RNAs and have attracted attention for their utility as clinical biomarkers of cancer and potential for novel cancer treatment targets (7, 8). They exert effects on gene expression which influence tumor development, progression and therapeutic responses, being involved in the osteomimicry, EMT and formation of osteoblasts and osteoclasts (9, 10). Indeed, dysregulation of the tumor suppressor or oncogene functions of miRNAs have been implicated in the onset of many cancers. Mimics of miRNAs and antagonists (antimiRNAs) look promising in preclinical development with some having entered clinical trials. A mimic of the tumor suppressor miRNA, miRNA-34, is currently in first stage clinical trials for cancer treatment (11). Stage 2 clinical trials of antimiRNA-s against miRNA-122 are being conducted for hepatitis patients (12). Ectopic expression of miRNA-203 in PC3, a Pca bone metastatic cell-line, has been shown to induce phenotypical morphology alterations from fibroblast-like to epithelial-like and suppress metastatic development in a mouse model of bone metastasis (13). This observation illustrates the importance of searching for miRNAs that are downregulated in Pca bone metastases and may constitute potential biomarkers for the occurrence of metastatic lesions. Moreover, the identification of downregulated miRNAs reveals the potential for the use of mimics as a new target in treating Pca bone metastasis.

Materials and methods

Patients

20 Pca patients at the University of Hong Kong-Shenzhen Hospital were enrolled in this study. Patients underwent pelvic magnetic resonance imaging (MRI), whole body bone scan or positron emission tomography-computed tomography (PET-CT) scan before prostate needle biopsy and immunohistochemical staining to confirm Pca diagnosis. Patients were allocated to one of two groups (n=10) according to the presence or absence of bone metastases. Bone metastasis was evaluated from a whole body bone scan or a PET-CT scan. All patients signed written informed consent for the use of Pca tissue specimens. Baseline information of the patient cohort is presented in Table 1. Approval was granted by the local Research Ethics Committee (No (2019).260) and the current study was performed in compliance with the Declaration of Helsinki (1964).

RNA isolation and sequencing

TRIpure Total RNA Extraction Reagent (ELK Biotechnology, Wuhan, China) was used in accordance with the manufacturer's instructions for isolation of total RNA from Pca tissues. Pellets containing RNA were rinsed with 75% ethanol, air-dried and resuspended in RNase inhibitor-containing RNase-free water (Thermo-Fisher-Scientific, Austria) for storage at -80°C. The concentration and purity of RNA were quantified by Agilent 2100 Bioanalyzer (Agilent Technologies Inc., USA) and sequencing libraries prepared using QIAseq miRNA Library Kit (QIAGEN, Germany) for sequencing with Illumina HiSeq2500. FastQC was employed to examine the quality of the microRNA sequencing reads by alignment with the human genome reference (GRCh38, Ensembl release 76) using FANSe3 with default parameter. miRNA expression was quantified with HTSeq v0.6.1p1 based on miRNA-base (https://www.miRNA-base.org/).

Differential miRNA expression

Differential miRNA expression was analyzed by DESeq2 (version 1.20.0). The Benjamini-Hochberg approach allowed calculation of the false discovery rate (FDR)-adjusted p-values with multiple testing correction. FDR-adjusted p-values of < 0.01 and fold-change of > 2 were considered to indicate differential

TABLE 1 Baseline characteristics of prostate cancer patients with and without bone metastases.

Variables	Prostate cancer with bone metastasis (n=10)	Prostate cancer without bone metastasis (n=10)	*F / Z*	*p value*
Age (years)				
x̄±s	69.0±6.83	65.30±6.85	0.045	0.242
BMI (kg/m^2)				
x̄±s	21.20±1.81	22.53±2.00	0.402	0.137
tPSA (ng/mL)				
x̄±s	53.10±61.06	19.85±11.05	7.73	0.107
Tumor stage, n (%)				
T1	0 (0)	1(10%)	-2.1	0.036*
T2	2(20%)	4(40%)		
T3	4(40%)	5(50%)		
T4	3(30%)	0 (0)		
Gleason score, n (%)				
≤6	1 (10%)	3 (30%)	-1.73	0.084
7	2 (20%)	4 (40%)		
≤8	7 (70%)	3 (30%)		
Alkaline phosphatase				
x̄±s, (U/L)	106.20±59.12	106.30±25.59	3.276	0.996
Serum Creatinine				
x̄±s, (umol/L)	87.90±15.26	85.90±14.95	0.131	0.771
Glycosylated hemoglobin				
x̄±s, (%)	5.50±0.81	5.50±0.90	0.46	1

* indicates significant difference.

expression. miRNA target genes were predicted using the miRNA-TarBase database. KOBAS annotation was used for enrichment analyses, including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) analyses.

Validation of miRNA by real-time quantitative PCR

Total RNA was extracted and used to synthesize cDNA using the EntiLink™ 1st Strand cDNA Synthesis Kit (ELK Biotechnology, Wuhan, China), by following the manufacturer's instructions. RT-qPCR was conducted using EnTurbo™ SYBR Green PCR SuperMix (ELK Biotechnology). Relative gene expression levels of miRNA-145-5p were detected using U6 as the endogenous normalization control. All stem-loop primer sequences were as follows: hsa-miRNA-145-5p (MIMAT 0000437): forward primer: CAGTTTTCCCAGGAATCCCT, reverse primer: CTCAACTGGTG TCGTGGAGTC; U6 (NR_004394.1): forward primer: CTCGCTTCGGCAGCACAT, reverse primer: AACGCTTCACGAATTTGCGT. Changes in miRNA expression were quantified using the double delta Ct equation.

Cell culture and transfection

PC-3 (bone metastatic Pca cells) were cultured in DMEM (Gibco, USA) containing 10% FBS (Gibco) and penicillin-streptomycin and maintained at 5% CO_2. Aliquots of 3×10^5 cells were grown in 6-well plates and transfected with an hsa-miRNA-145-5p mimic or control (inactive) vector using Lipofectamine 2000 (Invitrogen, USA) by following the kit's protocol.

Cell proliferation and invasiveness

Cells were grown in a 96-well plate and cell numbers were counted using CCK-8 (Cell Counting Kit-8, Biosharp) with additional wound healing, colony formation and Transwell assays. Cell culture medium was supplemented with CCK8 reagent and absorbance was determined at 450 nm after

incubation for 1 h. For the migration/wound healing assays, 3 × 10^5 cells/well were grown in a 24-well plate, incubated for 16-18 h and cell monolayers scraped with a pipette tip to create a wound which was washed with PBS. After incubation for 24 h in culture medium, an inverted microscope with a digital camera was used to photograph wound closure. Colony formation was measured by resuspending the cells with 1ml medium and seeding a six-well plate with 500 cells per well. After 2 weeks, 6-well plates were fixed with paraformaldehyde (4%) for 30min at room temperature before washing with PBS, the addition of crystal violet staining and photographs taken under the microscope. Transwell assay was conducted to assess invasion. Briefly, cells (3×10^5 cells/well) were grown in the upper Transwell chamber and incubated for 24 h at 37°C and 5% CO_2. Cells were detached, rinsed with PBS and fixed with paraformaldehyde for 20 min. After washing, cells were stained with crystal violet (0.1%) for 10 min, rinsed with PBS and counted using a microscope (Olympus, Japan)

Flow cytometry analysis

Flow cytometry-based apoptosis analysis was conducted by Annexin V-FITC cell apoptosis analysis kit (Sungen Biotech, Tianjin, China) and cell cycle analysis was carried out using a cell cycle analysis kit (YEASEN, Shanghai, China). Samples were visualized by FACSCalibur (BD Biosciences, USA) and data were analyzed with FlowJo software (Tree star Inc, CA).

Enzyme linked immunosorbent assay

The cell culture medium was removed and centrifuged at 2000rpm for 20 minutes to remove impurities and cell fragments. Detection of human IGF, human TGF-β and human bFGF in the supernatant was performed by ELISA kits (Mlbio, Shanghai, China).

Western blotting

Cellular protein was isolated with RIPA buffer and separated by SDS-PAGE with 10% Bis-Tris (Invitrogen, USA) before transfer onto nitrocellulose membranes. Membranes were blocked with a 5% solution of skimmed milk at 4°C for 1 h. Membranes were incubated with primary antibodies (Abcam, UK) raised against the following proteins: caspase 9 (ab115792), E-cadherin (ab1416), MMP2 (ab97779), MMP9 (ab137867) and GAPDH (ab8245) overnight at 4°C and rinsed for 20 min in Tween-TBS before incubation with secondary antibodies (1:10000, ASPEN, China). After a 20 min washing with T-TBS, proteins were visualized with an electroluminescence kit (ASPEN, Wuhan, China). The internal control was GAPDH.

Statistical analysis

Means ± SD of three independent experiments were presented, and statistical analysis was conducted using GraphPad v4.1 (CA, USA). Data were compared between groups using a two-tailed unpaired Student's t-test. A p-value of <0.05 was deemed statistically significant.

Results

Expression of miRNAs in Pca patients

Patient diagnosis included a combination of pelvic magnetic resonance imaging (MRI), whole body bone scan or PET-CT scan, and histological analysis involving periodic acid-Schiff (PAS) and hematoxylin-eosin (HE) staining of tissue sections (Figure 1). High-throughput microRNA sequencing analysis was conducted on 5 Pca and 3 Pca bone metastatic samples. 122 microRNAs have been previously identified as having modulatory activity on Pca bone metastasis (Figure 2A). Of the set of 122 miRNAs, 78 (n=78) were upregulated and 44 downregulated in Pca with bone metastases compared to non-metastatic Pca (Supplementary Data 1). miRNA-145-5p was expressed at the one of the lowest levels in Pca tissues with bone metastasis with a false discovery rate>0.0001 (Figure 2B). miR-145-5p target genes were predicted using miRNA-TarBase (Supplementary Data 2). KEGG pathway analysis showed that the target genes of miR-145-5p exerted the regulatory activity over many tumor-related signaling pathways, including that of TGF-β and the cell-cell and cell-matrix adherens junction. (Figure 2C). Such target pathways have potential relevance concerning the metastasis of Pca to a bone site and indicate that miRNA-145-5p suppression may be responsible for the process.

miRNA-145-5p suppressed proliferation of the Pca bone metastatic PC3 cells

miRNA-145-5p expression was detected by RT-qPCR and showed significant decreases in Pca tissues with bone metastasis compared with those without metastasis (Figure 3A). The metastatic Pca cell line, PC3, expressed lower levels of miRNA-145-5p than the non-metastatic, 22RV1, or non-cancerous prostate epithelial, RWPE-1, cell-lines (Figure 3B). PC3 cells were transfected with an exogenous miRNA-145-5p



FIGURE 1
Pca with and without bone metastasis: diagnosis. **(A)** Pelvic MRI allowed visualization of a tumor in the prostate left lobe (red arrow). No metastases were found. **(B)** A tumor in the prostate right lobe with bone metastases (red arrow). **(C)** Whole body bone scanning showed Pca with bone metastases (red arrow). **(D)** Whole body bone scanning showed Pca without bone metastases. **(E, F)** HE staining images (objective 20X) showing prostate cancer morphology in the presence and absence of bone metastases. **(G, H)** Prostate-specific antigen (PSA) staining images (objective 20X) showing prostate cancer cells with flaky distribution in the presence and absence of bone metastases.



FIGURE 2
Gene expression profile for non-metastatic and bone metastatic prostate cancer. **(A, B)** Heat map and volcano plot showing miRNA expression levels. Right column: genes; red pixels: upregulated expression; blue pixels: downregulated expression. **(C)** KEGG pathway miRNA analysis. X axis: enriched genes; Y axis: KEGG pathway; dot color: p-value; dot size: gene number.

mimic or control miRNA and expression of miRNA-145-5p shown to be increased by RT-qPCR in transfected cells compared with controls (Figure 3C). PC3 cells with higher miRNA-145-5p expression had reduced rates of proliferation, measured by CCK-8 and clone assay (Figure 3D and Figures 3H–J). Higher miRNA-145-5p expression also lengthened the G1 phase to slow proliferation (flow cytometry results shown in Figures 3K–M). Higher miRNA-145-5p expression attenuated the production of bFGF, IGF and TGF-β proteins in PC3 cells, as determined by ELISAs (Figures 3E–G). Thus, miRNA-145-5p changed the protein expression profile and influenced the cell cycle with the result that PC3 cells became less proliferative.

miRNA-145-5p reduced invasion and migration by regulating the EMT

Assessments of PC3 cells apoptosis demonstrated that miRNA-145-5p expedited this process (Figures 4A–C). Scratch and Transwell assays showed that transfection with the miRNA-145-5p mimic reduced PC3 cells migration and invasion



FIGURE 3
miRNA-145-5p inhibited proliferation of bone metastatic Pca cells, PC-3. **(A)** RT-qPCR data for miRNA-145-5p expression in Pca bone metastases. **(B)** RT-qPCR data for miRNA-145-5p expression in PC3, 22RV1 and RWPE-1 cell lines. **(C)** miRNA-145-5p expression after PC3 transfection. **(D)** Proliferation rate of PC3 cells. **(E–G)** Expression of βFGF, IGF and TGF-β in PC3 cells. **(H–J)** Clone formation rate of PC3 cells. **(K–M)** Flow cytometry cell cycle analysis of PC3 cells. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

(Figures 4D–I). Furthermore, upregulation of miRNA-145-5p enhanced expression of E-cadherin (an epithelial marker), and decreased expression of MMP-2 and MMP-9 (mesenchymal markers) as measured by Western blotting (Figures 4J, K). Moreover, miRNA-145-5p activated the apoptosis-associated protein, caspase 9, implying the promotion of programmed cell death in PC3 cells. In summary, miRNA-145-5p appeared to enhance the expression of epithelial marker (E-cadherin) while suppressing expression of mesenchymal markers (MMP-2 and MMP-9), implying a regulatory action on the epithelial to



FIGURE 4
miRNA-145-5p affected the EMT to inhibit invasion and migration in bone metastatic Pca cells. **(A, B)** Flow cytometry cell apoptosis analysis of PC3 cells. Cells are distributed differently throughout the four quadrants of the plot depending on the degree of apoptosis undergone by cell population. Apoptotic cells appear in the greatest concentration in quadrant, Q2. The percentage of cells in Q2 relative to the total population of cells is shown in **(C)**. **(D–F)** Scratch tests of PC3 cell migration following miRNA-145-5p mimic transfection. (mean ± SEM, n = 3, Student's t-test). **(G–I)** Transwell results of PC3 cell invasions after miRNA-145-5p mimic transfection. **(J, K)** Caspase 9, E-cadherin, MMP-2 and MMP-9 protein expression in PC3 cell line after miRNA-145-5p mimic transfection. $^{**}P < 0.01$, $^{***}P < 0.001$.

mesenchymal transition. Increased expression of caspase-9, an enzyme associated with apoptosis, implies that increased expression of miRNA-145-5p may act to induce apoptosis of bone metastatic Pca cells (Figure 5).

Discussion

Pca patients with bone metastasis may suffer severe complications, including severe back and extremity pain, pathological fracture, deep vein thrombosis and urinary tract infection (14–16). The prognosis for these patients remains poor and more advanced treatment strategies are needed. miRNAs have great versatility and have been incorporated into various cancer treatments to enhance specificity and therapeutic efficacy (8). The current study identified miRNAs that were differentially expressed when Pca metastasized into bone and indicated the potential for the development of the miRNA-145-5p mimic into a novel treatment for metastatic Pca.

Ozen *et al.* reported the SOX-2 regulatory activity of miRNA-145-5p which inhibited Pca cell proliferation. The current study found low levels of miRNA-145-5p expression in Pca bone metastatic tissues and cell lines. Upregulation of its expression suppressed the migratory and invasive behavior of the cells. It has previously been found that miRNA-145-5p attenuated the invasive properties of glioblastoma cells and reduced osteosarcoma progression (17, 18). The target gene of miRNA-145-5p was associated with the TGF-β signaling pathway, a multi-functional regulatory pathway responsible for cell proliferation, migration, apoptosis and adhesion (19). TGF-β signaling has tumor suppressive functions in untransformed and early cancer cells in which it promotes cell cycle arrest and apoptosis (19). However, its activation in advanced cancer promotes tumorigenesis, including metastasis and drug resistance. The dual function and pleiotropy of TGF-β signaling make it a challenging therapeutic target (20). Other growth factors were also found to be altered in expression during the current study. Increased bFGF expression has previously been shown to stimulate osteoclastogenesis, inducing bone metastasis in Pca (21). In addition, high levels of IGF in the primary tumor environment may induce tumor cells to metastasize to bone (22). Prostate tumors within bone tissue promote osteoclast-mediated bone resorption to release TGF-β. Blocking TGF-β may thus improve patient survival (23). In this study, TGF-β2 was predicted using miRNA-TarBase as a target gene of miR-145-5p. The current findings regarding reduced bFGF, IGF and TGF-β expression on upregulation of miRNA-145-5p indicate that miR-145-5p may influence the TGF-β signaling pathway by suppressing epithelial to mesenchymal transition and tumor growth to bring about inhibition of bone metastasis.

The EMT involves the loss of epithelial phenotypic characteristics and adoption of those of the mesenchymal phenotype, including enhanced migratory and invasive properties. Overactivation of the transition is considered to promote cancer metastasis (24). Cancer cell invasion and metastasis is assisted by activities of MMP-2 and MMP-9 which are associated with promoting cell-cell and cell-matrix interactions during the EMT (25). The current study demonstrated that MMP-2 and MMP-9 expression were reduced by miRNA-145-5p. Loss of the tumor suppressor, E-cadherin, has frequently been related to tumor metastasis and its



FIGURE 5
Study design flowchart.

expression was shown to be stimulated by miRNA-145-5p during the present study (26, 27). EMT master genes transcription factors include SLUG, SNAIL, ZEB1, ZEB2/SIP1, TWIST1, TWIST2, the homeobox proteins (GSC and SIX1) and the forkhead-box protein FOXC2, which function as direct or indirect suppressors of the E-cadherin (epithelial marker) and inducers of MMP2 and MMP9 (mesenchymal markers) (27). This study indicated that miR-145-5p might be transcriptionally regulated by EMT master genes transcription factors. Caspase 9 is noteworthy as a promoter of apoptosis and its expression was also stimulated by miRNA-145-5p (28). In summary, we find that miRNA-145-5p reduces makers of migration and invasiveness and stimulates tumor suppressor and apoptosis stimulatory proteins in PC3 cells. These effects combine to indicate an anti-metastatic action for miRNA-145-5p. Moreover, previous work has established reduced miRNA-145-5p expression in the apocrine and spindle cells of transforming tumor cells compared with *in situ* carcinoma or nontumor structures which further substantiates the role of miRNA-145-5p in regulating metastasis (29). RNA-based therapeutics, including miRNAs, messenger RNAs (mRNAs), antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and aptamers, are a rapidly developing new field with inspiring potential (30–32). However, RNA-based therapeutic drug delivery remain critical hurdles. Lipid-based nanoparticle delivery systems, containing a variety of effective RNA-base therapeutic payloads, can ensure specific delivery of therapeutic drugs to tissues and exert attractive properties (31–33). From the part of the clinical trials, RNA-based therapeutics will provide a promising treatment approach for various human diseases.

Conclusions

In summary, profiles of miRNAs differentially expressed in Pca with and without bone metastasis were characterized. This study revealed that miR-145-5p was a negative regulator of EMT and promoted apoptosis in Pca bone metastasis. Moreover, over-expression of miRNA-145-5p reduced invasiveness and proliferation in prostate cancer bone metastatic cell-line. We suggest that mimicry of miRNA-145-5p may constitute a novel target in the treatment of Pca bone metastasis.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The studies involving human participants were reviewed and approved by The University of Hong Kong-Shenzhen Hospital Research Ethics Committee approved this research (No. [2019] 260). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

BL and YY conceived and designed the project. BL wrote the paper. YZ, SL, RD, JH, PL, and YX acquired the data. G-MK and ZL analyzed and interpreted the data. RL modified the language of the article. All authors contributed to the article and approved the submitted version.

Funding

This research is supported by the project "High Level Hospital Program, Health Commission of Guangdong Province, China" (No. HKUSZH201901024 and No. HKUSZH201901012) and Research project of Health Commission of Guangdong Province, China (B2021176). The funders had no role in study design, data collection and analysis, decision to publish,or preparation of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.988794/full#supplementary-material

SUPPLEMENTARY TABLE 1
A List of differentially expressed genes associated with bone metastases from prostate cancer.

SUPPLEMENTARY TABLE 2
KEGG analysis of miR-145-5p target genes.

References

1. Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. *Lancet* (2021) 398(10305):1075–90. doi: 10.1016/S01406736

2. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nat Rev Cancer* (2003) 3(6):453–8. doi: 10.1038/nrc1098

3. DiNatale A, Fatatis A. The bone microenvironment in prostate cancer metastasis. *Adv Exp Med Biol* (2019) 1210:171–84. doi: 10.1007/978-3-030-32656-2_9

4. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. *Mol Cancer Res* (2008) 6 (8):1259–67. doi: 10.1158/1541-7786.MCR-08-0077

5. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. *Cancer Metastasis Rev* (2001) 20(3-4):287–96. doi: 10.1023/A:1015539612576

6. Buenrostro D, Park SI, Sterling JA. Dissecting the role of bone marrow stromal cells on bone metastases. *BioMed Res Int* (2014) 2014:875305. doi: 10.1155/2014/875305

7. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. *A comprehensive review. EMBO Mol Med* (2017) 9 (6):852. doi: 10.15252/emmm.201707779

8. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer–a brief overview. *Adv Biol Regul* (2015) 57:1–9. doi: 10.1016/j.jbior.2014.09.013

9. Brabletz T. To differentiate or not–routes towards metastasis. *Nat Rev Cancer* (2012) 12(6):425–36. doi: 10.1038/nrc3265

10. Croset M, Santini D, Iuliani M, Fioramonti M, Zoccoli A, Vincenzi B, et al. MicroRNAs and bone metastasis: a new challenge. *Molecules* (2014) 19(7):10115–28. doi: 10.3390/molecules190710115

11. Bouchie A. First microRNA mimic enters clinic. *Nat Biotechnol* (2013) 31 (7):577. doi: 10.1038/nbt0713-577

12. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discovery* (2017) 16 (3):203–22. doi: 10.1038/nrd.2016.246

13. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. *Clin Cancer Res* (2011) 17(16):5287–98. doi: 10.1158/1078-0432.CCR-10-2619

14. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. *Urology* (2004) 63(5):940–5. doi: 10.1016/j.urology.2004.01.034

15. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen- independent carcinoma of the prostate: a randomised phase II trial. *Lancet* (2001) 357(9253):336–41. doi: 10.1016/S0140-6736(00)03639-4

16. Winquist E, Berry S. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* (2004) 96(15):1183. doi: 10.1093/jnci/djh234

17. Kurogi R, Nakamizo A, Suzuki SO, Mizoguchi M, Yoshimoto K, Amano T, et al. Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-5p co-overexpression in human mesenchymal stem cells. *J Neurosurg* (2018) 130 (1):44–55. doi: 10.3171/2017.8.JNS1788

18. Li H, Pan R, Lu Q, Ren C, Sun J, Wu H, et al. MicroRNA-145-5p inhibits osteosarcoma cell proliferation by targeting E2F transcription factor 3. *Int J Mol Med* (2020) 45(5):1317–26. doi: 10.3892/ijmm.2020.4504

19. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. *Cancer Metastasis Rev* (2006) 25(3):435–57. doi: 10.1007/s10555-006-9006-2

20. Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. *Trends Cancer* (2017) 3(1):56–71. doi: 10.1016/j.trecan.2016.11.008

21. Meng X, Vander Ark A, Daft P, Woodford E, Wang J, Madaj Z, et al. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis. *Cancer Lett* (2018) 418:109–18. doi: 10.1016/j.canlet.2018.01.018

22. Rieunier G, Wu X, Macaulay VM, Lee AV, Weyer-Czernilofsky U, Bogenrieder T. Bad to the bone: The role of the insulin-like growth factor axis in osseous metastasis. *Clin Cancer Res* (2019) 25(12):3479–85. doi: 10.1158/1078-0432.CCR-18-2697

23. Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. *Cell* (2019) 179(5):1177–90.e13. doi: 10.1016/j.cell.2019.10.029

24. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. *Trends Cell Biol* (2019) 29(3):212–26. doi: 10.1016/j.tcb.2018.12.001

25. Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, et al. The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. *Anal Cell Pathol (Amst)* (2019) 2019:9423907. doi: 10.1155/2019/9423907

26. Na TY, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of e-cadherin controls tumor cell metastasis at multiple steps. *Proc Natl Acad Sci U S A* (2020) 117(11):5931–7. doi: 10.1073/pnas.1918167117

27. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. *Mol Cancer* (2016) 15:18. doi: 10.1186/s12943-016-0502-x

28. Johnson CR, Jarvis WD. Caspase-9 regulation: an update. *Apoptosis* (2004) 9 (4):423–7. doi: 10.1023/B:APPT.0000031457.90890.13

29. Koleckova M, Ehrmann J, Bouchal J, Janikova M, Brisudova A, Srovnal J, et al. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer. *Sci Rep* (2021) 11(1):5145. doi: 10.1038/s41598-021-84350-2

30. Garbo S, Zwergel C, Battistelli C. m6A RNA methylation and beyond - the epigenetic machinery and potential treatment options. *Drug Discov Today* (2021) 26(11):2559–74. doi: 10.1016/j.drudis.2021.06.004

31. Zogg H, Singh R, Ro S. Current advances in RNA therapeutics for human diseases. *Int J Mol Sci* (2022) 23(5):2736. doi: 10.3390/ijms23052736

32. Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The limitless future of RNA therapeutics. *Front Bioeng Biotechnol* (2021) 9:628137. doi: 10.3389/fbioe.2021.628137

33. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. *N Engl J Med* (2020) 383(27):2603–15. doi: 10.1056/NEJMoa2034577

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 27 September 2022
DOI 10.3389/fonc.2022.852358

OPEN ACCESS

EDITED BY
Michelle Matter,
University of Hawaii Cancer Center,
United States

REVIEWED BY
Doina Ganea,
Temple University, United States
Vasiliki Gkretsi,
European University Cyprus, Cyprus

*CORRESPONDENCE
Satoshi Asano
sasano@hiroshima-u.ac.jp
Yukio Ago
yukioago@hiroshima-u.ac.jp

SPECIALTY SECTION
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

RECEIVED 12 January 2022
ACCEPTED 24 August 2022
PUBLISHED 27 September 2022

CITATION
Asano S, Yamasaka M, Ozasa K, Sakamoto K, Hayata-Takano A, Nakazawa T, Hashimoto H, Waschek JA and Ago Y (2022) Vasoactive intestinal peptide–VIPR2 signaling regulates tumor cell migration.
Front. Oncol. 12:852358.
doi: 10.3389/fonc.2022.852358

Vasoactive intestinal peptide–VIPR2 signaling regulates tumor cell migration

Satoshi Asano[1,2]*, Misa Yamasaka[2], Kairi Ozasa[2], Kotaro Sakamoto[3], Atsuko Hayata-Takano[4,5], Takanobu Nakazawa[4,6], Hitoshi Hashimoto[4,5,7,8,9], James A. Waschek[10] and Yukio Ago[1,2]*

[1]Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan, [2]School of Dentistry, Hiroshima University, Hiroshima, Japan, [3]Research and Development Department, Ichimaru Pharcos Company Limited, Gifu, Japan, [4]Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, [5]Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan, [6]Laboratory of Molecular Biology, Department of Bioscience, Graduate School of Life Sciences, Tokyo University of Agriculture, Tokyo, Japan, [7]Division of Bioscience, Institute for Datability Science, Osaka University, Osaka, Japan, [8]Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan, [9]Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Osaka, Japan, [10]Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, United States

Phosphoinositide metabolism is critically involved in human cancer cell migration and metastatic growth. The formation of lamellipodia at the leading edge of migrating cells is regulated by metabolism of the inositol phospholipid PI(4,5)P_2 into PI(3,4,5)P_3. The synthesized PI(3,4,5)P_3 promotes the translocation of WASP family verprolin homologous protein 2 (WAVE2) to the plasma membrane and regulates guanine nucleotide exchange factor Rac-mediated actin filament remodeling. Here, we investigated if VIPR2, a receptor for vasoactive intestinal peptide (VIP), has a potential role in regulating cell migration *via* this pathway. We found that silencing of *VIPR2* in MDA-MB-231 and MCF-7 human breast cancer cells inhibited VIP-induced cell migration. In contrast, stable expression of exogenous VIPR2 promoted VIP-induced tumor cell migration, an effect that was inhibited by the addition of a PI3-kinase (PI3K)γ inhibitor or a VIPR2-selective antagonist. VIPR2 stably-expressing cells exhibited increased PI3K activity. Membrane localization of PI(3,4,5)P_3 was significantly attenuated by *VIPR2*-silencing. *VIPR2*-silencing in MDA-MB-231 cells suppressed lamellipodium extension; in VIPR2-overexpressing cells, VIPR2 accumulated in the cell membrane on lamellipodia and co-localized with WAVE2. Conversely, *VIPR2*-silencing reduced WAVE2 level on the cell membrane and inhibited the interaction between WAVE2, actin-related protein 3, and actin. These findings suggest that VIP–VIPR2 signaling controls cancer

migration by regulating WAVE2-mediated actin nucleation and elongation for lamellipodium formation through the synthesis of PI(3,4,5)P_3.

KEYWORDS

breast cancer, cell migration, cytoskeleton, GPCR, phosphatidylinositol signaling, VIPR2

Introduction

Cell migration is an evolutionarily conserved mechanism that plays a role in normal and pathogenic processes, including embryogenesis, immunity, angiogenesis, wound healing, and cancer metastases. Orchestrated cell motility is regulated by polarized intracellular signaling, which leads to the formation of protrusive structures, such as lamellipodia, at the leading edge of cells (1). Specific extracellular stimuli, including growth factors, cytokines, and chemokines, induce the formation of lamellipodia. In the case of signaling through chemokines and their G-protein-coupled receptors (GPCRs), GTP-bound Gαi directly activates SRK-like kinases, which upregulate phosphatidylinositol 3 kinase (PI3K) signaling (2–4). A well-established effector of the Gβγ subunits is PI3Kγ (5). Activated PI3Ks convert phosphatidylinositol 4,5-bisphosphate [PI(4,5)P_2] into phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P_3]. Therefore, both the α and βγ subunits are involved in the production of PI(3,4,5)P_3, stimulating its rapid formation in the leading edge of migrating cells (4). PI(3,4,5)P_3 promotes the translocation of WASP family verprolin homologous protein 2 (WAVE2) to the plasma membrane and regulates GEF-Rac-mediated actin filament remodeling (6). *In vitro*, PI(3,4,5)P_3 directly binds WAVE2 with nanomolar affinity within the basic domain, and this mediates membrane phosphoinositide signaling (7). WAVE2 drives lamellipodium formation by enhancing actin nucleation *via* the actin-related protein 2 and 3 (ARP2/3) complex (8). Gain-of-function mutations in PI3K (i.e., mutations in the p110 catalytic subunit of PI3K) enhance the PI(3,4,5)P_3 signaling pathway and are frequently found in breast cancers and other cancers (9, 10). These activated PI(3,4,5)P_3 pathways induce cancer cell growth and motility, resulting in enhanced cancer cell migration and invasion (11, 12). Higher levels and co-expression of WAVE2 and ARP2 have also been found in human metastatic lung adenocarcinoma and breast carcinoma and are closely associated with poor patient outcome (13, 14).

Pituitary adenylate cyclase-activating polypeptide (PACAP) and the closely related neuropeptide vasoactive intestinal peptide (VIP), exhibit widespread expression in the central and peripheral nervous systems (15). Their receptors PAC1, VIPR1 and VIPR2 (also known as VPAC1 and VPAC2) are widely expressed in the brain but are also present in a multitude of peripheral target organs, including those of cardiovascular, renal, digestive, immune, endocrine, and reproductive systems (16). PACAP is an autocrine growth factor for some lung cancer cells (17, 18). The activated PAC1 receptor causes PI turnover, elevates cAMP, and increases the proliferation of lung cancer cells. Additionally, VIP stimulates growth of several tumors including breast, lung, pancreas, prostate, in addition to various central nervous system tumors (19–22). VIP-immunoreactivity occurs in a number of tumors, and VIPR1 is overexpressed, resulting in high densities, in numerous cancers including bladder, breast, colon, lung, pancreatic, and prostate cancers (22, 23), although there are some inconsistencies with other studies (24, 25). In contrast, VIPR2 has been less well-studied, but is present in thyroid, gastric and lung carcinomas, pancreatic adenocarcinomas, sarcomas and neuroendocrine tumors (23, 26, 27). Notably, increased *VIPR2* mRNA expression and/or *VIPR2* gene copy number has been documented in some types of cancers, such as ovarian epithelial tumor, glioblastoma, and invasive breast carcinoma [The cBioPortal for Cancer Genomics (http://cbioportal.org)]. However, the pathophysiological roles of VIPR2 in cancer remain largely unknown.

VIPR2 is strongly coupled through Gαs protein to adenylyl cyclase. VIP stimulation leads to cAMP production and subsequent activation of protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) (15, 28, 29). Both of these activated proteins are involved in activation of the downstream effector extracellular signal-regulated kinase (ERK). Other signaling pathways activated by VIPR2 have also

Abbreviations: ARP2/3, actin-related protein 2 and 3; cAMP, cyclic adenosine monophosphate; EGFP, enhanced green fluorescent protein; ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GEF, guanine nucleotide exchange factor; GPCR, G protein-coupled receptor; EPAC, exchange protein directly activated by cAMP; PACAP, pituitary adenylate cyclase-activating polypeptide; PI, phosphatidylinositol; PI3K, phosphatidylinositol 3 kinase; PKA, protein kinase A; PTEN, phosphatase and tensin homologue; VIP, vasoactive intestinal peptide; VIPR, vasoactive intestinal peptide receptor; WAVE2, WASP family verprolin homologous protein 2.

been reported. For example, VIPR2 couples with Gαi and Gαq proteins, which regulate signaling molecules as diverse as SRC, PI3K, phospholipase C, and protein kinase C (15, 30–32). VIP caused a concentration-dependent increase in both cAMP and [^{3}H]inositol phosphate production in GH3 rat pituitary tumor cells that natively express VIPR2 but not other VIP-responsive receptors. PACAP also induced cAMP and [^{3}H]inositol phosphate production in COS7 cells transiently expressing rat VIPR2 (32). Additionally, PACAP promoted the phosphorylation of AKT, an effector molecule of PI(3,4,5)P_3, in the MCF-7 breast cancer cell line that expresses VIPR1 and VIPR2 (33), suggesting that activation of VIP receptor-mediated signaling may increase PI(3,4,5)P_3 and promote cancer cell migration. Overexpression of VIPR1 has been shown to inhibit migration and invasion of human lung adenocarcinoma H1299 cells (25). However, a role for VIPR2 signaling in cancer cell migration has not been completely elucidated.

In the present study, we investigated the potential roles and mechanisms of VIPR2 in controlling the PI3K/PI(3,4,5)P_3 pathway and influencing cancer cell migration.

Materials and methods

Plasmids, siRNAs, and synthetic peptide

The pCMV6-AN-Myc-DDK vector (PS100016) and a negative control siRNA (S10C-0600) were purchased from Cosmo Bio (Tokyo, Japan). The pEGFP-N2 vector and pmCherry-N1 vector were purchased from Takara Clontech (Kyoto, Japan). The pCMV6-VIPR2-Myc-DDK plasmid was constructed from the pCMV6-AN-Myc-DDK vector and VIPR2 cDNA. The VIPR2-Myc region from the resultant plasmid was cloned into the pEGFP-N2 vector, and the VIPR2-Myc-DDK region was cloned into pmCherry-N1 vector. The AKT-PH-EGFP vector was described previously (34). Human *VIPR2*-siRNAs (si1, 3024813653-000080 and -000090; si2, 3024813653-000020 and -000030; si3, 3024813653-000050 and -000060) were purchased from Sigma-Aldrich (St. Louis, MO, USA). A VIPR2-selective antagonistic peptide KS-133 was synthesized at SCRUM Inc. (Tokyo, Japan) as previously reported (35).

Antibodies

Anti-ARP3 (#4738), anti-GAPDH (#2118), anti-PI3-kinase p110α (#4249), anti-PI3-kinase p110β (#3011), anti-PI3-kinase p110γ (#5405), anti-PI3 Kinase Class III (#3358), anti-WAVE2 (#3659), anti-pan AKT (#4691), anti-phospho-AKT (Thr308; #2965), HRP-conjugated anti-rabbit IgG (#7074) and HRP-conjugated anti-mouse IgG (#7076) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-mCherry (ab167453) and anti-VIPR2 (ab183334) were purchased from Abcam (Cambridge, United Kingdom). Anti-GFP (sc-9996) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-GAPDH (60004-1-Ig) was purchased from Proteintech (Chicago, IL, USA). Alexa Fluor 594 anti-rabbit IgG (A-11012), Alexa Fluor 405 anti-mouse IgG (A-31553) and Alexa Fluor 555 anti-mouse IgG (A-21422) were purchased from Invitrogen (Carlsbad, CA, USA).

Cells, cell transfection and production of stable cell lines

The MDA-MB-231 cell line was purchased from JCRB Cell Bank (JCRB; Tokyo, Japan). The development of MCF-7 cells stably expressing EGFP was described previously (34). Cells were cultured under conventional growth conditions.

Cells were transfected with siRNAs or plasmids using Lipofectamine 3000 (Invitrogen) in accordance with the manufacturer's instructions.

To establish stable cell lines, MDA-MB-231 and MCF-7 cells were transfected with an expression vector encoding VIPR2-EGFP or a control EGFP vector and cultured in the presence of 1 mg/ml G418 (Nacalai Tesque, Kyoto, Japan) for 14 days. Stably EGFP-expressing colonies were selected. HeLa cells stably expressing VIPR2-mCherry were produced using similar methods. LLC-PK1 cells stably expressing EGFP-actin were kindly supplied by Dr. Keiju Kamijo (Tohoku Medical and Pharmaceutical University).

Reverse transcription-PCR analysis

Total RNA was isolated from cells using a RNeasy mini kit (Qiagen, Hamburg, German). RNA (5 μg) was then subjected to reverse transcription reactions using a cDNA synthesis kit (Takara Bio, Tokyo, Japan). Human *ADCYAP1R1* (*PAC1*), *VIPR1*, *VIPR2* and *GAPDH* sequences were amplified by PCR using the following primers: 5′-TTCAATGATTCC TCTCCAGGCTG-3′ and 5′-GGCCTTCACTGACAGGTAG TAATA-3′ for *PAC1*, 5′-TGTGAAGACCGGCTACACCA -3′ and 5′-TCCACCAGCAGCCAGAAGAA-3′ for *VIPR1*, 5′-CATGGACTGCGGCCAGG-3′ and 5′-GAACGACCCGAGG CACAG-3′ for *VIPR2*, and 5′-ACCACAGTCCATG CCATCAC-3′ and 5′- TCCACCACCCTGTTGCTGTA-3′ for *GAPDH*. The PCR products were distinguished by agarose gel electrophoresis.

Thin-layer chromatography

For the assessment of PI3K activity *in vitro*, cells were lysed and the lysates were incubated with BODIPY FL-PtdIns(4,5)P_2 (C-45F6a; Echelon, San Jose, CA, USA) in the manufacturer's buffer containing DTT and ATP for 60 min at 37°C. The lipids were extracted by $CHCl_3$/MeOH (v/v=2:1) using the methods of Bligh and Dyer (36). Samples were applied to thin-layer chromatography plates and developed in $CHCl_3$/acetone/

MeOH/AcOH/water (v/v/v/v/v = 40:15:13:12:7) using the methods of Huang et al. (37). The fluorescent lipids were visualized by UV irradiation using the ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA).

Measurement of PI(3,4,5)P_3 levels at the plasma membrane

The AKT-PH-EGFP vector was co-expressed in MDA-MB-231 cells transfected with *VIPR2* siRNA1 or *VIPR2*-mCherry, and the cells were treated with 100 nM of VIP for 10 min. The EGFP intensities on the plasma membrane were measured and normalized by the intensity of whole cells.

Immunofluorescence, western blotting, and pull-down assay

Immunofluorescence and western blotting were carried out following previously described methods (38, 39). The co-localization analysis of fluorescence microscopy images was performed using Image-Pro premier ver.9.4.

Pull-down assays with GFP-tagged protein complexes were performed using GFP-Trap_A beads (ChromoTek, Planegg-Martinsried, Germany) in accordance with the manufacturer's instructions. LLC-PK1 cells stably expressing EGFP-actin were lysed with the manufacturer's buffer containing protease inhibitors and then centrifuged at 15,000 × g for 30 min at 4°C. The resulting supernatant was incubated with GFP-Trap_A beads overnight at 4°C with gentle rotation. After gentle centrifugation, the precipitates in the pull-down fraction were boiled in SDS sample buffer, separated by SDS-PAGE, and analyzed by western blotting using anti-WAVE2 and anti-ARP3 antibodies.

Random migration assay, transwell migration assay and scratch wound closure assay

MCF-7 cells (1.5×10^4) were seeded in 35 mm culture dishes in serum-free medium, cultured until attached, and stimulated with 100 nM VIP (Cayman Chemical Company, Ann Arbor, MI, USA). For the migration assay, cells were monitored every 1 h for 12 h on a thermo plate (Tokai Hit, Shizuoka, Japan) at 37°C by live-cell imaging (BZ-X800; Keyence, Osaka, Japan). Tracking analysis of cells was performed using Image-Pro premier ver.9.4 (Media Cybernetics, Rockville, MD, USA).

Cell migration was also examined using a Boyden chamber following previously described methods (40). Briefly, the lower chamber was filled with 600 µL of 200 nM VIP in serum-free culture medium. MDA-MB-231 cells stably expressing EGFP (1×10^4 cells) were suspended in 100 µL of serum-free culture medium and transferred to the cell culture insert. The cells were allowed to migrate for 30 or 48 h at 37°C. Non-migrating cells on the upper surface of the membrane were scraped off, and migratory cells attached to the lower surface were fixed by 4% paraformaldehyde and counted under a fluorescence microscope.

For a scratch assay, MDA-MB-231 cells transfected with *VIPR2* siRNA1 or *VIPR2*-EGFP were seeded into 12-well tissue culture dishes coated with fibronectin (50 µg/mL) and cultured in medium containing 10% FBS to nearly confluent cell monolayers. Then, a linear wound was generated in the monolayer with a sterile plastic pipette tip. Any cellular debris was removed by washing with serum-free medium. The serum-free culture medium with 100 nM VIP and 50 mM Hepes (pH 7.4) was added to each well, and cells were monitored for 24 h on a thermo plate at 37°C by live-cell imaging on a BZ-X800 microscope.

Kymograph analysis of the extension of cell leading edge

To observe the extension of the leading edge of migrating cells, cells were seeded on µ-dishes (Ibidi, Martinsried, Germany), cultured until confluent, wounded with a pipet tip, and stimulated with 100 nM VIP. The cells were recorded every 2 min for 60 min by live-cell imaging on a BZ-X800 microscope. Kymography analysis of the leading edge was performed using the MultipleKymograph plug-in of ImageJ 1.53a (National Institutes of Health; developed by J. Rietdorf and A. Seitz).

Statistical analysis

GraphPad Prism was used for the statistical analyses. A non-parametric Mann–Whitney *U* test (for two groups) and Kruskal–Wallis test (for more than two groups) followed by Dunn's multiple comparison test were used. A p-value of less than 0.05 was considered statistically significant.

Results

VIP–VIPR2 signaling promotes the PI3K/PI(3,4,5)P_3 pathway in cancer cells

To investigate whether VIP–VIPR2 signaling is involved in PI3K/PI(3,4,5)P_3 pathway-mediated cell migration, we examined the effects of VIP on the phosphorylation of AKT in cancer cells. PI3Ks are activated by the stimulation of several kinds of chemokines. Activated PI3K produces PI(3,4,5)P_3 and recruits AKT to the plasma membrane by binding between AKT PH domain and PI(3,4,5)P_3, which induces AKT Thr308 phosphorylation, followed by AKT Ser473 phosphorylation by mammalian target of rapamycin 2 (mTORC2) (41, 42). All cancer cell lines examined in this study expressed *VIPR2* mRNA (Figure S1), and VIPR2 protein was detected in MCF-7 and MDA-MB-231 cells (human breast cancer cell lines) and HeLa cells (human cervical cancer cell line) (Figure S2A).

We observed increased phosphorylation of AKT at Thr308 in MDA-MB-231 cells treated with 100 nM and 1000 nM VIP at 10 min (Figure 1A). Silencing of *VIPR2* in MDA-MB-231 cells



FIGURE 1
VIP–VIPR2 signaling regulates the phosphorylation of AKT in MDA-MB-231 cells. **(A)** MDA-MB-231 cells were starved for 3 h and then stimulated with the indicated doses of VIP for 10 min. Treated cells were lysed and evaluated by western blotting using specific antibodies for the indicated proteins. A set of representative images is shown. The graph shows the density of pAKT (Thr308) normalized against the corresponding density of the respective pan AKT. The data are presented as means ± SD (n = 3); ***p < 0.001 (versus 0 nM VIP; Kruskal–Wallis test followed by Dunn's multiple comparison test). **(B)** MDA-MB-231 cells transfected with the indicated siRNAs were stimulated with 100 nM VIP for 10 min. Cell lysates were analyzed by western blotting to detect the indicated proteins. The graphs show the density of pAKT (Thr308 or Ser473) normalized against the corresponding density of the respective pan-antibody bands. The data are presented as means ± SD (n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). n.s. indicates not statistically significant. **(C)** MDA-MB-231 cells stably expressing EGFP (Empty) or VIPR2-EGFP were stimulated with VIP for 10 min. Cell lysates were analyzed by western blotting using the indicated specific antibodies. The graphs show the density of pAKT (Thr308 or Ser473) normalized against the corresponding density of the respective pan AKT. The data are presented as means ± SD (n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test) ns, not significant..

(Figure S2A) markedly inhibited the phosphorylation of AKT (Figure 1B). Together these results indicate that VIPR2 couples to the AKT pathway in these cells.

We next established several cancer cell lines stably expressing exogenous VIPR2 (Figures S2A, B). In the presence of 100 nM VIP, phosphorylated AKT at Thr308 and Ser473 was markedly increased in cells stably expressing VIPR2 compared with that of empty vector-expressing MDA-MB-231 cells (Figure 1C).

We also observed increased phosphorylation of AKT at Ser473 in MCF-7 cells treated with 100 nM VIP, with the maximum effect observed at 5 to 10 min (Figures S3A, B). Silencing of *VIPR2* in MCF-7 cells (Figure S2A) markedly inhibited the phosphorylation of AKT (Figure S3B). These results suggest that 100 nM VIP may stimulate the PI3K/PI(3,4,5)P_3 pathway through VIPR2. VIP-VIPR2 signaling also strongly activates ERK through a Gαs protein–dependent pathway (15). ERK1/2 phosphorylation in *VIPR2*-silenced MCF-7 cells was similar to that of control cells (Figure S3B), suggesting that other receptors binding to VIP compensated for the deficiency of VIPR2 for ERK1/2 phosphorylation.

VIP–VIPR2 signaling regulates PI3K activity and consequently controls cell membrane PI(3,4,5)P_3 levels

To investigate the involvement of VIPR2 in the PI3K/PI(3,4,5)P_3 pathway, we analyzed phospholipid metabolism in whole cell lysates from VIP-stimulated VIPR2-mCherry-expressing HeLa cells (Figures S2A, B) using an *in vitro* PI3K activity assay. HeLa cells have no expression of *VIPR1* and *PAC1* mRNA (Figure S1), suggesting that HeLa cells are suitable for analysis of VIP–VIPR2 signaling. The metabolism of PI(4,5)P_2 to PI(3,4,5)P_3 was increased approximately four-fold in VIPR2-overexpressing HeLa cell lysates compared with that in controls (Figure 2A), but the expression of the catalytic subunit of PI3K in whole cell lysates showed no changes in the control or exogenous VIPR2-expressing cells (Figure 2B).

We next examined changes in PI(3,4,5)P_3 on the plasma membrane after VIP stimulation using *VIPR2*-silenced MDA-MB-231 cells that overexpressed an EGFP-tagged Akt PH domain (Akt PH-EGFP), a probe for PI(3,4,5)P_3. Accumulation of AKT PH-EGFP signals on the plasma membrane of control siRNA-transfected MDA-MB-231 cells was observed at 10 min after VIP stimulation (Figure 2C). However, the signals were decreased in *VIPR2*-silenced cells (Figure 2C) and markedly increased in cells stably expressing VIPR2 (Figure 2D). Together, these data suggest that VIP–VIPR2 signaling regulates PI3K activity and the subsequent production of PI(3,4,5)P_3 in the plasma membrane.

VIPR2 is involved in cell migration of MDA-MB-231 and MCF-7 breast cancer cells

To investigate whether VIPR2 expression affects cancer cell motility, we examined the cell migration of MDA-MB-231 cells. We used a transwell chamber assay (Figures 3A, B) and scratch wound closure assay (Figure 3C) to evaluate the migration of MDA-MB-231 cells. The migration of *VIPR2* siRNA-transfected cells stimulated by VIP was reduced compared with that of control siRNA-transfected cells (Figures 3A, C); in contrast, the motility of MDA-MB-231 cells was promoted by the expression of VIPR2-EGFP (Figures 3B, C). A random migration assay also revealed that MCF-7 cells transfected with *VIPR2* siRNA moved shorter distances (Figures S4A, B) with a slower migration speed (Figure S3C) compared with control siRNA-transfected cells. We next generated MCF-7 cells stably expressing VIPR2-EGFP (Figures S2A, B) and performed random migration assays. In line with the effects of *VIPR2*-silencing, the migration speed was higher in VIPR2-EGFP-expressing MCF-7 cells than that in EGFP-expressing cells (Figure S4C). Notably, treatment with KS-133, a potent and selective VIPR2 antagonist (35), dose-dependently inhibited VIP-induced cell migration in VIPR2-overexpressing MDA-MB-231 cells (Figure 3D). These results suggest that VIPR2 mediates cell migration induced by VIP.

VIPR2-mediated upregulation of PI3K is essential for VIP-induced cell migration

To investigate the role of increased PI3K activity in VIP-induced VIPR2-mediated cell migration, we applied PI3K inhibitors to VIP-stimulated MDA-MB-231 cells. Western blot analysis revealed that either 10 μM of ZSTK474 (a pan-PI3K class I inhibitor) or 6 μM of AS605240 (a PI3Kγ inhibitor) treatment markedly suppressed the VIP-induced phosphorylation of AKT in both EGFP-expressing MDA-MB-231 cells and MDA-MB-231 cells stably expressing VIPR2-EGFP (Figure 4A).

We then performed transwell chamber migration assays with MDA-MB-231 cells treated with the inhibitors. Both ZSTK474 and AS605240 significantly decreased cell migration of VIPR2-EGFP-expressing MDA-MB-231 cells to the level observed in EGFP-expressing MDA-MB-231 cells (Figure 4B, upper panels). In contrast, cell migration was almost completely suppressed by transfection with *VIPR2* siRNA, and *VIPR2*-silenced cells were no longer affected by the treatment with ZSTK474 or AS605240 (Figure 4B, lower panels). These results indicate that VIP–VIPR2 signaling thus regulates PI3Kγ-mediated cell migration, most likely *via* increased PI3Kγ activity.

10.3389/fonc.2022.852358



FIGURE 2
VIP–VIPR2 signaling regulates the activity of PI3K and subsequent PI(3,4,5)P_3 level. **(A)** HeLa cells stably expressing mCherry-tagged VIPR2 or control vector were used for experiments. The cell lysates were incubated with BODIPY FL-PI(4,5)P_2 for 1 h at 37°C, and the lipids extracted from cells were distinguished by thin layer chromatography. The lower panel was obtained using a high sensitivity mode (high exposure). The intensities of BODIPY bands in the top panel were quantified using ImageJ software, and the data are presented in the graph as means ± SD (n = 3). **p < 0.01 (Mann–Whitney U test). **(B)** Cell lysates were analyzed by western blotting to detect the indicated proteins. The density of mCherry-VIPR2, p110α, p110β, p110γ and classIII were normalized against that of GAPDH. The data are presented as means ± SD (n = 3). ***p < 0.001 (Mann–Whitney's U test). n.s.: not significant. **(C)** MDA-MB-231 cells transfected with EGFP-tagged AKT-PH plasmid and either *VIPR2* siRNA1 or control siRNA were stimulated with 100 nM VIP for 10 min and then fixed; EGFP was detected by fluorescent microscopy. A set of representative images from 3 independent experiments is shown. The plasma membrane was defined as the region 3 μm from the cell periphery. Relative fluorescence intensity of AKT PH-EGFP (plasma membrane/whole cell) was calculated. The data are presented in the graph as means ± SD [n = 30 (30 cells in each group)]. **p < 0.01, between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). n.s. indicates not statistically significant. **(D)** MDA-MB-231 cells transfected with EGFP-tagged AKT-PH plasmid and either empty vector or *VIPR2*-mCherry were stimulated with 100 nM VIP for 10 min and then fixed; EGFP and mCherry were detected by fluorescent microscopy. A set of representative images from 3 independent experiments is shown. Relative fluorescence intensity of AKT PH-EGFP (plasma membrane/whole cell) was calculated. The data are presented in the graph as means ± SD [n = 20 (20 cells in each group)]. *p < 0.05, ***p < 0.001, between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test) ns, not significant.



FIGURE 3
Cell motility in *VIPR2*-silenced and VIPR2-expressing MDA-MB-231 cells. (A and B) Migration of EGFP-expressing MDA-MB-231 cells transfected with either control siRNA or *VIPR2* siRNA1 **(A)** and that of MDA-MB-231 cells stably transfected with either *VIPR2-EGFP* or *EGFP* plasmid **(B)** was measured using a transwell migration assay. VIP (200 nM) was added to the lower chamber of the vessel. Cells were added to the upper chamber and incubated for 48 h **(A)** or 30 h **(B)** at 37°C. Quantification of migrating cells is shown in graphs. The data are presented as means ± SD [n = 9 (3 independent experiments; 3 areas were randomly selected in each group at each experiment)]. *p < 0.05, ***p < 0.001 between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). **(C)** Wound healing *in vitro* in the scratch assay using confluent monolayer of *VIPR2*-silenced or VIPR2-expressing MDA-MB-231 cells was monitored for 18 h after 100 nM VIP stimulation. The dotted line indicates top position of the cell population. The distance migrated during 6 h was measured at 10 randomly selected points (*see* schematic diagram), and the average speed is shown in graphs. The data are presented as means ± SD [n = 90 (3 independent experiments; 10 points in 3 areas randomly selected in each group at each experiment)]. *p < 0.05, ***p < 0.001 between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). **(D)** Migration of MDA-MB-231 cells stably transfected with *VIPR2-EGFP* was measured using a transwell migration assay. VIP (200 nM) was added to the lower chamber of the vessel. The indicated doses of KS-133 were added to both chambers. Cells were added to the upper chamber and incubated for 48 h at 37°C. Quantification of migrating cells is shown in graph. The data are presented as means ± SD [n = 9 (3 independent experiments; 3 areas were randomly selected in each group at each experiment)]. **p < 0.01, ***p < 0.001 between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test).



FIGURE 4
PI3Kγ inhibitor attenuates VIPR2-mediated cell migration. **(A)** MDA-MB-231 cells stably expressing the indicated proteins were stimulated with 100 nM VIP for 10 min (upper panels) or 0 min (lower panels) in the presence of the indicated drugs (10 μM ZSTK, 6 μM AS605240, 0.2% DMSO). Cell lysates were analyzed by western blotting to detect the indicated proteins. The graphs display the density of pAKT (Thr308 or Ser473) normalized against the corresponding density of the respective pan AKT. The data are presented as means ± SD (n = 3); ***p < 0.001 between the indicated bars (Kruskal–Wallis test followed by Dunn's multiple comparison test). **(B)** Migration of MDA-MB-231 cells transfected with either *VIPR2-EGFP* or *EGFP* plasmid (upper panels) or *EGFP* plasmid together with the indicated siRNAs (lower panels) was measured using a transwell migration assay. VIP (200 nM) and the indicated drugs (10 μM ZSTK, 6 μM AS605240, 0.2% DMSO) were added to the lower chamber. Cells were added to the upper chamber with the indicated drugs and incubated for 24 h at 37°C. Quantification of the migrating cells is shown in the graph. The data are presented as means ± SD [n = 9 (3 independent experiments; 3 areas were randomly selected in each group at each experiment)]. *p < 0.05, **p < 0.01, ***p < 0.001 between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). n.s. indicates not statistically significant.

VIPR2 regulates PI(3,4,5)P_3-mediated downstream signaling

WAVE2 binds to PI(3,4,5)P_3 on the plasma membrane and then interacts with the ARP2/3 complex, which leads to actin polymerization (7). To investigate whether upregulation of PI (3,4,5)P_3 on the plasma membrane in VIPR2-overexpressing MDA-MB-231 cells affect WAVE2 localization to the plasma membrane, we performed immunocytochemistry with an anti-WAVE2 antibody (Figure 5A). In the absence of VIP stimulation, VIPR2-EGFP was distributed across most of the plasma membrane; upon treatment of cells with VIP, VIPR2-EGFP localized to the plasma membrane in lamellipodia (Figure 5A). The area of lamellipodia in VIP-induced cell extension was increased in VIPR2-overexpressing MDA-MB-231 cells compared with that in control cells at 10 min after stimulation (Figure 5B). Without VIP stimulation, the WAVE2 signal on the plasma membrane was hardly detected in either cell

10.3389/fonc.2022.852358



FIGURE 5
VIPR2 overexpression promotes accumulation of WAVE2 in the cell membrane. **(A)** MDA-MB-231 cells transfected with *VIPR2-EGFP* or *EGFP* were stimulated with (+) or without (–) 100 nM VIP for 10 min. Cells were evaluated by immunocytochemistry using the antibodies against the indicated proteins. Arrowheads indicate lamellipodia membrane. The white color regions show the co-localization between EGFP and WAVE2. Arrow indicates co-localization on the lamellipodia membrane. Similar images were obtained from three independent experiments, and representative images are shown. **(B)** Bar graph shows quantification of the area of the lamellipodia membrane. **(C)** WAVE2 intensity on the cell membrane was calculated from data shown in **(A)** and normalized by the intensity of GAPDH (whole cell). The data are presented as means ± SD [n = 30 (30 cells in each condition)]. *p < 0.05, **p < 0.01, ***p < 0.001, between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). n.s. indicates not statistically significant **(B, C)**.

line. In contrast, at 10 min after VIP stimulation, WAVE2 accumulated at the plasma membrane (Figure 5A), and the signals on the plasma membrane were stronger in VIPR2-overexpressing MDA-MB-231 cells than that in EGFP vector-transfected MDA-MB-231 cells (Figure 5C). The WAVE2 signal was co-localized with VIPR2-EGFP signals at the plasma membrane in lamellipodia (Figure 5A).

To further verify the involvement of VIPR2 in WAVE2 translocation to the plasma membrane, we silenced *VIPR2* and examined the localization of WAVE2 (Figure 6). In response to VIP stimulation, MDA-MB-231 cells transfected with *VIPR2* siRNA showed lower levels of WAVE2 signal at the plasma membrane than those in control cells (Figures 6A, B).

Activated WAVE2 binds to the ARP2/3 complex and actin (7). We thus examined the interaction between WAVE2, ARP3 and EGFP-actin *in vitro* by pull-down assays using cell lysates of LLC-PK1 pig kidney epithelial cells stably expressing EGFP-actin (provided by Dr. Keiju Kamijo). Both endogenous WAVE2 and ARP3 co-precipitated with EGFP-actin to a lesser degree in *VIPR2*-silenced cells treated with VIP compared with that in control siRNA-transfected LLC-PK1 cells treated with VIP (Figure 6C). However, *VIPR2*-silencing had no effects on the total expression levels of WAVE2 and ARP3 (Figure 6D).

VIPR2 participates in lamellipodium extension in MDA-MB-231 cells

WAVE2-mediated actin nucleation and subsequent conformation of actin filament drives lamellipodium formation and extension (7). We next performed a scratch wound closure assay to investigate the effect of VIPR2 on lamellipodium



FIGURE 6
VIPR2 mediates the interaction between WAVE2, ARP and actin. **(A)** MDA-MB-231 cells transfected with either control siRNA or *VIPR2* siRNA1 were stimulated with (+) or without (–) 100 nM VIP for 10 min. Cells were evaluated by immunocytochemistry using an anti-WAVE2 antibody. Representative images are shown. **(B)** Bar graph shows quantification of the fluorescence intensity of WAVE2 on the plasma membrane. The data are presented as means ± SD [VIP **(-)** and control si, 76 cells; VIP **(-)** and *VIPR2* si1, 104 cells; VIP (+) and control si, 66 cells; VIP (+) and *VIPR2* si1, 130 cells in total]. **p < 0.01, ***p < 0.001, between the indicated groups (Kruskal–Wallis test followed by Dunn's multiple comparison test). n.s. indicates not statistically significant. **(C, D)** Pull-down assay using GFP-Trap_A beads was performed to evaluate the amount of WAVE2 and ARP3 bound to EGFP-actin. LLC-PK1 cells stably expressing EGFP-actin were transfected with *VIPR2* siRNA3; the pull-down fraction was collected using GFP-Trap_A beads and centrifugation. Western blotting of the obtained fractions (pull down, C) and whole cell lysates **(D)** was performed using the specific antibodies for the indicated proteins. EGFP-actin was detected by a GFP antibody. Similar data were obtained from three independent experiments, and representative images are shown.

extension at the leading edge of migrating cells and analyzed lamella dynamics at the leading edge by kymography (Figure 7). VIP stimulation-induced lamellipodium extension was attenuated in *VIPR2*-silenced MDA-MB-231 cells compared with that in control cells (Figure 7A). In contrast, the lamellipodium extension extended further in MDA-MB-231 cells transfected with VIPR2-EGFP plasmid compared with the distance in empty vector-transfected cells (Figure 7B).

Discussion

The results of this study revealed that VIP–VIPR2 signaling participates in a PI3K-induced PI(3,4,5)P_3 production-mediated signaling pathway involved in cell migration. VIPR2 strongly couples with Gαs protein and mediates PKA and its downstream signaling pathway; in some cases, VIPR2 also couples with Gαi and Gαq proteins (15, 30–32). Signaling through Gαi protein promotes the PI3K/AKT pathway, which is associated with increased PI(3,4,5)P_3. Indeed, we found that VIPR2 overexpression leads to further activation of PI3K and additional increase of PI(3,4,5)P_3 followed by WAVE2-dependent cell extension and cancer cell migration (Figure 8). These results contribute to the understanding of the PI3K/PI(3,4,5)P_3 signaling pathway and suggest VIPR2 as a new potential therapeutic target against cancer.

Constitutive activation of the PI3K/AKT signaling cascade is common in cancer. Aberrant activation of PI3K/AKT signaling



FIGURE 7
VIPR2 regulates lamellipodium extension in MDA-MB-231 cells. **(**A, B) Extension of the leading-edge (arrowheads in the middle panels) in MDA-MB-231 cells transfected with either control siRNA or *VIPR2* siRNA1 **(A)** and MDA-MB-231 cells stably expressing either EGFP or VIPR2-EGFP **(B)** was monitored during wound healing. The images were acquired at 2-min intervals for 60 min after 100 nM VIP stimulation. Top panels show images at time 0. The kymographs (middle panels) were analyzed at the red lines for 0–60 min. Similar results were obtained from three independent experiments and representative images are shown. Quantification of the extended leading-edge for 1 h is shown in graphs (bottom panels). The data are presented as means ± SD [n = 15 (3 independent experiments; 5 cells were randomly selected in each group at each time)]. ***p < 0.001 (Mann–Whitney's U test).



FIGURE 8
Schematic representation of the role of VIPR2 in breast cancer cell migration. Increased *VIPR2* mRNA expression and/or *VIPR2* gene copy number has been found in invasive breast carcinoma. VIPR2 couples with Gαs, Gαi and Gαq proteins. Gαi-coupled VIPR2 and its Gβγ subunits regulate PI3Ks activity. PI3Ks convert phosphatidylinositol 4,5-bisphosphate [PI(4,5)P_2] into phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P_3]. The synthesized PI(3,4,5)P_3 promotes the translocation of WASP family verprolin homologous protein 2 (WAVE2) to the plasma membrane. WAVE2 drives lamellipodium formation by enhancing actin nucleation *via* the actin-related protein 2 and 3 (ARP2/3) complex, resulting in promotion of breast cancer cell migration.

in cancer typically occurs from mutations in genes encoding receptor tyrosine kinases, PI3K, phosphatase and tensin homologue (PTEN), or AKT. Moreover, the reduced expression or ablation of PTEN, a PI(3,4,5)P_3 phosphatase, results in malignant transformation (11, 12, 43). The deregulation of PI3K activity (e.g., by H1047R and E542K in p110α) is associated with high malignancy and an increased resistance to chemotherapeutic and radiation therapies in breast cancer. The elucidation of the roles of VIPR2 in PI3K activity revealed in this study and the increased *VIPR2* gene expression in some cancers suggest the possibility that VIPR2 may play a part in cancer development.

Our experiments with PI3K inhibitors revealed that phosphorylated AKT level in VIP-stimulated VIPR2-EGFP-expressing cells was almost completely eliminated by treatment with a PI3Kγ-specific inhibitor AS605240. AS605240 also suppressed the VIP-induced cell migration in VIPR2-EGFP-expressing cells to the level observed in the treatment with a pan-PI3K class I inhibitor ZSTK474. Moreover, in *VIPR2*-silenced cells, treatment with either AS605240 or ZSTK474 had no further effects on cell migration. Together, these results suggest that PI3Kγ plays a key role as a downstream molecule of VIPR2 signaling in regulating cell migration. Since PI3Kγ is activated by Gβγ (5), VIP–VIPR2 signaling likely activates PI3Kγ in a Gβγ-dependent manner, leading to increased cell migration.

VIP is a ligand for both VIPR1 and VIPR2, which are expressed in MDA-MB-231 cells. In our transwell migration study, silencing *VIPR2* suppressed the VIP-induced migration to levels similar to that in unstimulated MDA-MB-231 cells. In the scratch wound closure assay, two siRNAs of different sequences targeting *VIPR2* decreased the migration speed by the same degree. Additionally, treatment with KS-133, a selective VIPR2 antagonist, at concentrations above 100 nM almost completely suppressed cell migration induced by VIP (200 nM) in VIPR2-overexpressing MDA-MB-231 cells. Thus, our study demonstrates that VIPR2 modulates cell migration without the need for support from other VIP receptors and implies that VIPR2-dependent downstream signaling may specifically control cell migration induced by VIP.

VIPR2 and VIPR1 are also coupled to a Gαs protein pathway that signals the phosphorylation of ERK (15). In the current study, the onset time of ERK phosphorylation was slightly delayed from 5 min in control cells to 30 min in MCF-7 cells transfected with VIPR2 siRNA, but ERK phosphorylation was less affected by VIPR2 silencing; the peak time of phospho-ERK level was 30 min in both transfected cells and the level was similar at 30 min and 60 min. Thus, VIPR2 may contribute only weakly to ERK activation in these cells or the deficiency of VIPR2 may have been supplemented by pathways through VIPR1 and unknown VIP receptors in MCF-7 cells.

Migration is a polarized cellular process, and the polarity regulates cell mobility in a specific direction (44). Our scratch wound closure assays revealed that the expression of VIPR2 affects VIP-induced protrusive front edge formation, which was regulated by actin remodeling *via* PI3Kγ-WAVE2-ARP2/3 signaling. Moreover, cell migration is regulated by WAVE2-ARP2/3 signaling as well as phosphorylated AKT. AKT phosphorylated through PI3K signaling phosphorylates p21-activated kinase, which promotes myosin II assembly followed

by actomyosin contractions for cell migration (45). Indeed, in the scratch wound closure assay, the migration speed, regardless of the polarity and despite the forced straight movement, was also modulated depending on the fluctuation of VIPR2. VIPR2 signaling may confer both the driving force produced by actomyosin contraction and the directional polarity to moving cells to promote cell motility.

This is the first study to examine the newly emerging roles of VIPR2 in cell migration. Our findings conclusively demonstrated that VIPR2 regulates cancer cell migration. Deregulation of VIPR2 signaling may be a potential mechanism underlying the development of cancer cell pathology. We propose that VIP/VIPR2-induced activation of PI3Kγ and consequent production of $PI(3,4,5)P_3$ may represent a key step in driving cancer cell motility. Hence, VIPR2 signaling represents a potential therapeutic target for protection against metastatic progression. These findings provide a rationale for the development of VIPR2 antagonists to suppress cancer metastasis *in vivo*.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

SA designed the project, performed the experiments, and wrote the manuscript. MY and KO performed parts of the experiments. KS, AH-T, TN, and HH contributed reagents and analysis tools. JAW and YA conceived and coordinated the study and wrote the paper. All authors contributed to the article and approved the submitted version.

Funding

This work was supported in part by Core Research for Organelle Diseases in Hiroshima University (the MEXT program for promoting the enhancement of research universities, Japan) (S.A.) and collaborative research between Hiroshima University and Ichimaru Pharcos Co. Ltd. (Y.A.). This work was also partially supported by grants from JSPS KAKENHI (grant numbers 20K09905 (S.A.), JP20H00492 (H.H.), 20H03392 (Y.A.), 21K19714 (Y.A.)) and the JSPS Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (S2603; H.H.).

Acknowledgments

We thank Gabrielle White Wolf, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Conflict of interest

Kotaro Sakamoto is a full-time employee of Ichimaru Pharcos Co. Ltd. The authors declare that this study received funding from Ichimaru Pharcos Co. Ltd. The funder had the following involvement in the study: interpretation of data.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.852358/full#supplementary-material

References

1. Ridley AJ. Life at the leading edge. *Cell* (2011) 145:1012–22. doi: 10.1016/j.cell.2011.06.010

2. Pleiman CM, Hertz WM, Cambier JC. Activation of phosphatidylinositol-3' kinase by src-family kinase SH3 binding to the p85 subunit. *Science* (1994) 263:1609–12. doi: 10.1126/science.8128248

3. Ma YC, Huang J, Ali S, Lowry W, Huang XY. Src tyrosine kinase is a novel direct effector of G proteins. *Cell* (2000) 102:635–46. doi: 10.1016/s0092-8674(00)00086-6

4. Thelen M. Dancing to the tune of chemokines. *Nat Immunol* (2001) 2:129–34. doi: 10.1038/84224

5. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis PC, Hawkins PT. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. *Cell* (1994) 77:83–93. doi: 10.1016/0092-8674(94)90237-2

6. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. *Nat Rev Mol Cell Biol* (2005) 6:167–80. doi: 10.1038/nrm1587

7. Oikawa T, Yamaguchi H, Itoh T, Kato M, Ijuin T, Yamazaki D, et al. PtdIns (3,4,5)P3 binding is necessary for WAVE2-induced formation of lamellipodia. *Nat Cell Biol* (2004) 6:420–6. doi: 10.1038/ncb1125

8. Miki H, Takenawa T. Regulation of actin dynamics by WASP family proteins. *J Biochem* (2003) 134:309–13. doi: 10.1093/jb/mvg146

9. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The *PIK3CA* gene is mutated with high frequency in human breast cancers. *Cancer Biol Ther* (2004) 3:772–5. doi: 10.4161/cbt.3.8.994

10. Toker A. Double trouble for cancer gene. *Science* (2019) 366:685–6. doi: 10.1126/science.aaz4016

11. Brown KK, Toker A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. *F1000Prime Rep* (2015) 7:13. doi: 10.12703/p7-13

12. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. *Curr Opin Cell Biol* (2017) 45:62–71. doi: 10.1016/j.ceb.2017.02.007

13. Semba S, Iwaya K, Matsubayashi J, Serizawa H, Kataba H, Hirano T, et al. Coexpression of actin-related protein 2 and wiskott-Aldrich syndrome family verproline-homologous protein 2 in adenocarcinoma of the lung. *Clin Cancer Res* (2006) 12:2449–54. doi: 10.1158/1078-0432.CCR-05-2566

14. Iwaya K, Norio K, Mukai K. Coexpression of Arp2 and WAVE2 predicts poor outcome in invasive breast carcinoma. *Mod Pathol* (2007) 20:339–43. doi: 10.1038/modpathol.3800741

15. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. *Pharmacol Rev* (2009) 61:283–357. doi: 10.1124/pr.109.001370

16. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. *Br J Pharmacol* (2012) 166:4–17. doi: 10.1111/j.1476-5381.2012.01871.x

17. Moody TW, Osefo N, Nuche-Berenguer B, Ridnour L, Wink D, Jensen RT. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells. *J Pharmacol Exp Ther* (2012) 341:873–81. doi: 10.1124/jpet.111.190033

18. Moody TW, Ramos-Alvarez I, Jensen RT. Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases. *Peptides* (2021) 137:170480. doi: 10.1016/j.peptides.2020.170480

19. Jaworski DM. Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury. *Cell Tissue Res* (2000) 300:219–30. doi: 10.1007/s004410000184

20. Moody TW, Hill JM, Jensen RT. VIP As a trophic factor in the CNS and cancer cells. *Peptides* (2003) 24:163–77. doi: 10.1016/s0196-9781(02)00290-5

21. Nakamachi T, Sugiyama K, Watanabe J, Imai N, Kagami N, Hori M, et al. Comparison of expression and proliferative effect of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors on human astrocytoma cell lines. *J Mol Neurosci* (2014) 54:388–94. doi: 10.1007/s12031-014-0362-z

22. Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. *Curr Opin Endocrinol Diabetes Obes* (2016) 23:38–47. doi: 10.1097/med.0000000000000218

23. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. *Cancer Res* (2000) 60:3105–12.

24. Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, et al. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. *Int J Oncol* (2005) 26:1629–35. doi: 10.3892/ijo.26.6.1629

25. Zhao L, Yu Z, Zhao B. Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells. *Med Oncol* (2019) 36:91. doi: 10.1007/s12032-019-1312-y

26. Szilasi M, Buglyo A, Treszl A, Kiss L, Schally AV, Halmos G. Gene expression of vasoactive intestinal peptide receptors in human lung cancer. *Int J Oncol* (2011) 39:1019–24. doi: 10.3892/ijo.2011.1122

27. Schulz S, Mann A, Novakhov B, Piggins HD, Lupp A. VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235. *Endocr. Connect.* (2015) 4:18–26. doi: 10.1530/ec-14-0051

28. Waschek JA. VIP And PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. *Br J Pharmacol* (2013) 169:512–23. doi: 10.1111/bph.12181

29. Takeuchi S, Kawanai T, Yamauchi R, Chen L, Miyaoka T, Yamada M, et al. Activation of the VPAC2 receptor impairs axon outgrowth and decreases dendritic arborization in mouse cortical neurons by a PKA-dependent mechanism. *Front Neurosci* (2020) 14:521. doi: 10.3389/fnins.2020.00521

30. MacKenzie CJ, Lutz EM, McCulloch DA, Mitchell R, Harmar AJ. Phospholipase c activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. *Ann N Y. Acad Sci* (1996) 805:579–84. doi: 10.1111/j.1749-6632.1996.tb17523.x

31. Straub SG, Sharp GW. A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. *J Biol Chem* (1996) 271:1660–8. doi: 10.1074/jbc.271.3.1660

32. MacKenzie CJ, Lutz EM, Johnson MS, Robertson DN, Holland PJ, Mitchell R. Mechanisms of phospholipase c activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor. *Endocrinology* (2001) 142:1209–17. doi: 10.1210/endo.142.3.8013

33. Zibara K, Zeidan A, Mallah K, Kassem N, Awad A, Mazurier F, et al. Signaling pathways activated by PACAP in MCF-7 breast cancer cells. *Cell Signal* (2018) 50:37–47. doi: 10.1016/j.cellsig.2018.06.009

34. Asano S, Taniguchi Y, Yamawaki Y, Gao J, Harada K, Takeuchi H, et al. Suppression of cell migration by phospholipase c-related catalytically inactive protein-dependent modulation of PI3K signalling. *Sci Rep* (2017) 7:5408. doi: 10.1038/s41598-017-05908-7

35. Sakamoto K, Chen L, Miyaoka T, Yamada M, Masutani T, Ishimoto K, et al. Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activity that counteracts cognitive decline in a mouse model of psychiatric disorders. *Front Pharmacol* (2021) 12:751587. doi: 10.3389/fphar.2021.751587

36. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* (1959) 37:911–7. doi: 10.1139/o59-099

37. Huang W, Jiang D, Wang X, Wang K, Sims CE, Allbritton NL, et al. Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives. *Anal Bioanal. Chem* (2011) 401:1881–8. doi: 10.1007/s00216-011-5257-z

38. Asano S, Nemoto T, Kitayama T, Harada K, Zhang J, Harada K, et al. Phospholipase c-related catalytically inactive protein (PRIP) controls KIF5B-mediated insulin secretion. *Biol Open* (2014) 3:463–74. doi: 10.1242/bio.20147591

39. Asano S, Ikura Y, Nishimoto M, Yamawaki Y, Hamao K, Kamijo K, et al. Phospholipase c-related catalytically inactive protein regulates cytokinesis by protecting phosphatidylinositol 4,5-bisphosphate from metabolism in the cleavage furrow. *Sci Rep* (2019) 9:12729. doi: 10.1038/s41598-019-49156-3

40. Asano S, Kitatani K, Taniguchi M, Hashimoto M, Zama K, Mitsutake S, et al. Regulation of cell migration by sphingomyelin synthases: sphingomyelin in lipid rafts decreases responsiveness to signaling by the CXCL12/CXCR4 pathway. *Mol Cell Biol* (2012) 32:3242–52. doi: 10.1128/mcb.00121-12

41. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* (2005) 307:1098–101. doi: 10.1126/science.1106148

42. Manning BD, Toker A. AKT/PKB signaling: Navigating the network. *Cell* (2017) 169:381–405. doi: 10.1016/j.cell.2017.04.001

43. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer* (2009) 9:550–62. doi: 10.1038/nrc2664

44. Vicente-Manzanares M, Horwitz AR. Cell migration: an overview. *Methods Mol Biol* (2011) 769:1–24. doi: 10.1007/978-1-61779-207-6_1

45. Chung CY, Potikyan G, Firtel RA. Control of cell polarity and chemotaxis by Akt/PKB and PI3 kinase through the regulation of PAKa. *Mol Cell* (2001) 7:937–47. doi: 10.1016/S1097-2765(01)00247-7

frontiers | Frontiers in Oncology

TYPE Mini Review
PUBLISHED 23 November 2022
DOI 10.3389/fonc.2022.1038121

OPEN ACCESS

EDITED BY
Vasiliki Gkretsi,
European University Cyprus, Cyprus

REVIEWED BY
Honghao Yu,
Huazhong University of Science and Technology, China

*CORRESPONDENCE
Allal Ouhtit
aouhtit@qu.edu.qa

SPECIALTY SECTION
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

RECEIVED 06 September 2022
ACCEPTED 11 October 2022
PUBLISHED 23 November 2022

CITATION
Ahmad SMS, Al-Mansoob M and Ouhtit A (2022) SIRT1, a novel transcriptional downstream target of CD44, linking its deacetylase activity to tumor cell invasion/metastasis. *Front. Oncol.* 12:1038121. doi: 10.3389/fonc.2022.1038121

SIRT1, a novel transcriptional downstream target of CD44, linking its deacetylase activity to tumor cell invasion/metastasis

Salma M. S. Ahmad, Maryam Al-Mansoob and Allal Ouhtit*

Biological Sciences Program, Department of Biological & Environmental Sciences, College of Arts and Science, Qatar University, Doha, Qatar

Our tetracycline-off-inducible CD44 expression system previously established in mouse model, revealed that activation of CD44 with its major ligand hyaluronan (HA) promoted breast cancer (BC) metastasis to the liver. To identify the mechanisms that underpin CD44-promoted BC cell invasion, microarray gene expression profiling using RNA samples from (Tet)-Off-regulated expression system of CD44s in MCF7 cells, revealed a set of upregulated genes including, nuclear sirtuin-1 (*SIRT1* also known as NAD-dependent deacetylase), an enzyme that requires NAD^+ as a cofactor to deacetylate several histones and transcription factors. It stimulates various oncogenic pathways promoting tumorigenesis. This data suggests that *SIRT1* is a potential novel transcriptional target of CD44-downstream signaling that promote BC cell invasion/metastasis. This review will discuss the evidence supporting this hypothesis as well as the mechanisms linking *SIRT1* to cell proliferation and invasion.

KEYWORDS

***SIRT1*, breast cancer, CD44, hyaluronan, metastasis**

Background

Breast Cancer (BC) is the most common malignant tumor in women worldwide including the state of Qatar, which may arise either as a result of family history or exposure to harmful environmental factors such as radiation, high alcohol consumption, and lifestyle (1–3). Unfortunately, malignant tumors has the capability to metastasize,

Abbreviations: APC, Adenomatous polyposis coli; AKT, Protein kinase B; BC, Breast cancer; CAM, Cell adhesion molecule; CD44, Cluster of differentiation 44; DNMT1, DNA Methyltransferase 1; ECM, Extracellular matrix; EMT, Epithelial-mesenchymal transition; ERK, Extracellular-signal-regulated kinase; HA, Hyaluronic acid; NAD, Nicotinamide Adenine Dinucleotide; SIRT1, Sirtuin1; PI3K, phosphoinositide 3-kinase; Tet, Tetracycline; TGF-β2, Transforming growth factor-beta 2.

which involves both migration and invasion of cancer cells (4). The process of metastasis begins when cancerous cells detach from the primary tumor found in a specific organ or tissue and start invading through the extracellular matrix to the blood vessels. Cancerous cells will keep circulating in blood vessels unless it is detected by immune cells for degradation or until it finds a suitable organ with a good blood supply to invade into, forming a secondary tumor (5). The process of invasion encompasses three major components including, cell adhesion molecules (CAMs) (6, 7) found on the cell surface to help invading cells adhere to the surrounding extracellular matrix (ECM) (8).

Since CAMs play a vital role in invasion, our own work has concentrated since 2006 on a CAM protein family known as CD44 (9–14). CD44 is a cell surface receptor for its main ligand hyaluronic acid (HA) (15, 16) which stimulates various oncogenic signaling pathways (e.g. Rho GTPases, PI3K/AKT, and MAPK signaling pathways) resulting in tumor cell survival, proliferation, migration and invasion (17). A better understanding of the various CD44-downstream mechanisms promoting metastasis will ultimately help in developing effective anti-metastatic therapeutic strategies. Consequently, to further investigate CD44 mechanisms associated with the process of invasion, we have previously developed a tetracycline (Tet)-Off-regulated expression system of CD44 in both *in vitro* (9) and *in vivo* (18). A microarray analysis was further carried out to identify CD44-transcriptional target genes. Based on the microarray results we have previously validated three target genes along with their signaling pathways (Cortactin, Survivin and TGF-β2) as novel downstream target genes that underpin CD44-promoted breast tumor cell invasion (9, 10, 19). From the same microarray data, *Sirtuin 1 (SIRT1)*, was selected for further validation studies as potential target of CD44 because of its involvement in cell proliferation, invasion, and metastasis.

SIRT1 is one of the seven members of the Sirtuins family belonging to the third class of histone deacetylase enzymes, that require a significant co-factor known as nicotinamide adenine dinucleotide (NAD^+) (20). Nuclear *SIRT1* was reported to catalyze the deacetylation of lysin residues found within histone proteins including H1, H3, and H4; It deacetylates several oncogenes and transcription factors thereby affecting their function (21, 22). Furthermore, recent studies demonstrated that cytoplasmic *SIRT1* plays a significant role in cell proliferation, cell cycle, apoptosis, energy metabolism, and DNA repair, suggesting that *SIRT1* plays a key role in tumorigenesis, development, and drug resistance (21). This review focuses on discussing the literature data supporting *SIRT1* as a potential novel target of CD44-downstream signaling underlying the process of BC cell invasion.

Structure of SIRT1

SIRT1 is encoded by a gene located on the long arm of chromosome 10 (10q21.3), that is composed of 747 amino acids forming four regions, the nuclear localization signal 41-46 amino acids found at the N-terminal, the allosteric side located from 184 to 243 amino acid, the preserved catalytic domain, where deacetylation occur at the centre of the domain, and the C-terminal region located from 631 to 365 amino acid. The N-terminal region is significant as it is where the nuclear reading occurs allowing *SIRT1* to translocate to the nucleus (23, 24).

The catalytic domain is composed of 277 residues consisting of a larger NAD^+-binding subdomain containing a Rossmann-fold, and a smaller subdomain that is created by two insertions in the NAD^+-binding domain: i) a helical module (residues 269 to 324) and ii) a Zn^{2+}-binding module (residues 362-419). The NAD^+-binding domain consists of six-stranded parallel β sheets and eight α helices. However, the Zn^{2+}-binding domain is composed of 3 β strands and a single α helices. *SIRT1* C-terminal regulatory segment was found to form a quaternary complex with NAD^+-binding domain, by binding to its lower edge to match the central parallel β sheet of its Rossmann fold (25). *SIRT1* transfers the acetyl group from ε-N-acetyl lysine amino acids on the histones that wraps the DNA, controlling the transcription of genes in a NAD^+-dependant manner (24).

Functions of SIRT1

Physiologically, *SIRT1* is expressed in both normal and malignant cells. The following sections will discuss the role of *SIRT1* in both normal and malignant cells.

Physiological functions of SIRT1 in normal cells

SIRT1 was found to be upregulated in the body during fasting and calorie restriction, as it is a key regulator of metabolism. Its overexpression controls mitochondrial biogenesis, stimulating the catabolism of fat and cholesterol found in the liver, skeletal muscle, and adipose tissues. Moreover, upregulation of *SIRT1* will induce the expression of gluconeogenic gene, the activation of fatty acid oxidation and the suppression of glycolytic genes, by controlling the transcription of PGC-1α (20). Moreover, *SIRT1* doesn't only coordinate with PGC-1α, but also enhances the expression of SIRT6 and SIRT5. SIRT6 enhances the production of metabolic intermediates by regulating the mitochondrial activity. On the other hand, SIRT5 is involved in the apoptotic pathways, as it deacetylates cytochrome c (20). Furthermore,

SIRT1 is also found to be expressed in pro-opiomelanocortin neurons, which are significant in controlling normal body weight by regulating glucose homeostasis. The knock-down of *SIRT1* in these neurons causes hypersensitivity and anterior pituitary cell defects failing to regulate changes in pituitary signaling (20, 26). In addition, *SIRT1* acts as a positive regulator monitoring insulin secreted by the pancreas. The presence of *SIRT1* enhances glucose tolerance in pancreatic β-cells by improving the process of insulin secretion. Nevertheless, suppression of *SIRT1* damages insulin secretion process stimulated by glucose (26).

Functions of SIRT1 in cancer cells and its association with CD44

Previous studies have stated that *SIRT1* expression was overexpressed in BC compared to its expression in normal cells. Overexpressing *SIRT1* in MCF-7 cells has promoted their proliferation, migration, and invasion (21). Moreover, *SIRT1* has an oncogenic activity in BC cells as it inhibits the expression of the tumour suppressor gene p53 *via* activation of Mdm2, interfering with cell proliferation, cell cycle, apoptosis, and DNA repair, predisposing breast cells to neoplastic transformation (21, 27). Further studies have shown that *SIRT1* is upregulated in BC cells, promoting cell proliferation and cell cycle progression through its interaction with PI3K/AKT oncogenic pathway (28). Likewise, silencing *SIRT1* inhibited the activation of PI3K/AKT pathway (29). On one hand, we have previously demonstrated that CD44 activates PI3K/AKT pathway to promote cellular migration, invasion, and survival (12, 13). On the other hand, PI3K/AKT activates *SIRT1* (30), all this data put together suggest that CD44 might activate *SIRT1 via* PI3K/AKT.

Cytoplasmic *SIRT1* directly interact with MAPK/Ras/ERK pathways promoting neuronal differentiation and survival. Furthermore, the suppression of *SIRT1* decreased the phosphorylation of JNK/ERK/MAPK signalling pathways in cerebral ischemia in both rats and humans (31). Similarly, CD44 activates ERK phosphorylation, activating both extracellular and intracellular signals to promote cell proliferation and migration (32). In addition, CD44 also phosphorylates ERK/MAPK and RAS/MAPK signalling pathway to promote tumour angiogenesis, migration, and invasion (12, 33, 34).

Cytoplasmic *SIRT1* was also found to directly interact with cytoplasmic cortactin promoting cell migration, invasion, and metastasis, through IGF-1 activation in non-small cell lung cancer. Several studies stated that cortactin was upregulated in various human cancers such as breast, head, oesophagus, and hepatic cancers (35). Our previous studies showed that CD44 activates cortactin *via* the transcription factor NF-κB (9); This data suggest that CD44 might activate *SIRT1 via* activation of cortactin or its associated signalling pathways. *SIRT1* also plays a significant role in activating Wnt signaling acting as tumour promoter in colorectal cancer. First, Adenomatous polyposis coli (APC) regulate Wnt Signaling pathway by translocating β-catenin from the cytoplasm into the nucleus activating several oncogenic pathways. The cytoplasmic *SIRT1* colocalizes dsh protein in the cytoplasm and enhances the expression of DNA Methyl-transferase 1 (DNMT1) that promote DNA hypermethylation in the promoter domain of APC, thereby inhibiting its tumour suppressor function. The Dsh protein will inhibit the phosphorylation of β-catenin allowing its accumulation in the nucleus, upregulating the transcription factors TCF/LEF (T-cell factor/Lymphoid enhancer factor). Nuclear *SIRT1* will bind to the LEF1 lysine residue to deacetylate the present histones regulating the transcription of the downstream targets such as cyclin D1, C-Myc, and surviving, thereby inducing tumour proliferation and migration (24). Moreover, the activation of Wnt signaling activates *SIRT1* to interact with Dsh forming a complex that will phosphorylate and activate PI3K/AKT signaling pathway, that will also result in the translocation of β-catenin into the nucleus to activate its downstream targets promoting cell migration in colon and BC cells (24, 36, 37). Correspondingly, the activation of Wnt/β-catenin pathway will activate the direct interaction of CD44 with cortactin and will enhance the transcription of CD44 and c-myc in indicating positive feedback of Wnt signaling-CD44 loop promoting cell adhesion, migration, and invasion of BC and melanoma (9, 38). In addition, overexpression of CD44 upregulates the expression of cyclin D1 through the activation of ERK pathway that will promote tumour proliferation and migration of BC, ovarian cancer, and squamous cell carcinoma (32). Our previous study has proven that activated HA/CD44 has activated PI3K signalling pathway to phosphorylate the transcription factor E2F1 promoting the expression of Survivin, resulting in breast tumour invasion (10). Furthermore, using bioinformatics tools, various transcription factors were identified including, C-Myc/Max, NFAT2, SREBP1, EGR-1 and USF1, that can bind the promoter of *SIRT1 via* induction of MAPK/ERK and PI3K/AKT signalling pathways as shown in Figure 1 (39).

In summary and as shown in Figure 1, SIRT1 is activated by the WNT cell surface transmembrane receptor known as frizzled to inhibit the expression of P53 through MDM2 phosphorylation, either by direct phosphorylation of MDM2 or by activating PI3K/AKT pathway. Moreover, CD44 activates PI3K//AKT pathway allowing the translocation of SIRT1 to the nucleus and its binding to β-catenin and LEF1 to transcribe C-myc, Cyclin D1, and Survivin. Furthermore, CD44 activate the MAPK/ERK pathway which enhance the transcription of SIRT1 by activating C-myc, MAX, NFAT2, SREBP1, Egr1 and USF1 transcription factors. Put together, all the evidence collected from the literature support our hypothesis that *SIRT1* is a novel downstream transcriptional target of CD44/HA



FIGURE 1
Validated (→) and proposed (– – – →) mechanisms linking CD44 activation by hyaluronan to induce SIRT1 transcription promoting tumor cell progression and metastasis.

regulating pro-metastatic signalling pathways that are involved in tumour proliferation, migration, and invasion.

Potential therapeutic strategies targeting *SIRT1*

Several studies have been performed to develop suitable inhibitors targeting *SIRT1* to guide the design of applicable therapeutic strategies against BC. Splitomicin, Sirtinol and ILS-JGB-1741 are the inhibitor drugs used to inhibit the expression of *SIRT1* in BC cells, which have been shown to inhibit cell proliferation, induce cell cycle arrest and apoptosis (20, 24).

Conclusion

SIRT1 shows a significant role in the development and metastasis of breast tumours, but its underlying mechanisms are still poorly understood. *SIRT1* interferes with various signalling pathways that promote breast tumour cell proliferation, migration, and invasion. *SIRT1* inhibits the expression of P53, interfering with apoptosis leading to survival and tumor cell proliferation. To summarize, it is clear that CD44 activates *SIRT1* most likely *via* two intermediate players PI3K/AKT and MAPK/ERK signalling pathways. These findings support our hypothesis suggesting that *SIRT1* is a novel downstream target that underpin CD44/HA enhancing tumour cell development and metastasis.

Author contributions

SMSA: writing—original draft (lead), MA-M: Editing, AO: Conceptualization (lead), funding acquisition (lead), writing-review and editing. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by Qatar University Internal grant number: QUST-1-CAS2019-22 and the Qatar Foundation grant number: UREP24-117-1-027.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* (2019) 144:1941–53. doi: 10.1002/ijc.31937

2. Narayan AK, Al-Naemi H, Aly A, Kharita MH, Khera RD, Hajaj M, et al. Breast cancer detection in Qatar: Evaluation of mammography image quality using a standardized assessment tool. *Eur J Breast Health* (2020) 16:124–8. doi: 10.5152/ejbh.2020.5115

3. Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, et al. Group: Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. *The Lancet* (1996) 348(9029):708–13. doi: 10.1016/s0140-6736(96)02133-2

4. Mcsherry EA, Donatello S, Hopkins AM, Mcdonnell S. Molecular basis of invasion in breast cancer. *Cell Mol Life Sci* (2007) 64:3201–18. doi: 10.1007/s00018-007-7388-0

5. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. (2007) 8 (5):341–352. doi: 10.1038/nrg2101

6. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. *Biochim Biophys Acta* (2009) 1788:872–91. doi: 10.1016/j.bbamem.2008.11.005

7. Martin T, Ye L, Sanders AJ, Lane J, Jiang WG. Cancer invasion and metastasis: Molecular and cellular perspective. In: Jandial R, editor. *Madame curie bioscience database*. Austin (TC: Landes Bioscience (2013).

8. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. *Int J Cell Biol* (2012) 2012:676731. doi: 10.1155/2012/676731

9. Hill A, Mcfarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, et al. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. *Oncogene* (2006) 25:6079–91. doi: 10.1038/sj.onc.1209628

10. Abdraboh ME, Gaur RL, Hollenbach AD, Sandquist D, Raj MH, Ouhtit A. Survivin is a novel target of CD44-promoted breast tumor invasion. *Am J Pathol* (2011) 179:555–63. doi: 10.1016/j.ajpath.2011.04.042

11. Ouhtit A, Madani S, Gupta I, Shanmuganathan S, Abdraboh ME, Al-Riyami H, et al. TGF-β2: A novel target of CD44-promoted breast cancer invasion. *J Cancer* (2013) 4:566–72. doi: 10.7150/jca.6638

12. Ouhtit A, Rizeq B, Saleh HA, Rahman MM, Zayed H. Novel CD44-downstream signaling pathways mediating breast tumor invasion. *Int J Biol Sci* (2018) 14:1782–90. doi: 10.7150/ijbs.23586

13. Al-Mansoob M, Gupta I, Stefan Rusyniak R, Ouhtit A. KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion. *J Cell Mol Med* (2021) 25:2309–14. doi: 10.1111/jcmm.16296

14. Al-Mansoob M, Ahmad SMS, Ouhtit A. PCF11, a novel CD44-downstream transcriptional target, linking its 3'-end polyadenylation function to tumor cell metastasis. *Front Oncol* (2022) 12:878034. doi: 10.3389/fonc.2022.878034

15. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. *Curr Opin Cell Biol* (2000) 12:581–6. doi: 10.1016/S0955-0674(00)00135-6

16. Isacke CM, Yarwood H. The hyaluronan receptor, CD44. *Int J Biochem Cell Biol* (2002) 34:718–21. doi: 10.1016/S1357-2725(01)00166-2

17. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. *Crit Rev Clin Lab Sci* (2002) 39:527–79. doi: 10.1080/10408360290795574

18. Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MHG. *In vivo* evidence for the role of CD44s in promoting breast cancer metastasis to the liver. *Am J Pathol* (2007) 171:2033–9. doi: 10.2353/ajpath.2007.070535

19. Ouhtit A, Madani S, Gupta I, Shanmuganathan S, Abdraboh ME, Al-Riyami H, et al. TGF-beta2: A novel target of CD44-promoted breast cancer invasion. *J Cancer* (2013) 4:566–72. doi: 10.7150/jca.6638

20. Villalba JM, Alcaín FJ. Sirtuin activators and inhibitors. *Biofactors* (2012) 38:349–59. doi: 10.1002/biof.1032

21. Xu Y, Qin Q, Chen R, Wei C, Mo Q. SIRT1 promotes proliferation, migration, and invasion of breast cancer cell line MCF-7 by upregulating DNA polymerase delta1 (POLD1). *Biochem Biophys Res Commun* (2018) 502:351–7. doi: 10.1016/j.bbrc.2018.05.164

22. Chen C, Zhou M, Ge Y, Wang X. SIRT1 and aging related signaling pathways. *Mech Ageing Dev* (2020) 187:111215. doi: 10.1016/j.mad.2020.111215

23. Dai H, Case AW, Riera TV, Considine T, Lee JE, Hamuro Y, et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. *Nat Commun* (2015) 6:7645. doi: 10.1038/ncomms8645

24. Subramaniyan B, Jagadeesan K, Ramakrishnan S, Mathan G. Targeting the interaction of aurora kinases and SIRT1 mediated by wnt signaling pathway in colorectal cancer: A critical review. *BioMed Pharmacother* (2016) 82:413–24. doi: 10.1016/j.biopha.2016.05.027

25. Davenport AM, Huber FM, Hoelz A. Structural and functional analysis of human SIRT1. *J Mol Biol* (2014) 426:526–41. doi: 10.1016/j.jmb.2013.10.009

26. Li X. SIRT1 and energy metabolism. *Acta Biochim Biophys Sin (Shanghai)* (2013) 45:51–60. doi: 10.1093/abbs/gms108

27. Adamkova K, Yi YJ, Petr J, Zalmanova T, Hoskova K, Jelinkova P, et al. SIRT1-dependent modulation of methylation and acetylation of histone H3 on lysine 9 (H3K9) in the zygotic pronuclei improves porcine embryo development. *J Anim Sci Biotechnol* (2017) 8:83. doi: 10.1186/s40104-017-0214-0

28. Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R, et al. SIRT1 promotes formation of breast cancer through modulating akt activity. *J Cancer* (2018) 9:2012–23. doi: 10.7150/jca.24275

29. Qi W, Ren D, Wang P, Song Z, Wu H, Yao S, et al. Upregulation of Sirt1 by tyrosol suppresses apoptosis and inflammation and modulates extracellular matrix remodeling in interleukin-1β-stimulated human nucleus pulposus cells through activation of PI3K/Akt pathway. *Int Immunopharmacol* (2020) 88:106904. doi: 10.1016/j.intimp.2020.106904

30. Koga T, Suico MA, Shimasaki S, Watanabe E, Kai Y, Koyama K, et al. Endoplasmic reticulum (ER) stress induces sirtuin 1 (SIRT1) expression *via* the PI3K-Akt-GSK3β signaling pathway and promotes hepatocellular injury. *J Biol Chem* (2015) 290:30366–74. doi: 10.1074/jbc.M115.664169

31. Teertam SK, Prakash Babu P. Differential role of SIRT1/MAPK pathway during cerebral ischemia in rats and humans. *Sci Rep* (2021) 11:1–14. doi: 10.1038/s41598-021-85577-9

32. Bourguignon LYW. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. *Semin Cancer Biol* (2008) 18:251–9. doi: 10.1016/j.semcancer.2008.03.007

33. Li XP, Zhang XW, Zheng LZ, Guo WJ. Expression of CD44 in pancreatic cancer and its significance. *Int J Clin Exp Pathol* (2015) 8:6724–31.

34. Lu CH, Lin CH, Li KJ, Shen CY, Wu CH, Kuo YM, et al. Intermediate molecular mass hyaluronan and CD44 receptor interactions enhance neutrophil phagocytosis and IL-8 production *via* p38- and ERK1/2-MAPK signalling pathways. *Inflammation* (2017) 40:1782–93. doi: 10.1007/s10753-017-0622-5

35. Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ, et al. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. *Pathol Res Pract* (2013) 209:365–70. doi: 10.1016/j.prp.2013.03.011

36. Holloway KR, Calhoun TN, Saxena M, Metoyer CF, Kandler EF, Rivera CA, et al. SIRT1 regulates dishevelled proteins and promotes transient and constitutive wnt signaling. *Proc Natl Acad Sci U.S.A.* (2010) 107:9216–21. doi: 10.1073/pnas.0911325107

37. Zhou Y, Song T, Peng J, Zhou Z, Wei H, Zhou R, et al. SIRT1 suppresses adipogenesis by activating wnt/β-catenin signaling *in vivo* and *in vitro*. *Oncotarget* (2016) 7:77707–20. doi: 10.18632/oncotarget.12774

38. Wei C-Y, Zhu M-X, Yang Y-W, Zhang P-F, Yang X, Peng R, et al. Downregulation of RNF128 activates wnt/β-catenin signaling to induce cellular EMT and stemness *via* CD44 and CTTN ubiquitination in melanoma. *J Hematol Oncol* (2019) 12:21. doi: 10.1186/s13045-019-0711-z

39. Daily K, Patel VR, Rigor P, Xie X, Baldi P. MotifMap: integrative genome-wide maps of regulatory motif sites for model species. *BMC Bioinf* (2011) 12:495. doi: 10.1186/1471-2105-12-495

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 08 December 2022
DOI 10.3389/fonc.2022.1055648

OPEN ACCESS

EDITED BY
Vasiliki Gkretsi,
European University Cyprus, Cyprus

REVIEWED BY
Martyna Filipska,
Fundació Institut Mar d'Investigacions Mèdiques (IMIM), Spain
Jia Li,
University of North Carolina at Charlotte, United States

*CORRESPONDENCE
Wentao Yue
yuewt@ccmu.edu.cn
Xiaoting Zhao
zhao_xiaoting@ccmu.edu.cn
Chenghong Yin
yinchh@ccmu.edu.cn

SPECIALTY SECTION
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

RECEIVED 28 September 2022
ACCEPTED 22 November 2022
PUBLISHED 08 December 2022

CITATION
Li J, Li Z, Gao Y, Zhao H, Guo J, Liu Z, Yin C, Zhao X and Yue W (2022) Integrating single-cell RNA sequencing and prognostic model revealed the carcinogenicity and clinical significance of FAM83D in ovarian cancer.
Front. Oncol. 12:1055648.
doi: 10.3389/fonc.2022.1055648

Integrating single-cell RNA sequencing and prognostic model revealed the carcinogenicity and clinical significance of FAM83D in ovarian cancer

Jie Li[1], Zhefeng Li[1], Yan Gao[1], Hongyu Zhao[1], Jiahao Guo[1], Zhibin Liu[1], Chenghong Yin[2]*, Xiaoting Zhao[1]* and Wentao Yue[1]*

[1]Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China, [2]Department of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China

Background: Ovarian cancer (OC) is a fatal gynecological tumor with high mortality and poor prognosis. Yet, its molecular mechanism is still not fully explored, and early prognostic markers are still missing. In this study, we assessed carcinogenicity and clinical significance of family with sequence similarity 83 member D (FAM83D) in ovarian cancer by integrating single-cell RNA sequencing (scRNA-seq) and a prognostic model.

Methods: A 10x scRNA-seq analysis was performed on cells from normal ovary and high-grade serous ovarian cancer (HGSOC) tissue. The prognostic model was constructed by Lasso-Cox regression analysis. The biological function of FAM83D on cell growth, invasion, migration, and drug sensitivity was examined *in vitro* in OC cell lines. Luciferase reporter assay was performed for binding analysis between FAM83D and microRNA-138-5p (miR-138-5p).

Results: Our integrative analysis identified a subset of malignant epithelial cells (C1) with epithelial-mesenchymal transition (EMT) and potential hyperproliferation gene signature. A FAM83D$^+$ malignant epithelial subcluster (FAM83D$^+$ MEC) was associated with cell cycle regulation, apoptosis, DNA repair, and EMT activation. FAM83D resulted as a viable prognostic marker in a prognostic model that efficiently predict the overall survival of OC patients. FAM83D downregulation in

SKOV3 and A2780 cells increased cisplatin sensitivity, reducing OC cell proliferation, migration, and invasion. MiR-138-5p was identified to regulate FAM83D's carcinogenic effect in OC cells.

Conclusions: Our findings highlight the importance of miR-138 -5p/FAM83D/EMT signaling and may provide new insights into therapeutic strategies for OC.

KEYWORDS

ovarian cancer, single-cell RNA sequencing, bioinformatics, prognostic signature, FAM83D

Introduction

Ovarian cancer (OC) is one of the most common fatal malignant tumors in women. Despite notable progress in surgery, targeted therapy, chemotherapy, and neoadjuvant chemotherapy, the 5-year overall survival rate of OC patients is still unsatisfactory owing to a high rate of chemoresistance, recurrence, and distant metastasis (1). Moreover, accurate prediction of early-stage OC remains challenging due to profound genetic heterogeneity, which limits the reproducible prognostic classifications (2). Therefore, there is a pressing requirement to comprehensively elucidate the complicated molecular properties and heterogeneity of OC development to explore new biomarkers for predicting prognosis.

In recent years, bulk analysis of gene expression patterns has often been used to explore prognostic markers of cancer (3–5). It measures the average expression level of individual genes across, allowing us to understand the differences in gene expression between samples. In addition, the whole-genome analysis of OC by multiple methods, including copy number variation and methylation level of key genes, have also been used to identify operable markers (6). However, there is still a problem of low accuracy of the screened markers in multi-sample validation and therefore cannot be applied in clinical practice. A meta-analysis has shown that the accuracy of most models in the new data set was lower than the validation set provided in their publications (7). As a result, the studies rely on bulk sample analysis, blurring the molecular markers of different cell subsets, thus hindering the identification of the precise molecular mechanism of OC. Fortunately, emerging single-cell technologies could address these limitations by providing powerful ways to probe genetic and functional heterogeneity at the single-cell level (8). The latest single-cell RNA sequencing (scRNA-seq) studies depicted a landscape of OC, advancing our understanding of its molecular mechanisms (9, 10). Still, there are only a few studies on prognostic markers based on scRNA-seq from OC.

Herein, we performed 10x scRNA-seq to analyze the transcriptomic profiles of 13890 cells from the normal ovary and OC tissues. We revealed a cluster of malignant epithelial cells with epithelial-mesenchymal transition (EMT) and potential hyperproliferation gene signature and constructed a robust prediction model including 10-EMT-related genes. Among them, a family with sequence similarity 83 member D ($FAM83D^{+}$) malignant epithelial cells were significantly associated with multiple carcinogenic pathways. Furthermore, we discovered that FAM83D promotes OC cell progression and cisplatin resistance, and confirmed that miR-138-5p could directly target FAM83D and notably restrain the progress of OC cells by bioinformatics analysis and experiments.

Materials and methods

Preparation of single-cell suspensions from normal ovary and OC samples

In this study, tissue from one patient with HGSOC and one patient with normal ovary were used for single cell suspension preparation. Fresh specimens were collected at the time of surgical excision under the supervision of a qualified pathologist. Tissues were transported using MACS Tissue Storage Solution (MACS, Cat. no.130-100-008F) on ice to preserve viability. Then we washed the tissues 2–3 times with phosphate buffered saline (PBS; Hyclone, Cat. no. SH30256.01) and minced them on ice. We used the Tumor Dissociation Kit (MACS, Cat. no.130-095-929) to digest the human tissues gently to generate single-cell suspensions. The OC and control tissues were dissociated at 37°C with a shaking speed of 30 rpm for about six minutes. Then, we collected the dissociated cells to digest sufficiently with 0.25% trypsin (Gibco, Cat. no.25200056) for about two minutes. Cell suspensions were filtered using a 40μm nylon cell strainer (Falcon, Cat. no. 352340), and red blood cells were removed by red blood cell lysis buffer (Solarbio). Single-cell suspensions were stained with AO/PI fluorescent dyes (Logos Biosystems, Cat. no. LB F23001) to check viability with LUNA (Logos Biosystems, Cat. no. LUNA-STEM). Then we diluted them to approximately 1×10^6 cells/ml with PBS containing 0.02% BSA for single-cell sequencing. Cells were loaded according to the standard

protocol of the Chromium single cell 3′ kit, capturing 5,000 cells to 10,000 cells/chip position (V3 chemistry). Libraries for scRNA-seq were generated using the 10x Genomics Chromium platform and sequenced on an Illumina Novaseq 6000 system. Finally, a gene-barcode matrix containing barcoded cells and gene expression counts was generated.

Single-cell RNA seq data analysis

The matrices of samples were combined and treated using Seurat V3 (11). Low quality cells (< 300 genes/cell, < 3 cells/gene, > 20% mitochondrial genes) were removed. The find clusters function and t-distributed Stochastic Neighbor Embedding (tSNE) function of the Seurat software package were performed for data clustering, and the visualization of major clusters.The estimation algorithm was conducted to calculate each cell's immune and stromal scores using the estimate package (12).The initial copy number variations (CNV) of each region was inferred by the infer-CNV package (13). The overall average was used as a baseline. The CNV of all cells was counted by the expression level of scRNA-seq data, and the cut-off value was 0.1. Finally, denoising was performed to produce CNV profiles. The single-cell trajectory was studied by the monocle2 package (14). The "differential gene test" function was used to count differentially expressed genes in the pseudo-time of cluster cell transformation. To probe the interactions between different clusters of the malignant epithelium cells, Cellchat (15) was used.

Validation and functional enrichment analysis of hub genes

TCGA database and Oncomine database were exploited to detect FAM83D expression. Kaplan-Meier (KM) plotter was used to assess the prognostic value of FAM83D in 1656 patients with OC (http://www.kmplot.com). In order to investigate the biological function in OC, Gene Sets gained from the MSigDB database were used to perform Gene Set Enrichment Analysis (GSEA) (16), GSVA enrichment analysis (17), the enriched Kyoto Encyclopedia of Genes, Genomes (KEGG), and Gene Ontology (GO) analysis. Three miRNA-mRNA predictors (Starbase, TargetScan, and miRDB) were used to predict the miRNAs regulating FAM83D.

Construction and validation of the prognosis model

The 153 EMT gene signatures were collected from GOBP_EPITHELIAL_TO_MESENCHYMAL_TRANSITION gene set (http://www.gsea-msigdb.org/gsea/msigdb/index.jsp). GSE18520 (adjusted $P < 0.001$ and $|\log FC| > 2$) identified 41 differentially expressed EMT genes. A total of 276 OC samples from GSE9891 were used as a training cohort. A total of 374 TCGA OC samples were used as test cohorts. Univariate Cox regression was used to screen prognostic genes among the 41 genes in the training set. Furthermore, the most useful prognostic markers were found by the lasso Cox regression model. Finally, 10 EMT gene features with non-zero coefficients were selected by R package glmnet (18), and the best lambda was determined by 10x cross-validation.

Cell culture and siRNA transfection

Human OC cell lines (SKOV3, A2780, OVCAR3, CAOV3, and HEY) and ovarian surface epithelium (OSE) cells were cultured according to a previous protocol (19). Cells were transfected with 100 nmol/L FAM83D siRNA2 and siRNA3 or control siRNA (JTS scientific) by Lipofectamine 3000 (Invitrogen).

Western blot analysis and quantitative real-time RT-PCR

Cells were lysed with RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA). The protein concentration was detected by a BCA protein assay kit (Beyotime Biotechnology, Jiangsu, China) and separated by SDS-PAGE (Gene Molecular Biotech Inc, Shanghai, China). The primary antibodies were used: anti-FAM83D (1:1000, Biorbyt), GAPDH, Vimentin, E-cadherin, and N-cadherin (1:1000, CST). Anti-GAPDH antibody was used as the loading control.

Total RNA was extracted by TRIzol reagent (Invitrogen, Calsbad, CA) and reversely transcribed using the ReverTraAceqPCR RT kit (Toyobo, Shanghai, China). The qRT-PCR was performed using SYBR Premix DimerEraser (Perfect Real Time) kit (TaKaRa Bio Inc) on an ABI 7500 Real-Time PCR system (Applied Biosystems, Foster City, USA) under the following conditions: 10 min at 95°C, followed by 40 cycles at 95°C for 15 sec and 60°C for 60 sec. Data were analyzed using the $-2\Delta\Delta ct$ method and the expression of GAPDH was used as normalization control. All primer sequences used are summarized in Table S1.

Cell proliferation

Three thousand cells were seeded in 96-well plates for 24, 48, or 72 h. After each time point, 10μL of sterile Cell Counting Kit-8 (CCK-8; Dojindo, Rockville, MD, USA) was added to each well and incubated for another 2 h at 37°C. The absorbance was determined at 450 nm (Tecan, Switzerland).

Cell apoptosis

A2780 and SKOV3 transfected cells were exposed to 8μg/ml and 10μg/ml cisplatin, respectively. After 24 hours, apoptosis cells were measured by annexin V-FITC and propidium iodide (PI) kit (BD Biosciences, San Jose, California, USA). BD flow cytometry was used to analyze the double-stained cells.

Cell migration and invasion

Wound-healing assay was applied to assess cell migration ability. Briefly, 1×10^6 cells were seeded on 6-well plates for 24h. Then, a line was drawn using a marker on the bottom of the dish, and a sterile 20-μl pipet tip was used to scratch three separate wounds through the cells (moving perpendicular to the line). The cells were gently rinsed twice with PBS to remove floating cells and incubated in 3 ml of medium. Images of the scratches were taken using an inverted microscope at 0 and 72 h of incubation. The scratch area was measured by image J software. The percentage of wound healing is the ratio of 72h migrated area (scratch area at 0h - scratch area at 72h) to 0h area. Transwell assays were used to evaluate cell migration and invasion ability. The cells were plated into the upper chamber of uncoated or matrigel-coated transwell chambers. The procedure was the same as previously described (19).

MiRNAs and plasmid transfection

The miRNA-mimics were used to upregulate miR-138-5p (GenePharma, Shanghai, China). The overexpression plasmid (GenePharma) pcDNA3.1-FAM83D was constructed to upregulate the expression of FAM83D. The empty vector served as a negative control. Puromycin (GeneCHEM) was used to screen the stably transfected cell lines.

Luciferase reporter assay

The FAM83D 3'-UTR fragment containing wildtype or the mutated miR-138-5p binding sites was amplified and subcloned into the pmirGLO Luciferase vector. OC cells were co-transfected with pmirGLO-wildtype/mutant FAM83D 3'-UTR and mimics, and relative luciferase activity was analyzed by the Dual-Luciferase Reporter assay system (TRAN, China).

Statistical analysis

All experiments were conducted for at least three independent times. The statistical differences between experimental groups were detected by the student's t test. All data were presented as the means ± SDs based on three independent samples. Graphpad prism 8.0.1 software and R 4.1.0 were used for statistical analyses. Statistical significance was indicated by $^*p < 0.05$.

Results

Single-cell sequencing revealed diverse cell types of OC and normal ovary

To investigate OC heterogeneity, we performed 10x scRNA-seq of one HGSOC and one normal ovary. After data preprocessing including quality control and removal of low-quality cells, 6235 OC cells and 7655 normal ovary cells were analyzed. According to the expression of known markers, these cells were clustered into six groups: C0 and C1 (epithelial cluster), C2 (T cell cluster), C3 (macrophage cluster), C4 (mesenchyme cluster), and C5 (B cell cluster) (Figures 1A, B). Then, we delineated the distinctive gene signatures of each cluster and presented the top 5 significant differential expression genes (Figure 1C). The clusters were evaluated by annotation enrichment analysis of GO terms and KEGG pathway. C0 and C1 were characterized by cell junction, RNA regulation pathways, and cell cycle. The three clusters of immune cells C2, C3 and C5 showed gene enrichment for immune-related pathways. C4, mesenchymal cells were found to be strongly associated with focal adhesion, and extracellular matrix (ECM)-receptor interaction (Figures S1A, B). Consistent with immune scores and stromal scores, mesenchymal cells (C4) showed a higher stromal score and immune cells (C2, C3, and C5) exhibited a higher immune score (Figure 1D). In addition, large-scale copy number variation (CNV) helped to identify malignant clusters. The results showed the CNV level of C1 was significantly higher than other cell types (Figure 1E). This data suggested that OC originated from the epithelium and that OC is highly heterogeneous and consists of various cell types.

Construction of a RiskScore model based on molecular characteristics of malignant epithelial cluster

We focused on the malignant features and molecular characteristics of C0 and C1 epithelial cells. We found that normal tissue is mainly composed of C0. In contrast, the tumor tissue is dominated by C1 (Figure 2A). Pseudo-time analysis was performed during tumor development to stratify tumor cells. Along the trajectory of normal to the tumor, the pseudo-time diagram illustrated the differentiation process from C0 to C1, which confirmed that C1 represents an advanced stage of epithelial cell differentiation of OC (Figure 2B).

Then, we identified genes whose expression patterns were drastically altered throughout differentiation and divided them



FIGURE 1
Single-cell expression profile of OC and normal ovary. **(A)** OC cell clusters from 10x Genomics scRNA-seq analysis visualized by UMAP. The number and percentage of cells for each cell type were summarized in the right panel. **(B)** Violin diagram showing the expression of marker genes in different cell types. **(C)** The dot map shows the top 5 genes in each cell type. **(D)** Violin plots show estimates of immune scores and stromal scores for different cell types. **(E)** The heatmap displayed large-scale CNVs of C0-C5. The red color represents a high CNV level and the blue represents a low CNV level.

into three subgroups according to their dynamic expression along the trajectory (Figure S2A). KEGG and GO analysis of these dynamically expressed genes illustrated that C1 was enriched in many carcinogenic pathways, such as DNA replication, signal transduction by p53 class mediator, TGF-beta signaling pathway, and Focal adhesion (Figures S2B, C, cluster 1 and 3). GSVA showed that C1 was more enriched in carcinogenic terms of cell cycle and invasion, such as EPITHELIAL_MESENCHYMAL_TRANSITION (EMT), E2F_TARGETS, etc. (Figure 2C). Of note, the expression of key epithelial markers (CDH1) of EMT progression was found to be downregulated or fluctuated, while the mesenchymal marker (CDH2) was increased, indicating dynamic changes in EMT are crucial during OC progression (Figures S2D, E). In brief, the above results display dynamic gene expression profiling during OC progress and suggest that C1 is a malignant epithelial cluster with excessive activation of EMT and proliferation-related pathways.

To probe into the clinical application of the EMT gene set, we used clinical data of 285 OC patients in GSE9891 to search for genes with significant prognostic significance among 41 genes (Figure S2F). The prognosis-related genes *via* univariate Cox analysis are presented in Figure 2D. FAM83D, PHLDB2, HMGA2, SFRP2, TGFB2, TGFBR2, MCRIP1, and DDX5 were risk genes for the prognosis of OC patients, while ELL3 and FOXA2 were protective genes. Then, we constructed a RiskScore model using the above 10 genes with the method of LASSO regression analysis (Figure S2G). The risk score for each OC patient was calculated using the following formula: ELL3× (-0.99548) + FAM83D × (0.39404) + PHLDB2× (0.11511) + HMGA2 × (0.10286) + SFRP2× (0.05705) + FOXA2× (-0.47186) + TGFB2× (0.17726) + TGFBR2× (0.36395) + MCRIP1× (0.4506) + DDX5× (0.27404). A nomogram with 10 gene signatures was constructed to evaluate the 1-, 3- and 5-year



FIGURE 2
Distinct molecular characteristics of epithelial cells in OC and construction of EMT gene set risk factor model. **(A)** The proportion of different cell types in different samples. **(B)** The developmental pseudo-time of epithelial cells inferred by analysis with Monocle2. **(C)** GSVA analysis for C0 and C1. **(D)** The forest plot of the association between 10 gene signature levels and overall survival in the training cohort. HR, 95% CI, and P values were determined by univariate Cox regression analysis. **(E)** A nomogram for predicting the 1-, 3- and 5-year OS for OC patients. **(F)** Calibration curves for nomogram. The light grey line indicates the ideal reference line where predicted probabilities would match the observed survival rates. The red dots are calculated by bootstrapping and represent the performance of the nomogram. The closer the solid red line is to the light grey line, the more accurately the model predicts survival. **(G)** The ROC curves of the diagnostic performance of the model. **(H)** Risk score distribution, survival status, and gene expression profile of patients in high-risk score group and low-risk score group in the training dataset. **(I)** Kaplan Meier curve of OS in a high-risk group and low-risk group of the training dataset.

survival rates of OC patients (Figure 2E). Subsequently, the calibration curve of the nomogram showed that the predicted survival was in good agreement with the actual survival of the OC cohort (Figure 2F). In addition, the AUC for the OS was 0.722 (Figure 2G). To verify the accuracy of our model, KM survival curves were plotted in the GSE9891 cohort and TCGA cohort, respectively. According to the median RiskScore, patients were divided into low-risk and high-risk groups. We found that the higher the RiskScore, the higher the mortality rate (Figure 2H and Figure S2H). Besides, the KM survival curve

showed that there were significant differences in prognosis between the two groups ($p < 0.0001$ in the GSE9891 cohort, Figure 2I; $p = 0.018$ in the TCGA cohort, Figure S2I).

FAM83D was a potential oncogene related to the poor prognosis of OC

In order to portray the essential characteristics of malignant epithelial cells, the C1 cluster was further subdivided into 9 different subgroups based on the Umap graph (Figure 3A). Firstly, we used cellchat to study the communication network among 9 subclusters. The data showed that S5 had a significant cell ratio in C1 and closely interacted with other subclusters, indicating its leading role in OC (Figure 3B). We further explored the biological functions of different subclusters through GSVA analysis (Figure S3A). As shown in Figures 3C; S5 was enriched in multiple HALLMARK pathways compared with other subclusters, such as G2M_CHECKPOINT, E2F_TARGETS, APOPTOSIS, DNA_REPAIR, and P53_PATH WAY. Hence, we deduced that S5 dominates the carcinogenic role



FIGURE 3
Malignant epithelial marker FAM83D overexpression is associated with a poor prognosis in OC. **(A)** The tSNE plot of nine subgroups generated from malignant epithelial cells. **(B)** The circle chart showed the number and intensity of interaction between different cell subgroups. The size of the circle is proportional to the number of cells in cell subgroups. **(C)** GSVA analysis score of S0-S8 in hallmark pathway. **(D)** The Venn diagram shows the intersection gene of S5 top100 Markers and riskscore model. **(E)** Positive expression ratio of FAM83D in S0-S8. **(F)** qRT-PCR and Western blot analysis of FAM83D expression in the ovarian cell lines and the normal ovarian cell line OSE. The right panel, the level of proteins was quantified by gray analysis. *P < 0.05 *vs.* OSE cells (t-test, N = 3). **(G)** The expression levels of FAM83D between OC and adjacent tissues in the Oncomine database. **(H)** The GSEA shows the high FAM83D group was associated with the G2M checkpoint and WANG_CISPLATIN_RESPONSE_AND_XPC_UP in the TCGA OC dataset. **(I)** Kaplan–Meier plots indicate the overall survival and progression-free survival for OC patients categorized by FAM83D expression. **(J)** FAM83D was related to survival in different subgroups (grade, stage, etc.) of OC patients.

in OC. Furthermore, we detected the expression of RiskScore model genes in S5. Interestingly, FAM83D was the only overlapping gene among the top 100 genes of S5 and RiskScore model genes (Figure 3D). It is worth mentioning that S5 specifically highly expressed FAM83D (Figures S3B, 3E). Thus, we named S5 as FAM83D$^+$ malignant epithelial cells (FAM83D$^+$ MEC). Taken together, these data suggest that FAM83D$^+$ MEC has a crucial role in OC progression.

Then, we analyzed the expression of FAM83D in cell lines and tissues. qRT-PCR and Western blot showed that FAM83D is significantly upregulated in HEY and SKOV3 cell lines (Figure 3F). Moreover, the Oncomine database showed that FAM83D was more highly expressed in OC tissues than in adjacent control ($p < 0.001$) (Figure 3G). Besides, the TCGA database demonstrated that FAM83D was considerably elevated in various cancers, including OC, BRCA, PAAD, and UCEC (Figure S3C).

To further study the role of FAM83D in OC progression, subjects in the TCGA OC dataset were divided into two groups based on the median value of FAM83D. GSEA showed that the high FAM83D group was related to the G2M checkpoint and WANG_CISPLATIN_RESPONSE_AND_XPC_UP (Figure 3H). In GSE45553, the expression of FAM83D in the cisplatin-resistant group was higher than cisplatin-sensitive group ($p = 0.0002$) (Figure S3D). These results indicate that FAM83D might regulate cell proliferation and induce cisplatin resistance.

Subsequently, we focused on the prognosis effect of FAM83D in 1656 OC patients. KM displayed that high FAM83D expression was significantly relevant to poor OS (p=4.5e-06) and progression-free survival (p=0.00018) in OC (Figure 3I). We also determined the relationship between FAM83D and clinical features by Forest plot. In clinical stages analysis, patients with high FAM83D had a poor prognosis in the stageIII/IV (hazard ratio: 1.42; 95% CI: 1.13-1.78) or gradeIII (hazard ratio:1.38; 95%CI: 1.06-1.79). Furthermore, in the chemotherapy analysis, high FAM83D expression of patients treated with platina or taxol was related to poor survival (Figure 3J). Taken together, these results suggested that FAM83D is an indicator of poor prognosis of OC.

FAM83D promoted the progression of OC *in vitro*

To further examine the role of FAM83D, we constructed FAM83D knockdown cell lines by transfecting siRNA duplexes (Figures S4A, B). FAM83D knockdown inhibited the proliferation capacity and was more sensitive to cisplatin toxicity (A2780-siCON: IC50 = 5.443μg/ml, A2780-siFAM83D: IC50 = 2.647μg/ml; SKOV3-siCON: IC50 = 14.31μg/ml, SKOV3-siFAM83D: IC50 = 7.763μg/ml) (Figures 4A, B). Moreover, cisplatin-induced apoptosis cells were significantly increased in FAM83D knockdown cells ($p = 0.0001$ in A2780; $p= 0.016$ in SKOV3) (Figure 4C). These results suggest that FAM83D knockdown increases the cisplatin sensitivity of OC cells.

In order to study the role of FAM83D on the migration and invasion of OC cells, Scratch and Transwell experiments were carried out. Scratch assay revealed that the number of migrated cells was decreased in FAM83D knockdown cells ($p < 0.05$, Figure 5A). Transwell showed FAM83D knockdown reduced migration and invasion ability of SKOV3 and HEY ($p < 0.01$, Figure 5B). Therefore, FAM83D was considered to be an irritation to OC migration and invasion.

GSEA analysis showed FAM83D was related to EMT (Figure 5C). Western blot (Figure 5D) and qRT-PCR (Figure 5E) showed that FAM83D knockdown increases the expression of E-cadherin (epithelial marker), and decreases the expression of N-cadherin and vimentin (mesenchymal markers), indicating that FAM83D knockdown could inhibit EMT, thus inhibiting OC progression. These results suggest that FAM83D induces the migration and invasion of OC cells by EMT.

MiR-138-5p targeted the expression of FAM83D in OC

Three databases (TargetScan, miRDB, and Starbase) were used to forecast possible miRNAs targeting the FAM83D 3'-UTR (Figure 6A), and miR-138-5p was identified.

In order to confirm whether FAM83D was a target of miR-138-5p, we constructed luciferase vectors containing the miR-138-5p binding site wild-type or mutated FAM83D 3 '-UTR (Figure 6B). The luciferase reporter assay suggested that miR-138-5p mimics notably reduced the luciferase activity of FAM83D-wt in SKOV3 and HEY cells ($p < 0.05$, respectively; Figure 6C). Western blot and qRT-PCR confirmed that miR-138-5p mimics decrease the expression of FAM83D in SKOV3 and HEY cells (Figure 6D). The above results showed that FAM83D was a novel target of miR-138-5p in OC cells.

To determine the role of miR-138-5p in OC, we overexpressed the expression of miR-138-5p in OC cells by transfection mimics. CCK8 confirmed that the miR-138-5p overexpression observably restrained cell proliferation in SKOV3 and HEY cells (Figure 6E). Scratch and Transwell assay indicated that miR-138-5p overexpression remarkably restrained the migration and invasion ability of SKOV3 and HEY cells (Figures 6F, G, respectively). Meanwhile, miR-138-5p overexpression increased E-cadherin and inhibited N-cadherin and vimentin, suggesting miR-138-5p inhibited the EMT pathway (Figure 6H). Therefore, these results confirmed that miR-138-5p inhibited OC cells' migration, invasion, and EMT.



FIGURE 4
FAM83D deficiency inhibits the proliferation and promoted cisplatin sensitivity. **(A)** CCK8 assays for proliferation rates in SKOV3 and HEY cells transfected with siCON and siFAM83D. **(B)** Cisplatin sensitivity in SKOV3 and HEY cells transfected with siCON and siFAM83D. **(C)** Apoptotic cells detected by flow cytometry in siCON and siFAM83D treated or untreated cells with cisplatin. siCON, cells transfected with siRNA negative control; siFAM83D, cells transfected with FAM83D siRNA. ns, no significance, *P < 0.05, **P < 0.01 and ***P < 0.001.

MiR-138-5p eliminates the effect of FAM83D on the progress of OC cells

To confirm whether miR-138-5p restrains the migration and invasion of OC cells by regulating FAM83D, the JLV-Puro-FAM83D expression plasmid was used to construct FAM83D overexpression OSE and SKOV3 cell lines ($OSE_{FAM83D\text{-}OE}$ and $SKOV3_{FAM83D\text{-}OE}$) for rescue experiment. MiR-138-5p mimics observably inhibited the expression of FAM83D in $OSE_{FAM83D\text{-}OE}$ and $SKOV3_{FAM83D\text{-}OE}$ cells (Figures 7A, B). Scratch (Figures 7C and S5A) and Transwell assays (Figure 7D) confirmed that the FAM83D overexpression significantly promoted cell migration, while miR-138-5p mimics weakened the ability of cell migration in $OSE_{FAM83D\text{-}OE}$ and $SKOV3_{FAM83D\text{-}OE}$ cells. The result of CCK8 demonstrated miR-138-5p mimics could abrogate the facilitation of FAM83D in cell proliferation (Figure S5B).

Furthermore, overexpression of FAM83D markedly inhibited the expression of E-cadherin and enhanced the expression of N-cadherin and vimentin, whereas miR-138-5p mimics reversed the role of FAM83D on EMT (Figures 7E, F). These results confirmed that miR-138-5p could inhibit EMT phenotype partially by targeting FAM83D, and miR-138-5p/FAM83D/EMT axis is conducive to the progression of OC cells.

Discussion

OC is a heterogeneous disease with distinct genetic and molecular features (20). Therefore, accurate prognoses and efficacious therapies are urgently needed. A combination of scRNA-seq technology and bioinformatics methods has shown to be an efficient tool for us to identify key genes associated with OC and get a prefound understanding of its pathogenesis and heterogeneity. Consistent with them (21, 22), we confirmed the great heterogeneity of OC. We identified different cell types of OC, including two epithelial cell types, mesenchyme cells, macrophages, B cells, and T cells. Two groups of epithelial cells accounted for about 80% of the total cells, which supports that OC mostly originates from the epithelium (23). Through trajectory analysis and CNV analysis (24), we found that malignant epithelial cells (C1) highly expressed the malignant marker PAX8 and genes related to DNA replication pathways and WNT, KRAS, and other carcinogenic pathways. It has been proven that dysregulated ribosomal organisms occur in the progress of most spontaneous cancers (25). Intriguingly, in this study, the overall upregulation of ribosomal biogenesis-related genes was found to be accompanied by the deterioration of ovarian epithelial cells (Figures S1A, B). This suggested that ribosomal biogenesis has a critical role the progression of OC.



FIGURE 5
FAM83D knockdown suppresses cell migration, invasion, and EMT in HEY and SKOV3 cells. **(A)** Migratory ability by scratch wound healing assay. The closure areas were quantified by comparison with the original wound area by Image J. Scale bar: 500 μm. The migration activity is expressed as mean ± SEM. *p < 0.05 *vs.* cells transfected with siCON cells (t-test, N = 3). **(B)** Representative images of migration and invasion were detected by transwell assay in SKOV3 and HEY cells transfected with siCON and siFAM83D cell groups. Scale bar: 200 μm. **p < 0.01 *vs.* cells transfected with siCON cells, ***p < 0.001 *vs.* cells transfected with siCON cells (t-test, N = 3). **(C)** GSEA analysis of the relationship between FAM83D and EMT. **(D)** The protein expression of GAPDH, E-cadherin, N-cadherin, and vimentin detected by Western blot in SKOV3 and HEY cells transfected with siCON and siFAM83D. The right panel, the level of proteins was quantified by gray analysis. *P < 0.05, ** P< 0.01 and *** P< 0.001 *vs.* cells transfected with siCON cells (t-test, N = 3). **(E)** The mRNA expression of GAPDH, E-cadherin, N-cadherin, and vimentin were detected by qRT-PCR in SKOV3 and HEY cells transfected with siCON and siFAM83D. *p < 0.05 *vs.* cells transfected with siCON cells, **p < 0.01 *vs.* cells transfected with siCON cells, ***p < 0.001 *vs.* cells transfected with siCON cells (t-test, N = 3).

Moreover, our data revealed multiple subpopulations of epithelial cells, particularly a predominant subgroup (FAM83D$^+$ MEC). FAM83D is a microtubule-associated protein that can induce polar ejection forces and mitotic progression (26). Previous studies have confirmed that high expression of FAM83D in various cancers and the upregulation of FAM83D may be related to cancer progression (27–29). Consistently, we found FAM83D$^+$ MEC exhibited mostly ligand-receptor pairs with other clusters and was associated with multiple carcinogenic pathways, including DNA replication and repair, and P53 pathways. Altogether, attention to the molecular characteristics of epithelial cell subsets contributed to our understanding of OC.

EMT can transform epithelial phenotypic characteristics into aggressive and metastatic characteristics, resulting in poor prognosis (30–32). Recently, more studies have shown that cells resistant to carboplatin and/or paclitaxel have a mesenchymal phenotype, indicating that EMT is a key factor in treating drug sensitivity (33–35). Recently, a single-cell transcriptional analysis confirmed the activation of EMT, enabling OC cells to obtain additional chemoresistance and metastasis (21). In this study, trajectory analysis of scRNA-seq data was conducted to characterize EMT changes during OC development. Consistent with previous studies, our results showed that the EMT-related pathway was activated during C0 to C1 differentiation. Previous studies have reported that additional ablation of CDH1 (E-cadherin) induces the persistence of OC diffusion and ascites accumulation, enhances peritoneal metastasis, and leads to poor prognosis (36, 37). Furthermore, CDH2 (N-cadherin) has been reported to enhance the adhesion to organotypic meso mimetic cultures and peritoneal explant and increase invasive and migratory properties (38). Herein, the expression of CDH1 was downregulated, and CDH2 was upregulated in the malignant epithelial clusters. In summary, our results strongly suggested that malignant epithelial cells have the molecular characteristics of excessive EMT.

Considerable evidence suggests that the heterogeneity of OC is the main reason for poor prognosis. The traditional clinicopathological indicators, e.g., tumor size, vascular infiltration, and TNM stage, cannot meet the current needs for predicting the individual prognosis (39, 40). Therefore,



FIGURE 6
FAM83D is a novel target of miR-138-5p in OC cells. **(A)** Bioinformatics analysis predicted that FAM83D was the target of miR-138-5p. **(B)** Schematic representation of the FAM83D 3′ -UTR containing the binding site for miR-138-5p. **(C)** The dual luciferase reporter assay confirmed that FAM83D is the direct target gene of miR-138-5p. ns, no significance, *P < 0.05, **P < 0.01 and ***P < 0.001 *vs*. cells transfected with NC mimics cells (t-test, N = 3) **(D)** Western Blot and qRT-PCR analysis of FAM83D expression in SKOV3 and HEY cells transfected with miR-138-5p mimics or NC mimics for 48 h The protein levels were quantified by grey analysis and showed in the right panel. **P < 0.01 and ***P < 0.001 *vs*. cells transfected with NC mimics cells (t-test, N = 3). **(E)** Growth curve of HEY and SKOV3 cells upon transfection with NC mimics and miR-138-5p mimics examined by CCK8 assay. *P < 0.05 *vs*. cells transfected with NC mimics cells (t-test, N = 3). **(F)** Scratch wound healing showed the migratory capacities of HEY and SKOV3 cells upon transfection with NC mimics and miR-138-5p mimics. Scale bar: 500 μm. **P < 0.01 *vs*. cells transfected with NC mimics cells (t-test, N = 3). **(G)** Cell migration and invasion ability were measured by Transwell assays. Scale bar: 200 μm. **P < 0.01 and ***P < 0.001 *vs*. cells transfected with NC mimics cells (t-test, N = 3). **(H)** Western blot and qRT-PCR analysis of the expression of EMT markers. The protein levels were quantified by grey analysis and showed in the right panel. *P < 0.05, **P < 0.01 and ***P < 0.001 *vs*. cells transfected with NC mimics cells (t-test, N = 3).

screening prognostic markers that can fully represent biological characteristics is of huge value in the individualized prevention and treatment of OC patients. In this study of OC, we identified malignant epithelial cells with EMT signatures using 10x single-cell technology. Furthermore, combined with GEO and TCGA databases, we constructed a RiskScore prognostic model. The AUC, nomogram, and KM curves were performed to demonstrate the model's effectiveness in predicting OC risk. Furthermore, we demonstrated the carcinogenic effect of FAM83D, a key gene in the model, *in vitro*, indicating FAM83D is related to poor prognosis. Similarly, another EMT-related five-gene panel, including FAM83D, can predict the prognosis of HCC reliably and independently (41). In conclusion, we integrated single-cell sequencing and public databases to construct a model that may function as a powerful prognostic indicator for OC patients and demonstrated the clinical value of FAM83D, which may be a therapeutic target for OC.



FIGURE 7
Overexpression of miR-138-5p reverses the facilitation of FAM83D on OC cell progression and EMT. **(A, B)** qRT-PCR and Western blot analysis of FAM83D expression in $OSE_{FAM83D\text{-}OE}$ and $SKOV3_{FAM83D\text{-}OE}$ cells transfected with miR-138-5p mimics. The protein levels were quantified by grey analysis and showed in the lower panel. *P < 0.05, **P < 0.01 and ***P < 0.001 (test =3). **(C)** The closure areas in the scratch wound healing assays were shown by Image J **P < 0.01 and ***P < 0.001 (test =3). **(D)** Migration of $OSE_{FAM83D\text{-}OE}$ and $SKOV3_{FAM83D\text{-}OE}$ cells transfected with miR-138-5p mimics were determined by Transwell assay. Scale bar: 200 μm. **P < 0.01 and ***P < 0.001 (test =3). **(E, F)** qRT-PCR and Western blot analysis of EMT markers in $OSE_{FAM83D\text{-}OE}$ and $SKOV3_{FAM83D\text{-}OE}$ cells transfected with miR-138-5p mimics. The protein levels were quantified by grey analysis and showed in the right panel. *P < 0.05, **P < 0.01 and ***P < 0.001 (test =3) NC, cells infected with the JLV-Puro-FAM83D expression plasmid negative control; FAM83D-OE, cells infected with the JLV-Puro-FAM83D expression plasmid.

There are few reports on the transcriptional regulation of FAM83D. Recently, studies have demonstrated that microRNA (miRNA) offers a novel sight to study the regulation mechanism of cancer (42–44). We used bioinformatics methods to find that miR-138-5p could target FAM83D. A previous study showed that miR-138-5p represses breast cancer cell invasion, migration, and EMT through targeting regulation of RHBDD1 (45). Another study suggested that miR-138-5p is a vital regulator of chemoresistance in colorectal cancer cells by acting on the NFIB-Snail1 axis (46). MiR-138-5p regulates the tumor microenvironment to inhibit NSCLC cells by targeting PD-L1/PD-1 (47). Herein, we confirmed that miR-138-5p directly binds to the FAM83D sequence through luciferase reporter gene assay. MiR-138-5p overexpression could decrease the mRNA and protein levels of FAM83D. We further studied the biological significance of miR-138-5p in OC *in vitro* and confirmed that the ectopic expression of miR-138-5p remarkably repressed the migration, invasion, and EMT of OC cells. Taken together, we confirmed that miR-138-5p inhibit OC progression by targeting FAM83D.

Conclusions

ScRNA-seq uncovered new molecular features of OC malignant epithelial cells. Moreover, a robust RiskScore prognostic model was constructed combined with public databases. Through integrated analysis, FAM83D was identified as an indicator of poor prognosis of OC and its carcinogenic role in OC cells was further confirmed *in vitro*. In addition, we discovered that miR-138-5p could regulate FAM83D expression, which could be a novel target for OC therapy. Our work clarified the molecular characteristics of OC malignant epithelial cells based on scRNA-seq, thus providing clinical guidance for the prognosis and treatment of OC patients.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author contributions

JL, XZ, and WY conceived and designed the study. JL and ZFL carried out all experiments and wrote the manuscript. HZ and JG participated in bioinformatics analysis. ZBL supported the study. YG, XZ, and WY supervised the study. CY, XZ and WY revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

The study is supported by the National Natural Science Foundation of China (No. 81672838, No. 82002739), Beijing Municipal Science and Technology Commission (No. Z181100001718193), Beijing Natural Science Foundation (No. 7212039) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding (No. XMLX201705).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.1055648/full#supplementary-material

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA: Cancer J Clin* (2021) 71(1):7–33. doi: 10.3322/caac.21654

2. Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue RS, Henzler CM, et al. Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. *Cancer Res* (2020) 80(20):4335–45. doi: 10.1158/0008-5472.Can-20-0521

3. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. *Nat Med* (2021) 27(1):141–51. doi: 10.1038/s41591-020-1125-8

4. Wang X, Li X, Lin F, Sun H, Lin Y, Wang Z, et al. The lnc-Ctslp8 upregulates Ctsl1 as a competitive endogenous rna and promotes ovarian cancer metastasis. *J Exp Clin Cancer Res: CR* (2021) 40(1):151. doi: 10.1186/s13046-021-01957-z

5. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol* (2016) 2 (4):482–90. doi: 10.1001/jamaoncol.2015.5495

6. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole-genome characterization of chemoresistant ovarian cancer. *Nature* (2015) 521(7553):489–94. doi: 10.1038/nature14410

7. Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, Wang XV, et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. *J Natl Cancer Institute* (2014) 106(5):dju049. doi: 10.1093/jnci/dju049

8. Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T, et al. High-grade serous tubo-ovarian cancer refined with single-cell rna sequencing: Specific cell subtypes influence survival and determine molecular subtype classification. *Genome Med* (2021) 13(1):111. doi: 10.1186/s13073-021-00922-x

9. Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer Cell* (2021) 39(7):928–44.e6. doi: 10.1016/j.ccell.2021.04.004

10. Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. *Cancer Cell* (2020) 37 (2):226–42.e7. doi: 10.1016/j.ccell.2020.01.003

11. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* (2018) 36(5):411–20. doi: 10.1038/nbt.4096

12. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612

13. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell rna-seq highlights intratumoral heterogeneity in primary

glioblastoma. *Sci (New York NY)* (2014) 344(6190):1396–401. doi: 10.1126/science.1254257

14. Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol* (2014) 32(4):381–6. doi: 10.1038/nbt.2859

15. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using cellchat. *Nat Commun* (2021) 12(1):1088. doi: 10.1038/s41467-021-21246-9

16. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: An r package for comparing biological themes among gene clusters. *Omics: J Integr Biol* (2012) 16 (5):284–7. doi: 10.1089/omi.2011.0118

17. Hänzelmann S, Castelo R, Guinney J. Gsva: Gene set variation analysis for microarray and rna-seq data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7

18. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models *Via* coordinate descent. *J Stat Softw* (2010) 33(1):1–22. doi: 10.18637/jss.v033.i01

19. Zhao H, Gao Y, Chen Q, Li J, Ren M, Zhao X, et al. Rad51ap1 promotes progression of ovarian cancer *Via* tgf-β/Smad signalling pathway. *J Cell Mol Med* (2021) 25(4):1927–38. doi: 10.1111/jcmm.15877

20. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, et al. Classification of high-grade serous ovarian cancer using tumor morphologic characteristics. *JAMA Netw Open* (2022) 5(10):e2236626. doi: 10.1001/jamanetworkopen.2022.36626

21. Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, et al. A single-cell landscape of high-grade serous ovarian cancer. *Nat Med* (2020) 26(8):1271–9. doi: 10.1038/s41591-020-0926-0

22. Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, et al. Single-cell rna sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. *Clin Cancer Res* (2022) 28(16):3590–602. doi: 10.1158/1078-0432.Ccr-22-0296

23. Bell DA. Origins and molecular pathology of ovarian cancer. *Modern Pathol* (2005) 18 Suppl 2:S19–32. doi: 10.1038/modpathol.3800306

24. Manasa P, Sidhanth C, Krishnapriya S, Vasudevan S, Ganesan TS. Oncogenes in high grade serous adenocarcinoma of the ovary. *Genes Cancer* (2020) 11(3-4):122–36. doi: 10.18632/genesandcancer.206

25. Pelletier J, Thomas G, Volarević S. Ribosome biogenesis in cancer: New players and therapeutic avenues. *Nat Rev Cancer* (2018) 18(1):51–63. doi: 10.1038/nrc.2017.104

26. Fulcher LJ, He Z, Mei L, Macartney TJ, Wood NT, Prescott AR, et al. Fam83d directs protein kinase Ck1α to the mitotic spindle for proper spindle positioning. *EMBO Rep* (2019) 20(9):e47495. doi: 10.15252/embr.201847495

27. Wang D, Han S, Peng R, Wang X, Yang XX, Yang RJ, et al. Fam83d activates the Mek/Erk signaling pathway and promotes cell proliferation in hepatocellular carcinoma. *Biochem Biophys Res Commun* (2015) 458(2):313–20. doi: 10.1016/j.bbrc.2015.01.108

28. Yang XX, Ma M, Sang MX, Zhang XY, Zou NY, Zhu SC. Knockdown of Fam83d enhances radiosensitivity in coordination with irradiation by inhibiting emt *Via* the Akt/Gsk-3β/Snail signaling pathway in human esophageal cancer cells. *OncoTargets Ther* (2020) 13:4665–78. doi: 10.2147/ott.S245681

29. Yin C, Lin X, Wang Y, Liu X, Xiao Y, Liu J, et al. Fam83d promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the Akt/Mtor pathway in non-Small-Cell lung cancer. *Cell Oncol (Dordrecht)* (2020) 43(3):395–407. doi: 10.1007/s13402-020-00494-9

30. Liang H, Zhao X, Wang C, Sun J, Chen Y, Wang G, et al. Correction to: Systematic analyses reveal long non-coding rna (Ptaf)-mediated promotion of emt and invasion-metastasis in serous ovarian cancer. *Mol Cancer* (2020) 19(1):173. doi: 10.1186/s12943-020-01296-1

31. Jinesh GG, Brohl AS. Classical epithelial-mesenchymal transition (Emt) and alternative cell death process-driven blebbishield metastatic-witch (Bmw) pathways to cancer metastasis. *Signal Transduction Targeted Ther* (2022) 7 (1):296. doi: 10.1038/s41392-022-01132-6

32. Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, et al. Stat3-emt axis in tumors: Modulation of cancer metastasis, stemness and therapy response. *Pharmacol Res* (2022) 182:106311. doi: 10.1016/j.phrs.2022.106311

33. Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, et al. Mir-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. *Oncogene* (2016) 35(3):323–32. doi: 10.1038/onc.2015.84

34. Zhang J, Guan W, Xu X, Wang F, Li X, Xu G. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression *Via* Smad4/Zeb1/Mir-142-5p in human ovarian cancer. *Oncogene* (2021) 40(30):4906–18. doi: 10.1038/s41388-021-01891-6

35. Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of emt in tumor progression and metastasis. *J Hematol Oncol* (2022) 15 (1):129. doi: 10.1186/s13045-022-01347-8

36. Shi M, Whorton AE, Sekulovski N, Paquet M, MacLean JA, Song Y, et al. Inactivation of Trp53, pten, Rb1, and/or Cdh1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis. *Biol Reprod* (2020) 102 (5):1055–64. doi: 10.1093/biolre/ioaa008

37. Lin HW, Fu CF, Chang MC, Lu TP, Lin HP, Chiang YC, et al. Cdh1, Dlec1 and Sfrp5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. *Epigenomics* (2018) 10(11):1397–413. doi: 10.2217/epi-2018-0035

38. Klymenko Y, Johnson J, Bos B, Lombard R, Campbell L, Loughran E, et al. Heterogeneous cadherin expression and multicellular aggregate dynamics in ovarian cancer dissemination. *Neoplasia (New York NY)* (2017) 19(7):549–63. doi: 10.1016/j.neo.2017.04.002

39. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the uk collaborative trial of ovarian cancer screening (Ukctocs): A randomised controlled trial. *Lancet (London England)* (2016) 387(10022):945–56. doi: 10.1016/s0140-6736(15)01224-6

40. Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. *Mol Cancer* (2022) 21(1):114. doi: 10.1186/s12943-022-01588-8

41. Zhu G, Xia H, Tang Q, Bi F. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. *Cancer Cell Int* (2021) 21(1):166. doi: 10.1186/s12935-021-01864-5

42. Quirico L, Orso F, Cucinelli S, Paradzik M, Natalini D, Centonze G, et al. Mirna-guided reprogramming of glucose and glutamine metabolism and its impact on cell Adhesion/Migration during solid tumor progression. *Cell Mol Life Sci: CMLS* (2022) 79(4):216. doi: 10.1007/s00018-022-04228-y

43. Patel M, Wang Y, Bartom ET, Dhir R, Nephew KP, Matei D, et al. The ratio of toxic-to-Nontoxic mirnas predicts platinum sensitivity in ovarian cancer. *Cancer Res* (2021) 81(15):3985–4000. doi: 10.1158/0008-5472.Can-21-0953

44. Cho JG, Kim SW, Lee A, Jeong HN, Yun E, Choi J, et al. Microrna-dependent inhibition of Wee1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. *Mol Ther Nucleic Acids* (2022) 29:803–22. doi: 10.1016/j.omtn.2022.08.028

45. Zhao C, Ling X, Li X, Hou X, Zhao D. Microrna-138-5p inhibits cell migration, invasion and emt in breast cancer by directly targeting Rhbdd1. *Breast Cancer (Tokyo Japan)* (2019) 26(6):817–25. doi: 10.1007/s12282-019-00989-w

46. Xu W, Chen B, Ke D, Chen X. Microrna-138-5p targets the nfib-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance. *Cancer Cell Int* (2020) 20:475. doi: 10.1186/s12935-020-01573-5

47. Song N, Li P, Song P, Li Y, Zhou S, Su Q, et al. Microrna-138-5p suppresses non-small cell lung cancer cells by targeting pd-L1/Pd-1 to regulate tumor microenvironment. *Front Cell Dev Biol* (2020) 8:540. doi: 10.3389/fcell.2020.00540

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 26 January 2023
DOI 10.3389/fonc.2023.1039654

OPEN ACCESS

EDITED BY
Michelle Matter,
University of Hawaii Cancer Center,
United States

REVIEWED BY
Weiping Teng,
The First Affiliated Hospital of China
Medical University, China
David Alvarado,
Washington University in St. Louis,
United States

*CORRESPONDENCE
Murilo Vieira Geraldo
murilovg@unicamp.br

SPECIALTY SECTION
This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 08 September 2022
ACCEPTED 10 January 2023
PUBLISHED 26 January 2023

CITATION
Alves LF and Geraldo MV (2023) *MiR-495-3p* regulates cell migration and invasion in papillary thyroid carcinoma.
Front. Oncol. 13:1039654.
doi: 10.3389/fonc.2023.1039654

MiR-495-3p regulates cell migration and invasion in papillary thyroid carcinoma

Letícia Ferreira Alves and Murilo Vieira Geraldo*

Department of Structural and Functional Biology, University of Campinas (UNICAMP), São Paulo, Brazil

Background: Papillary thyroid carcinoma (PTC) is the most prevalent histotype of thyroid cancer and the presence of BRAFV600E mutation in these tumors is related to the malignancy and prognosis of the disease. In recent years attention has been focused on the role of microRNAs in the biology of PTC cells, especially in their role in the modulation of pathways related to tumorigenesis. DLK1-DIO3-derived miRNAs have been shown to play important roles in tumor context and are globally downregulated in PTC.

Methods: Based on a previous in silico target prediction and gene enrichment analysis, we identified miR-495-3p as the candidate with the highest tumor suppressor potential role in PTC among DLK1-DIO3-derived miRNAs. We used bioinformatics and an in vitro model of miR-495-3p overexpression to further understand the influence of this molecule on the tumorigenic processes of PTC.

Results: Overexpression of miR-495-3p impaired cell migration and invasion of PTC cells harboring the BRAFV600E mutation and affected the expression of targets predicted in the bioinformatic analysis, such as TGFB2, EREG and CCND1.

Conclusion: Overall, our results indicate that the loss of miR-495-3p expression during PTC development might play an important role in its progression.

KEYWORDS

***miR-495-3p*, papillary thyroid carcinoma, cell migration, cell invasion, bioinformatics**

1 Introduction

Carcinoma is the prevalent form in which malignant tumors are observed in the thyroid gland. The group of well-differentiated carcinomas includes the follicular subtype (FTC), which represents about 15% of cases, and the papillary subtype (PTC), which represents about 85% of all cases of thyroid cancer in the US (1). The best characterized genetic alteration in PTC is the one that encodes the $BRAF^{V600E}$ oncoprotein. This mutation is the most common genetic alteration found in PTC and is associated with more aggressive biological properties of papillary carcinoma (2–4). In the last decade, the number of studies

exploring the abnormal expression of miRNAs as molecular markers for cancer diagnosis and prognosis increased in the literature (5–8). Regarding the biological role of miRNAs, their interaction with mRNAs constitutes an overly complex network, especially in humans. A single miRNA regulates a miscellaneous of mRNAs, and a single gene might be under the control of a wide variety of miRNAs, generating a robust network of post-transcriptional regulation involved in multiple cell processes, such as cell differentiation, metabolic regulation, and apoptosis (9).

Studies on distinct types of cancer show correlation between tumorigenesis and miRNA roles (10–13). Moreover, diverse miRNAs present tumor promoter or suppressor roles, indicating the intricate function of these molecules in the development and progression of thyroid neoplasms (14–16).

The aberrant levels of miRNAs found in thyroid tumor samples and the relationship of these molecules with classic oncogenes and tumor suppressors highlight this subtype of RNAs as important therapeutic targets. The long arm of chromosome 14 hosts the largest miRNA cluster in the human genome, known as DLK1-DIO3 region. This region is highly conserved and harbors more than 50 miRNA genes (17). The large-scale analysis of miRNA expression in a PTC murine model revealed the global downregulation of several miRNAs situated in the DLK1-DIO3 genomic region (18). Altogether, the comprehension of the functional role of these molecules in thyroid cells offers tumorigenesis intervention perspectives and remains unclear.

The intricate and complex post-transcriptional regulation network which miRNAs determine is the principal limitation for functional analysis involving these molecules. To overcome this limitation, we previously performed the bioinformatic prediction of the potential regulation network controlled by DLK1-DIO3 region miRNAs (19). The results pointed *miR-495-3p* as one of the top-ranked miRNAs from DLK1-DIO3 region regarding the number of targets involved with several cell processes. Importantly, when only targets involved with cancer-related processes or oncogenes were analyzed, *miR-495-3p* stood out in the first position of the ranking.

The literature indicates involvement of *miR-495-3p* with the suppression of several types of tumors (e.g., mammary, prostate, gastric and glioma), by targeting key factors for carcinogenesis (20–23). As *miR-495-3p* emerges as a promising candidate in the study of thyroid oncogenesis and progression, this study aimed to investigate the biological role of *miR-495-3p* in PTC development and progression.

2 Material and methods

2.1 *miR-495-3p* target prediction

MiRWalk version 2.0 (24) was used to predict miRNA-target sequence-based interactions by 12 different algorithms. Only interactions predicted by TargetScan and 6 more algorithms were considered valid. The resulting list was filtered to only keep genes that were found upregulated in our Differential Gene Expression analysis. The construction of a Protein-Protein Interaction (PPI) network and STRING enrichment analysis of predicted targets were performed using Cytoscape 2.0 (25).

2.2 Differential expression analysis

To investigate PTC's expression landscape, we downloaded 570 RNA-seq datasets available for normal and tumor thyroid samples on GDC Data Portal (TCGA-THCA project, downloaded on August 4th, 2020). R programming language (version 4.0.4) was used for data manipulation and analysis. We started our analysis by joining all the data on a single file, samples that were of no use for our analysis were excluded. The exclusion factors were: non-PTC tumor samples; non-primary (metastatic) samples; non-BRAF^{V600E} point mutations; samples with non-available metadata and with unknown BRAF status. By the end of sample trimming the resulting 536 samples were split into 58 normal (healthy tissue) samples and 478 primary tumor samples.

With data filtered and joined, quality control and differential expression analysis were performed using the DESeq2 Bioconductor package (26). Genes were considered differentially expressed when abs(log2FC) > 0.58 and P-adjusted value <0.01. Category netplot was created using the DOSE Bioconductor package (27), where the top five enriched categories among DEG genes are shown.

miRNA-seq files were also downloaded from GDC Data Portal as described above. Given the low levels and wide variation of miRNAs expression, only paired samples from our dataset were used to analyze *miR-495-3p* expression. 55 pairs of samples were kept after filtering. Fold changes were calculated after normalization of counts.

2.3 Weighted gene coexpression network analysis

We used WGCNA to identify coexpressed genes in the list of differentially expressed genes (DEG) generated as described above. WGCNA analysis was performed following procedures indicated by the package developers (28). Soft thresholding was set to 5. The genes in the modules obtained were crossed with the list of *miR-495-3p* predicted targets to find target representation for each module. GO enrichment analyses were performed for the modules with target representation >10% and composed of more than 80 genes.

2.4 Cell culture

N-Thy-ORI, TPC-1, BCPAP and KTC cell lines were a courtesy of Professor Edna Teruko Kimura (University of Sao Paulo, Brazil). Cell lines were cultivated in conditions described in Table 1.

All experimental groups were maintained in a 37°C incubator with 5% of CO_2 with antibiotics (penicillin 100 U/mL and streptomycin 100 µg/mL, Thermo Fisher) and antifungal (amphotericin B 1 µg/mL, Thermo Fisher).

2.5 DNA constructs and plasmid transfection

The *MIR495* genomic region was amplified and cloned in pGEM-T Easy Vector System (Promega). Then, the insert was removed from the plasmid by double digestion with *Xho*I and *Eco*RI and ligated in MSCV puro vector previously digested with the cited restriction

TABLE 1 Cell line features and culture conditions.

Cell line	Features	Genetic alterations	Media	FBS	Supplementation
TPC-1	Derived from PTC	RET/PTC1 (spontaneous)	DMEM	5%	–
BCPAP	Derived from PTC	$BRAF^{V600E}$ (spontaneous)	DMEM	10%	–
KTC-2	Derived from ATC	$BRAF^{V600E}$ (spontaneous)	RPMI	5%	–
N-Thy-ORI	Normal immortalized	–	RPMI	10%	2 mM L-glutamine

enzymes. The presence and integrity of the insert was confirmed by PCR amplification and sanger sequencing. Transfection of the plasmid constructions were performed using Lipofectamine 2000 (Thermo Fisher) according to manufacturer's instructions. Following transfection, the cell lines were maintained in cell medium containing 5 µg/mL of puromycin. Overexpression of *miR-495-3p* was confirmed by RT- qPCR.

2.6 Scratch assay

Forty-to-sixty thousand cells were plated in a 24 well plate, in triplicates. Following transfection, a wound was made by scratching the plate with a pipette tip. Photomicrographs were taken with a Nikon Eclipse E600 microscope (40x magnification), after 16 and 24 h of the scratch making and the quantitative analysis was performed with ImageJ by measuring the wound's area of each acquired field and comparing the results statistically.

2.7 Transwell assay

The cell migration and invasion assays were performed using 8.0 µm pore membrane inserts (Millipore, MA). Twenty thousand cells were resuspended in cell media containing 0.5% fetal bovine serum and plated in the upper chamber compartment. The lower compartment was filled with DMEM with 10% FBS. After 12 h, the cell media was removed, and the chamber was washed twice with PBS. The cells in the upper compartment were removed with cotton swabs and the cells in the lower compartment were then fixed, stained with 0.5% crystal violet, and photographed under a Nikon Eclipse E600 microscope (100x magnification). For cell invasion, 30 µL of extracellular matrix gel (ECM Gel from Engelbreth-Holm-Swarm murine sarcoma - liquid, BioReagent 8.42 µg) diluted on DMEM were plated on top of each insert and after 1h the same number of cells were seeded on top of the ECM coat.

2.8 Expression analysis

For total RNA extraction, $2x10^5$ cells were seeded in a 60 mm cell culture plastic dish. Cells were collected in TRIzol after 72 h. RNA extraction protocol was performed according to Chomczynski & Sacchi, (29). *miR-495-3p* and RNU6B (endogenous control) expression were analyzed using Taqman MiRNA Assays Kit (Thermo Fisher), specific for each molecule. Ten nanograms of total RNA was used for cDNA synthesis using Taqman miRNA Reverse Transcription kit (Thermo Fisher), according to the manufacturer instructions.

cDNA synthesis for *miR-495-3p* predicted targets was performed according to *Invitrogen's M-MLV* instructions with 1 µg of total RNA per reaction. RPL19 was used as endogen control. The oligonucleotides used for qPCR reaction are shown in Supplementary Table 1. For quantification of the cDNA for miRNAs we performed the RT-qPCR reactions according to *Taqman® MiRNA Assay* kit instructions, and for the targets we used the *SYBR Master Mix* (Thermo Fisher). Expression of extracellular matrix and adhesion genes was quantified using Human Extracellular Matrix & Adhesion Molecules Array plate (Thermo-Fisher), according to the manufacturer's instructions. All amplification reactions were performed using universal cycling conditions in 7500 Real-Time PCR System (Applied Biosystems) and the differential gene expression was calculated according to Pfaffl, (30) for all reactions apart from the array plates were analyzed using ThermoCloud platform (Thermo Fisher).

2.9 Statistical analysis

All statistical analyses were performed using GraphPad Prism (version 5.0). Graphically, results are presented as mean ± standard errors of the means (SEMs). Functional and gene expression data were submitted to Student's t test for comparisons between two groups and statistical significance was considered when $P<0.05$.

3 Results

3.1 *miR-495-3p* is downregulated in PTC

The underexpression of *miR-495-3p* in PTC was previously identified by our group both in human samples and in the transgenic mouse model Tg-Braf (18). Additionally, a computational analysis pointed *miR-495-3p* as the key modulator of cancer-related genes in thyroid cancer datasets (Marson & Alves et al.; in review). The analysis of TCGA expression data from 55 paired samples revealed that *miR-495-3p* is underexpressed in tumor context (Figure 1A). In this cohort, we observed downregulation of *miR-495-3p*, with no significant impact of $BRAF^{V600E}$mutation on the expression of *miR-495-3p* in PTC samples (Figures 1A, B). Moreover, *miR-495-3p* is downregulated in the three thyroid cancer cell lines analyzed (TPC-1, BCPAP, KTC) in comparison with the non-tumoral N-Thy-ORI cells, with lower levels observed in the cell lines with a more aggressive phenotype (Figure 1C). Interestingly, the



FIGURE 1
miR-495-3p is down regulated in PTC. **(A)** Boxplot (Whiskers: Tukey) shows the differential expression between normal samples and tumor samples bearing or not the $BRAF^{V600E}$ mutation (individual normalized RPM values/mean of normalized RPM values for the normal group). **(B)** Waterfall plot for 55 paired tumor/healthy tissue samples analyzing *miR-495-3p* expression shows that the downregulation of *miR-495-3p* is a common event during carcinogenesis. Expression data for the plot is from TCGA. Gray bars on the waterfall plot represent $BRAF^{V600E}$-positive samples and white bars the PTC samples where the mutation is absent. **(C)** Bar plot shows the expression of *miR-495-3p* in four different thyroid cell lines. As previously described, the malignant cells have progressive decreases in *miR-495-3p* expression. Data are presented as the average of triplicates of a single experiment and bars represent the standard errors of the means (SEMs). *P<0.05, ***P<0.001.

expression of *miR-495-3p* is significantly lower in the $BRAF^{V600E}$-positive cell lines (BCPAP and KTC-2) when compared to the tumoral $BRAF^{V600E}$-*negative* cell line (TPC-1).

3.2 Post-transcriptional regulation by *miR-495-3p* in PTC

The pipeline used from bioinformatic investigation to functional validation is illustrated on Figure 2A. To take a better view on PTC's gene expression landscape we performed differential gene expression (DGE) analysis of 536 samples (58 healthy tissue samples and 478 tumor samples) (Figures 2B, C). To assess the impact of *BRAF* mutation status on the post-transcriptional regulation by *miR-495-3p* in the PTC samples, we used the likelihood-ratio test (LRT) to test for any differences across the grouping variable. Following LRT, we used a clustering tool to group the differentially expressed genes (DEGs) based on the changes on their expression across the sample groups. Clusterization of LRT-derived DEGs reinforced the distinction of $BRAF^{V600E}$ and *BRAF WT* PTC samples regarding their expression levels (Figure 3A). Focusing on the two largest clusters (>100 genes), we observed that the $BRAF^{V600E}$ PTC samples show higher differences from the healthy tissue. Next, we used the pairwise approach to look for DEGs between healthy tissue (normal) samples and PTC $BRAF^{V600E}$ samples. Category netplot of these DEGs revealed the top 5 enriched categories among these genes: cell junction assembly, regulation of cell morphogenesis, extracellular matrix organization, extracellular structure organization and regulation of GTPase activity (Figure 3B).

Based on the observations above and in the support of literature on the relevance of the $BRAF^{V600E}$ mutation to malignancy and prognosis of PTC, we decided to further explore the influence of *miR-495-3-p* in this condition. The list of *miR-495-3p* predicted targets was filtered to exclude downregulated DEGs on the PTC



FIGURE 2
Differentially expressed genes in PTC. **(A)** Pipeline of investigation shows, briefly, the steps we followed to validate *miR-495-3p* influence on PTC progression. **(B)** Heatmap of the top 200 DEG (abs(log2FC) > 0.58 and adjusted p value < 0.01). **(C)** Volcano plot of DGE analysis. Upregulated genes are shown in red and down regulated genes in blue.

BRAF^{V600E} context, meeting the inverse correlation expected from the miRNA-target dynamics. PPI network of the resulting filtered list revealed the potential interactions among the predicted targets. Functional enrichment of network nodes revealed processes that are essential for tumor progression, such as Focal adhesion, Proteoglycans in cancer, PI3K-Akt signaling pathway and Regulation of actin cytoskeleton (Figure 4A).

Ten genes from the list of *miR-495-3p* targets were selected for experimental validation. We generated BCPAP (PTC BRAF^{V600E}-positive cell line) stably overexpressing *miR-495-3p* (Figure 4B). Overexpression of *miR-495-3p* in these cells resulted in the downregulation of *TGFB2*, *CCND1*, *EPHA10* and *EREG*, corroborating our bioinformatic findings (Figure 4C).

3.3 *miR-495-3p* targets representation in WGCNA modules

Well known for its utility on identifying coexpressed gene modules in large datasets, weighted gene coexpression network analysis (WGCNA) was used to further understand the correlation patterns among DEGs. The analysis resulted in 31 modules of coexpressed genes (Figures 5A, B). Functional enrichment was performed for all WGCNA modules (Figure 5C) and the modules were then crossed with the list of *miR-495-3p* predicted targets (Figure 5D). Interestingly, the modules with high target representation include enriched categories mostly related to cell adhesion (Figure 5D, blue), angiogenesis (Figure 5D, grey60) and extracellular matrix organization (Figure 5D, purple and pink).

3.4 *miR-495-3p* overexpression impairs cell migration and invasion

Considering the recurrence of terms related to cell adhesion and migration, we decided to investigate the influence of *miR-495-3p* on these processes. As shown in Figure 6, overexpression of *miR-495-3p* significantly impaired cell migration both in the scratch and Transwell assay (Figures 6A, B). Cell invasion was also significantly impaired in front of *miR-495-3p* overexpression (Figure 6B). Importantly, the overexpression of *miR-495-3p* also induced a transcriptional reprogramming of adhesion/migration-related genes. As shown in figure 7, we observed a major impact on the expression of key genes for cell migration and invasion such as *MMP3, FN1, TIMP3* and *VCAN* (Figure 7A), most of them whose aberrant expression is associated with increased risk in PTC (Figure 7B). Finally, no significant changes were observed on the expression of genes related to thyroid cell differentiation (*TG*, *TPO*, *SLC5A5* and *TSHR*)



FIGURE 3
DEGs main clusters reinforce the $BRAF^{V600E}$ signature on PTC samples and functional enrichment reveals top modulated processes. **(A)** The plot shows the result of the clustering of the top 1000 DEGs obtained using LRT for the mRNA seq dataset. Min genes = 100. **(B)** Category netplot shows the correlation between the genes associated with the top five most enriched GO terms and the fold changes of the significant genes associated with these terms (colors).



FIGURE 4
Overexpression of *miR-495-3p* causes a shift in the expression of predicted targets. **(A)** Predicted targets of *miR-495-3p* whose expression were found increased in PTC were submitted to a STRING enrichment analysis using Cytoscape. Targets with higher fold changes are shown in more intense red tones. Chart colors (borders) represent different KEGG enrichment categories. **(B)** Bar plot shows the expression of *miR-495-3p* among transfected different clones. The one with the highest expression (BCPAP_495 (1)) was used to perform functional validation. **(C)** Bar plot shows the log2FC of some of *miR-495-3p* predicted targets in BCPAP cells over expressing the miRNA. Data is presented as the average of at least three independent experiments and bars represent the standard errors of means (SEMs). *RPL19* was used as the endogen control. Student's tests were used to compare expression of each gene between groups (*P<0.05, **P<0.01, ***P<0.001).

key players on the tumor progression and survival rates in PTC (data not shown).

4 Discussion

Alterations in miRNAs' expression pattern between healthy and tumor tissues have been reported in several types of cancer, establishing a link between the modulation of these molecules and tumor development and progression (31). MiRNAs with abnormal expression in cancer cells may act as oncogenes or tumor suppressors, depending on the targets they regulate. The biological function of DLK1-DIO3-derived miRNAs in PTC has been previously explored by our group, revealing decreased expression of *miR-495-3p* in PTC samples and in thyroid tumor tissue derived from transgenic mice (18). Here we show that *miR-495-3p* plays a central role in the regulation of cell migration and invasion in PTC, key processes for tumor progression, suggesting a potential tumor suppressor role for this molecule in PTC.

MiR-495-3p's capacity of interacting with several key modulators of cancer-related processes (e.g., cell growth, migration, apoptosis, and angiogenesis) indicates its potential as an important regulator of



FIGURE 5
miR-495-3p target representation on WGCNA modules. **(A)** WGCNA dendrogram of differentially expressed genes (clustered based on 1-TOM) **(B)** Heatmap of the topological overlap matrix. Rows and columns correspond to single genes, light colors represent low topological overlap, and progressively darker orange and red colors represent higher topological overlap. **(C)** Bar plot shows the top enriched category for each module from WGCNA. **(D)** Bar plot shows GO enriched categories for WGCNA modules (>80 genes) with higher *miR-495-3p* target representation. Numbers on the right indicate the target representation for each module.

tumor cells malignancy (21, 23, 32–34). The analysis of the PTC expression landscape revealed that larger shifts of gene expression are found between healthy tissue and tumor samples with the $BRAF^{V600E}$ mutation, confirming data from the literature. In our panel of cell lines, we observed a pattern of decreasing *miR-495-3p* expression according to the degree of differentiation of each cell line, where the cell line related to a less aggressive phenotype (TPC-1) showed levels of expression closer to the non-malignant cell line (N-Thy-ORI) whereas the more aggressive cell lines (BCPAP, KTC-2) presented lower levels of expression of the molecule.

The bioinformatic investigation of *miR-495-3p* targets revealed a myriad of genes potentially regulated by this molecule in PTC, several of them involved with crucial processes for cancer genesis and progression. We observed that a selected panel of predicted target genes were modulated in response to the *miR-495-3p* overexpression in thyroid cancer cell line. To narrow our focus and better understand how this complexity of predicted interactions could be affecting PTC development and progression, we crossed the data obtained for *miR-495-3p* predicted targets with the analysis of PTC expression landscape. The results showed the involvement of this miRNA in



FIGURE 6
miR-495-3p overexpression impairs PTC cell's migration and invasion. **(A)** Figure shows BCPAP cells stably transfected with *miR-495-3p* after 0, 16 and 24h of the wound making in the scratch assay. Cells transfected with the empty vector were used as control (40x magnification). Bar plot on the right shows the difference in wound area between the control and transfected groups after 16 and 24h of the wound making. **(B)** Representative photomicrographs of cells that migrated through the Transwell in the migration and invasion assays (100x magnification). Bar plots on the right show the count of migrated/invaded cells of both control groups and the stably transfected with *miR-495-3p*. Data is presented as one representative experiment (from three independent experiments), bars represent the standard errors of means (SEMs). Student's t tests were used to compare values between the two groups (*P<0.05, **P<0.01).

highly enriched processes in PTC (e. g. Focal adhesion, Proteoglycans in cancer, PI3K-Akt signaling pathway and Regulation of actin cytoskeleton). Further, we crossed the list of predicted targets with WGCNA modules of DEG to check the distribution of *miR-495-3p* predicted targets on these groups of coexpressed genes. Higher target representation was found in the modules whose enrichment revealed categories similar to the ones previously identified.

To validate the involvement of *miR-495-3p* in the most recurrent processes obtained in our bioinformatics investigation, we performed functional assays and observed that the overexpression of this miRNA alters the pattern of migration and invasion of BCPAP cells. These results corroborate previous studies concerning the biological function of the whole DLK1-DIO3 region which revealed the involvement of the miRNAs from this region in the regulation of focal adhesion and extracellular matrix remodeling, essential processes for cell migration (35–37). Further, we have shown that the overexpression of this single miRNA resulted in the reprogramming of important genes for cell migration, adhesion,



FIGURE 7
miR-495-3p overexpression modulates migration/adhesion related genes. **(A)** Bar plots show genes modulated by *miR-495-3p* overexpression. We considered modulated, genes from the Human Extracellular Matrix and Adhesion Molecules plate whose expression suffered a 0.25 alteration on fold-change. **(B)** Box plots show association between the expression of some genes shown on "a" and risk on PTC (TCGA data downloaded from cBioPortal).

and extracellular matrix remodeling. Some of the modulated genes, such as *MMP3, FN1, COL12A1* and *VCAN* have their expression associated with high risk and moderate extrathyroidal invasion in PTC samples, according to TCGA data. We believe that the modulations on gene expression are consistent with those observed in the functional assays and reinforce the influence of *miR-495-3p* on the above-mentioned processes. Overall, our results reveal *miR-495-3p* as a promising tumor suppressor which plays a role in the regulation of key processes on genesis and progression of PTC.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

Experiments were planned and designed by both authors. LA carried out all bioinformatic and functional analysis. Manuscript was written and revised by both authors. All authors contributed to the article and approved the submitted version.

Funding

This work was financed by the Sao Paulo Research Foundation (grant: 2017/21660-0 and 2017/3635-8).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1039654/full#supplementary-material

References

1. Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. *N Engl J Med* (2016) 375(11):1054–67. doi: 10.1056/NEJMra1501993

2. Kim S, Lee KE, Myong JP, Park J, Jeon YK, Min HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. *World J Surg* (2012) 36 (2):310–7. doi: 10.1007/s00268-011-1383-1

3. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, et al. Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. *Oncogene* (2011) 30 (28):3153–62. doi: 10.1038/onc.2011.44

4. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. *J Clin Endocrinol Metab* (2005) 90(12):6373–9. doi: 10.1210/jc.2005-0987

5. Chou C-K, Yang KD, Chou F-F, Huang C-C, Lan Y-W, Lee Y-F, et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. *J Clin Endocrinol Metab* (2013) 98(2):E196–205. doi: 10.1210/jc.2012-2666

6. Geraldo MV, Fuziwara CS, Friguglieti CUM, Costa RB, Kulcsar MAV, Yamashita AS, et al. MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report. *Arq Bras Endocrinol Metabol* (2012) 56(8):552–7. doi: 10.1590/S0004-27302012000800015

7. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. *J Clin Endocrinol Metab* (2008) 93(5):1600–8. doi: 10.1210/jc.2007-2696

8. Geraldo MV, Kimura ET. Integrated analysis of thyroid cancer public datasets reveals role of post-transcriptional regulation on tumor progression by targeting of immune system mediators. *PloS One* (2015) 10(11):e0141726. doi: 10.1371/journal.pone.0141726

9. Bartel DP. MicroRNAs: Target recognition and regulatory functions. *Cell* (2009) 136 (2):215–33. doi: 10.1016/j.cell.2009.01.002

10. Chan B, Manley J, Lee J, Singh SR. The emerging roles of microRNAs in cancer metabolism. *Cancer Letters.* (2015) 356:301–8. doi: 10.1016/j.canlet.2014.10.011

11. Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. *Oncotarget* (2015) 6(9):6472–98. doi: 10.18632/oncotarget.3052

12. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. *Nat Rev Cancer.* (2011) 11(12):849–64. doi: 10.1038/nrc3166

13. Pallante P, Battista S, Pierantoni GM, Fusco A. Deregulation of microRNA expression in thyroid neoplasias. *Nat Rev Endocrinol* (2014) 10(2):88–101. doi: 10.1038/nrendo.2013.223

14. Colamaio M, Puca F, Ragozzino E, Gemei M, Decaussin-Petrucci M, Aiello C, et al. miR-142–3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1. *J Clin Endocrinol Metab* (2015) 100(1):E59–69. doi: 10.1210/jc.2014-2280

15. Lima CR, Geraldo MV, Fuziwara CS, Kimura ET, Santos MF. MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells. *BMC Cancer* (2016) 16(1):108. doi: 10.1186/s12885-016-2146-z

16. Xiong Y, Kotian S, Zeiger MA, Zhang L, Kebebew E. MiR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. *PloS One* (2015) 10(8):e0130496. doi: 10.1371/journal.pone.0130496

17. Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, et al. The microRNAs within the DLK1-DIO3 genomic region: Involvement in disease pathogenesis. *Cell Mol Life Sci* (2013) 70:795–814. doi: 10.1007/s00018-012-1080-8

18. Geraldo MV, Nakaya HI, Kimura E. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. *Oncotarget* (2017) 8(6):9597–607. doi: 10.18632/oncotarget.14162

19. Marson LA, Alves LF, Sielski MS, Vicente CP, Kimura ET, Geraldo MV. DLK1-DIO3 region as a source of candidate tumor suppressor miRNAs in papillary thyroid carcinoma. *PREPRINT* (2020) 53(9):1689–99. doi: 10.21203/rs.3.rs-121114/v1

20. Chen H, Wang X, Bai Ju, He A. Expression, regulation and function of miR-495 in healthy and tumor tissues. *Oncol Lett* (2017) 13:2021–6. doi: 10.3892/ol.2017.5727

21. Li J-Z, Wang Z-L, Xu W-H, Li Q, Gao L, Wang Z-M. MicroRNA-495 regulates migration and invasion in prostate cancer cells *Via* targeting akt and mTOR signaling. *Cancer Invest* (2016) 34(4):181–8. doi: 10.3109/07357907.2016.1156690

22. Ye Y, Zhuang J, Wang G, He S, Zhang S, Wang G, et al. MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1. *Exp Ther Med* (2017) 15(1):1150–8. doi: 10.3892/etm.2017.5467

23. Zhang B, Yuan F, Liu J, Li Y, Zhou F, Liu X, et al. Hsa-miR-495 acts as a tumor suppressor gene in glioma *via* the negative regulation of MYB. *Mol Med Rep* (2016) 14 (1):977–82. doi: 10.3892/mmr.2016.5327

24. Sticht C, de la Torre C, Parveen A, Gretz N. Mirwalk: An online resource for prediction of microrna binding sites. *PloS One* (2018) 13(10):e0206239. doi: 10.1371/journal.pone.0206239

25. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: Network analysis and visualization of proteomics data. *J Proteome Res* (2019) 18(2):623–632. doi: 10.1021/acs.jproteome.8b00702

26. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8

27. Yu G, Wang LG, Yan GR, He QY. DOSE: An R/Bioconductor package for disease ontology semantic and enrichment analysis. *Bioinformatics* (2015) 31(4):608–9. doi: 10.1093/bioinformatics/btu684

28. Langfelder P, Horvath S. WGCNA: An r package for weighted correlation network analysis. *BMC Bioinf* (2008) 9:559. doi: 10.1186/1471-2105-9-559

29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* (1987) 162 (1):156–9. doi: 10.1016/0003-2697(87)90021-2

30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. *Nucleic Acids Res* (2001) 29(9):e45. doi: 10.1093/nar/29.9.e45

31. Croce CM. Causes and consequences of microRNA dysregulation in cancer. *Nat Rev Genet* (2009) 10:704–14. doi: 10.1038/nrg2634

32. Bastle RM, Oliver RJ, Gardiner AS, Pentkowski NS, Bolognani F, Allan AM, et al. In silico identification and in vivo validation of miR-495 as a novel regulator of motivation for cocaine that targets multiple addiction-related networks in the nucleus accumbens. *Mol Psychiatry* (2018) 23:434–43. doi: 10.1038/mp.2016.238

33. Chen Y, Luo D, Tian W, Li Z, Zhang X. Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer. *Oncol Rep* (2017) 37(6):3581–9. doi: 10.3892/or.2017.5621

34. Mao Y, Li L, Liu J, Wang L, Zhou Y. MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. *Oncotarget* (2016) 7(32):51223–36. doi: 10.18632/oncotarget.9981

35. Fan C, Lin Y, Mao Y, Huang Z, Liu AYA, Ma H, et al. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2. *Oncotarget* (2016) 7(16):21825–39. doi: 10.18632/oncotarget.7989

36. Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y, et al. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression. *Cell Death Dis* (2016) 7:e2159. doi: 10.1038/cddis.2016.27

37. Zhang H, Li S, Yang X, Qiao B, Zhang Z, Xu Y. MIR-539 inhibits prostate cancer progression by directly targeting SPAG5. *J Exp Clin Cancer Res* (2016) 35(1):60. doi: 10.1186/s13046-016-0337-8

frontiers | Frontiers in Oncology

TYPE Review
PUBLISHED 13 February 2023
DOI 10.3389/fonc.2023.1118171

OPEN ACCESS

EDITED BY
Michelle L. Matter,
Tulane University, United States

REVIEWED BY
Erdem Tabdanov,
College of Medicine, The Pennsylvania State University, United States
Christina Stuelten,
National Cancer Institute (NIH), United States

*CORRESPONDENCE
Aneta Škarková
aneta.skarkova@natur.cuni.cz

SPECIALTY SECTION
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

RECEIVED 07 December 2022
ACCEPTED 31 January 2023
PUBLISHED 13 February 2023

CITATION
Legátová A, Pelantová M, Rösel D, Brábek J and Škarková A (2023) The emerging role of microtubules in invasion plasticity. *Front. Oncol.* 13:1118171. doi: 10.3389/fonc.2023.1118171

The emerging role of microtubules in invasion plasticity

Anna Legátová[1,2], Markéta Pelantová[1,2], Daniel Rösel[1,2], Jan Brábek[1,2] and Aneta Škarková[1,2]*

[1]Department of Cell Biology, Charles University, Prague, Czechia, [2]Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Vestec u Prahy, Czechia

The ability of cells to switch between different invasive modes during metastasis, also known as invasion plasticity, is an important characteristic of tumor cells that makes them able to resist treatment targeted to a particular invasion mode. Due to the rapid changes in cell morphology during the transition between mesenchymal and amoeboid invasion, it is evident that this process requires remodeling of the cytoskeleton. Although the role of the actin cytoskeleton in cell invasion and plasticity is already quite well described, the contribution of microtubules is not yet fully clarified. It is not easy to infer whether destabilization of microtubules leads to higher invasiveness or the opposite since the complex microtubular network acts differently in diverse invasive modes. While mesenchymal migration typically requires microtubules at the leading edge of migrating cells to stabilize protrusions and form adhesive structures, amoeboid invasion is possible even in the absence of long, stable microtubules, albeit there are also cases of amoeboid cells where microtubules contribute to effective migration. Moreover, complex crosstalk of microtubules with other cytoskeletal networks participates in invasion regulation. Altogether, microtubules play an important role in tumor cell plasticity and can be therefore targeted to affect not only cell proliferation but also invasive properties of migrating cells.

KEYWORDS

microtubules, invasion plasticity, amoeboid, mesenchymal, cancer, 3D migration

1 Introduction

Cells have adopted various migration/invasion modes which vary in their nature of force generation and dependency on cell-cell and cell-extracellular matrix (ECM) adhesion. Collective migration requires both cell-cell and cell-ECM adhesion, mesenchymal migration omits intercellular adhesion but strongly relies on cell-ECM contact and amoeboid migration can be independent of adhesion altogether. The large range of invasion modes ensures physiological migration of cells in various environments, but in the hands of cancer cells it has become a dangerous trait. The ability of cancer cells to utilize one or more of the invasion modes, and to switch among them in response to changing circumstances is termed invasion plasticity and represents a large complication on the road to treating metastatic disease.

Due to the requirements for dynamic changes of cell morphology during invasion, it is evident the invading cell must readily reorganize its cytoskeleton (1–4). This is even more prominent in cells with high invasion plasticity that switch among the elongated mesenchymal and round amoeboid phenotype, in a process termed mesenchymal-amoeboid transition (MAT) or amoeboid-mesenchymal transition (AMT) (5–7). During MAT, cells retract protrusions, round up and initiate intense membrane blebbing, which may be due to loss in cell adhesivity (8) and/or fast increase of hydrostatic pressure that detaches the membrane from the cortex (9). The rapid membrane blebbing is often reduced after transitioning to a motile amoeboid phenotype. Opposingly, AMT is accompanied by loss of blebbing activity and cell elongation through stabilization of protrusions.

Actin reorganization in migrating cells is well described, with RhoGTPases playing a key role (10). Rac and Cdc42 are known to be responsible for promoting actin polymerization leading to the formation of lamellipodia and filopodia as a result of stimulating the Arp2/3 complex through activation of either WASP or SCARE/WAVE family (11–13). Due to its function as an initiator of lamellipodia formation, Rac is preferentially active at the leading edge of migrating cells (14). Opposingly, RhoA activity is higher at the cell rear, where its signaling mediates rear contractility and detachment (15). This is achieved by RhoA-mediated activation of ROCK, which in turn leads to phosphorylation (therefore inhibition) of MLCP, resulting in higher phosphorylation of the myosin light chain and increased contractility (16, 17). ROCK is also responsible for the phosphorylation of LIMK and subsequently of cofilin, which stabilizes actin bundles (18), resulting in formation of stress fibers. Due to the different requirement of protrusive activity and contractility of mesenchymal and amoeboid migration, each is dominated by different RhoGTPase signaling. Amoeboid cells require RhoA/ROCK signaling for their migration and inhibition of this pathway leads to a switch to mesenchymal invasion (19, 20). Similarly, inducing constitutively active RhoA/ROCK can induce the mesenchymal-to-amoeboid switch (21, 22). On the other hand, Rac signaling promotes mesenchymal traits (23, 24).

Moreover, signaling mediated by RhoGTPases interconnects the actin cytoskeleton with the microtubule (MT) network (Figure 1). For example, in fibroblasts, MTs growth stimulates Rac1 activity, therefore promoting lamellipodia formation (25, 26). On the other hand, Rac1/Cdc42 signaling can lead to MTs polymerization *via* stathmin inhibition (27, 28), and RhoA can promote stabilization of MTs by its effector, mDia1, which interacts with MTs and induces their capping and alignment with actin bundles (29, 30).

Apart from actin, MTs also interact with intermediate filaments (IFs). This can be either indirectly through linker proteins, such as APC, or directly, and the mutual interaction stabilizes MTs and promotes directed migration (31, 32).

The role of microtubules in cell migration is multifaceted, encompassing intracellular transport and delivery of migration associated cargo, protrusion stabilization and regulation of adhesions (33–35). Less is known about the role of microtubules in 3D migration, yet alone specifically in amoeboid or mesenchymal invasion. Thus, we would like to summarize current knowledge on the role of microtubule cytoskeleton in cell invasion in the context of mesenchymal and amoeboid phenotypes and transitions among them (Figure 2).



FIGURE 1
Microtubules and RhoGTPase signaling. **(A)** The length and stability of MTs in migrating cells is interconnected with RhoGTPase signaling and depends on cell polarization. MTs preferentially elongate toward the leading edge, where their growth is enhanced by various MT end-binding proteins and MT stabilizing proteins, which further interact with numerous Rac1 and Cdc42 activators (see TRIO, TIAM and complex IQGAP/CLIP-170). At the leading edge, Rac1 and Cdc42 signaling contributes to actin polymerization (pink network), but also MT stabilization by phosphorylation of stathmin. MT stability at the leading edge is supported by $p27^{Kip}$, which binds stathmin, preventing its activation. Similarly, $p27^{Kip}$ prevents RhoA pathway activation. On the contrary, at the trailing edge, MTs are depolymerized and Rho/ROCK signaling pathway dominates. Stathmin is not phosphorylated by Rac1 or Cdc42 and remains active – able to sequester tubulin dimers and destabilize MTs. MT disruption leads to release, and thus activation, of GEFH1 from MTs into the cytoplasm, where it promotes activation of the RhoA/ROCK pathway. Roman numerals labeling MTs refer to part **(B)** of the Figure. **(B)** Schematic illustration showing interaction between MT stabilizing (green)/destabilizing (red) factors and RhoGTPases. *Created with BioRender.com.*



	Characteristics of invasion	Characteristics of MTs		MT-associated dominant signaling
Mesenchymal	ECM degradation Numerous strong adhesions Protrusive activity	Leading edge	Stabilized MTs contributing to extension of protrusions	Rac1, Cdc42 mDia, p27Kip P-stathmin inactive GEFH1
		Trailing edge	Depolymerized MTs to enable retraction	RhoA/ROCK stathmin free GEFH1
Amoeboid blebby	Dynamic cell blebbing High contractility ECM degradation not required	MTs unstable, depolymerized		RhoA/ROCK stathmin free GEFH1 within the cell
Amoeboid pseudopodal	Cell blebbing Contractility Extension of pseudopods ECM degradation not required	MTs stabilized in protrusions contributing to navigation		RhoA/ROCK stathmin free GEFH1 at the cell rear

FIGURE 2
Microtubules in different invasive modes. In mesenchymal cells (left), MTs are elongated and stabilized at the front and depolymerized at the retracting end. Mesenchymal cells contain many adhesion structures, such as focal adhesions and invadopodia, that are tightly coupled to MT dynamics. At the leading edge, protrusive activity is regulated by CLASP and SLAIN, which reduce MT catastrophes and contribute to MT growth persistence and elongation of protrusions. In mesenchymal cells, GEFH1 is predominantly bound to MTs, which keeps it in an inactive state. On the other hand, amoeboid migration modes (right) are generally associated with a less stable MT network. Accordingly, increased stathmin activity or downregulation of MT-stabilizing proteins such as mDia2 or p27Kip has been shown to cause the mesenchymal-amoeboid transition (MAT). In pseudopodal amoeboid cells, MTs contribute to circumnavigation and pseudopod extension. In blebby amoeboid cells, MTs are generally disrupted and thus MT-destabilizing drugs, such as vincristine and nocodazole, promote transition to the blebby amoeboid phenotype. In amoeboid cells, GEFH1 can be found free in the cytoplasm, where it activates the RhoA/ROCK pathway. Note that the MTOC is located in front of the nucleus in both mesenchymal and amoeboid cells, although in some pseudopodal amoeboid cells, such as leukocytes, the MTOC is found at the cell rear. This information, together with the basic characteristics of the individual invasion modes, is summarized in the table at the bottom of the figure. *Created with BioRender.com.*

2 Microtubule associated proteins in cell migration

The stability and dynamics of the MT network are modulated by numerous MT associated proteins, some of which have been directly linked to cell invasion plasticity, see below and in Figure 1.

2.1 EB1

End binding protein 1 (EB1) binds +end of MTs, localizing to the distal tips of MTs, the centrosome or MT ends in the mitotic spindle. It is sometimes referred to as the „master regulator of plus-end-tracking proteins (+TIPs)" for its ability to recruit various +TIPs and thus influence not only MTs themselves, but other processes such as membrane-anchoring or actin polymerization as well (36). EB1 binding to MTs stimulates MT elongation, whereas its dissociation causes slower growth of MTs and can influence cells' direction of movement (37). Interestingly, depletion of EB1 has much bigger consequences on migration and protrusion branching in 3D migration. Whereas in 2D there is no significant effect on protrusions and overall migration speed, in 3D, depleting EB1 in mesenchymally migrating cells results in slower invasion and defects in cell directionality (38). In mesenchymal cells, EB1 mediates the binding of proteins CLASP1 and SLAIN2 to MTs, which contributes

to their growth persistence in protrusions by reducing catastrophes (Figure 2). This was shown to be necessary for the invasive shape and 3D mesenchymal invasion (39).

2.2 IQGAP

IQ motif-containing GTPase-activating protein 1/2/3 (IQGAP1-3) are scaffold proteins that integrate many signaling pathways *via* direct and indirect binding of over 90 proteins (40), including RhoGTPases (Figure 1).

IQGAP proteins directly affects the dynamics of both the actin and the microtubule cytoskeleton. IQGAP1 is able to cross-link F-actin filaments (41–44) or by binding barbed ends of actin filaments, inhibit their growth, and protect them from depolymerization (42). IQGAP1 interacts with N-WASP and Arp2/3 forming a complex able to nucleate branched actin filaments (45, 46). In agreement, IQGAP1 was shown to be localized at the leading edges of polarized cells and in the lamellipodia of motile cells (43, 44, 46–48). One of the main functions of IQGAP1 is anchoring MTs to the cell cortex enabling directional movement.

With regard to MTs in migration, one of the main functions of IQGAP1 is anchoring MTs to the cell cortex enabling directional movement, a process regulated by multiple mechanisms. IQGAP1 interacts with +TIP CLIP-170 and activated Rac1 and Cdc42 (but not RhoA) forming a tripartite complex leading MTs to the cortex to areas with activated Rac1/Cdc42. Impaired binding of IQGAP1 caused by mutation at its C-terminus results in multiple leading edges in cells (49, 50). In addition, IQGAP1 and active Rac1/Cdc42 form a complex with adenomatous polyposis coli (APC) cortical filaments and depletion of either APC or IQGAP1 inhibits polarized migration (51). Another +TIP linking IQGAP1 to MTs at the cell cortex is protein SKAP (+TIP known to bind to EB1), yet again, disrupting the interaction of SKAP and IQGAP1 impairs cell migration (52).

Overall, IQGAP1 overexpression can promote cell migration and neurite outgrowth, while its depletion leads to decreased cell migration (47, 53, 54), providing evidence that the actin/microtubule crosstalk is necessary for polarized, directed cell movement.

2.3 Navigators

Navigator proteins 1-3 (NAV1/2/3) are microtubule + end binding proteins that are implicated in axon guidance and neurite outgrowth in the brain (55, 56). In neurons, NAV1 is localized at the neurite tips where it binds actin-rich domains and crosslinks with the MTs in an EB1-dependant manner (55, 57). It also forms a complex with the protein TRIO, a guanine nucleotide exchange factor (GEF) known to activate Rac1 and RhoG (56–59). Thus, NAV1 does not influence MTs polymerization per se, but it promotes +end rescue and prevents catastrophes in the F-rich-domain periphery. Cells depleted in NAV1 were shown to be defective in migration during embryonic development (55). Similarly, NAV3 binds to MTs +end *via* EB1 and increases their polarized growth in response to EGF signaling in cancer cells by protecting them from catastrophes. Cells overexpressing NAV3 displayed higher MTs acetylation and resistance to nocodazole treatment, both distinctive of stabilized MTs (60). On the other hand, cells depleted in NAV3 showed more random migration and lost the ability to migrate persistently after EGF induction (60). Since persistent, protrusion dependent migration is characteristic of mesenchymal cells, Navigators are likely to be more crucial for mesenchymal than amoeboid migration.

2.4 Stathmin 1

Stathmin, also known as oncoprotein 18 (Opt18), is an important microtubule destabilizing protein able to cause MT depolymerization. Two modes of action have been described – first, by stimulating MT catastrophes (61), and second, by sequestrating αβ tubulin dimers to prevent their assembly (62) - which seems to depend on environmental conditions (63).

Stathmin is regulated by several kinases, and its phosphorylation on at least one of its four serins suppresses its destabilizing activity (64, 65). Moreover, Stat3 can bind to stathmin at its tubulin-binding site to prevent its function (66). Similarly, p27Kip (see further) binding prevents stathmin-regulated MT destabilization (67, 68). Of note, p27Kip expression is partially regulated by Stat3 (69).

The regulation of stathmin phosphorylation is key for cell migration, as it enables creation of a gradient of MT stability from the leading edge to the trailing edge. At the leading edge, high levels of Cdc42 and Rac1 prevent stathmin activation (27) resulting in stabilized MTs in these parts of the cell. On the trailing edge stathmin is not phosphorylated by Cdc42 or Rac and its MTs-destabilizing activity increases, leading to MT network disassembly and proper contraction of this end during cell movement (70) (Figure 1).

Generally, stathmin is a strong pro-migratory factor as evidenced by a number of studies (67, 71), although in in certain conditions its inhibition may stimulate migration (66). This may be dependent on whether the cells utilize the mesenchymal and amoeboid type of invasion, since stathmin SQ18E, which is unable to undergo inhibitory phosphorylation, was directly linked to promotion of the round, amoeboid-like phenotype in sarcoma cells (71) (Figure 2).

2.5 P27^{Kip}

Protein p27^{Kip} is mainly known for its nuclear role as a cyclin dependent kinase inhibitor and thus inhibitor of cell cycle progression (72). However, it also plays an important role in the cytoplasm where it interacts with other proteins through its C-terminal domain to modulate cell motility and tumor progression (67, 73, 74). One of the interaction partners of p27^{Kip} is stathmin, binding of which inhibits stathmin´s activity leading to more stable MTs. In mesenchymal cells, this interaction limits migratory potential (67, 68) (Figure 1).

P27^{Kip} does not influence only the MT network, it also affects actin filament reorganization. It was shown that p27^{Kip} is able to interact with RhoA, inhibiting its ability to bind GEFs and thus preventing its activation (73). Cytoplasmatic p27^{Kip} affects the actin cytoskeleton also indirectly *via* Rac1 dependent actin rearrangement and polymerization, leading to an increase in cell migration (75).

Of note, transformed fibroblasts lacking p27 ^{Kip} adopted a rounded morphology with cortical actin formation and loss of β1 integrin clusters, corresponding to the mesenchymal-amoeboid transition (76). Here both the actin and MT cytoskeleton were altered, showing a synergic effect of p27 ^{Kip} in regulation of cell invasion. In macrophages, p27 ^{Kip} contributes to the onset of mesenchymal migration by inhibition of RhoA/ROCK and lack of p27 ^{Kip} promotes amoeboid migration (77). Collectively, cytoplasmic p27 regulates invasion plasticity and exerts pro-mesenchymal signaling (Figure 2).

2.6 mDia2

mDia2 protein (mammalian homolog of Drosophila diaphanous; also known as DIAPH3) belongs to the group of formins (78), which are proteins involved in actin nucleation and elongation. In addition, mDia2 is able to bind and stabilize MT polymers. Its silencing leads to MT catastrophes and rewires EGFR and ERK signaling, resulting in increased ameboid traits (79). A different study showed that mDia2 in complex with its inhibitor induces amoeboid morphology in cells (80). Accordingly, depletion of mDia2 promoted individual dissemination of amoeboid cells from tumor spheres (81). Importantly, this affects cancer treatment, since cells without mDia2, exerting unstable MTs and amoeboid characteristics, are more susceptible to taxane chemotherapy (82). Overall, mDia2 regulates invasion plasticity through MT stabilization and actin nucleation, and its absence promotes the amoeboid invasion phenotype (Figure 2), suggesting its pro-mesenchymal role.

2.7 GEFH1

An important molecule which interconnects MT dynamics and the actomyosin network is guanosine exchange factor H1 for GTPase RhoA (GEFH1), also known as ARHGEF2. GEFH1 is a one of the few GEFs that associate with polymerized microtubules. Upon MT depolymerization, GEFH1 is released and its guanosine exchange activity increases, leading to higher activation of RhoA and its downstream signaling (Figure 1). This mechanism regulates RhoA activity in different parts of the migrating cell based on MT dynamics (83). Of note, GEFH1 activity can be further potentiated by phosphorylation mediated by Src kinase at the protruding cell edge (84). GEFH1 also affects focal adhesions (FAs) turnover in migrating cells and dysfunctional GEFH1-RhoA activation can disrupt cell motility (83). In lymphoma cells, Stat3 signaling induced destabilization of MTs, which led to the release of GEFH1 and as a result, amoeboid invasion (85).

In summary, the GEFH1-RhoA signaling pathway is induced by MTs destabilization, and its extent promotes either mesenchymal or amoeboid migration. In mesenchymal cells, activation of this pathway by dynamic growth of MTs contributes to protrusion regulation and faster FA turnover. In cells with disrupted MTs, GEFH1-RhoA signaling dominates and induces amoeboid invasion through the RhoA/ROCK pathway (Figure 2).

2.8 MAPs (MAP1B, MAP4, MAP2)

There is also a large group of microtubule associated proteins (MAPs) that bind to MTs, but surprisingly, despite their unified function of stabilizing MT, they have different roles in tumor progression and may function as both pro- and anti-metastatic factors (86–88). We hypothesize that this inconsistency may be due to the different dependency of the amoeboid and mesenchymal migration on the MT network. Specifically, a change in invasive behavior was connected to MAP1B, MAP2, MAP4 and MAP7. Although there is no direct link between invasion plasticity and MAPs described so far, they likely participate by indirect signaling affecting RhoGTPases signaling. For example, MAP1B increases Rac1 activity through interaction with TIAM-1, a Rac1-GEF (89). Another possible mechanism involves phosphorylation of MAP4, which inhibits its MT stabilizing activity (90) and leads to MT disruption, which can increase RhoA through GEHH1 release (91).

2.9 Microtubule organizing center in invasion

For efficient cell migration, cells need to be polarized to maintain directionality of movement. The polarity of the cell is determined, amongst others, by the position of the nucleus and centrosome, forming the nuclear-centrosomal axis. By moving the centrosome, also known as the microtubule organizing center (MTOC), to a different position within the cell, the polarity of a cell can be shifted (92).

When cells gain a mesenchymal migratory phenotype, the centrosome position shifts to a central position in front of the nucleus relative to the future movement of the cell (93). However, this positioning of the centrosome is not a rule, as some studies show localization of the centrosome behind the nucleus (94, 95). Some studies also show that the position of the centrosome is influenced by the geometrical limitation of the cell's surroundings rather than its function (96).

In most amoeboid cells, the location of the MTOC corresponds to mesenchymal cells. Interestingly though, in amoeboid leukocytes, the MTOC is placed behind the nucleus toward the cell rear (Figure 2) (97, 98) and participates in the path finding mechanism. Once the cell's nucleus, which represents the bulkiest part of the cell, and the associated MTOC successfully pass through a pore, protrusions directed to the smaller pores are retracted and the cell continues its movement through the path of least resistance. In this case, disrupting MTs leads to loss of cell coherency and results in fragmentation of the cell (97).

3 Microtubules and cell adhesive structures in invasion

One of the main distinctions between ameboid and mesenchymal migration is their adhesion-dependency. Unlike ameboid cells that do not require stable ECM attachment for their movement, mesenchymally migrating cells establish numerous interactions with

the ECM, including the formation of integrin-based adhesions and proteolytically active structures that enable contact-driven invasion (Figure 2) (99–101). Microtubules play a role in regulation and dynamics of these adhesive structures and are therefore an integral part of signaling regulating adhesion-dependent invasion.

3.1 Focal adhesions

FAs are integrin-based structures responsible for strong adhesion of cells to the ECM. Importantly, they also transmit information about the surrounding environment such as its stiffness by signaling to cytoskeleton associated proteins (102–104). Both Rac and RhoA play role in FA regulation – whereas Rac activity is prominent in the formation of FAs, RhoA activity and Rac inhibition are needed for the maturation of FAs (105, 106).

The main role of MTs within FAs is the transport of integrins and metalloproteases (MMPs) to the cell membrane and the regulation of FAs turnover (107). Although there is no evidence of direct binding of MTs to FAs so far, MTs are known to be guided towards them and anchored in their proximity (108–111). The targeting of mature FAs by MTs results in FA disassembly and cell edge retraction, and preventing the contact between MTs and FAs leads to enlarged FAs (112). In agreement, nocodazole-induced MTs depolymerization also results in larger FAs, whereas MT regrowth after nocodazole washout disassembles FAs (112–114). Nevertheless, these studies were done in 2D environments, where the structure, composition and dynamics of FAs is different than in 3D environments (115), and many mechanisms valid in 2D systems are yet to be verified for 3D migration.

3.2 Podosomes

Podosomes and invadopodia are similar actin-based structures that play role in cell migration and ECM degradation, which is a key feature of mesenchymal invasion. Whereas podosomes are small, dot-like dynamic structures at the leading edge or organized rings exhibiting shallow ECM degradation, invadopodia are larger, irregularly shaped clusters usually localized in the central area of the cell. They are less dynamic and form outstretched extensions into the matrix resulting in deeper and more focused ECM degradation (116).

An intact MT network is necessary for the formation of podosomes since MT depolymerization (induced e.g. by nocodazole) leads to podosomal disassembly (117, 118). MTs are directed to podosomes through +TIPs such as EB1 and CLASPs (119, 120). Targeting of podosomes by MTs is associated with their higher dynamics, and podosomes without MTs show increased stability similarly to FAs (109, 112, 121).

The lifespan of MTs in podosomal structures is regulated by RhoGTPases. Inhibition of RhoA is able to increase the stability of MTs in podosomes, promoting podosome belt assembly (122). Accordingly, activation of RhoA leads to podosome disassembly through the RhoA/ROCK/MLCP axis as actomyosin contractility increases podosomes turnover and their disassembly (123–125). Altering Cdc42 and Rac1 activity was also shown to disrupt podosomes (118, 122, 126).

3.3 Invadopodia

Invadopodia are invasive structures commonly found in various cancers (127). Unlike podosomes, microtubules are not required for invadopodia formation but are necessary for their elongation and correct function (128, 129). Invadopodia first form as a smaller actin-based structure with microtubules excluded from their core (130). Only after maturation of invadopodia, intermediate filaments and microtubules (typically 1-2 MTs per protrusion) invade their structure and allow invadopodia elongation. The microtubules that invade the shaft of invadopodia are stable, whereas at the base of the invadopodium more dynamic MTs are found (128). Accordingly, MT depolymerization does not affect the formation of small invadopodia, but limits their elongation and maturation (129).

One important role of MTs in invadopodia is the polarized trafficking of components such as matrix MMPs to the cell membrane (128, 131, 132). Moreover, the MT associated protein IQGAP1 accumulates in invadopodia where it interacts with exocyst components, and this interaction promotes invadopodia proteolysis by accumulation of MT1-MMP in a MT-regulated manner (133). Also, the exocytosis of MMP2 and MMP9 in melanoma cells is MTs-dependent (132) supporting the role of MTs in trafficking invadopodia components.

4 Microtubules and ECM conditions

It is well known that the conditions of the surrounding environment and its physical properties largely influence the choice of the migration mode. Amoeboid cells favor the large pores found in less dense ECM (134, 135) or confining conditions (100, 136), while mesenchymal cells with their proteolytic activity are able to migrate through stiff ECM and take advantage of the increased number of adhesion sites (101, 135, 137). Unsurprisingly, the MT network is receptive to ECM cues *via* posttranslational modifications that respond to ECM stiffness such as acetylation and glutamylation.

Generally, acetylated MTs are more stable and resilient. The acetylation of α tubulin is driven by α tubulin N-acetyltransferase 1 (αTAT1), and opposingly, histone deacetylase 6 (HDAC6) elicits tubulin deacetylation. Confusingly, both acetylation and deacetylation have been linked to accelerated cell migration. αTAT1 stabilizes MTs at the leading edge of migrating cells to promote cell motility and tumor progression (138). HDAC6 elicits pro-invasive signaling by activating Rho family GTPase, specifically by Rac1 (139). In addition to MTs, αTAT1 and HDAC6 are able to acetylate/deacetylate other substrates, such as cortactin. Cortactin contributes to actin filament assembly and is also required for MT1-MMP delivery to the leading edge of migrating cell (140), a process important for mesenchymal migration of tumor cells (141).

A recent study describes that ECM characteristics, MT dynamics and cell metabolism are interlinked to regulate cell invasion. Stiff substrates induce the conversion of glutamine to glutamate,

increasing MT stability by glutamylation, resulting in an invasive phenotype and metastasis of breast cancer cells (142). However, a different study showed that higher density of collagen destabilizes MTs and induces GEFH1 mediated RhoA signaling (143).

Another characteristic of the surrounding environment that affects cell migration is oxygen availability. Hypoxia leads to MT depolymerization as a consequence of MAP4 and stathmin phosphorylation (144, 145). Subsequently, MTs depolymerization promotes RhoA activity by releasing GEFH1, a mechanism known to promote amoeboid invasion. In agreement, hypoxic conditions trigger the collective-amoeboid transition (146).

4.1 Microtubule targeting drugs

Microtubule drugs, due to their immense effect on MT structure and dynamics, have extensive impact on cell behavior. They are commonly used as chemotherapeutic agents based on their ability to arrest cell proliferation and cause cell death (147). Nevertheless, MT drugs exhibit more extensive behavior than just antimitotic effects, including deregulation of cell migration (148). They also interfere with invasion plasticity manifesting different effects on each invasion mode. Drugs inhibiting MT polymerization promote the amoeboid mode as it is less MT-dependent (Figure 2). For example, vincristine which is able to sequester tubulin dimers and prevent MT polymerization, induces the amoeboid phenotype through GEFH1/RhoA signaling (149). Similar results were observed with nocodazole, which also leads to MT disassembly and subsequent RhoA activation (150). In fibroblasts, nocodazole treatment prevented cells to adopt an elongated morphology and instead induced a round morphology, typical of the amoeboid phenotype (151). Treatment of cells with paclitaxel (taxol) stabilizes microtubules, but does not promote mesenchymal migration, instead it induces a non-motile phenotype (152–154). In lymphocytes that utilize the amoeboid migration mode, taxol treatment inhibited migration in both 2D and microstructured environments, whereas nocodazole treatment increased membrane blebbing without increase in migration in 2D (155), but was able to promote amoeboid invasion in 3D (156).

The wide clinical usage of classic MT drugs is hampered by notable drug resistance and toxicity, fueling the chase for novel compounds with improved characteristics (157), many of which are in clinical trials (158). Moreover, in recent years it has become evident that the requirement for anti-metastatic behavior should be evaluated as well as primary growth shrinkage (159–162). In point of fact, the prototypic antimitotic drugs paclitaxel and vincristine can in certain instances promote metastasis (163, 164). On the other hand, vinorelbine treatment in mice reduced metastasis more effectively than primary tumor growth (165). Another microtubule inhibitor, eribulin, exerts migrastatic behavior both in experimental conditions (166, 167) and in patients with advanced metastatic breast cancer (168).

Taken together, a suitable combination of microtubule drugs with invasion specific inhibitors could synergically target cell proliferation and both amoeboid and mesenchymal invasion, i.e., elicit both anti-proliferative and migrastatic effects.

5 Concluding remarks

The invasion phenotype is a result of the orchestration of all three cytoskeletal systems. Here, we have summarized evidence that MT dynamics can directly affect cancer invasion plasticity and described its role in both amoeboid and mesenchymal cells (Figure 2). Nevertheless, the contribution of the individual cytoskeletal components specifically during the transitions between amoeboid and mesenchymal invasion modes remains to be described. For example, it is not clear whether during MAT the disintegration of MTs precedes, follows, or accompanies formation of the actomyosin cortex. Moreover, the cells´ reaction to the rearrangement of the MTs network is dependent on several factors including differences between 2D and 3D environments, cell type, RhoGTPase signaling or presence of MT drugs, and thus the role of MTs in invasion is not uniform.

Above mentioned evidence shows that amoeboid migration is possible even if MTs are unstable or depleted and destabilization of MTs can directly induce amoeboid invasion. This is contrary to the finding that MTs are retained in amoeboid leukocytes and in fact promote migration by contributing to path-finding mechanisms or protrusion retraction (97, 169). These seemingly contradictory findings may be explained by the existence of multiple types of amoeboid invasion that include blebby, stable-bleb and pseudopodal subtypes that differ in their extent of adhesion, and protrusive and contractile activity, which occur based on cell type and/or ECM conditions (99, 170, 171). For example, leukocytes are known to adopt the pseudopodal amoeboid mode, which is dependent on MT and actin-driven pseudopod extension. On the other hand, the highly contractile bleb-based amoeboid modes are reliant on actomyosin activity, but do not require MTs (171) (Figure 2). Interestingly, the varying structure of the MT network in amoeboid cells is reflected also in Amoebozoa, unicellular protists after which the amoeboid migration mode is named. Based on immunocytochemistry staining of MTs, in some amoebae MTs are present as short cytoplasmic fibers, other contain long, parallel MT bundles and in some cases fibrous MTs where not detected at all (172). It thus seems that indeed forms of amoeboid migration dependent and independent on MT network exist.

On the other hand, mesenchymal migration requires the role of MT for multiple processes. Especially at the leading edge MTs contribute to extension and stabilization of protrusions, but also to formation of adhesive and proteolytic structures. However, pharmacological stabilization of MTs limits migration and invasion of cells, suggesting that excessive stabilization halts migration altogether.

In this context, it is not easy to conclude whether increased depolymerization of MTs leads to higher invasiveness or the opposite. On the contrary, what we can confirm is that MT dynamics directly affects the ability of the cell to choose among the invasive modes that are most profitable for them under the given conditions.

Author contributions

AŠ, DR, and JB contributed to the conception and processing of the article. AL, AŠ, and MP wrote the original manuscript. AL and AŠ contributed significantly to the first design of the images, AL created

the images and all authors contributed to their finalization. All authors contributed to the article revision and approved the submitted version.

Funding

This work was supported by Charles University grant GAUK, project n. 922120 and by the National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) - funded by the European Union - Next Generation EU. This work was also funded by Operational Programme Research, Development and Education, within the projects: Centre for Tumour Ecology—Research of the Cancer Microenvironment Supporting Cancer Growth and Spread (reg. No. CZ.02.1.01/0.0/0.0/16_019/0000785).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

References

1. Alexandrova AY, Chikina AS, Svitkina TM. Actin cytoskeleton in mesenchymal-to-amoeboid transition of cancer cells. In: *International review of cell and molecular biology*. Elsevier (2020). p. 197–256. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1937644820300782.

2. Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis: Cytoskeleton and cancer metastasis. *Br J Pharmacol* (2014) 171 (24):5507–23. doi: 10.1111/bph.12704

3. Gandalovičová A, Vomastek T, Rosel D, Brábek J. Cell polarity signaling in the plasticity of cancer cell invasiveness. *Oncotarget* (2016) 7(18):25022–49. doi: 10.18632/oncotarget.7214

4. Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M, Rosel D. Vimentin intermediate filaments as potential target for cancer treatment. *Cancers* (2020) 12(1):184. doi: 10.3390/cancers12010184

5. Paňková K, Rösel D, Novotný M, Brábek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. *Cell Mol Life Sci* (2010) 67(1):63–71. doi: 10.1007/s00018-009-0132-1

6. te Boekhorst V, Friedl P. Plasticity of cancer cell invasion–mechanisms and implications for therapy. In: *Advances in cancer research*. Elsevier (2016). p. 209–64. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0065230X16300562.

7. Tolde O, Gandalovičová A, Křížová A, Veselý P, Chmelík R, Rosel D, et al. Quantitative phase imaging unravels new insight into dynamics of mesenchymal and amoeboid cancer cell invasion. *Sci Rep* (2018) 8(1):12020. doi: 10.1038/s41598-018-30408-7

8. Norman LL, Brugés J, Sengupta K, Sens P, Aranda-Espinoza H. Cell blebbing and membrane area homeostasis in spreading and retracting cells. *Biophys J* (2010) 99 (6):1726–33. doi: 10.1016/j.bpj.2010.07.031

9. Schick J, Raz E. Blebs–formation, regulation, positioning, and role in amoeboid cell migration. *Front Cell Dev Biol* (2022) 10:926394. doi: 10.3389/fcell.2022.926394

10. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. *Dev Biol* (2004) 265(1):23–32. doi: 10.1016/j.ydbio.2003.06.003

11. Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and nck. *Nature* (2002) 418 (6899):790–3. doi: 10.1038/nature00859

12. Rohatgi R, Ho H yi H, Kirschner MW. Mechanism of n-wasp activation by Cdc42 and phosphatidylinositol 4,5-bisphosphate. *J Cell Biol* (2000) 150(6):1299–310. doi: 10.1083/jcb.150.6.1299

13. Weaver AM, Young ME, Lee WL, Cooper JA. Integration of signals to the Arp2/3 complex. *Curr Opin Cell Biol* (2003) 15(1):23–30. doi: 10.1016/S0955-0674(02)00015-7

14. Kraynov VS, Chamberlain C, Bokoch GM, Schwartz MA, Slabaugh S, Hahn KM. Localized rac activation dynamics visualized in living cells. *Science* (2000) 290(5490):333–7. doi: 10.1126/science.290.5490.333

15. Alblas J, Ulfman L, Hordijk P, Koenderman L. Activation of RhoA and ROCK are essential for detachment of migrating Leukocytes *Mol Biol Cell* (2001) 12:9. doi: 10.1091/mbc.12.7.2137

16. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. Phosphorylation and activation of myosin by rho-associated kinase (Rho-kinase). *J Biol Chem* (1996) 271(34):20246–9. doi: 10.1074/jbc.271.34.20246

17. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by rho and rho-associated kinase (Rho-kinase). *Science.* (1996) 273 (5272):245–8. doi: 10.1126/science.273.5272.245

18. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, et al. Signaling from rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. *Science* (1999) 285(5429):895–8. doi: 10.1126/science.285.5429.895

19. Kosla J, Paňková D, Plachý J, Tolde O, Bicanová K, Dvořák M, et al. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. *Cell Commun Signal* (2013) 11(1):51. doi: 10.1186/1478-811X-11-51

20. Orgaz JL, Herraiz C, Sanz-Moreno V. Rho GTPases modulate malignant transformation of tumor cells. *Small GTPases* (2014) 5(4):e983867. doi: 10.4161/sgtp.29019

21. Čermák V, Gandalovičová A, Merta L, Harant K, Rösel D, Brábek J. High-throughput transcriptomic and proteomic profiling of mesenchymal-amoeboid transition in 3D collagen. *Sci Data* (2020) 7(1):160. doi: 10.1038/s41597-020-0499-2

22. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. *Nat Cell Biol* (2003) 5(8):711–9. doi: 10.1038/ncb1019

23. MacKay JL, Kumar S. Simultaneous and independent tuning of RhoA and Rac1 activity with orthogonally inducible promoters. *Integr Biol* (2014) 6(9):885–94. doi: 10.1039/c4ib00099d

24. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. *Cell* (2008) 135 (3):510–23. doi: 10.1016/j.cell.2008.09.043

25. Waterman-Storer CM, Worthylake RA, Liu BP, Burridge K, Salmon ED. Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts. *Nat Cell Biol* (1999) 1(1):45–50. doi: 10.1038/9018

26. Waterman-Storer CM, Salmon E. Positive feedback interactions between microtubule and actin dynamics during cell motility. *Curr Opin Cell Biol* (1999) 11 (1):61–7. doi: 10.1016/S0955-0674(99)80008-8

27. Daub H, Gevaert K, Vandekerckhove J, Sobel A, Hall A. Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. *J Biol Chem* (2001) 276(3):1677–80. doi: 10.1074/jbc.C000635200

28. Zeitz M, Kierfeld J. Feedback mechanism for microtubule length regulation by stathmin gradients. *Biophys J* (2014) 107(12):2860–71. doi: 10.1016/j.bpj.2014.10.056

29. Ishizaki T, Morishima Y, Okamoto M, Furuyashiki T, Kato T, Narumiya S. Coordination of microtubules and the actin cytoskeleton by the rho effector mDia1. *Nat Cell Biol* (2001) 3(1):8–14. doi: 10.1038/35050598

30. Palazzo AF, Cook TA, Alberts AS, Gundersen GG. mDia mediates rho-regulated formation and orientation of stable microtubules. *Nat Cell Biol* (2001) 3(8):723–9. doi: 10.1038/35087035

31. Sakamoto Y, Boëda B, Etienne-Manneville S. APC binds intermediate filaments and is required for their reorganization during cell migration. *J Cell Biol* (2013) 200 (3):249–58. doi: 10.1083/jcb.201206010

32. Schaedel L, Lorenz C, Schepers AV, Klumpp S, Köster S. Vimentin intermediate filaments stabilize dynamic microtubules by direct interactions. *Nat Commun* (2021) 12 (1):3799. doi: 10.1038/s41467-021-23523-z

33. Bouchet BP, Akhmanova A. Microtubules in 3D cell motility. *J Cell Sci* (2017) 130 (1):39–50. doi: 10.1242/jcs.189431

34. Etienne-Manneville S. Microtubules in cell migration. *Annu Rev Cell Dev Biol* (2013) 29(1):471–99. doi: 10.1146/annurev-cellbio-101011-155711

35. Garcin C, Straube A. Microtubules in cell migration. *Essays Biochem* (2019) 63 (5):509–20. doi: 10.1042/EBC20190016

36. Vaughan KT. TIP maker and TIP marker; EB1 as a master controller of microtubule plus ends. *J Cell Biol* (2005) 171(2):197–200. doi: 10.1083/jcb.200509150

37. van Haren J, Charafeddine RA, Ettinger A, Wang H, Hahn KM, Wittmann T. Local control of intracellular microtubule dynamics by EB1 photodissociation. *Nat Cell Biol* (2018) 20(3):252–61. doi: 10.1038/s41556-017-0028-5

38. Jayatilaka H, Giri A, Karl M, Aifuwa I, Trenton NJ, Phillip JM, et al. EB1 and cytoplasmic dynein mediate protrusion dynamics for efficient 3-dimensional cell migration. *FASEB J* (2018) 32(3):1207–21. doi: 10.1096/fj.201700444RR

39. Bouchet BP, Noordstra I, van Amersfoort M, Katrukha EA, Ammon YC, ter Hoeve ND, et al. Mesenchymal cell invasion requires cooperative regulation of persistent microtubule growth by SLAIN2 and CLASP1. *Dev Cell* (2016) 39(6):708–23. doi: 10.1016/j.devcel.2016.11.009

40. White CD, Erdemir HH, Sacks DB. IQGAP1 and its binding proteins control diverse biological functions. *Cell Signal* (2012) 24(4):826–34. doi: 10.1016/j.cellsig.2011.12.005

41. Bashour AM, Fullerton AT, Hart MJ, Bloom GS. IQGAP1, a rac- and Cdc42-binding protein, directly binds and cross-links microfilaments. *J Cell Biol* (1997) 137 (7):1555–66. doi: 10.1083/jcb.137.7.1555

42. Hoeprich GJ, Sinclair AN, Shekhar S, Goode BL. Single-molecule imaging of IQGAP1 regulating actin filament dynamics. *Mol Biol Cell* (2022) 33(1):ar2. doi: 10.1091/mbc.E21-04-0211

43. Kuroda S, Fukata M, Kobayashi K, Nakafuku M, Nomura N, Iwamatsu A, et al. Identification of IQGAP as a putative target for the small GTPases, Cdc42 and Rac1. *J Biol Chem* (1996) 271(38):23363–7. doi: 10.1074/jbc.271.38.23363

44. Fukata M, Kuroda S, Fujii K, Nakamura T, Shoji I, Matsuura Y, et al. Regulation of cross-linking of actin filament by IQGAP1, a target for Cdc42. *J Biol Chem* (1997) 272 (47):29579–83. doi: 10.1074/jbc.272.47.29579

45. Benseñor LB, Kan HM, Wang N, Wallrabe H, Davidson LA, Cai Y, et al. IQGAP1 regulates cell motility by linking growth factor signaling to actin assembly. *J Cell Sci* (2007) 120(4):658–69. doi: 10.1242/jcs.03376

46. Le Clainche C, Schlaepfer D, Ferrari A, Klingauf M, Grohmanova K, Veligodskiy A, et al. IQGAP1 stimulates actin assembly through the n-Wasp-Arp2/3 pathway. *J Biol Chem* (2007) 282(1):426–35. doi: 10.1074/jbc.M607711200

47. Mataraza JM, Briggs MW, Li Z, Entwistle A, Ridley AJ, Sacks DB. IQGAP1 promotes cell motility and invasion. *J Biol Chem* (2003) 278(42):41237–45. doi: 10.1074/jbc.M304838200

48. Hart MJ, Callow MG, Souza B, Polakis P. IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. *EMBO J* (1996) 15 (12):2997–3005. doi: 10.1002/j.1460-2075.1996.tb00663.x

49. Etienne-Manneville S, Hall A. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCζ. *Cell* (2001) 106(4):489–98. doi: 10.1016/S0092-8674(01)00471-8

50. Fukata M, Watanabe T, Noritake J, Nakagawa M, Yamaga M, Kuroda S, et al. Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170. *Cell* (2002) 109 (7):873–85. doi: 10.1016/S0092-8674(02)00800-0

51. Watanabe T, Wang S, Noritake J, Sato K, Fukata M, Takefuji M, et al. Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. *Dev Cell* (2004) 7(6):871–83. doi: 10.1016/j.devcel.2004.10.017

52. Cao D, Su Z, Wang W, Wu H, Liu X, Akram S, et al. Signaling scaffold protein IQGAP1 interacts with microtubule plus-end tracking protein SKAP and links dynamic microtubule plus-end to steer cell migration. *J Biol Chem* (2015) 290(39):23766–80. doi: 10.1074/jbc.M115.673517

53. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, Dikalov SI, Chen YE, Tojo T, et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species–dependent endothelial migration and proliferation. *Circ Res* (2004) 95(3):276–83. doi: 10.1161/01.RES.0000136522.58649.60

54. Li S, Guan JL, Chien S. Biochemistry and biomechanics of cell motility. *Annu Rev BioMed Eng* (2005) 7(1):105–50. doi: 10.1146/annurev.bioeng.7.060804.100340

55. Sánchez-Huertas C, Bonhomme M, Falco A, Fagotto-Kaufmann C, van Haren J, Jeanneteau F, et al. The +TIP navigator-1 is an actin–microtubule crosslinker that regulates axonal growth cone motility. *J Cell Biol* (2020) 219(9):e201905199. doi: 10.1083/jcb.201905199

56. van Haren J, Draegestein K, Keijzer N, Abrahams JP, Grosveld F, Peeters PJ, et al. Mammalian navigators are microtubule plus-end tracking proteins that can reorganize the cytoskeleton to induce neurite-like extensions. *Cell Motil Cytoskeleton* (2009) 66 (10):824–38. doi: 10.1002/cm.20370

57. van Haren J, Boudeau J, Schmidt S, Basu S, Liu Z, Lammers D, et al. Dynamic microtubules catalyze formation of navigator-TRIO complexes to regulate neurite extension. *Curr Biol* (2014) 24(15):1778–85. doi: 10.1016/j.cub.2014.06.037

58. Bellanger JM, Lazaro JB, Diriong S, Fernandez A, Lamb N, Debant A. The two guanine nucleotide exchange factor domains of trio link the Rac1 and the RhoA pathways in vivo. *Oncogene* (1998) 16(2):147–52. doi: 10.1038/sj.onc.1201532

59. Briançon-Marjollet A, Ghogha A, Nawabi H, Triki I, Auziol C, Fromont S, et al. Trio mediates netrin-1-Induced Rac1 activation in axon outgrowth and guidance. *Mol Cell Biol* (2008) 28(7):2314–23. doi: 10.1128/MCB.00998-07

60. Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, et al. Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. *EMBO Mol Med* (2015) 7(3):299–314. doi: 10.15252/emmm.201404134

61. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. *Cell* (1996) 84(4):623–31. doi: 10.1016/S0092-8674(00)81037-5

62. Curmi PA, Andersen SSL, Lachkar S, Gavet O, Karsenti E, Knossow M, et al. The Stathmin/Tubulin interaction in vitro. *J Biol Chem* (1997) 272(40):25029–36. doi: 10.1074/jbc.272.40.25029

63. Howell B, Larsson N, Gullberg M, Cassimeris L. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/Stathmin. *Mol Biol Cell* (1999) 10(1):105–18. doi: 10.1091/mbc.10.1.105

64. Melander Gradin H, Marklund U, Larsson N, Chatila TA, Gullberg M. Regulation of microtubule dynamics by Ca2+/calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18. *Mol Cell Biol* (1997) 17(6):3459–67. doi: 10.1128/MCB.17.6.3459

65. Gavet O, Ozon S, Manceau V, Lawler S, Curmi P, Sobel A. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. *J Cell Sci* (1998) 111(22):3333–46. doi: 10.1242/jcs.111.22.3333

66. Ng DCH, Lin BH, Lim CP, Huang G, Zhang T, Poli V, et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. *J Cell Biol* (2006) 172(2):245–57. doi: 10.1083/jcb.200503021

67. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, et al. p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. *Cancer Cell* (2005) 7(1):51–63. doi: 10.1016/j.ccr.2004.11.025

68. Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S, Di Stefano D, et al. p27 ^{Kip1} expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. *Mol Cancer Ther* (2008) 7(5):1164–75. doi: 10.1158/1535-7163.MCT-07-2154

69. Klausen P, Pedersen L, Jurlander J, Baumann H. Oncostatin m and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. *Oncogene* (2000) 19(32):3675–83. doi: 10.1038/sj.onc.1203707

70. Niethammer P, Bastiaens P, Karsenti E. Stathmin-tubulin interaction gradients in motile and mitotic cells. *Science* (2004) 303(5665):1862–6. doi: 10.1126/science.1094108

71. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, et al. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. *Mol Biol Cell* (2008) 19(5):2003–13. doi: 10.1091/mbc.e07-09-0894

72. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. *J Clin Invest* (1999) 104(7):865–74. doi: 10.1172/JCI6443

73. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27 ^{Kip1} modulates cell migration through the regulation of RhoA activation. *Genes Dev* (2004) 18(8):862–76. doi: 10.1101/gad.1185504

74. Morelli G, Even A, Gladwyn-Ng I, Le Bail R, Shilian M, Godin JD, et al. p27Kip1 modulates axonal transport by regulating α-tubulin acetyltransferase 1 stability. *Cell Rep* (2018) 23(8):2429–42. doi: 10.1016/j.celrep.2018.04.083

75. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF. Novel p27 ^{kip1} c-terminal scatter domain mediates rac-dependent cell migration independent of cell cycle arrest functions. *Mol Cell Biol* (2003) 23(1):216–28. doi: 10.1128/MCB.23.1.216-228.2003

76. Berton S, Belletti B, Wolf K, Canzonieri V, Lovat F, Vecchione A, et al. The tumor suppressor functions of p27 ^{kip1} include control of the Mesenchymal/Amoeboid transition. *Mol Cell Biol* (2009) 29(18):5031–45. doi: 10.1128/MCB.00144-09

77. Gui P, Labrousse A, Van Goethem E, Besson A, Maridonneau-Parini I, Le Cabec V. Rho/ROCK pathway inhibition by CDK inhibitor p27kip1 participates in the onset of macrophage 3D-mesenchymal migration. *J Cell Sci* (2014) 127(18):4009–23. doi: 10.1242/jcs.150987

78. Chalkia D, Nikolaidis N, Makalowski W, Klein J, Nei M. Origins and evolution of the formin multigene family that is involved in the formation of actin filaments. *Mol Biol Evol* (2008) 25(12):2717–33. doi: 10.1093/molbev/msn215

79. Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, et al. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. *EMBO Mol Med* (2012) 4(8):743–60. doi: 10.1002/emmm.201200242

80. Wyse MM, Goicoechea S, Garcia-Mata R, Nestor-Kalinoski AL, Eisenmann KM. mDia2 and CXCL12/CXCR4 chemokine signaling intersect to drive tumor cell amoeboid morphological transitions. *Biochem Biophys Res Commun* (2017) 484(2):255–61. doi: 10.1016/j.bbrc.2017.01.087

81. Pettee KM, Dvorak KM, Nestor-Kalinoski AL, Eisenmann KM. An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids. *Aspenstrom P editor PloS One* (2014) 9(2):e90371. doi: 10.1371/journal.pone.0090371

82. Morley S, You S, Pollan S, Choi J, Zhou B, Hager MH, et al. Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. *Sci Rep* (2015) 5(1):12136. doi: 10.1038/srep12136

83. Nalbant P, Chang YC, Birkenfeld J, Chang ZF, Bokoch GM. Guanine nucleotide exchange factor-H1 regulates cell migration *via* localized activation of RhoA at the leading edge. *Forscher P editor Mol Biol Cell* (2009) 20(18):4070–82. doi: 10.1091/mbc.e09-01-0041

84. Azoitei ML, Noh J, Marston DJ, Roudot P, Marshall CB, Daugird TA, et al. Spatiotemporal dynamics of GEF-H1 activation controlled by microtubule- and src-mediated pathways. *J Cell Biol* (2019) 218(9):3077–97. doi: 10.1083/jcb.201812073

85. Pan YR, Chen CC, Chan YT, Wang HJ, Chien FT, Chen YL, et al. STAT3-coordinated migration facilitates the dissemination of diffuse large b-cell lymphomas. *Nat Commun* (2018) 9(1):3696. doi: 10.1038/s41467-018-06134-z

86. Soltani MH, Pichardo R, Song Z, Sangha N, Camacho F, Satyamoorthy K, et al. Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. *Am J Pathol* (2005) 166(6):1841–50. doi: 10.1016/S0002-9440(10)62493-5

87. Ou Y, Zheng X, Gao Y, Shu M, Leng T, Li Y, et al. Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. *Urol Oncol Semin Orig Investig* (2014) 32(1):47.e21–8. doi: 10.1016/j.urolonc.2013.06.017

88. Jiang YY, Shang L, Shi ZZ, Zhang TT, Ma S, Lu CC, et al. Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma. *Oncogene* (2016) 35(37):4846–56. doi: 10.1038/onc.2016.17

89. Tortosa E, Montenegro-Venegas C, Benoist M, Härtel S, González-Billault C, Esteban JA, et al. Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation. *J Biol Chem* (2011) 286(47):40638–48. doi: 10.1074/jbc.M111.271320

90. Chang W, Gruber D, Chari S, Kitazawa H, Hamazumi Y, Hisanaga S, et al. Phosphorylation of MAP4 affects microtubule properties and cell cycle progression. *J Cell Sci* (2001) 114(15):2879–87. doi: 10.1242/jcs.114.15.2879

91. Krendel M, Zenke FT, Bokoch GM. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. *Nat Cell Biol* (2002) 4(4):294–301. doi: 10.1038/ncb773

92. Luxton GG, Gundersen GG. Orientation and function of the nuclear–centrosomal axis during cell migration. *Curr Opin Cell Biol* (2011) 23(5):579–88. doi: 10.1016/j.ceb.2011.08.001

93. Burute M, Prioux M, Blin G, Truchet S, Letort G, Tseng Q, et al. Polarity reversal by centrosome repositioning primes cell scattering during epithelial-to-Mesenchymal transition. *Dev Cell* (2017) 40(2):168–84. doi: 10.1016/j.devcel.2016.12.004

94. Doyle AD, Wang FW, Matsumoto K, Yamada KM. One-dimensional topography underlies three-dimensional fibrillar cell migration. *J Cell Biol* (2009) 184(4):481–90. doi: 10.1083/jcb.200810041

95. Zhang J, Wang Y. Centrosome defines the rear of cells during mesenchymal migration. *Mol Biol Cell* (2017) 28(23):3240–51. doi: 10.1091/mbc.e17-06-0366

96. Pouthas F, Girard P, Lecaudey V, Ly TBN, Gilmour D, Boulin C, et al. In migrating cells, the golgi complex and the position of the centrosome depend on geometrical constraints of the substratum. *J Cell Sci* (2008) 121(14):2406–14. doi: 10.1242/jcs.026849

97. Renkawitz J, Kopf A, Stopp J, de Vries I, Driscoll MK, Merrin J, et al. Nuclear positioning facilitates amoeboid migration along the path of least resistance. *Nature.* (2019) 568(7753):546–50. doi: 10.1038/s41586-019-1087-5

98. Sánchez-Madrid F, Serrador JM. Bringing up the rear: defining the roles of the uropod. *Nat Rev Mol Cell Biol* (2009) 10(5):353–9. doi: 10.1038/nrm2680

99. Friedl P, Wolf K. Plasticity of cell migration: A multiscale tuning model. *J Cell Biol* (2010) 188(1):11–9. doi: 10.1083/jcb.200909003

100. Liu YJ, Le Berre M, Lautenschlaeger F, Maiuri P, Callan-Jones A, Heuzé M, et al. Confinement and low adhesion induce fast amoeboid migration of slow mesenchymal cells. *Cell* (2015) 160(4):659–72. doi: 10.1016/j.cell.2015.01.007

101. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, et al. Compensation mechanism in tumor cell migration. *J Cell Biol* (2003) 160(2):267–77. doi: 10.1083/jcb.200209006

102. Doyle AD, Carvajal N, Jin A, Matsumoto K, Yamada KM. Local 3D matrix microenvironment regulates cell migration through spatiotemporal dynamics of contractility-dependent adhesions. *Nat Commun* (2015) 6(1):8720. doi: 10.1038/ncomms9720

103. Seetharaman S, Etienne-Manneville S. Integrin diversity brings specificity in mechanotransduction: Integrin diversity brings specificity in mechanotransduction. *Biol Cell* (2018) 110(3):49–64. doi: 10.1111/boc.201700060

104. Wozniak MA, Modzelewska K, Kwong L, Keely PJ. Focal adhesion regulation of cell behavior. *Biochim Biophys Acta BBA - Mol Cell Res* (2004) 1692(2–3):103–19. doi: 10.1016/j.bbamcr.2004.04.007

105. Huveneers S, Danen EHJ. Adhesion signaling – crosstalk between integrins, src and rho. *J Cell Sci* (2009) 122(8):1059–69. doi: 10.1242/jcs.039446

106. Lawson CD, Burridge K. The on-off relationship of rho and rac during integrin-mediated adhesion and cell migration. *Small GTPases* (2014) 5(1):e27958. doi: 10.4161/sgtp.27958

107. Stehbens S, Wittmann T. Targeting and transport: How microtubules control focal adhesion dynamics. *J Cell Biol* (2012) 198(4):481–9. doi: 10.1083/jcb.201206050

108. Kaverina I, Rottner K, Small JV. Targeting, capture, and stabilization of microtubules at early focal adhesions. *J Cell Biol* (1998) 142(1):181–90. doi: 10.1083/jcb.142.1.181

109. Krylyshkina O, Anderson KI, Kaverina I, Upmann I, Manstein DJ, Small JV, et al. Nanometer targeting of microtubules to focal adhesions. *J Cell Biol* (2003) 161(5):853–9. doi: 10.1083/jcb.200301102

110. Seetharaman S, Etienne-Manneville S. Microtubules at focal adhesions – a double-edged sword. *J Cell Sci* (2019) 132(19):jcs232843. doi: 10.1242/jcs.232843

111. Byron A, Askari JA, Humphries JD, Jacquemet G, Koper EJ, Warwood S, et al. A proteomic approach reveals integrin activation state-dependent control of microtubule cortical targeting. *Nat Commun* (2015) 6(1):6135. doi: 10.1038/ncomms7135

112. Kaverina I, Krylyshkina O, Small JV. Microtubule targeting of substrate contacts promotes their relaxation and dissociation. *J Cell Biol* (1999) 146(5):1033–44. doi: 10.1083/jcb.146.5.1033

113. Bershadsky A, Chausovsky A, Becker E, Lyubimova A, Geiger B. Involvement of microtubules in the control of adhesion-dependent signal transduction. *Curr Biol* (1996) 6 (10):1279–89. doi: 10.1016/S0960-9822(02)70714-8

114. Ezratty EJ, Partridge MA, Gundersen GG. Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. *Nat Cell Biol* (2005) 7 (6):581–90. doi: 10.1038/ncb1262

115. Tolde O, Rösel D, Janostiak R, Vesely P, Brábek J. Dynamics and morphology of focal adhesions in complex 3D environment. *Folia Biol (Praha)* (2012) 58:177–84.

116. Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. *Trends Cell Biol* (2007) 17(3):107–17. doi: 10.1016/j.tcb.2007.01.002

117. Linder S, Hufner K, Wintergerst U, Aepfelbacher M. Microtubule-dependent formation of podosomal adhesion structures in primary human macrophages. *J Cell Sci* (2000) 113(23):4165–76. doi: 10.1242/jcs.113.23.4165

118. Ory S, Destaing O, Jurdic P. Microtubule dynamics differentially regulates rho and rac activity and triggers rho-independent stress fiber formation in macrophage polykaryons. *Eur J Cell Biol* (2002) 81(6):351–62. doi: 10.1078/0171-9335-00255

119. Biosse Duplan M, Zalli D, Stephens S, Zenger S, Neff L, Oelkers JM, et al. Microtubule dynamic instability controls podosome patterning in osteoclasts through EB1, cortactin, and src. *Mol Cell Biol* (2014) 34(1):16–29. doi: 10.1128/MCB.00578-13

120. Efimova N, Grimaldi A, Bachmann A, Frye K, Zhu X, Feoktistov A, et al. Podosome-regulating kinesin KIF1C translocates to the cell periphery in a CLASP-dependent manner. *J Cell Sci* (2014) 127(24):5179–88. doi: 10.1242/jcs.149633

121. Kopp P, Lammers R, Aepfelbacher M, Rudel T, Machuy N, Steffen W, et al. The kinesin KIF1C and microtubule plus ends regulate podosome dynamics in Macrophages□D □V. *Mol Biol Cell* (2006) 17:13. doi: 10.1091/mbc.e05-11-1010

122. Destaing O, Saltel F, Gilquin B, Chabadel A, Khochbin S, Ory S, et al. A novel rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts. *J Cell Sci* (2005) 118(13):2901–11. doi: 10.1242/jcs.02425

123. Bhuwania R, Cornfine S, Fang Z, Krüger M, Luna EJ, Linder S. Supervillin couples myosin-dependent contractility to podosomes and enables their turnover. *J Cell Sci* (2012) 125(9):2300–14. doi: 10.1242/jcs.100032

124. van den Dries K, Meddens MBM, de Keijzer S, Shekhar S, Subramaniam V, Figdor CG, et al. Interplay between myosin IIA-mediated contractility and actin network integrity orchestrates podosome composition and oscillations. *Nat Commun* (2013) 4 (1):1412. doi: 10.1038/ncomms2402

125. van Helden SFG, Oud MM, Joosten B, Peterse N, Figdor CG, van Leeuwen FN. PGE2-mediated podosome loss in dendritic cells is dependent on actomyosin contraction downstream of the RhoA–rho-kinase axis. *J Cell Sci* (2008) 121(7):1096–106. doi: 10.1242/jcs.020289

126. Ory S, Brazier H, Pawlak G, Blangy A. Rho GTPases in osteoclasts: Orchestrators of podosome arrangement. *Eur J Cell Biol* (2008) 87(8–9):469–77. doi: 10.1016/j.ejcb.2008.03.002

127. Gimona M, Buccione R, Courtneidge SA, Linder S. Assembly and biological role of podosomes and invadopodia. *Curr Opin Cell Biol* (2008) 20(2):235–41. doi: 10.1016/j.ceb.2008.01.005

128. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. *J Cell Biol* (2010) 189(3):541–56. doi: 10.1083/jcb.200909113

129. Kikuchi K, Takahashi K. WAVE2- and microtubule-dependent formation of long protrusions and invasion of cancer cells cultured on three-dimensional extracellular matrices. *Cancer Sci* (2008) 99(11):2252–9. doi: 10.1111/j.1349-7006.2008.00927.x

130. Revach OY, Weiner A, Rechav K, Sabanay I, Livne A, Geiger B. Mechanical interplay between invadopodia and the nucleus in cultured cancer cells. *Sci Rep* (2015) 5 (1):9466. doi: 10.1038/srep09466

131. Caldieri G, Buccione R. Aiming for invadopodia: organizing polarized delivery at sites of invasion. *Trends Cell Biol* (2010) 20(2):64–70. doi: 10.1016/j.tcb.2009.10.006

132. Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M, et al. Microtubule-dependent matrix metalloproteinase-2/Matrix metalloproteinase-9 exocytosis. *Cancer Res* (2004) 64(24):8924–31. doi: 10.1158/0008-5472.CAN-04-0324

133. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, Camonis J, et al. The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. *J Cell Biol* (2008) 181(6):985–98. doi: 10.1083/jcb.200709076

134. Brábek J, Mierke CT, Rösel D, Veselý P, Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. *Cell Commun Signal* (2010) 8(1):22. doi: 10.1186/1478-811X-8-22

135. Wolf K, te Lindert M, Krause M, Alexander S, te Riet J, Willis AL, et al. Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction force. *J Cell Biol* (2013) 201(7):1069–84. doi: 10.1083/jcb.201210152

136. Ruprecht V, Wieser S, Callan-Jones A, Smutny M, Morita H, Sako K, et al. Cortical contractility triggers a stochastic switch to fast amoeboid cell motility. *Cell* (2015) 160(4):673–85. doi: 10.1016/j.cell.2015.01.008

137. Plotnikov SV, Waterman CM. Guiding cell migration by tugging. *Curr Opin Cell Biol* (2013) 25(5):619–26. doi: 10.1016/j.ceb.2013.06.003

138. Montagnac G, Meas-Yedid V, Irondelle M, Castro-Castro A, Franco M, Shida T, et al. αTAT1 catalyses microtubule acetylation at clathrin-coated pits. *Nature* (2013) 502 (7472):567–70. doi: 10.1038/nature12571

139. Pham TQ, Robinson K, Xu L, Pavlova MN, Skapek SX, Chen EY. HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma. *Oncogene* (2021) 40(3):578–91. doi: 10.1038/s41388-020-01550-2

140. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. *Cancer Res* (2007) 67(9):4227–35. doi: 10.1158/0008-5472.CAN-06-3928

141. Castro-Castro A, Janke C, Montagnac G, Paul-Gilloteaux P, Chavrier P. ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion. *Eur J Cell Biol* (2012) 91(11–12):950–60. doi: 10.1016/j.ejcb.2012.07.001

142. Torrino S, Grasset EM, Audebert S, Belhadj I, Lacoux C, Haynes M, et al. Mechano-induced cell metabolism promotes microtubule glutamylation to force metastasis. *Cell Metab* (2021) 33(7):1342–57. doi: 10.1016/j.cmet.2021.05.009

143. Heck JN, Ponik SM, Garcia-Mendoza MG, Pehlke CA, Inman DR, Eliceiri KW, et al. Microtubules regulate GEF-H1 in response to extracellular matrix stiffness. *Mol Biol Cell* (2012) 23(13):2583–92. doi: 10.1091/mbc.e11-10-0876

144. Hu JY, Chu ZG, Han J, Dang Y, Yan H, Zhang Q, et al. The p38/MAPK pathway regulates microtubule polymerization through phosphorylation of MAP4 and Op18 in hypoxic cells. *Cell Mol Life Sci* (2010) 67(2):321–33. doi: 10.1007/s00018-009-0187-z

145. Zhang J, Li L, Zhang Q, Yang X, Zhang C, Zhang X, et al. Phosphorylation of microtubule- associated protein 4 promotes hypoxic endothelial cell migration and proliferation. *Front Pharmacol* (2019) 10:368. doi: 10.3389/fphar.2019.00368

146. Lehmann S, te Boekhorst V, Odenthal J, Bianchi R, van Helvert S, Ikenberg K, et al. Hypoxia induces a HIF-1-Dependent transition from collective-to-Amoeboid dissemination in epithelial cancer cells. *Curr Biol* (2017) 27(3):392–400. doi: 10.1016/j.cub.2016.11.057

147. Čermák V, Dostál V, Jelínek M, Libusová L, Kovář J, Rösel D, et al. Microtubule-targeting agents and their impact on cancer treatment. *Eur J Cell Biol* (2020) 99(4):151075. doi: 10.1016/j.ejcb.2020.151075

148. Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs: MDA mechanisms of action. *Br J Clin Pharmacol* (2017) 83(2):255–68. doi: 10.1111/bcp.13126

149. Eitaki M, Yamamori T, Meike S, Yasui H, Inanami O. Vincristine enhances amoeboid-like motility *via* GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells. *BMC Cancer* (2012) 12(1):469. doi: 10.1186/1471-2407-12-469

150. Chang YC, Nalbant P, Birkenfeld J, Chang ZF, Bokoch GM. GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility *via* RhoA. *Mol Biol Cell* (2008) 19(5):2147–53. doi: 10.1091/mbc.e07-12-1269

151. Belletti B, Pellizzari I, Berton S, Fabris L, Wolf K, Lovat F, et al. p27 ^{kip1} controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. *Mol Cell Biol* (2010) 30(9):2229–40. doi: 10.1128/MCB.00723-09

152. Carey SP, Rahman A, Kraning-Rush CM, Romero B, Somasegar S, Torre OM, et al. Comparative mechanisms of cancer cell migration through 3D matrix and physiological microtracks. *Am J Physiol-Cell Physiol* (2015) 308(6):C436–47. doi: 10.1152/ajpcell.00225.2014

153. Tran TA, Gillet L, Roger S, Besson P, White E, Le Guennec JY. Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness. *Biochem Biophys Res Commun* (2009) 379(2):304–8. doi: 10.1016/j.bbrc.2008.12.073

154. Yvon AMC, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. *Mol Biol Cell* (1999) 10(4):947–59. doi: 10.1091/mbc.10.4.947

155. Takesono A, Heasman SJ, Wojciak-Stothard B, Garg R, Ridley AJ. Microtubules regulate migratory polarity through Rho/ROCK signaling in T cells. *PloS One* (2010) 5(1): e8774. doi: 10.1371/journal.pone.0008774

156. Tabdanov ED, Rodríguez-Merced NJ, Cartagena-Rivera AX, Puram VV, Callaway MK, Ensminger EA, et al. Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. *Nat Commun* (2021) 12(1):2815. doi: 10.1038/s41467-021-22985-5

157. Dumontet C, Jordan MA. Microtubule-binding agents: A dynamic field of cancer therapeutics. *Nat Rev Drug Discov* (2010) 9(10):790–803. doi: 10.1038/nrd3253

158. Škubník J, Jurášek M, Ruml T, Rimpelová S. Mitotic poisons in research and medicine. *Molecules* (2020) 25(20):4632. doi: 10.3390/molecules25204632

159. Fernandes M, Rosel D, Brábek J. Translation in solid cancer: are size-based response criteria an anachronism? *Clin Transl Oncol* (2015) 17(1):1–10. doi: 10.1007/s12094-014-1207-5

160. Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, et al. Migrastatics–anti-metastatic and anti-invasion drugs: Promises and challenges. *Trends Cancer* (2017) 3(6):391–406. doi: 10.1016/j.trecan.2017.04.008

161. Rosel D, Fernandes M, Sanz-Moreno V, Brábek J. Migrastatics: Redirecting R&D in solid cancer towards metastasis? *Trends Cancer* (2019) 5(12):755–6. doi: 10.1016/j.trecan.2019.10.011

162. Solomon J, Raškova M, Rösel D, Brábek J, Gil-Henn H. Are we ready for migrastatics? *Cells* (2021) 10(8):1845. doi: 10.3390/cells10081845

163. Li Q, Ma Z, Liu Y, Kan X, Wang C, Su B, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. *FEBS J* (2016) 283(15):2836–52. doi: 10.1111/febs.13767

164. Zenitani M, Nojiri T, Hosoda H, Kimura T, Uehara S, Miyazato M, et al. Chemotherapy can promote liver metastasis by enhancing metastatic niche formation in mice. *J Surg Res* (2018) 224:50–7. doi: 10.1016/j.jss.2017.11.050

165. Thompson KN, Ju JA, Ory EC, Pratt SJP, Lee RM, Mathias TJ, et al. Microtubule disruption reduces metastasis more effectively than primary tumor growth. *Breast Cancer Res* (2022) 24(1):13. doi: 10.1186/s13058-022-01506-2

166. Watanabe K, Yui Y, Sasagawa S, Suzuki K, Kanamori M, Yasuda T, et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. *Oncotarget* (2019) 10(2):161–74. doi: 10.18632/oncotarget.26536

167. Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states. *Br J Cancer* (2014) 110(6):1497–505. doi: 10.1038/bjc.2014.80

168. O'Shaughnessy J, Kaklamani V, Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. *Future Oncol* (2019) 15(14):1641–53. doi: 10.2217/fon-2018-0936

169. Kopf A, Renkawitz J, Hauschild R, Girkontaite I, Tedford K, Merrin J, et al. Microtubules control cellular shape and coherence in amoeboid migrating cells. *J Cell Biol* (2020) 219(6):e201907154. doi: 10.1083/jcb.201907154

170. Welch MD. Cell migration, freshly squeezed. *Cell* (2015) 160(4):581–2. doi: 10.1016/j.cell.2015.01.053

171. Lämmermann T, Sixt M. Mechanical modes of a'moeboid' cell migration. *Curr Opin Cell Biol* (2009) 21(5):636–44. doi: 10.1016/j.ceb.2009.05.003

172. Tekle YI, Williams JR. Cytoskeletal architecture and its evolutionary significance in amoeboid eukaryotes and their mode of locomotion. *R Soc Open Sci* (2016) 3 (9):160283. doi: 10.1098/rsos.160283

frontiers | Frontiers in Oncology

TYPE Review
PUBLISHED 01 May 2023
DOI 10.3389/fonc.2023.1117867

OPEN ACCESS

EDITED BY
Vasiliki Gkretsi,
European University Cyprus, Cyprus

REVIEWED BY
Ranjit Kumar Mehta,
University of Michigan, United States
Deng Zhouming,
Wuhan University, China

*CORRESPONDENCE
Xinhui Du
zlyyduxinhui2785@zzu.edu.cn

†These authors have contributed equally to this work

RECEIVED 07 December 2022
ACCEPTED 18 April 2023
PUBLISHED 01 May 2023

CITATION
Du X, Wei H, Zhang B, Wang B, Li Z, Pang LK, Zhao R and Yao W (2023) Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.
Front. Oncol. 13:1117867.
doi: 10.3389/fonc.2023.1117867

Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities

Xinhui Du[1,2,3*†], Hua Wei[4†], Boya Zhang[1,2,3], Bangmin Wang[1,2,3], Zhehuang Li[1,2,3], Lon Kai Pang[5], Ruiying Zhao[6] and Weitao Yao[1,2,3]

[1]Bone Soft Tissue Department, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, [2]Key Laboratory for Digital Assessment of Spinal-Pelvic Tumor and Surgical Aid Tools Design (Zhengzhou), Zhengzhou, Henan, China, [3]Key Laboratory for Perioperative Digital Assessment of Bone Tumors (Henan), Zhengzhou, Henan, China, [4]Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, [5]Baylor College of Medicine, Houston, TX, United States, [6]Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States

In osteosarcoma patients, metastasis of the primary cancer is the leading cause of death. At present, management options to prevent metastasis are limited and non-curative. In this study, we review the current state of knowledge on the molecular mechanisms of metastasis and discuss promising new therapies to combat osteosarcoma metastasis. Genomic and epigenomic changes, metabolic reprogramming, transcription factors, dysregulation of physiologic pathways, and alterations to the tumor microenvironment are some of the changes reportedly involved in the regulation of osteosarcoma metastasis. Key factors within the tumor microenvironment include infiltrating lymphocytes, macrophages, cancer-associated fibroblasts, platelets, and extracellular components such as vesicles, proteins, and other secreted molecules. We conclude by discussing potential osteosarcoma-limiting agents and their clinical studies.

KEYWORDS

osteosarcoma, metastasis, reprogramming, tumor microenvironment, mechanism

Abbreviations: BMDCs, bone marrow-derived cells; CAF, cancer-associated fibroblast; DCR, disease control rate; DNMTs, DNA methyltransferases; ECM, extracellular matrix; EFS, event-free survival; ERK, extracellular signal-regulated kinase; EVs, extracellular vesicles; GLS-1, glutaminase-1; MAPK, mitogen-activated protein kinase; MMPs, matrix metalloproteinases; NPs, nanoparticles; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SCNAs, somatic copy number alterations.

Introduction

Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Current treatment options for osteosarcoma include neoadjuvant chemotherapy, wide tumor resection, and adjuvant chemotherapy. Unfortunately, these treatment options are limited in efficacy, and management outcomes have not improved in the last 30 years. The 5-year overall survival of osteosarcoma patients with primary localized tumors is 60%–70%, whereas survival drops to approximately 20% in patients with metastasis (1). Distant metastasis is found in approximately 10% of patients at diagnosis, but eventually develops in approximately 50% of patients, commonly contributing to death (2). Hence, one approach to improving overall survival in patients with osteosarcoma is to prevent or delay tumor metastasis. While the mechanisms governing osteosarcoma metastasis remain unclear, developments in molecular technology have enabled us to study osteosarcoma and other cancers more closely. These findings help to pave the way towards novel, effective, and hopefully curative therapies.

In this review, we discuss recent studies that highlight potential factors implicated in osteosarcoma metastasis (Figure 1), and highlight a few emerging anti-cancer agents with potential anti-metastatic activity.

Tumor cell alterations

Genomic alterations

The genomic profile of osteosarcoma differs greatly from that of other malignant tumors. For example, unlike in breast cancer or melanoma, few targetable recurrent point mutations exist within the protein-coding genes identified in osteosarcoma. In addition, widespread recurrent somatic copy number alterations (SCNAs) and structural rearrangements have been detected and proposed to be responsible for osteosarcoma carcinogenesis and progression. Even among osteosarcoma patients, SCNAs and structural rearrangements are highly heterogeneous (3).

Among osteosarcoma samples, metastatic tumors demonstrate significantly higher mutational burden and genomic instability than primary tumors. Mutated genes are enriched in the PI3K-Akt pathway at both the early and late stages of tumor evolution and in the MAPK pathway at the metastatic stage (4).

Examination of metastatic samples of osteosarcoma revealed alterations in key genes that may play vital roles in metastasis. These alterations include the loss of TP53, RB1, and CDKN2A, or the gain of MYC and MDM2 (4). TP53 is commonly mutated in various cancers including osteosarcoma, and most of the mutations occur in the DNA-binding domain and are characterized as either structural or contact mutations. In addition to inhibitory effects on wild-type TP53 activity, gain-of-function activity promoting tumor progression was also noted. Studies have shown that contact mutations are stronger drivers of osteosarcoma metastasis (5).

RB1 is a well-established tumor suppressor gene reported to be mutated in multiple malignant tumor types including osteosarcoma. RB1 mutation in osteosarcoma is responsible for tumor carcinogenesis and progression. At a molecular level, RB1 loss leads to aberrant spliceosome function due to the upregulation of E2F3a, a mediator of spliceosome gene expression (6).



FIGURE 1
Changes to the tumor cell and tumor microenvironment that facilitate osteosarcoma metastasis.

Amplification of 17p11.2 chromosomal region containing TOP3A led to increased expression of TOP3A, which supported the maintenance of telomeres through the alternative lengthening of telomeres (ALT) mechanism in osteosarcoma (3).

Structural rearrangements in osteosarcoma can also result in novel fusion genes that may participate in tumor progression and metastasis. For example, the fusion gene Rab22a-NeoF1 was detected in osteosarcoma samples. The resultant fusion protein activates RhoA and promotes cell migration, invasion, and lung metastasis after acetylation on K7 (7). When secreted, it also alters the function of adjacent tumor-negative cells and stimulates macrophages toward M2 polarization (8).

Personalized therapy targeting patient-specific genes with copy number alterations and expression changes was tested in patient-derived tumor xenografts and showed a significant decrease in tumor burden (9).

Epigenomic changes

Epigenetic changes are commonly found in osteosarcoma and are involved in multiple aspects of tumor progression including metastasis (10). For example, the methyltransferase DNMT3A inhibits miR-149 expression by DNA methylation to activate the NOTCH1/Hedgehog pathway, thereby promoting the proliferation and metastasis of osteosarcoma (11). The long non-coding RNA (lncRNA) THAP9-AS1 binds to and promotes methylation of the SOCS3 promoter region with DNA methyltransferases (DNMTs) and activates the JAK2/STAT3 signaling pathway to facilitate osteosarcoma growth and metastasis (12). In fact, inhibiting DNMT-1 sensitized osteosarcoma cells to cabozantinib and other targeted agents by repressing the Notch pathway and subsequently upregulating expression of miR-34a (13).

RNA modifications also play a role in osteosarcoma metastasis. The m6A demethylase FTO mediates mRNA demethylation, promoting the decay of KLF3 mRNA and decreasing its expression, consequently facilitating osteosarcoma proliferation and metastasis (14). Also, the destabilizing effects of FTO on DACT1 mRNA promotes Wnt signaling and consequently osteosarcoma metastasis (15). In addition, ALKBH5-mediated m6A methylation upregulates the expression of USP22 and RNF40, subsequently inhibiting the ubiquitination of histone H2A, promoting osteosarcoma growth and metastasis (16). Upregulation of TRIM7 due to the loss of m6A RNA modifications has also been reported to promote osteosarcoma metastasis and chemoresistance by inducing the ubiquitination of BRMS1 (17).

The prognostic role of epigenetic changes in osteosarcoma have also been extensively studied. Immune-related DNA methylation patterns can be used to predict survival and tumor microenvironment patterns (18). RNA methylation-related signatures of metabolic genes and lncRNAs have also been proposed to be useful tools in the estimation of patient survival and immune landscapes of osteosarcoma (19, 20).

Metabolic reprogramming

Metabolic reprograming is one of the key features of osteosarcoma, and its role in tumor progression, drug resistance, and metastasis is well established (21). Various metabolic gene signatures have been found to predict survival in osteosarcoma patients (19, 22–24). For example, comprehensive metabolic profiling of osteosarcoma based on UHPLC-HRMS unveiled a panel of two metabolites, 5-aminopentanamide and 13(S)-HpOTrE (FA 18:3 + 2O), which was found to be an accurate indicator of lung metastases (25).

Aerobic glycolysis, also known as the Warburg effect, supports biosynthesis and metabolic processes necessary for osteosarcoma growth and metastasis (26). Key enzymes involved in this process, such as PGC1α, PKM2, ALDOA, and LDHA, can directly influence tumor progression and metastasis. For instance, miR-23b-3p downregulates PGC1α and promotes a metabolic shift from oxidative phosphorylation to glycolysis, supporting osteosarcoma progression (27).

PKM2 is another key enzyme regulating glycolysis, which acts on its substrate phosphoenolpyruvate (PEP) to form pyruvate (28). IRF7 was found to downregulate PKM2 *via* transcriptional suppression, inhibiting aerobic glycolysis in osteosarcoma (29). The SLIT2/ROBO1 axis contributes to the Warburg effect by activating the SRC/ERK/c-MYC/PFKFB2 pathway in osteosarcoma (30). ROCK2 can promote glycolysis and osteosarcoma tumor growth by upregulating HKII *via* the pPI3K/AKT signaling pathway (31). Aldolase A (ALDOA) stimulation by the lncRNA KCNQ1OT1 sponging miR-34c-5p promotes aerobic glycolysis in osteosarcoma to support metastasis (32).

Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate. The upregulation of LDHA is involved in cancer cell growth and migration, the development of stem-cell like traits, and chemoresistance (33). KDM6B regulates H3K27me3 demethylation in the promoter region of LDHA, thereby promoting LDHA expression and aerobic glycolysis in osteosarcoma cells, and hence facilitating tumor metastasis (34).

The m^6A-reading protein YTH N^6-methyladenosine RNA-binding protein 3 (YTHDF3) contributes to osteosarcoma progression by promoting aerobic glycolysis through enhancement of PGK1 mRNA stability in an m^6A-dependent manner (35).

IDH1 is an important TCA cycle enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate. High levels of IDH1 have been detected in osteosarcoma and correlated with poor survival. Hsp90-AHA1 was found to upregulate IHD1 and promote growth and metastasis in osteosarcoma (36).

Besides glucose metabolism, changes in lipid and amino acid metabolism have also been reported to participate in osteosarcoma metastasis. Lipid profiles differ in metastatic osteosarcoma cell lines compared to non-metastatic cells. For example, diacylglycerols are overexpressed in metastatic osteosarcoma cells, and the blockage of its synthesis can in fact inhibit cell migration (37). Highly metastatic osteosarcoma cell lines require glutamine for proliferation, and conversely, glutaminase-1 (GLS-1) inhibition limits metastatic progression in osteosarcoma (38).

CD47 is a key factor mediating immune evasion of tumor cells from the innate immune system. Increased uptake of leucine and glutamine in osteosarcoma cells through upregulation of LAT2 activates mTORC1 and subsequent c-Myc-mediated transcription

of CD47, enabling evasion of innate immune mechanisms and thereby promoting metastasis (39).

Dysregulated pathways

Dysregulated signaling pathways have also been reported to be involved in osteosarcoma metastasis (Figure 2).

Wnt/β-catenin signaling pathway

The Wnt/β-catenin signaling pathway is reported to play a crucial role in cell fate determination, proliferation, and migration in cancer. Cytoplasmic β-catenin undergoes ubiquitination and proteasomal degradation mediated by a destruction complex composed of Axin, APC, PP2A, GSK3, and CK1α. On the other hand, nuclear translocated β-catenin acts as a transcriptional coactivator for the TCF/LEF family of transcription factors promoting the expression of Wnt-target genes such as C-myc, RUNX2, and CyclinD1, which subsequently promotes the epithelial–mesenchymal transition and facilitates osteosarcoma metastasis (40, 41).

RUVBL1 can be regulated by CircMYO10/miR-370-3p in osteosarcoma and influences osteosarcoma progression. Molecularly, RUVBL1 enhances the transcriptional activity of the β-catenin/LEF1 complex by mediating chromatin remodeling at the promoter regions of LEF1 target genes, consequently promoting osteosarcoma metastasis (42).

C-Jun-MMP9/Bcl-2 pathway

As upstream signaling agents of MMPs, mitogen-activated protein kinase (MAPK) is a family of serine/threonine kinases that includes extracellular signal-regulated kinase (ERK)1/2, c-Jun N-terminal kinase (JNK) 1/2, and p38. Activation of MAPK is followed by the phosphorylation of various cytosolic substrates that participate in numerous cellular activities such as cell proliferation, differentiation, invasion, migration, and death (43, 44).

Activated by CERB3, c-Jun upregulates MMP9 and Bcl-2 to promote osteosarcoma proliferation and metastasis (45).

Rho GTPases

Rho GTPases belong to the Ras superfamily of GTPases, which are implicated in cell proliferation, cell cycle progression, and migration. Dysregulation of Rho GTPase functions is involved in osteosarcoma progression and metastasis (46).

RhoA activation in tumor cells leads to osteosarcoma metastasis to the lung (47, 48). The fusion protein Rab22a-NeoF1 either directly binds and activates RhoA, or is secreted together with its binding partner PKY2 by tumor-positive cells, taken up by tumor-negative cells, and facilitating RhoA activation *via* PYK2 (3, 49).

The Rho-associated coiled-coil containing protein kinase 1 (ROCK1) was reported to be a proliferation- and metastasis-related gene in various cancers including osteosarcoma (50). ROCK1 is regulated in osteosarcoma by lncRNA DANCR/miR-335-5p/miR-1972 (51).

JAK-STAT pathways

Signal transducer and activator of transcription (STAT) consists of seven members involved in the regulation of cell proliferation, differentiation, and survival. The activation of STAT1 in osteosarcoma cells suppressed EMT, resulting in increased apoptosis and cell cycle arrest, and decreased colony formation, cell migration, and invasion. Increased expression of COL6A1 promoted STAT1 degradation, which subsequently facilitated osteosarcoma metastasis (52). Furthermore, STAT3 is overexpressed in osteosarcoma and associated with poor survival. Activation of STAT3 upregulates the expression of target oncogenes and facilitates osteosarcoma metastasis (53).

Transcription factors

Dysregulation of transcription factors also contributes to osteosarcoma metastasis. NRF2 regulates intracellular ROS balance, the AMPK/mTOR autophagy signaling pathway, and the Warburg effect. TRIM22 inhibits osteosarcoma progression by binding to and destabilizing NRF2 in a KEAP1-independent manner (54).



FIGURE 2
Signaling pathways that contribute to osteosarcoma metastasis when dysregulated.

RUNX proteins are DNA-binding transcription factors that regulate the expression of multiple genes involved in cellular differentiation and cell-cycle progression. RUNX2 is essential to osteoblast maturation and bone development, and can either suppress or promote carcinogenesis based on the clinical condition (55). Studies of osteosarcoma tumors have revealed that levels of RUNX2 DNA, RNA, and protein are significantly elevated in osteosarcoma tumors. Chromobox homolog4 (CBX4) is overexpressed in osteosarcoma cell lines and tissues, and promotes osteosarcoma metastasis by transcriptionally upregulating RUNX2 *via* the recruitment of GCN5 to the RUNX2 promoter (56).

Cyclic AMP-responsive element-binding protein 3 (CERB3), also known as LZIP or LUMAN, is a member of the leucine zipper transcription factor family. Its tumor-promoting role in osteosarcoma is regulated by circular RNA circTADA2A-miR-203a-3p. Molecularly, CREB3 can bind directly to the c-Jun promoter and regulate the transcriptional activity of c-Jun in osteosarcoma. MMP9 and Bcl-2 can be regulated by c-Jun and participate in CREB3-c-Jun modulated osteosarcoma progression (45).

The transcription activators YAP/YAZ regulate EMT through AXL in osteosarcoma and influences cell differentiation, cell fate, and metastasis (57).

Tumor microenvironment

The tumor microenvironment includes cellular components, extracellular matrix, vesicles, and secreted molecules that interact with each other to regulate tumor progression, immune evasion, drug resistance, and metastasis (58, 59).

The cellular components of the tumor microenvironment are mainly composed of infiltrating lymphocytes, macrophages, fibroblasts, and platelets. The composition and functions of these cells are dynamically regulated by local tumor cells and can be influenced by therapeutic agents. The recruitment and/or activation of certain cells in the microenvironment play pivotal roles in osteosarcoma metastasis (60).

The prognostic role of tumor-infiltrating lymphocytes in the osteosarcoma tumor microenvironment has been explored. The presence of tumor-infiltrating CD4+ or CD8+ cells was correlated with improved overall survival and progression-free survival in osteosarcoma patients (61).

In addition to tumor-infiltrating lymphocytes, the functional states of macrophages in the tumor microenvironment have also been associated with osteosarcoma progression and metastasis. M1-polarized macrophages are generally regarded as tumor-suppressing, while M2-type macrophages exhibit tumor-promoting roles in osteosarcoma. Molecularly, M2-type macrophages secrete cytokines such as IL-10, TGF-β, and VEGF to promote osteosarcoma EMT and metastasis (62). The M2-polarized macrophages are primarily induced by the activation of Stat3 secondary to stimulation by tumor cell secretions such as exosomes or vesicles. For instance, tumor-derived exosomes have been reported to induce M2 macrophage polarization *via* Tim-3 to promote osteosarcoma metastasis (62). PYK2 secretion by osteosarcoma cells recruits bone marrow-derived cells (BMDCs) and induces M2 macrophage polarization by activating Stat3 in macrophage cells (8). In the presence of chemotherapy, macrophages secrete IL-18 and enable the upregulation of LAT2 in adjacent osteosarcoma cells, which, in turn, promotes tumor evasion by upregulating CD47 (39).

Cancer-associated fibroblasts (CAFs) comprise a large proportion of cells in the tumor microenvironment. These cells can be identified by the presence of α-smooth muscle actin, fibroblast activation protein, and vimentin. Activated CAFs are thought to promote tumor cell growth, invasion, metastasis, drug resistance, and reprogramming (63). At a molecular level, CAFs build up and remodel the extracellular matrix, enabling tumor cells to invade through the TME. In addition, CAFs modulate cancer cell behavior through the secretion of growth factors, cytokines, and chemokines such as IL-1beta, IL-6, IL-8, TGF-β, and collagen (63).

CAFs can be activated and reprogrammed by various mechanisms, contributing to tumor metastasis. Increased levels of COL6A1 in tumor cells are packaged into exosomes and transported to activated CAFs, which, in turn, promote tumor invasion and metastasis by secreting TGF-β (52). CAFs in the lung can also be reprogrammed to support osteosarcoma metastasis under the influence of TGF-β1 found in osteosarcoma-derived extracellular vesicles (64).

Platelet aggregation and activation can be induced by tumor cells to support tumor metastasis in osteosarcoma. Osteosarcoma cells highly express PDPN, which binds with CLEC-2 on the surface of platelets, leading to platelet activation and subsequent tumor metastasis. At a molecular level, activated platelets secrete various growth factors and cytokines such as PDGF, TGF-β, and LPA, thereby inducing EMT and promoting cell migration and invasion in osteosarcoma. In addition, aggregated platelets form clusters with tumor cells, which are then trapped in the microvasculature of various organs such as the lung, triggering tumor metastasis (65).

The extracellular matrix (ECM) is extensively altered in osteosarcoma, beginning with the collagens and proteoglycans that make it up. Increased expression of several sarcomatous matrix proteins has been associated with poor response to chemotherapy and poor prognosis in clinical studies of osteosarcoma. NELL1 is a secreted osteoinductive protein, which has bone anabolic and anti-osteoclastic effects. NELL1 can promote osteosarcoma metastasis by regulating the expression of key matricellular proteins through the induction of FAK/Src signaling (66).

The procollagen C-proteinase enhancer protein (PCOLCE) is a secreted glycoprotein that enhances procollagen C-proteinase participation in ECM reconstruction. PCOLCE is upregulated by TWIST1 in osteosarcoma and promotes osteosarcoma metastasis to the lung (67).

The extracellular matrix glycoprotein tenascin-C is highly expressed in the tumor microenvironment and promotes the migration, invasion, and metastatic progression of osteosarcoma. Tenascin-C functions by binding with its receptor integrin α9β1, which abolishes actin stress fiber formation and inhibits YAP and its downstream target gene expression (68).

Extracellular vesicles (EVs) are secreted by both tumor cells and their adjacent non-tumor counterparts with diameters ranging from 30 to 150 nm (69). These vesicles are rich in biologically active components such as proteins, lipids, and nucleic acids, and play important roles in the exchange of biomolecules between different cell types (70). Many studies have correlated EVs with carcinogenesis, progression, and metastasis in osteosarcoma (71–73).

Results of the recent clinical trials of advanced or metastatic osteosarcoma

To date, there remains no established effective treatment for metastatic osteosarcoma. Multiple clinical trials have been conducted in recent years to investigate the viability of novel agents or treatment combinations. We compiled key findings from clinical trials in advanced or metastatic osteosarcoma within the last 7 years (summarized in Table 1).

Wen et al. reported a Phase 1 clinical trial investigating the efficacy of the combination therapy of pegylated liposomal doxorubicin and cisplatin in metastatic and recurrent osteosarcoma (74). In 15 cases, the 6-week objective response rate was 13.3% and the disease control rate was 66.7%. Other trials on targeted therapies such as regorafenib (77, 78), dinutuximab (79), robatumumab (76), sorafenib, and everolimus (75) demonstrated limited success with the overall 6-month progression-free survival rate of less than 50%.

The efficacy of combinatorial chemotherapy and targeted therapy treatments has also been tested in metastatic or unresectable osteosarcoma. A single-arm Phase 2 clinical trial involving 28 patients treated with pazopanib and topotecan failed to show any significant improvement in survival (6-month progression-free survival of 45.4%) (80).

Immunotherapy is an emerging treatment modality that has shown promising results in selected cases in melanoma and lung cancers. However, osteosarcoma patients did not seem to respond well to immune checkpoint inhibitors (81–83). The addition of interleukin-2 immunotherapy to a four-agent chemotherapy regimen for treating metastatic osteosarcoma did result in a 3-year event-free survival of 34.3% and 3-year overall survival of 45.0% (84), but a combination of targeted therapy and immunotherapy did not elicit better outcomes (85, 86).

Radiotherapy with radium 223 was also assessed in a clinical trial that involved 18 patients with recurrent or metastatic osteosarcoma (87). This Phase 1 single-arm multi-center trial reported a median overall survival of 25 weeks.

Ongoing clinical trials

There are currently several ongoing clinical trials involving metastatic osteosarcoma registered in ClinicalTrials.gov (Table 2). These include Phase 1, 2, and 3 trials. Interventions being investigated include chemotherapy, immunotherapy, radiotherapy, or targeted therapy alone; and combinatorial chemotherapy and immunotherapy, chemotherapy and targeted therapy, and targeted therapy and immunotherapy. Favorable outcomes from these trials have the potential to transform the landscape of clinical management of metastatic osteosarcoma.

TABLE 1 Results of recent clinical trials involving patients with advanced or metastatic osteosarcoma.

Treatment type	Intervention agents	Inclusion criteria	Trial phase	Number of cases	Study design	Results	Year of publication	References
Chemotherapy	Pegylated liposomal doxorubicin +cisplatin	Metastatic and recurrent osteosarcoma	Phase 1	15	Single arm, multiple center	6-week ORR, 13.3%; DCR, 66.7%	2022	Xi-zhi Wen (74)
Targeted therapy	Sorafenib and everolimus	Relapsed or unresectable osteosarcoma progressing after standard treatment (methotrexate, cisplatin, and doxorubicin, with or without ifosfamide)	Phase 2	38	Single arm, multiple center	6-month PFS, 45%	2015	Giovanni Grignani (75)
	Robatumumab	Resectable osteosarcoma metastases (Group 1, *n* = 31), Unresectable osteosarcoma metastases (Group 2, *n* = 29)	Phase 2	60	Case–control study	>6-month DCR, 9.7% *vs.* 0; median OS 24 m *vs.* 8.2 m	2016	Peter M. Anderson (76)
	Regorafenib *vs.* placebo	Progressive metastatic osteosarcoma	Phase 2	42	Randomized double-blind, multi center	Median PFS 3.6 m *vs.* 1.7 m	2019	Lara E. Davis (77)

(Continued)

TABLE 1 Continued

Treatment type	Intervention agents	Inclusion criteria	Trial phase	Number of cases	Study design	Results	Year of publication	References
	Regorafenib *vs.* placebo	Metastatic osteosarcoma	Phase 2	43	Randomized double-blind, multi center	8-week PFS 65% *vs.* 0	2019	Florence Duffaud (78)
	Dinutuximab	Recurrent pulmonary osteosarcoma in complete surgical remission	Phase 2	39	Single arm, single center	12-month DCR (event-free survival), 28.2%	2022	Pooja Hingorani (79)
Chemotherapy and targeted therapy	Pazopanib +topotecan	Metastatic or unresectable osteosarcoma	Phase 2	28	Single arm, open	12-w PFS, 69.5%; 24-w PFS, 45.4%; 12-month PFS, 18.2%;median PFS, 4.5 months; median OS, 11.1 months; ORR, 4%.	2021	Brian Schulte (80)
Immunotherapy	Trivalent ganglioside vaccine + OPT-821 *VS* OPT-821	Metastatic osteosarcoma following complete metastasectomy as subgroup	Phase 2	14	Randomized double-blind, multi center	12-month RFS 34.5% *vs.* 34.8% in general, subgroup data not shown	2022	Evan Rosenbaum (81)
	Pembrolizumab	Advanced or metastatic osteosarcoma	Phase 2	22	Single arm, multiple center	BOR, 5%	2017	Hussein A Tawbi (82)
	Ipilimumab	Advanced or metastatic osteosarcoma	Phase 1	8	Single arm, multiple center	6-w PFS, 0%	2016	Melinda S. Merchant (83)
Chemotherapy and immunotherapy	Chemotherapy(4 agents) and interleukin-2	Primary metastatic osteosarcoma	Phase 2	35	Single arm, single center	3-y EFS, 34.3%; 3-y OS, 45.0%	2017	Cristina Meazza (84)
Targeted therapy and immunotherapy	Nivolumab +bempegaldesleukin	Advanced or metastatic osteosarcoma	Phase 2	10	Single arm, open	6-month DCR, 0%; median PFS, 2 months; median OS, 6.3 months	2022	Sandra P. D'Angelo (85)
	Durvalumab plus tremelimumab	Advanced or metastatic osteosarcoma	Phase 2	5	Single arm, single center	12-w PFS, 0%	2022	Neeta Somaiah (86)
Radiotherapy	Radium 223	Recurrent/metastatic osteosarcoma	Phase 1	18	Single arm, multiple center	Median OS, 25 w	2019	Vivek Subbiah (87)

ORR, objective response rate; PFS, progression free survival; DCR, disease control rate; OS: overall survival; RFS, recurrent free survival; BOR, best of response; EFS, event-free survival.

Discussion

Osteosarcoma is the most common primary bone malignancy affecting children and young adults. More than 10% of patients are diagnosed with distant metastasis, and the 5-year overall survival of these patients is approximately 20%. However, current management options to prevent metastasis are limited and ineffective.

Emerging treatment options

Growing research on tumor cell alterations, behavior, and their surrounding microenvironment has informed the investigation of novel treatment options in preclinical settings. These include inhibitors targeting key metastasis-promoting proteins, approved drugs with newly discovered anti-metastatic roles, bioactive nanoparticles, and traditional Chinese medicine agents (Figure 3).

Inhibitors targeting key metastasis-promoting proteins

Multiple key drivers of osteosarcoma metastasis have been reported, and inhibitors targeting these specific drivers have been developed and assessed. The covalent CDK7 inhibitor THZ2 demonstrated significant suppression of osteosarcoma tumor growth and metastasis by targeting super-enhancer-associated oncogenes (88). Tegavivint, a novel β-catenin/transducing β-like protein 1 (TBL1) inhibitor, exhibits anti-proliferative activity against osteosarcoma cells *in vitro* and *in vivo* through

10.3389/fonc.2023.1117867

TABLE 2 Ongoing clinical trials involving patients with metastatic osteosarcoma.

Intervention type	Interventions	Phases	Enrollment	Status	NCT Number
Chemotherapy	Methotrexate, Doxorubicin, Cisplatin, Ifosfamide, and Etoposide (MAPIE) with or without Zoledronic acid	Phase 3	318	Active, not recruiting	NCT00470223
	Drug: Ascorbate	Early Phase 1	20	Recruiting	NCT04634227
	Drug: Doxorubicin	Phase 1	11	Active, not recruiting	NCT02811523
Chemotherapy +immunotherapy	Drug: Mifamurtide|Combination Product: EI or M-API regimen depending on patient age	Phase 2	126	Recruiting	NCT03643133
	Drug: Cyclophosphamide|Drug: attIL2-T cells	Phase 1	40	Not yet recruiting	NCT05621668
	Genetic: GD2 T cells|Biological: VZV vaccine|Drug: Fludarabine|Drug: Cyclophosphamide	Phase 1	26	Active, not recruiting	NCT01953900
Chemotherapy +targeted therapy	Drug: Chemotherapy (gemcitabine and docetaxel) plus BIO-11006	Phase 2	10	Active, not recruiting	NCT04183062
	Methotrexate, Doxorubicin, and Cisplatin (MAP) with or without Cabozantinib	Phase 2| Phase 3	1,122	Not yet recruiting	NCT05691478
	Drug: Apatinib|Drug: GD regimen	Phase 2	43	Active, not recruiting	NCT03742193
	Drug: carboplatin|Drug: dasatinib|Drug: etoposide phosphate|Drug: ifosfamide	Phase 1| Phase 2	7	Active, not recruiting	NCT00788125
Immunotherapy	Biological: Dinutuximab|Biological: Sargramostim	Phase 2	41	Active, not recruiting	NCT02484443
	Biological: Denosumab	Phase 2	56	Active, not recruiting	NCT02470091
	Biological: Durvalumab|Biological: Oleclumab	Phase 2	75	Recruiting	NCT04668300
	Biological: Aerosolized Aldesleukin	Phase 1	70	Active, not recruiting	NCT01590069
	Drug: Iscador*P	Phase 2	32	Not yet recruiting	NCT05726383
	Biological: Ipilimumab|Biological: Nivolumab|Other: Quality-of-Life Assessment	Phase 2	164	Active, not recruiting	NCT02500797
Radiotherapy	Drug: Iodine I 131 MOAB 8H9	Phase 1	120	Active, not recruiting	NCT00089245
Targeted thearpy +immunotherapy	Biological: Atezolizumab|Drug: Cabozantinib	Phase 2	40	Not yet recruiting	NCT05019703
	Drug: Regorafenib 40 MG|Drug: Regorafenib 20MG|Drug: Nivolumab	Phase 2	48	Recruiting	NCT04803877
Targeted therapy	Drug: Natalizumab	Phase 1| Phase 2	20	Recruiting	NCT03811886
	Drug: Cabozantinib S-malate	Phase 2	90	Active, not recruiting	NCT02243605
	Drug: Regorafenib|Drug: Placebo	Phase 2	132	Recruiting	NCT02389244

downregulation of the Wnt signaling pathway (89). CDK12 has been reported to facilitate genome stability through the regulation of DDR genes; accordingly, the CDK12 inhibitors THZ531 and E9 were found to disrupt osteosarcoma metastasis (90). BMTP-11 targets IL-11R α and inhibits osteosarcoma tumor growth and lung metastasis (91). A quinoline-based DNA methyltransferase inhibitor can induce cell cycle arrest and osteoblastic differentiation in osteosarcoma. It also showed synergistic effects with doxorubicin and cisplatin in treating osteosarcoma (92).

Approved drugs with newly discovered anti-metastatic roles

Drugs previously FDA-approved for other indications have been reported to inhibit osteosarcoma progression and metastasis.



FIGURE 3
Novel therapies that have demonstrated anti-metastatic effects in osteosarcoma in preclinical studies.

The FDA-approved DNA methylation inhibitor decitabine has demonstrated the ability to decrease proliferation, induce osteoblast differentiation, and reduce metastasis to visceral organs. Decitabine exposure in osteosarcoma reduces the protein expression of the metastasis-associated markers VIMENTIN, SLUG, ZEB1, and MMP9, with a concurrent decrease in mRNA expression of the known stem cell markers SOX2, OCT4, and NANOG. Normal osteoblasts express estrogen receptor α (ERα), whereas osteosarcoma cells do not due to promoter DNA methylation. Treatment of 143B osteosarcoma cells with decitabine led to ERα expression and decreased proliferation and induction of osteoblast differentiation (93).

Pramlintide, an FDA-approved drug for type 2 diabetes, was found to inhibit glycolysis and osteosarcoma tumor growth both *in vitro* and *in vivo* by inducing apoptosis (94). Melatonin attenuates chemokine CCL24 levels through inhibition of the JNK pathway to hinder human osteosarcoma cell invasion (95). All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages (96).

Bioactive nanoparticles

Bioactive nanoparticles (NPs), such as gold NPs, copper oxide NPs, iron oxide NPs, and zinc oxide nanoparticles (ZnO NPs), have been recently discovered to possess significant tumor-suppressing roles (97–99). ZnO NPs can inhibit osteosarcoma metastasis by degrading β-catenin in the HIF-1 α/BNIP3/LC3B-mediated mitophagy pathway (100).

Traditional Chinese medicine agents

The anti-tumor roles of traditional Chinese medicines and herbs have been explored in osteosarcoma. Ailanthone (AIL), a major component of the Chinese medicine *Ailanthus altissima*, can induce metabolic reprogramming in osteosarcoma, leading to growth inhibition both *in vitro* and *in vivo*. Molecularly, AIL induces cell cycle arrest and apoptosis in osteosarcoma cells by downregulating the serine biosynthetic pathway (101). Other natural compounds or herbs such as degalactotigonin (102) and shikonin (103) have also been reported to inhibit osteosarcoma growth and metastasis.

Navigating the challenges of osteosarcoma

Osteosarcoma research is particularly challenging (Figure 4). The low prevalence of osteosarcoma makes the conducting of rigorous clinical trials especially challenging. Heterogeneity within and between patient tumors also limits the generalizability of study findings. Thankfully, advancements in biotechnology and molecular techniques have paved the way for solutions to some of these challenges. For example, patient-derived xenograft models and organoid cultures have emerged as viable cancer models for experimentation, offering increased biomimicry, which should lead to stronger correlations with patient outcomes. Furthermore, detailed molecular characterization of osteosarcoma has allowed for the development of personalized therapies that target specific biomarkers and patient genomic profiles, increasing efficacy of potential treatments.

Conclusion

We reviewed the current literature on contributors to osteosarcoma metastasis, including genomic and epigenomic changes, metabolic reprogramming, transcription factors, dysregulation of physiologic pathways, and alterations to the tumor microenvironment. In addition, we discussed potential emerging therapies to suppress osteosarcoma metastasis. Further research on the molecular mechanisms of osteosarcoma metastasis, combined with growing molecular technologies, can inform the development of novel, personalized, and targeted therapies to ultimately improve outcomes in osteosarcoma patients.

Author contributions

Conceptualization, XD and HW. Writing—original draft preparation, XD. Writing—review and editing, BZ, LP and RZ. Visualization, HW. Supervision, WY. Funding acquisition, XD and HW. All authors contributed to the article and approved the submitted version.



FIGURE 4
Features of, treatment challenges in, and potential solutions for osteosarcoma.

Funding

This study was jointly supported by the grants of the National Natural Science Foundation of China (Grant No. 82102258), the Natural Science Foundation of Henan Province (Grant No. 212300410252), the Henan Provincial Medical Science and Technology Research Project (Grant Nos. LHGJ20190217 and LHGJ20220194), and the Key Technologies R & D Program of Henan Province (Grant No. 212102310617).

Acknowledgments

Special thanks to Sunny and Jessica for their support in preparing the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Hu Z, Wen S, Huo Z, Wang Q, Zhao J, Wang Z, et al. Current status and prospects of targeted therapy for osteosarcoma. *Cells Switzerland;* (2022) 11. doi: 10.3390/cells11213507

2. Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. *N Engl J Med United States;* (2021) 385:2066–76. doi: 10.1056/NEJMra2103423

3. de Nonneville A, Salas S, Bertucci F, Sobinoff AP, Adélaïde J, Guille A, et al. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT. *EMBO Mol Med England;* (2022) 14:e15859. doi: 10.15252/emmm.202215859

4. Wang D, Niu X, Wang Z, Song C-L, Huang Z, Chen K-N, et al. Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases. *Cancer Res* (2019) 79:7–20. doi: 10.1158/0008-5472.CAN-18-1086

5. Xiong S, Chachad D, Zhang Y, Gencel-Augusto J, Sirito M, Pant V, et al. Differential gain-of-Function activity of three p53 hotspot mutants in vivo. *Cancer Res* (2022) 82:1926–36. doi: 10.1158/0008-5472.CAN-21-3376

6. Tu J, Huo Z, Yu Y, Zhu D, Xu A, Huang M-F, et al. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. *Proc Natl Acad Sci U S A United States;* (2022) 119:e2117857119. doi: 10.1073/pnas.2117857119

7. Liang X, Wang X, He Y, Wu Y, Zhong L, Liu W, et al. Acetylation dependent functions of Rab22a-NeoF1 fusion protein in osteosarcoma. *Theranostics.* (2020) 10:7747–57. doi: 10.7150/thno.46082

8. Zhong L, Liao D, Li J, Liu W, Wang J, Zeng C, et al. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. *Signal Transduct Target Ther* (2021) 6:59. doi: 10.1038/s41392-020-00414-1

9. Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu H-Y, et al. Genome-informed targeted therapy for osteosarcoma. *Cancer Discovery* (2019) 9:46–63. doi: 10.1158/2159-8290.CD-17-1152

10. Namløs HM, Skårn M, Ahmed D, Grad I, Andresen K, Kresse SH, et al. miR-486-5p expression is regulated by DNA methylation in osteosarcoma. *BMC Genomics* (2022) 23:142. doi: 10.1186/s12864-022-08346-6

11. Cheng S, Wang W. DNMT3A regulates miR-149 DNA methylation to activate NOTCH1/Hedgehog pathway to promote the development of junctional osteosarcoma. *BioMed Res Int* (2022) 2022:3261213. doi: 10.1155/2022/3261213

12. Yang S, Wang B, Liu C, Wang Q, Wang R, Su W, et al. THAP9-AS1 promotes tumorigenesis and reduces ROS generation through the JAK2/STAT3 signaling pathway by increasing SOCS3 promoter methylation in osteosarcoma. *Oxid Med Cell Longev* (2021) 2021:5620475. doi: 10.1155/2021/5620475

13. Wang J-H, Zeng Z, Sun J, Chen Y, Gao X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib *in vitro* and *in vivo* by targeting DNMT-1 correlated with disease severity in human patients. *Pharmacol Res Netherlands;* (2021) 173:105869. doi: 10.1016/j.phrs.2021.105869

14. Shan H-J, Gu W-X, Duan G, Chen H-L. Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of krüppel-like factor 3 (KLF3) promotes osteosarcoma progression. *Bioengineered.* (2022) 13:8038–50. doi: 10.1080/21655979.2022.2051785

15. Lv D, Ding S, Zhong L, Tu J, Li H, Yao H, et al. M(6)A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes wnt signaling to facilitate osteosarcoma progression. *Oncogene England;* (2022) 41:1727–41. doi: 10.1038/s41388-022-02214-z

16. Yadav P, Subbarayalu P, Medina D, Nirzhor S, Timilsina S, Rajamanickam S, et al. M6A RNA methylation regulates histone ubiquitination to support cancer growth and progression. *Cancer Res* (2022) 82:1872–89. doi: 10.1158/0008-5472.CAN-21-2106

17. Zhou C, Zhang Z, Zhu X, Qian G, Zhou Y, Sun Y, et al. N6-methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. *EBioMedicine.* (2020) 59:102955. doi: 10.1016/j.ebiom.2020.102955

18. Shi D, Mu S, Pu F, Liu J, Zhong B, Hu B, et al. Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma. *Mol Oncol* (2022) 16:2174–94. doi: 10.1002/1878-0261.13160

19. Wang G, Wang H, Cheng S, Zhang X, Feng W, Zhang P, et al. N1-methyladenosine methylation-related metabolic genes signature and subtypes for predicting prognosis and immune microenvironment in osteosarcoma. *Front Genet* (2022) 13:993594. doi: 10.3389/fgene.2022.993594

20. Wu Z-Y, Shi Z-Y. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma. *Eur Rev Med Pharmacol Sci Italy;* (2022) 26:5868–83.

21. He Q, Hao P, He G, Mai H, Liu W, Zhang W, et al. IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells. *J Transl Med England;* (2022) 20:348. doi: 10.1186/s12967-022-03549-7

22. Li L, Li Z, He X, Wang Y, Lu M, Gong T, et al. A nutritional metabolism related prognostic scoring system for patients with newly diagnosed osteosarcoma. *Front Nutr Switzerland;* (2022) 9:883308. doi: 10.3389/fnut.2022.883308

23. Wan L, Zhang W, Liu Z, Yang Z, Tu C, Li Z. A novel glutamine metabolism-related gene signature in prognostic prediction of osteosarcoma. *Int J Gen Med New Zealand;* (2022) 15:997–1011. doi: 10.2147/IJGM.S352859

24. Li L-Q, Zhang L-H, Yuan Y-B, Lu X-C, Zhang Y, Liu Y-K, et al. Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients. *Cancer Med United States;* (2021) 10:4493–509. doi: 10.1002/cam4.3984

25. Lv D, Zou Y, Zeng Z, Yao H, Ding S, Bian Y, et al. Comprehensive metabolomic profiling of osteosarcoma based on UHPLC-HRMS. *Metabolomics United States;* (2020) 16:120. doi: 10.1007/s11306-020-01745-4

26. Feng Z, Ou Y, Hao L. The roles of glycolysis in osteosarcoma. *Front Pharmacol Switzerland;* (2022) 13:950886. doi: 10.3389/fphar.2022.950886

27. Zhu R, Li X, Ma Y. miR-23b-3p suppressing PGC1α promotes proliferation through reprogramming metabolism in osteosarcoma. *Cell Death Dis England;* (2019) 10:381. doi: 10.1038/s41419-019-1614-1

28. Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. *Cell Biosci England;* (2019) 9:52. doi: 10.1186/s13578-019-0317-8

29. Li Z, Geng M, Ye X, Ji Y, Li Y, Zhang X, et al. IRF7 inhibits the warburg effect *via* transcriptional suppression of PKM2 in osteosarcoma. *Int J Biol Sci Australia;* (2022) 18:30–42. doi: 10.7150/ijbs.65255

30. Zhao S-J, Shen Y-F, Li Q, He Y-J, Zhang Y-K, Hu L-P, et al. SLIT2/ROBO1 axis contributes to the warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway. *Cell Death Dis England;* (2018) 9:390. doi: 10.1038/s41419-018-0419-y

31. Deng B, Deng J, Yi X, Zou Y, Li C. ROCK2 promotes osteosarcoma growth and glycolysis by up-regulating HKII *via* phospho-PI3K/AKT signalling. *Cancer Manag Res New Zealand;* (2021) 13:449–62. doi: 10.2147/CMAR.S279496

32. Shen Y, Xu J, Pan X, Zhang Y, Weng Y, Zhou D, et al. LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth *via* ALDOA enhanced aerobic glycolysis. *Cell Death Dis England;* (2020) 11:278. doi: 10.1038/s41419-020-2485-1

33. Sharma D, Singh M, Rani R. Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics. *Semin Cancer Biol Engl* (2022). doi: 10.1016/j.semcancer.2022.11.007

34. Jiang Y, Li F, Gao B, Ma M, Chen M, Wu Y, et al. KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma. *Theranostics.* (2021) 11:3868–81. doi: 10.7150/thno.53347

35. Liu D, Li Z, Zhang K, Lu D, Zhou D, Meng Y. N(6)-methyladenosine reader YTHDF3 contributes to the aerobic glycolysis of osteosarcoma through stabilizing PGK1 stability. *J Cancer Res Clin Oncol Germany* (2022). doi: 10.1007/s00432-022-04337-y

36. Zheng D, Liu W, Xie W, Huang G, Jiang Q, Yang Y, et al. AHA1 upregulates IDH1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma. *Signal Transduct Target Ther* (2021) 6:25. doi: 10.1038/s41392-020-00387-1

37. Roy J, Dibaeinia P, Fan TM, Sinha S, Das A. Global analysis of osteosarcoma lipidomes reveal altered lipid profiles in metastatic versus nonmetastatic cells. *J Lipid Res United States;* (2019) 60:375–87. doi: 10.1194/jlr.M088559

38. Ren L, Ruiz-Rodado V, Dowdy T, Huang S, Issaq SH, Beck J, et al. Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma. *Cancer Metab* (2020) 8:4. doi: 10.1186/s40170-020-0209-8

39. Wang Z, Li B, Li S, Lin W, Wang Z, Wang S, et al. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion. *Nat Commun England;* (2022) 13:6308. doi: 10.1038/s41467-022-34064-4

40. Vega OA, Lucero CMJ, Araya HF, Jerez S, Tapia JC, Antonelli M, et al. Wnt/β-catenin signaling activates expression of the bone-related transcription factor RUNX2 in select human osteosarcoma cell types. *J Cell Biochem United States;* (2017) 118:3662–74. doi: 10.1002/jcb.26011

41. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA. The role of RUNX2 in osteosarcoma oncogenesis. *Sarcoma.* (2011) 2011:282745. doi: 10.1155/2011/282745

42. Chen J, Liu G, Wu Y, Ma J, Wu H, Xie Z, et al. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex *via* effects on chromatin remodeling. *Mol Cancer* (2019) 18:150. doi: 10.1186/s12943-019-1076-1

43. Dana PM, Sadoughi F, Asemi Z, Yousefi B. Molecular signaling pathways as potential therapeutic targets in osteosarcoma. *Curr Med Chem United Arab Emirates;* (2022) 29:4436–44. doi: 10.2174/0929867329666220209110009

44. Su C, Cai X, Xu T, Wu Y, Wang L, Chen P, et al. LIMS2 is downregulated in osteosarcoma and inhibits cell growth and migration. *J Oncol Egypt;* (2022) 2022:4811260. doi: 10.1155/2022/4811260

45. Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y, et al. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. *Mol Cancer* (2019) 18:73. doi: 10.1186/s12943-019-1007-1

46. Wang J, Yuan L, Xu X, Zhang Z, Ma Y, Hong L, et al. Rho-GEF trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA. *Cell Death Dis England;* (2021) 12:1148. doi: 10.1038/s41419-021-04448-3

47. Du X, Ou Y, Zhang M, Li K, Huang W, Jiang D. The mevalonate pathway promotes the metastasis of osteosarcoma by regulating YAP1 activity *via* RhoA. *Genes Dis China;* (2022) 9:741–52. doi: 10.1016/j.gendis.2020.11.009

48. Zhan F, Deng Q, Chen Z, Xie C, Xiang S, Qiu S, et al. SAR1A regulates the RhoA/YAP and autophagy signaling pathways to influence osteosarcoma invasion and metastasis. *Cancer Sci Engl* (2022).

49. Xie K, Zhang X, Tao Y. Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis. *Signal Transduct Target Ther England;* (2020) 5:161. doi: 10.1038/s41392-020-00273-w

50. de Sousa GR, Vieira GM, das Chagas PF, Pezuk JA, Brassesco MS. Should we keep rocking? portraits from targeting rho kinases in cancer. *Pharmacol Res Netherlands;* (2020) 160:105093. doi: 10.1016/j.phrs.2020.105093

51. Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Teng S, et al. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. *Mol Cancer* (2018) 17:89. doi: 10.1186/s12943-018-0837-6

52. Zhang Y, Liu Z, Yang X, Lu W, Chen Y, Lin Y, et al. H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. *Theranostics.* (2021) 11:1473–92. doi: 10.7150/thno.51245

53. Liu Y, Liao S, Bennett S, Tang H, Song D, Wood D, et al. STAT3 and its targeting inhibitors in osteosarcoma. *Cell Prolif England;* (2021) 54:e12974. doi: 10.1111/cpr.12974

54. Liu W, Zhao Y, Wang G, Feng S, Ge X, Ye W, et al. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. *Redox Biol* (2022) 53:102344. doi: 10.1016/j.redox.2022.102344

55. Lee YM. RUNX family in hypoxic microenvironment and angiogenesis in cancers. *Cells Switzerland;* (2022) 11. doi: 10.3390/cells11193098

56. Wang X, Qin G, Liang X, Wang W, Wang Z, Liao D, et al. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma. *Nat Commun* (2020) 11:1141. doi: 10.1038/s41467-020-14870-4

57. Lamhamedi-Cherradi S-E, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, et al. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. *Cancer Gene Ther* (2021) 28:1325–38. doi: 10.1038/s41417-020-00281-6

58. Kirchhammer N, Trefny MP, Auf der Maur P, Läubli H, Zippelius A. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment. *Sci Transl Med United States* (2022) 14:eabo3605. doi: 10.1126/scitranslmed.abo3605

59. Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. *Mol Cancer England;* (2022) 21:208. doi: 10.1186/s12943-022-01670-1

60. Zhu T, Han J, Yang L, Cai Z, Sun W, Hua Y, et al. Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications. *Front Immunol Switzerland;* (2022) 13:907550. doi: 10.3389/fimmu.2022.907550

61. Casanova JM, Almeida J-S, Reith JD, Sousa LM, Fonseca R, Freitas-Tavares P, et al. Tumor-infiltrating lymphocytes and cancer markers in osteosarcoma: influence on patient survival. *Cancers (Basel) Switzerland;* (2021) 13. doi: 10.3390/cancers13236075

62. Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3. *Arch Med Res United States;* (2021) 52:200–10. doi: 10.1016/j.arcmed.2020.10.018

63. Wang J-W, Wu X-F, Gu X-J, Jiang X-H. Exosomal miR-1228 from cancer-associated fibroblasts promotes cell migration and invasion of osteosarcoma by directly targeting SCAI. *Oncol Res United States;* (2019) 27:979–86. doi: 10.3727/096504018X15336368805108

64. Mazumdar A, Urdinez J, Boro A, Migliavacca J, Arlt MJE, Muff R, et al. Osteosarcoma-derived extracellular vesicles induce lung fibroblast reprogramming. *Int J Mol Sci Switzerland;* (2020) 21. doi: 10.3390/ijms21155451

65. Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, et al. Targeting podoplanin for the treatment of osteosarcoma. *Clin Cancer Res United States;* (2022) 28:2633–45. doi: 10.1158/1078-0432.CCR-21-4509

66. Qin Q, Gomez-Salazar M, Tower RJ, Chang L, Morris CD, McCarthy EF, et al. NELL1 regulates the matrisome to promote osteosarcoma progression. *Cancer Res* (2022) 82:2734–47. doi: 10.1158/0008-5472.CAN-22-0732

67. Wang S, Zhong L, Li Y, Xiao D, Zhang R, Liao D, et al. Up-regulation of PCOLCE by TWIST1 promotes metastasis in osteosarcoma. *Theranostics.* (2019) 9:4342–53. doi: 10.7150/thno.34090

68. Sun Z, Schwenzer A, Rupp T, Murdamoothoo D, Vegliante R, Lefebvre O, et al. Tenascin-c promotes tumor cell migration and metastasis through integrin α9β1-mediated YAP inhibition. *Cancer Res* (2018) 78:950–61. doi: 10.1158/0008-5472.CAN-17-1597

69. Lak NSM, van der Kooi EJ, Enciso-Martinez A, Lozano-Andrés E, Otto C, Wauben MHM, et al. Extracellular vesicles: a new source of biomarkers in pediatric solid tumors? a systematic review. *Front Oncol Switzerland;* (2022) p:887210. doi: 10.3389/fonc.2022.887210

70. Gao X, Gao B, Li S. Extracellular vesicles: a new diagnostic biomarker and targeted drug in osteosarcoma. *Front Immunol Switzerland;* (2022) 13:1002742. doi: 10.3389/fimmu.2022.1002742

71. Sun N, Tran BV, Peng Z, Wang J, Zhang C, Yang P, et al. Coupling lipid labeling and click chemistry enables isolation of extracellular vesicles for noninvasive detection of oncogenic gene alterations. *Adv Sci (Weinheim Baden-Wurttemberg Ger Germany;* (2022) 9:e2105853. doi: 10.1002/advs.202105853

72. Wu SC, Kim A, Gu Y, Martinez DI, Zocchi L, Chen CC, et al. UHRF1 overexpression promotes osteosarcoma metastasis through altered exosome production and AMPK/SEMA3E suppression. *Oncogenesis United States;* (2022) 11:51. doi: 10.1038/s41389-022-00430-6

73. Han Z, Peng X, Yang Y, Yi J, Zhao D, Bao Q, et al. Integrated microfluidic-SERS for exosome biomarker profiling and osteosarcoma diagnosis. *Biosens Bioelectron England;* (2022) 217:114709. doi: 10.1016/j.bios.2022.114709

74. Wen X-Z, Pan Q-Z, Xu B-S, Xiao W, Weng D-S, Zhao J-J, et al. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. *Cancer Chemother Pharmacol Germany;* (2022) 89:209–15. doi: 10.1007/s00280-021-04371-6

75. Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. *Lancet Oncol England;* (2015) 16:98–107. doi: 10.1016/S1470-2045(14)71136-2

76. Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. *Pediatr Blood Cancer United States;* (2016) 63:1761–70. doi: 10.1002/pbc.26087

77. Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. *Lancet Oncol England;* (2019) 20:120–33. doi: 10.1016/S1470-2045(18)30742-3

78. Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. *J Clin Oncol United States;* (2019) 37:1424–31. doi: 10.1200/JCO.18.02374

79. Hingorani P, Krailo M, Buxton A, Hutson P, Sondel PM, Diccianni M, et al. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: a report from the children's oncology group. *Eur J Cancer England;* (2022) 172:264–75. doi: 10.1016/j.ejca.2022.05.035

80. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, et al. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. *Br J Cancer England;* (2021) 125:528–33. doi: 10.1038/s41416-021-01448-0

81. Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, et al. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. *Eur J Cancer England;* (2022) 176:155–63. doi: 10.1016/j.ejca.2022.09.003

82. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol England;* (2017) 18:1493–501. doi: 10.1016/S1470-2045(17)30624-1

83. Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. *Clin Cancer Res* (2016) 22:1364–70. doi: 10.1158/1078-0432.CCR-15-0491

84. Meazza C, Cefalo G, Massimino M, Daolio P, Pastorino U, Scanagatta P, et al. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2. *Med Oncol United States;* (2017) 34:191. doi: 10.1007/s12032-017-1052-9

85. D'Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, et al. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. *Nat Commun England;* (2022) 13:3477. doi: 10.1038/s41467-022-30874-8

86. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. *Lancet Oncol England;* (2022) 23:1156–66. doi: 10.1016/S1470-2045(22)00392-8

87. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, et al. Alpha particle radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. *Clin Cancer Res United States;* (2019) 25:3802–10. doi: 10.1158/1078-0432.CCR-18-3964

88. Zhang J, Liu W, Zou C, Zhao Z, Lai Y, Shi Z, et al. Targeting super-Enhancer-Associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor. *Clin Cancer Res United States;* (2020) 26:2681–92. doi: 10.1158/1078-0432.CCR-19-1418

89. Nomura M, Rainusso N, Lee Y-C, Dawson B, Coarfa C, Han R, et al. Tegavivint and the β-Catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma. *J Natl Cancer Inst* (2019) 111:1216–27. doi: 10.1093/jnci/djz026

90. Bayles I, Krajewska M, Pontius WD, Saiakhova A, Morrow JJ, Bartels C, et al. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. *J Clin Invest* (2019) 129:4377–92. doi: 10.1172/JCI127718

91. Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, et al. BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. *Proc Natl Acad Sci U S A* (2017) 114:8065–70. doi: 10.1073/pnas.1704173114

92. Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, et al. A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy. *Mol Cancer Ther United States;* (2018) 17:1881–92. doi: 10.1158/1535-7163.MCT-17-0818

93. Lillo Osuna MA, Garcia-Lopez J, El Ayachi I, Fatima I, Khalid AB, Kumpati J, et al. Activation of estrogen receptor alpha by decitabine inhibits osteosarcoma growth and metastasis. *Cancer Res* (2019) 79:1054–68. doi: 10.1158/0008-5472.CAN-18-1255

94. Yang Y, Peng Z, Flores ER, Kleinerman ES. Pramlintide: a novel therapeutic approach for osteosarcoma through metabolic reprogramming. *Cancers (Basel) Switzerland;* (2022) 14. doi: 10.3390/cancers14174310

95. Lu K-H, Su S-C, Lin C-W, Hsieh Y-H, Lin Y-C, Chien M-H, et al. Melatonin attenuates osteosarcoma cell invasion by suppression of c-c motif chemokine ligand 24 through inhibition of the c-jun n-terminal kinase pathway. *J Pineal Res England;* (2018) 65:e12507. doi: 10.1111/jpi.12507

96. Zhou Q, Xian M, Xiang S, Xiang D, Shao X, Wang J, et al. All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. *Cancer Immunol Res United States;* (2017) 5:547–59. doi: 10.1158/2326-6066.CIR-16-0259

97. Wang J, Liu N, Su Q, Lv Y, Yang C, Zhan H. Green synthesis of gold nanoparticles and study of their inhibitory effect on bulk cancer cells and cancer stem cells in breast carcinoma. *Nanomater (Basel Switzerland) Switzerland;* (2022) 12. doi: 10.3390/nano12193324

98. Soto KM, Luzardo-Ocampo I, López-Romero JM, Mendoza S, Loarca-Piña G, Rivera-Muñoz EM, et al. Gold nanoparticles synthesized with common mullein (Verbascum thapsus) and castor bean (Ricinus communis) ethanolic extracts displayed antiproliferative effects and induced caspase 3 activity in human HT29 and SW480 cancer cells. *Pharmaceutics Switzerland;* (2022) 14. doi: 10.3390/pharmaceutics14102069

99. Alshawwa SZ, Mohammed EJ, Hashim N, Sharaf M, Selim S, Alhuthali HM, et al. *In Situ* Biosynthesis of reduced alpha hematite (α-Fe(2)O(3)) nanoparticles by stevia rebaudiana l. leaf extract: insights into antioxidant, antimicrobial, and anticancer properties. *Antibiot (Basel Switzerland) Switzerland;* (2022) 11.

100. He G, Nie J-J, Liu X, Ding Z, Luo P, Liu Y, et al. Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin *via* HIF-1α/BNIP3/LC3B-mediated mitophagy pathway. *Bioact Mater* (2023) 19:690–702. doi: 10.1016/j.bioactmat.2022.05.006

101. Zhang Y, Gong R, Liu Y, Sun X, Liang J, Zhou Y, et al. Ailanthone inhibits proliferation, migration and invasion of osteosarcoma cells by downregulating the serine biosynthetic pathway. *Front Oncol Switzerland;* (2022) 12:842406. doi: 10.3389/fonc.2022.842406

102. Zhao Z, Jia Q, Wu M-S, Xie X, Wang Y, Song G, et al. Degalactotigonin, a natural compound from solanum nigrum l., inhibits growth and metastasis of osteosarcoma through GSK3β inactivation-mediated repression of the Hedgehog/Gli1 pathway. *Clin Cancer Res United States;* (2018) 24:130–44. doi: 10.1158/1078-0432.CCR-17-0692

103. Li S, Zhang T, Xu W, Ding J, Yin F, Xu J, et al. Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. *Theranostics.* (2018) 8:1361–75. doi: 10.7150/thno.18299

frontiers | Frontiers in Oncology

TYPE Review
PUBLISHED 19 May 2023
DOI 10.3389/fonc.2023.1115943

OPEN ACCESS

EDITED BY
Michelle L. Matter,
Tulane University, United States

REVIEWED BY
Yukio Ago,
Hiroshima University, Japan
Antonina Alexandrova,
Russian Cancer Research Center NN Blokhin, Russia
Nicholas Anagnou,
Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece

*CORRESPONDENCE
Jiefeng He
hejiefeng2005@163.com
Lei Zhang
zhangl7803@126.com

†These authors have contributed equally to this work and share first authorship

RECEIVED 04 December 2022
ACCEPTED 02 May 2023
PUBLISHED 19 May 2023

CITATION
Wang X, Zhang C, Song H, Yuan J, Zhang X, Yuan Y, Zhang L and He J (2023) Characterization of LIMA1 and its emerging roles and potential therapeutic prospects in cancers. *Front. Oncol.* 13:1115943. doi: 10.3389/fonc.2023.1115943

Characterization of LIMA1 and its emerging roles and potential therapeutic prospects in cancers

Xiaoxiao Wang[1†], Chao Zhang[1†], Huangqin Song[1†], Junlong Yuan[1], Xiaomin Zhang[1], Yiran Yuan[1], Lei Zhang[2,3*] and Jiefeng He[1,2*]

[1]Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China, [2]Department of Hepatobiliary Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China, [3]Hepatic Surgery Center, Institute of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Actin is the most abundant and highly conserved cytoskeletal protein present in all eukaryotic cells. Remodeling of the actin cytoskeleton is controlled by a variety of actin-binding proteins that are extensively involved in biological processes such as cell motility and maintenance of cell shape. LIM domain and actin-binding protein 1 (LIMA1), as an important actin cytoskeletal regulator, was initially thought to be a tumor suppressor frequently downregulated in epithelial tumors. Importantly, the deficiency of LIMA1 may be responsible for dysregulated cytoskeletal dynamics, altered cell motility and disrupted cell-cell adhesion, which promote tumor proliferation, invasion and migration. As research progresses, the roles of LIMA1 extend from cytoskeletal dynamics and cell motility to cell division, gene regulation, apical extrusion, angiogenesis, cellular metabolism and lipid metabolism. However, the expression of LIMA1 in malignant tumors and its mechanism of action have not yet been elucidated, and many problems and challenges remain to be addressed. Therefore, this review systematically describes the structure and biological functions of LIMA1 and explores its expression and regulatory mechanism in malignant tumors, and further discusses its clinical value and therapeutic prospects.

KEYWORDS

actin cytoskeleton, LIMA1, cells migration and metastatic, EMT, angiogenesis, cancer progression

1 Introduction

Actin-binding proteins mediate the assembly of actin monomers into distinct filamentous structures. Actin filaments assemble into a variety of networks and bundles that interconnect to form the actin cytoskeleton (1). This is a highly dynamic structure and the dynamic rearrangement of the actin cytoskeleton is fundamental to support a wide

range of cellular behaviors. It plays a key role in cell biological processes including cell polarity, adhesion and migration, cell division, intracellular transport and endocytosis (2, 3). Recent studies showed that LIM structural domain proteins are associated with mediating cytoskeletal homeostasis and coordinating these cellular behaviors (4). LIM domain and actin-binding protein 1 (LIMA1) is an actin-binding cytoskeletal protein containing a LIM structural domain. It is subcellularly localized to actin stress fibers and focal adhesion plaques (5, 6). The amino-terminal and carboxy-terminal ends of LIMA1 are located lateral to the central LIM structural domain. They are present in at least two actin-binding domains that are capable of cross-linking and stabilizing cytoskeletal filaments and promoting stress fiber formation (7). This ensures cytoskeletal homeostasis and maintains integration and coordination between different actin regulatory pathways to support dynamic cellular behaviors.

LIMA1 is also known as epithelial protein lost in neoplasms (EPLIN) and sterol regulatory element binding protein 3 (SREBP3). It was initially identified as a differentially expressed gene in oral epithelial cell carcinogenesis using cDNA differential analysis (8). Subsequently, Maul et al. (9) first described and identified LIMA1 as a novel cytoskeletal protein. LIMA1 exists as two distinct isoforms: LIMA1-α containing 600 amino acids and LIMA1-β containing 759 amino acids (10). The amino acid structural domain sequence of LIMA1 is unique. The LIM domain-containing protein as an interaction site for specific signal transduction proteins can form two closely spaced zinc-binding subdomains and allow LIMA1 to dimerize on its own or bind to other proteins (5, 11). Due to the importance of LIMA1 in regulating actin cytoskeleton dynamics and its potential involvement in cadherin-mediated cell adhesion (12), the loss of LIMA1 from cancer cells may affect cell behavior and further enhance invasive characteristics. LIMA1 deficiency may be responsible for dysregulated cytoskeletal dynamics, altered cell motility and disrupted cell-cell adhesion, which can promote tumor proliferation, invasion, and migration (13).

Recent studies, including those from our laboratory, demonstrate a broader role for LIMA1 in controlling cancer cell behaviors. The effects of LIMA1 also extend from cell migration and cytoskeleton dynamics to cell cycle, gene regulation, angiogenesis, and lipid metabolism, among others, providing new ideas for future exploration of cancer treatment strategies (14). In this paper, the latest research progress on the molecular characteristics, biological functions and regulatory mechanisms of LIMA1 could be expounded. It focuses on the roles and significance of LIMA in various cancers and provides insights into its future research prospects.

2 The characterization and functions of *LIMA1*

2.1 The structure of *LIMA1*

Current studies have identified the organization of the human LIMA1 gene, which is located on chromosome 12q13.12 and has a sequence length of 107,733 bp (5, 10). It consists of 11 exons spanning 100 kb and 10 introns. The LIMA1 gene is structured with two independent promoter regions. The DNA sequence at the transcription start site stimulates the expression of the promoter reporter gene constructs (13). Under the protection of 5' RACE and S1 nuclease, the transcription start site of LIMA1-α mRNA is approximately 50 kb downstream near the end of intron 3 and is positioned before exon 4 and contains 4-11 exons. Similarly, the transcription start site of LIMA1-β mRNA is located near the start of exon 1 of the gene and contains all 11 exons (10) (Figure 1). The amino acid sequences of these two isoforms are characterized by the presence of a centrally located LIM structural domain. The LIM structural domain is a cysteine-rich double zinc finger structural domain derived from the three homologous structural domain-containing transcription factors Lin-11, Isl-1 and Mec-3 (15, 16). The N-terminal and C-terminal sides of the LIM structural domain of LIMA1 can promote parallel formation of actin filament structures by cross-linking and binding actin filaments (7) (Figure 2).

Sequence analysis found that LIMA1-α and LIMA1-β isoforms are conserved across species (10). In subsequent working study, Maul et al. (17) isolated and characterized mouse and zebrafish LIMA1 homologous to humans. Akin to the human gene, both 593 aa LIMA1-α and 753 aa LIMA1-β isoforms were found in mouse, showing 77% and 75% identity with human isoforms (5, 17). In contrast, there was only one form in zebrafish, namely 629 aa LIMA1. The overall similarity between zebrafish and human amino acid sequences was not significant. Wang et al. (18) revealed two isoforms of the porcine LIMA1 gene with different expression patterns in muscle development and maintenance. LIMA1-α was preferentially expressed in developing skeletal muscles. Especially in the early stages, LIMA1-α played an important role in the process of muscle cell morphology and growth. LIMA1-β was not expressed during muscle development and only weak expression was detected in adult muscles (13, 18). Recent studies indicated that LIMA1-β regulated the distribution of OB-cadherin, which was involved in the assembly of cadherin-catenin protein complexes in osteoblasts, and affected bone formation (19).

2.2 The functions of LIMA1

2.2.1 Controlling for actin dynamics

LIMA1 controls actin dynamics by stabilizing the actin filament network. The expression of LIMA1 increases the number and size of actin stress fibers and inhibits active Rac-induced membrane folding (6). Furthermore, LIMA1 inhibits actin filament nucleation and F-actin depolymerization by mediating the actin-related protein complex 2/3 (Arp2/3) (13). Moreover, Han et al. (7) showed that LIMA1 was a novel extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) substrate and that ERK responded, both *in vitro* and *in vivo*, to LIMA1 Ser360, Ser602, and Ser692 phosphorylation. ERK-mediated phosphorylation of LIMA1 decreased C-terminal region binding activity to actin leading to reorganization of actin filaments and enhanced cell motility. In addition, Song et al. (20) found that LIMA1 was bound to the actin



FIGURE 1
Schematic representation of *LIMA1* structure. The *LIMA1* gene is located on chromosome 12 and consists of 11 exons and 10 introns. Its protein contains two isoforms, a *LIMA1-α* of 600 amino acids and a *LIMA1-β* of 759 amino acids.

cytoskeleton and inhibited anchorage-dependent growth of transformed NIH3T3 cells. LIMA1 exhibited a patchy pattern of distribution in the cytoplasm of Ras-transformed cells and activated Ras prevented or altered LIMA1 co-localization with actin stress fibers (21). These changes in subcellular localization of LIMA1 may represent a non-specific outcome of transformation, which frequently altered cell morphology and cytoskeleton. In this process, LIMA1-α is transcriptionally regulated by G-actin and megakaryoblastic acute leukemia (MAL)/myocardin related transcription factor (MRTF) coactivators. It is sensitive to drugs that can stabilize the inhibitory actin MAL complex and non-polymerizable actin mutants (22).

LIMA1 binds to α-catenin and mediates the interaction of the cadherin-catenin complex with F-actin, stabilizing the actin fibers and establishing the adhesion bands at the cell-cell junctions (12). Epithelial cells remodel their junctional structure by responding to mechanical forces. E-cadherin acts as a mechanosensitive regulator of this process of epithelial cell junctional remodeling and can interact with LIMA1 and Vinculin to maintain the *zonula adherens* (23). Chen et al. (24) identified the substrate of human cell division cycle 14A (CDC14A), the actin regulator LIMA1, by phosphorylated proteomics and the biotin identification proximity assay. LIMA1 phosphorylation regulated by ERK and CDC14A had shown reduced enrichment of α/β-catenin at the cell-cell junctions and downregulation of E-cadherin. Actin kinetic activity was reduced by local regulation of actin rearrangement.

In addition, the actin-stabilizing protein leucine zipper protein 1 (LUZP1) is localized to actin and microtubule structures (25). LIMA1 regulates actin and actin-related protein (myosin Va and ARP2/3) levels by interacting with LUZP1. It also regulates cell migration and ciliogenesis, which is associated with cancer development (26).



FIGURE 2
(A) Three-dimensional structure of *LIMA1* (PDB ID=2Y), from *AlphaFold Protein Structure Database* (https://alphafold.ebi.ac.uk/). *LIMA1* contains a LIM structural domain in the center and multiple actin-binding domains at the lateral end, which is capable of cross-linking and stabilizing a network of stabilized actin filaments. **(B)** Potential molecules and functional proteins interacting with *LIMA1*, which can be derived from the search tool *STRING* (http://www.string-db.org/) for retrieving interacting genes or proteins. DUSP5, Dual Specificity Phosphatase 5; CDH1, Cadherin 1; VCL, Vinculin; CTNND1, Catenin Delta 1; CTNNA1, Catenin Alpha 1; CTNNB1, Catenin Beta 1; SIPA1L1, Signal Induced Proliferation Associated 1 Like 1; CDH17, Cadherin 17; NEXN, Nexilin F-Actin Binding Protein; IFRD2, Interferon Related Developmental Regulator 2.

2.2.2 Regulation of cell adhesion and metastasis

Cells attach to the network of pre-adsorbed proteins in the extracellular matrix (ECM) or to neighboring cells by interacting with specialized molecules on the cell surface (27). This process is referred to as cell adhesion. Regulation of cell-cell interactions through adhesion junctions is largely dependent on the interaction mediated by E-cadherin and the assembly of a large number of adapter proteins with filamentous actin bundles (28).

LIMA1 acts as an adapter for adhesion junctions and localizes to the integrin adhesion sites of cells in a particularly interesting new cysteine-histidine rich protein 1 (PINCH-1) regulation-dependent manner (29). Depletion of LIMA1 induces the proliferation and migration of keratin-forming cells on collagen and fibronectin both *in vivo* and *in vitro*. Tsurumi et al. (30) showed high expression of the actin cross-linking protein LIMA1 in glomerular thylakoid cells. LIMA1 was concentrated in peripheral actin bundles at local adhesions and formed protein complexes with paxillin. Platelet derived growth factor (PDGF) regulated the interaction of LIMA1 with paxillin by inducing the mitogen-activated protein kinase (MEK)-ERK cascade and also induces subcellular localization of LIMA1 from local adhesion to peripheral folds (13, 30). In addition, ubiquitination of Rab40b-Cullin5 regulates LIMA1 localization and promotes cell migration and invasion by altering adhesion patch and cytoskeletal dynamics (31). Zhang et al. (32) showed that epidermal growth factor (EGF) activated phosphorylation, ubiquitination, and degradation of LIMA1 through an ERK1/2-dependent signaling cascade response. Point mutations in serine residues (serine362 and serine604) of LIMA1 have made it resistant to EGF-induced protein degradation.

Subsequent studies confirmed that LIMA1 was a direct transcriptional target of p53 (14, 33). Knockdown of LIMA1 significantly enhanced cancer cell invasion and partially reversed the p53-induced metastasis of cancer cells (33). It can be speculated that LIMA1 may be a novel prognostic predictor and therapeutic target for tumors. P73, a member of the p53 family, was shown to induce cell cycle arrest and apoptosis, negatively regulating cancer progression (34). Steder et al. (35) found that N-terminal truncation of the P73 gene family produced DNp73, which was frequently upregulated in high-grade tumors. DNp73 inhibited the repression of LIMA1 by interfering with p73, leading to the disruption of intercellular adhesion junctions, which further activated insulin like IGF1R-PKB/STAT3 signaling pathway to initiate the invasion and metastasis cascade response.

2.2.3 Dynamic maintenance of the epithelial mesenchymal transition

Epithelial mesenchymal transition (EMT) is the process by which epithelial cells lose apical-basal polarity and intercellular adhesion and then transform to invasive mesenchymal cells (36). During the transition, proteins characteristic of the epithelial phenotype such as E-cadherin, cytokeratins, or occludin are absent, while N-cadherin, vimentin, or fibronectin are upregulated due to the acquisition of mesenchymal cell characteristics (37). Zhang et al. (32) and Zhitnyak et al. (38) revealed that the actin-binding protein LIMA1 maintained the stability of the circumferential actin bundle, and that EGF induced EMT and increased invasive potential through phosphorylated degradation of LIMA1 leading to active remodeling of the actin cytoskeleton and disruption of intercellular adhesion. It is well known that the regulation of EMT requires the involvement of multiple signaling pathways, including the activation of Wnt/β-catenin, TGF-β, and Notch, among other pathways (39), leading to altered cell morphology, increase in cell motility, and enhanced secretion of growth factors or proteins (40). Subsequently, it was reported that DNp73 exhibited an EMT-like phenotype through dependent downregulation of LIMA1 with loss of E-cadherin and Slug (35). This led to the loss of apical cell polarization and stable cell adhesion, allowing the cells to acquire the ability to invade to promote metastatic potential.

Recent studies support that LIMA1 may regulate the epithelial to mesenchymal transition. Most of these studies suggest that LIMA1 deficiency appears to contribute to the development of EMT and metastasis of cancer cells. LIMA1 is a negative regulator of EMT and invasiveness in prostate cancers, inhibiting E-cadherin, activating β-catenin signaling pathway and enhancing chemoresistance (41, 42). Similarly, LIMA1 depletion was found to promote EMT and induced actin cytoskeleton remodeling in breast cancers (43) and epithelial ovarian cancers (44) significantly enhancing the migration and invasion of epithelial cancer cells both *in vivo and in vitro*. And another study found that the expression of LIMA1 was upregulated in head and neck tumors, driving invasion and metastasis by activating tumor-associated pathways such as PI3K-AKT and JAK-STAT signaling pathways to promote the EMT process (45). It is considered likely that DNA demethylation of the LIMA1 promoter region results in different expression levels of LIMA1 in HNSC.

For future studies on LIMA1 regulation of EMT, we propose constructive and rational research themes. It is possible to quantitatively assess the role of LIMA1 in EMT, explore the molecular mechanisms of LIMA1 regulation of EMT, establish LIMA1 targeting factors and explore their interactions with LIMA1. These studies can predict the cancer biomarkers and patient prognosis associated with LIMA1 and EMT, and help identify novel drugs and therapeutic approaches for cancers.

2.2.4 Modification of the epithelial defense against cancer

During the initial stages of oncogenic mutations, individual cells within the epithelium may undergo transformation (46). Normal epithelial cells can identify the presence of transformed cells and eliminate newly emerging transformed cells by competition, which is known as epithelial defense against cancer (EDAC) (47). Recent studies have shown that transformed cells of RasV12 are extruded from the tip by neighboring epithelial cells (48). This process is the most basic epithelial defense against cancer and involves various non-cellular autonomous changes in normal and transformed cells; however, this is unrelated to the anti-tumor properties of the immune system. The molecular mechanisms behind this

phenomenon remain largely elusive. Ohoka et al. (21) found that caveolin-1 (Cav-1) and LIMA1 accumulated in the apical and outer membrane structural domains and in the cytoplasmic matrix of RasV12 transformed cells. LIMA1 acted mainly upstream of Cav-1 to regulate the non-cellular, autonomous activation of myosin II and PKA in RasV12 transformed cells (21, 48). This resulted in extrusion of RasV12 transformed cells from the apical part of the normal epithelial cell monolayer.

In addition, Saitoh et al. (49) showed that Rab5-mediated endocytosis was enhanced in RasV12-transformed cells disrupting cell-to-cell adhesion based on E-cadherin through the dependent regulation of LIMA1. This process affected the accumulation of filamentous proteins in neighboring normal cells, which acted as mechano-sensors exerting the physical forces required for apical extrusion. Importantly, LIMA1 co-accumulated with plectins, microtubules and intermediate filaments in RasV12 transformed cells and positively regulated the apical elimination of transformed cells from the epithelium in a synergistic manner (50). Kasai et al. (51) showed that paxillin induced the acetylation of microtubulin by linking the plectin-LIMA1 complex. It inhibited histone deacetylase 6 (HDAC6) activity, partially rescuing the inhibitory effect of paxillin knockdown on apical extrusion in RasV12 cells (50, 51). In future studies, there is still a need to reveal the mechanism of cytoskeletal organization mechanism of apical extrusion in transformed cells to provide new avenues for establishing novel cancer prevention and treatment.

2.2.5 Promotion of the endothelial cell formation and angiogenesis

Angiogenesis is the process by which endothelial cells form new blood vessels from pre-existing vessels (52). This process includes many complex steps, including the activation, proliferation and migration of endothelial cells, the vascular rings formed by endothelial cell tubes, and the generation of neovascularization and basement membranes (53). Importantly, adherent junctions are required for the remodeling of cellular junctions and the maintenance of vascular endothelial integrity.

The vascular endothelial cadherin (VE-cadherin) is an endothelial cell-specific expressed protein, also known as cadherin 5. VE-cadherin mediates adhesive junctions between adjacent vascular endothelial cells by connecting chain proteins, including α-catenin, β-catenin and γ-catenin, to the actin cytoskeleton (54). Chervin-Pétinot et al. (55) previously presented evidence that LIMA1 co-localized with α-catenin of endothelial cells in the actin cortical loop. LIMA1 attached the VE-cadherin and catenin complexes to the actin cytoskeleton by interacting with α-catenin and actin filaments. It also strengthened cell-cell cohesion by recruiting vinculin, while enhancing endothelial adhesion junctions (55). In addition, ARP2/3 complex dynamically competes with VE-cadherin and a/β-catenin to bind actin filaments (56). This has been shown to be critical in the formation and maintenance of endothelial cell adhesion and integrity mediated by cadherin/catenin complexes.

Subsequently, Hofer et al. (57) used the fluorescent live cell imaging system to explore endothelial cell junctional dynamics under the static and shear stress conditions. By using fluorescent tags (mCherry and EGFP) with self-labelling tags (Halo and SNAP), it was demonstrated that VE-cadherin tagged with EGFP maintained cytoarchitectonic integrity during shear stress-induced junctional remodeling (57). And that two isoforms of LIMA1 were shown to be localized at the cell junctions of vascular endothelial cells (54, 57). However, whether these isoforms have different functions at the cell junctions remains to be investigated. Subsequently, Smith et al. (58) preliminarily verified that LIMA1 subtypes were dependent on stimulation both *in vivo* and *in vitro*. The LIMA1-α expression was increased in endothelial cells during the growth phase; this modulates subcellular localization somewhat and controls protrusion dynamics as driven by actin (58). LIMA1-α controlled the plasma membrane protrusion directly by interacting with the Arp2/3 complex and junction-associated intermittent lamellipodia (JAIL), to increase cell migration and cell junction adhesion (5, 6, 56). The LIMA1-β expression was higher in endothelial cells exposed to aortic endothelium and endothelial cells with high shear stress compared to the vena cava endothelium (58). The magnitude of the LIMA1-β expression in endothelial cells correlates with hemodynamics and acts to induce and stabilize stress fibers. In addition, some investigators conducted *in vitro* studies based on tumor vascular endothelial cells and *in vivo* studies based on animal models (59, 60).

Angiogenesis plays a crucial role in almost all stages of cancer growth, aggressiveness and metastasis. Tumor angiogenesis has been reported to be a hallmark of carcinogenesis (61). Sanders et al. (59) found that overexpression of LIMA1-α could regulate endothelial cell migration, stromal adhesion and formation of new vascular-like structures *in vitro*, and retard tumor formation *in vivo*. It is evident that LIMA1-α has anti-angiogenic effects. Notably, there is was more substantial interaction between LIMA1-α and ERK in endothelial angiogenesis. ERK inhibitors could rescue the tubule formation in HECV cells caused by the overexpression of LIMA1-α (7, 59). Liang et al. (60) also showed that miR-93-5p enhanced the migration and angiogenesis of human umbilical vein endothelial cells (HUVEC) through the downregulation of LIMA1 based on *in vitro* and *in vivo* studies. LIMA1 plays a disruptive role in angiogenesis during cancer development to a certain extent, thus providing a new theoretical basis for the molecular regulation mechanism of the tumor angiogenesis process.

2.2.6 Modulation of the inflammatory response

Endothelial cells are considered key regulators of the inflammatory response. When exposed to the proinflammatory cytokines IL-1β, TNF-α, and IFN-γ, it could lead to local breaks at endothelial cell-cell junctions and exacerbated endothelial barrier dysfunction during the inflammatory response (62). Maucher et al. (63) demonstrated significant changes in the miRNA expression profile of endothelial cells in response to the stimulation by inflammatory cytokines, which may be involved in endothelial permeability regulation. Among them, miR-29a-3p, miR-29b-3p and miR-155-5p expression was significantly increased and suppressed the adhesion protein expression in endothelial cells after transcription. Importantly, the target genes of these miRNAs

included β-catenin, p120-catenin and LIMA1, which are key mediators of endothelial cell adhesion junctions (14, 63). These results provide new insights into the dysfunction of the inflammation-induced endothelial barrier and the mechanism of cancer progression.

2.2.7 Maintaining the stability of cell division

Cell division is a fundamental process required for cell proliferation and DNA replication in the majority of organisms, which ensures relative genetic stability (64). During cytokinesis, actin-myosin II contractile loops and septal filaments act synergistically to generate the oval groove and control the contraction of microfilaments constricting it (65). The oval groove is gradually deepened to drive cell membrane invasion causing the parental cells to divide into two daughter cells to complete cytoplasmic division.

Chircop et al. (66) discovered that the actin-binding protein LIMA1 was localized in the oval groove during cytoplasmic division. LIMA1 recruited myosin II, septin 2, small GTP ases, and RhoA to locally accumulate in the oval groove to maintain its formation and contractile ring activity (67). The membrane protein supervillin co-localized with endogenous myosin II and LIMA1 in the oval sulcus and synergistically exerted the functions in regulating actin and microtubule motility (14, 67). Notably, deletion of supervillin could lead to an increase in the number of binucleated and multinucleated cells. Subsequently, Sundvold et al. (68) found that LIMA1 maintained proper cell division by recruiting ACAT-related protein required for viability 1 (Arv1) to the oval groove and driving efficient contraction of the actomyosin ring during the mitotic telomere phase. Both LIMA1 and Arv1 are required for efficient accumulation of myosin at the oval groove. Given that LIMA1 is frequently lost in multiple cancers (13), deletion of LIMA1 affects the recruitment of key cytoplasmic splitting proteins at the oval groove, which leads to the formation of multinucleated cells and increases genomic instability and oncogenicity.

2.2.8 Control of the membrane dynamics

Membrane dynamics is an important component of cellular metabolic processes (69). It includes contraction of the oval groove during cell division, tubularization of plasma membrane receptors, enhancement of laminar lipid formation, cell migration and invasion, and endocytosis during membrane protein sorting and transport (70). These processes are dependent on the structural and functional interconnection of the cell membrane with the cytoskeleton.

As the actin-binding protein, LIMA1 is a key effector molecule mediating pluripotency control of membrane dynamics and cellular metabolism. Duethorn et al. (71) revealed that LIMA1 was ectopically expressed in mouse and human pluripotent stem cells. The LIMA1 expression was transcriptionally controlled by naive pluripotency circuits and could inhibit the membrane vesicle formation (71). As that LIMA1 is required for normal mitochondrial energy in embryonic stem cells and is essential for solid tumor growth.

2.2.9 Regulation of lipid metabolism

Lipid metabolism is an important and complex biochemical reaction in the metabolic processes of human body (72). When the synthesis, decomposition, digestion, absorption, and transport of lipid substances in the body are abnormal, it will cause either too much or too little lipid to be present in each tissue resulting in abnormal lipid metabolism (73). Particularly, cholesterol is an important lipid in the process of lipid metabolism, which synthesizes cholesteryl esters under specific conditions and attaches to the walls of blood vessels and in the liver. High levels of low-density lipoprotein cholesterol (LDL-C) are strongly associated with an increased risk of myocardial infarction and death from vascular diseases due to increased blood cholesterol (74).

Cholesterol variability is controlled by genetic variability. Zhang et al. (75) verified that LIMA1-K306fs SNV was responsible for the low LDL-C variant by Sanger sequencing. The LIMA1 gene mutation was found to be a rare shift mutation in Chinese families with genetically low LDL-C Kazakhs (75). This was the first time that LIMA1 variability was proposed as a newly identified genetic player in the mechanisms controlling cholesterol homeostasis (76). The mutation resulted in low serum LDL-C concentrations and reduced cholesterol absorption in the intestine. Subsequently, Lim et al. (77) similarly demonstrated that cholesterol absorption is reduced with intestinal-specific deficiency of LIMA1 and that inhibition of LIMA1 could reduce LDL-C cholesterol levels. LIMA1 and niemann-pick c1-like 1 (NPC1L1) interactions are required during cholesterol absorption (77). Based on mouse models and tests on human samples, researches had shown that LIMA1 regulated cholesterol transport by recruiting myosin Vb to NPC1L1 to promote efficient intestinal absorption of cholesterol (75, 77). In addition, Su et al. (78) identified genes associated with low disease prevalence based on phenomic, genomic, and metabolomic features, including APOA5, LPL, HIF1A, LIMA1, and others. The association between these genes and lipid metabolism and inflammation is particularly striking, but the exact mechanisms remain unclear.

In the future, it is necessary to study in depth the detailed mechanisms by which LIMA1 controls cholesterol variability to add the meaningful mechanistic insights into the biology of cholesterol absorption. This can provide new therapeutic targets for hypercholesterolemia and abnormal lipid metabolism.

3 Roles of *LIMA1* in cancer development and progression

The roles and regulatory mechanisms of LIMA1 gene have received a great deal of scientific attention in a variety of malignancies. This is consistent with the findings that LIMA1 contributes to the maintenance of the epithelial cytoskeleton, supports cell-cell junctions, and regulates lipid metabolism and angiogenesis (6, 14) (Table 1). LIMA1 deficiency promotes the disassembly of adhesion-catenin complexes and redistribution of cadherin-catenin complex components (11, 12): it induces remodeling of the actin cytoskeleton and activation of β-catenin

signaling, which promotes epithelial to mesenchymal morphology and enhances plasticity and migration of cancer cells (31, 32). Overexpression of LIMA1 has been shown to be effective in manipulating tumor characteristics such as reducing cell growth and cell motility and rendering cells less aggressive (41, 42).

Recent studies have shown that the LIMA1 gene exhibits frequent downregulation and loss in cancers (Figure 3), and it can be involved in the development of malignancy through various mechanisms (13) (Figure 4). LIMA1 is associated with the progression and metastasis of various solid tumors including oral cancer (8), esophageal cancer (79), gastric cancer (80), prostate cancer (11, 41, 42, 81), breast cancer (43), ovarian cancer (44), and head and neck squamous cell carcinoma (45, 46), as well as osteosarcoma (82) and lymphoma (83, 84) (Table 2). Moreover, LIMA1 particularly plays a crucial role in biological processes such as tumor proliferation, apoptosis, migration, invasion, drug resistance, immune response (79, 80). This suggests that LIMA1 is expected to be a potential prognostic biological marker and therapeutic target for tumor therapy. Therefore, there is an urgent need to further explore the molecular mechanisms by which LIMA1 regulates tumor progression.

4 Expression of *LIMA1* and its regulatory mechanisms in digestive system tumors

Digestive system cancers are one of the most common leading causes of cancer deaths worldwide, with high morbidity and mortality (85). It is difficult to detect cancers at an early stage due to lack of effective biomarkers (86). Therefore, identification of potentially effective biomarkers can help in the early diagnosis of such cancers. The current research hot-spots on LIMA1 in digestive system tumors are mainly focused on esophageal cancer (79) and gastric cancer (80). While our laboratory has validated the regulatory mechanism of LIMA1 with liver cancer. LIMA1 is expected to be a new biomarker for tumor diagnosis, prognostic biomarker and targeted therapy to improve survival of cancer patients in the future.

4.1 *LIMA1* and esophageal cancer

Esophageal cancer is the most aggressive of all malignancies of the gastrointestinal tract. Esophageal cancer is prone to recurrence and metastasis, and the current five-year survival rate for patients remains low due to its high morbidity and mortality (87). Liu et al. (79) used the quantitative polymerase chain reaction (q-PCR) method to determine the aberrant expression of LIMA1-α transcripts in human esophageal tissues (tumor, paraneoplastic, and normal). It was also shown that overexpression of LIMA1-α reduced the aggressiveness of the esophageal cancer cell line *KYSE150* and attenuated the rate of cell invasion and growth *in vitro*. This is consistent with previous studies showing that LIMA1-α expression is frequently downregulated or lost in a variety of different cancer cell lines, including oral cancer cells (8), prostate cancer cells (11, 41), and breast cancer cell lines (43). There was a negative correlation between LIMA1-α expression levels and tumor grade, lymph node status, tumor stage, and whether patients remained disease-free or died from cancers (79).

TABLE 1 The molecular and biological functions associated with *LIMA1*.

Processes	The molecules that interacts with LIMA1	Biological significance	References
Actin dynamics	Arp2/3, ERK/MAPK, G-actin, MAL/MRTF, CDC14A, LUZP1, E-cadherin, α-catenin, β-catenin, F-actin, Vinculin, myosin Va	Stabilizing actin filament networks to control actin dynamics	(7, 12, 20–24, 26)
Cell adhesion and metastasis	PINCH-1, PDGF, paxillin, Rab40b-Cullin5, EGF, EPK signaling pathway, p53, DNp73, IGF1R-AKT/STAT3 signaling pathway	Regulation of adherens junctions and initiation of the invasion-metastasis cascade	(29–35)
EMT	EGF, DNp73, E-cadherin, β-catenin, Arp2/3, Slug, PI3K-AKT and JAK-STAT signaling pathway	Bidirectional regulation of the epithelial-to-mesenchymal transition	(32, 35, 38–45)
Epithelial defense against cancer	Cav-1, Myosin II, PKA, Rab5, paxillin	Promotion of apical extrusion in transformed cells	(21, 49–51)
Endothelial dynamics	VE-cadherin, α-catenin, β-catenin, ARP2/3, cLP, JAIL	Mediating the formation and maintenance of endothelial cell adherens junctions and integrity	(54–58)
Angiogenesis	ERK, miR-93-5p	Promotion of new angiogenesis during tumor development	(59, 60)
Inflammatory reaction	MiR-29a-3p, miR-29b-3p, miR-155-5p	Stimulation of inflammatory cytokines, leading to endothelial barrier dysfunction	(63)
Cell division	Arv1, supervillin, Myosin II, septin 2, small GTPases, RhoA	Cooperating to modulate actin and microtubule motor functions, drive the contraction of the cleavage furrow and maintain proper cell division	(66–68)
Membrane dynamics	Actin, β-catenin, p120, the naïve pluripotency transcription factors	Pluripotency control of membrane dynamics and cellular metabolism	(71)
Lipid metabolism	NPC1L1	Regulation of cholesterol transport and promotion of effective cholesterol absorption by the intestines	(75–77)



FIGURE 3
LIMA1 expression patterns in pan-cancer. **(A)** *LIMA1* expression levels in 33 different types of cancer and non-cancer samples based on *The Cancer Genome Atlas* Database (TCGA) (https://portal.gdc.cancer.gov/). **(B)** LIMA1 expression levels in cancer tissues and its paired normal tissues based on *TCGA* dataset. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. "ns" means that there is no statistical difference between the two comparison groups.

Combined with the findings of LIMA1-α inhibition of cell growth and invasion, it was found that LIMA1-α downregulation has a predictive value. This highlights the potential of LIMA1 as a prognostic indicator and that this molecule may act as a protective factor.

4.2 *LIMA1* and gastric cancer

Gastric cancer is one of the most common and highly aggressive malignancies worldwide. It accounts for more than 1 million new cases each year and remains the third leading cause of cancer death (88). Surgical resection is the best option for early-stage gastric cancer, while chemotherapy is mainly used in the intermediate and late stages of the disease (89), however, there are many reports of treatment failure in gastric cancer due to chemotherapy resistance. Combined with the low rate of early diagnosis, limited treatment and tumor heterogeneity, the prognosis of gastric cancer remains poor.

Gong et al. (80) explored the correlation between LIMA1 transcript expression and patient clinicopathological factors and its importance in neoadjuvant chemotherapy (NAC) responsiveness through two gastric cancer cohorts collected from Beijing Cancer Hospital. Additional studies have shown that the effect of NAC plays a key role in the prognosis of gastric cancer patients (90). Initially larger gastric cancer cohort to assess the association between LIMA1 expression and clinico-pathological features and prognosis. A second smaller cohort containing patients receiving NAC was evaluated to explore the role of LIMA1 in response to chemotherapy (14, 80). LIMA1 negatively regulates biological function in gastric cancers requiring NAC and may promote longer overall survival. Moreover, LIMA1 inhibits deep tumor infiltration and promotes differentiation, playing an important role in chemotherapy responsiveness. It is suggested that LIMA1 may be a potential prognostic indicator for gastric cancer.

Therefore, further studies and larger cohorts are necessary in the future the better to understand the role of LIMA1 in gastric cancer, particularly regarding its involvement in chemoresistance and therapeutic response. This will provide new targets for biomarkers or therapeutic strategies related to LIMA1 in gastric cancer.

4.3 *LIMA1* and hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a major global problem, with viral hepatitis B and C infection, alcohol abuse and metabolic disorders being multiple risk factors for the development of cirrhosis and HCC (91). Due to the lack of symptoms in the early stages of HCC, most patients are diagnosed with metastasis in the late stages of the disease (92). Therefore, the need to find promising biomarkers for HCC diagnosis is urgent.

Existing studies suggest that LIMA1 plays an inhibitory role in most malignant tumors, but some studies has been reported that

LIMA1 exerts an oncogenic effect in the head and neck tumors (41–43, 45, 81). However, the role and regulatory mechanisms of LIMA1 in hepatocellular carcinoma are still not well understood, and its biological function and clinical value need to be further explored. Increasing research evidences imply that LIMA1 affects cancer progression by regulating important biological processes such as actin dynamics, cell adhesion and metastasis, angiogenesis and lipid metabolism (5, 13, 14). There are no published articles on the effect of LIMA1 on the malignant phenotype of hepatocellular carcinoma. Our study found that the LIMA1 was highly expressed in hepatocellular carcinoma tissues and cell lines. Overexpression of LIMA1 enhanced the migration and invasion of hepatocellular carcinoma cells, which conflicted with our previous knowledge of LIMA1. Subsequently, we will focus on the specific mechanisms of how LIMA1 regulates HCC, which may provide novel therapeutic targets for the treatment of HCC patients.

5 Expression of *LIMA1* and its regulatory mechanisms in urinary system tumors

Research on LIMA1 in urologic system tumors is currently focused on prostate cancer. Prostate cancer (PCa) is the most common type of solid tumor in men and the second most



FIGURE 4
The biological functions and mechanisms of action of LIMA1 in cancers. LIMA1 couples with α-catenin protein, mediates the interaction of cadherin-catenin protein complex with actin. It controls actin dynamics and cell-cell junctions by stabilizing the actin filament networks. LIMA1 acts as a transcriptional target for a variety of factors (ERK, EZH2, CDC14A, Rab40b-Cullin5, STAB2, PINCH-1, miRNA, etc.) by regulating downstream signaling factors (paxillin, plectin, FAK, Src, Cav-1, Myosin II, PKA, etc.) to affect the plasticity and migration ability of cancer cells. LIMA1 deficiency induces the remodeling of the regulatory actin cytoskeleton and activation of signaling pathways, promoting EMT and EDAC, and affects tumor invasion and metastasis.

TABLE 2 Summary of *LIMA1* expression levels and profiles in cancers.

Cancer types	Cell lines	LIMA1 expression levels	Molecules associated with cancers	Functional roles	References
Esophageal cancer	KYSE150	Downregulated	/	Proliferation and invasion	(79)
Gastric cancer	/	Downregulated	/	Prognosis and NAC chemosensitivity	(80)
Prostate cancer	PC-3	Downregulated	/	Cell invasion, adhesion, growth *in vitro* and tumor development *in vivo*	(11)
	LNCaP, C4-2, MCF-7, ARCaP, PC3	Downregulated	E-cadherin, β-catenin	EMT, migration and invasion	(41)
	PC-3, LNCaP, CA-HPV-10	Downregulated	Paxillin, FAK/SRC signaling pathway	Proliferation, migration and invasion	(42)
	C4-2, C4-2B, ARCaP	Downregulated	EZH2	Metastasis and chemoresistance	(81)
Breast cancer	MDA MB-463, MDA MB-435s, MDA MB-436, MCF10A, MCF-7, ZR 7-51, MDA MB-468, BT-482, BT474, BT549, MDA MB-157 ANDMDA, MB 231, IBTG3 MRC5	Downregulated	ERK	Proliferation, migration and invasion *in vitro* and tumor development *in vivo*	(43)
Epithelial ovarian cancer	SKOV3, COV504	Downregulated	/	Cell growth, migration, invasion and adhesion	(44)
Head and neck squamous cell carcinoma	CAL27, HSC4	Upregulated	PI3K/AKT and JAK-STAT signaling pathway	Tumor metastasis, hypoxia, angiogenesis, and EMT	(45)
Osteosarcoma	KHOS, MNNG, U2OS	Downregulated	SATB2, RhoA, Rac1, FAK and Paxillin	Adhesion, migration and invasion	(82)
Mucosa-associated lymphoid tissue lymphoma	293T, 293FT, BJAB-Tet-On, SSK41	Downregulated	API2-MALT1, LIM domain-only fragment	Proliferation, migration, invasion, antibiotic resistance and B-cell oncogenesis	(83)
Diffuse large B-cell lymphoma	BJAB, SUDHL4, HEK 293T	Downregulated	MiR-142	Cell growth	(84)

"/" means that this aspect has not been studied out or or not covered in the relevant reference.

common cause of cancer-related deaths in men worldwide (93). Survival of PCa patients depends on early disease diagnosis and effective treatment options, however, lack of specificity to serum prostate specific antigen has been shown to lead to overdiagnosis and overtreatment of PCa (94). A growing number of studies have shown consistent results that LIMA1 is a negative regulator of EMT and aggressiveness, and LIMA1 is negatively correlated with PCa progression (11, 41, 42, 81).

Sanders et al. (41) cloned the full-length human LIMA1 cDNA gene into an expression vector and transfected the human prostate cancer cell line PC-3. Overexpression of LIMA1 in PCa resulted in reduced growth potential both in vitro and in vivo, and decreased cell invasiveness and extracellular matrix adhesion in multiple model assays. In addition, Collins et al. (42) generated LIMA1-α overexpression models and confirmed that overexpression of LIMA1-α reduced cell growth, migration and invasion and affected transcription and protein expression of paxillin, focal adhesion kinase (FAK) and tyrosine protein kinase (Src). Several earlier studies found that LIMA1 was associated with cell-cell adhesion through the interaction of cadherin-catenin complexes bound to F-actin (6, 13). Studies have also suggested a possible link between this molecule and Paxillin and a possible role in regulating cell adhesion to the extracellular matrix (51). Thus, it is evident that these studies confirmed the importance of LIMA1 in prostate cancer and further highlighted the importance of LIMA1 in regulating the growth and aggressiveness of prostate cancer cells.

Subsequently, Zhang et al. (11) identified a significant downregulation of LIMA1 after EMT by quantitative proteomics using an experimental model of prostate cancer metastasis. Biochemical and functional analyses showed that LIMA1 was a negative regulator of EMT and PCa cell invasiveness (13). LIMA1 downregulation significantly could disrupt epithelial architecture, induce actin cytoskeleton remodeling, affect specific gene expression profiles, and activate the pro-EMT program (95). In recent years, Wu et al. (81) established androgen-repressed prostate cancer (ARCaP) cells with temporary or permanent knockdown of

LIMA1 to determine the function of LIMA1 in PCa EMT and aggressiveness. The use of the ARCaP EMT model was demonstrated by the understanding of LIMA1 biology and the ARCaP model in the discovery of new drugs for the prevention and treatment of prostate cancer metastasis.

Future studies will need to focus on the generation and efficacy of recombinant forms of LIMA1 for the treatment of prostate cancer both in vitro and in vivo, thus facilitating the identification of new "druggable" therapeutic targets for the treatment of metastatic prostate cancer to help design new therapeutic strategies.

6 The expression of *LIMA1* and its regulatory mechanisms in breast and reproductive system tumors

6.1 *LIMA1* and breast cancer

Breast cancer is the most common malignancy that threatens the health of women worldwide. The incidence of breast cancer is increasing year-on-year, but the prognosis for patients remains pessimistic (96). Jiang et al. (43) first identified downregulation of the LIMA1-α expression in breast cancer cells and tissues. The LIMA1-α expression was associated with reduced growth of breast cancer cells both in vitro and in vivo and inhibited cell migration and invasiveness by relying on the ERK1/2 signaling pathway. Previous studies have shown that LIMA1 acts as a link between the E-Cadherin-β-Catenin -α-Catenin complex and actin filaments to maintain epithelial phenotype, stabilize the actin cytoskeletal network, and maintain functional epithelial junctions (23, 31). EGF phosphorylates LIMA1 thereby leading to LIMA1 degradation. Furthermore, there is a clear clinical correlation between the LIMA1 expression and tumor grade, lymph node status and tumor stage of breast cancers (43). It is evident that LIMA1 is a negative regulator of breast cancer cell migration. Upregulation of LIMA1 leads to the suppression of cell invasion ability, migration ability and growth rate in vitro and in vivo. Thus, it is hypothesized that LIMA1 is an important prognostic indicator and could be considered as an important target during targeted breast cancer therapy in the future.

6.2 *LIMA1* and epithelial ovarian cancer

Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies. It is diagnosed at the late stage in most women which explains the poor prognosis of this malignancy (97). Liu et al. (44) used reverse transcription-polymerase chain reaction (RT-PCR) and immune-histochemistry (IHC) methods to validate the downregulation of the LIMA1-α expression in human ovarian cancer tissues and cell lines at the mRNA and protein levels. Compared with control cells, the knockdown of LIMA1-α caused a significant increase in ovarian cancer cell growth, adhesion, invasion and migration ability. The inhibitory effect of LIMA1 on ovarian cancer cell growth is in line with findings in breast cancer (43), prostate cancer (41, 42), esophageal cancer (79), and endothelial cell lines (54, 55). This was the first article to confirm the LIMA1-α expression in human epithelial ovarian cancer tissues and its effect on the biological behavior of epithelial ovarian cancer cell lines (44).The precise molecular mechanism by which LIMA1-α inhibits the epithelial ovarian cancer phenotype remains unknown. However, relevant studies have provided conclusive evidence that reduction of LIMA1 has the potential to regulate cancer cell migration and invasion by disrupting cell-cell adhesion of adherens junctions, reducing E-cadherin expression and enhancing the EMT-like phenotype (31, 35). These findings suggest that prevention of LIMA1 degradation or partial restoration of the LIMA1 expression may be a novel strategy for the treatment of invasive ovarian cancer growth and metastasis. LIMA1 has the potential to be used as a prognostic predictor and this molecule, in patients with epithelial ovarian cancer, acts as a protective factor.

7 Expression of *LIMA1* and its regulatory mechanisms in the head and neck tumors

Oral cancer is the most common tumor of the head and neck region and is the sixth most common tumor worldwide (98). The incidence of oral cancer has increased significantly due to the oncogenic effect of human papillomavirus (HPV). It has one of the highest mortality rates and this has remained the case for more than 20 years (99). Given its difficulty in early diagnosis, susceptibility to metastasis, and poor prognosis, many studies aimed to find more sensitive, specific, and valuable tumor markers. LIMA1 was initially found to be a downregulated gene in oral cancer (8). Subsequently, Wirsing et al. (100) studied prognostic markers (CALML5, CD59, and LIMA1) selected from pathological profiles in patients with head and neck cancers. They also performed an unbiased analysis of these prognostic markers at the mRNA and protein levels in 121 oral cancer patients. Only CALML5 showed significant prognostic value, while the prognostic value of CD59 and LIMA1 could not be validated in this cohort, emphasizing the necessity to assess the head and neck cancer specificity by subgroup analysis (100).

Notably, another study has identified LIMA1 overexpression in the head and neck squamous cell carcinoma (HNSC) (45). High expression of LIMA1 is associated with carcinogenesis and predicts a poor prognosis, especially in HPV-negative and TP53-mutated HNSC. HPV is involved in 25% of HNSC cases and is strongly associated with prolonged survival in HPV-positive patients (45). The increased levels of TP53 mutation may lead to dysfunction of this gene, which has been shown to have oncogenic effects in several cancer types (101). It has been reported that TP53-induced LIMA1 inhibits cell invasion and that TP53 mutations lead to upregulation of LIMA1 expression levels, leading to EMT and further driving tumor invasion and metastasis (33, 45). DNA demethylation of the LIMA1 promoter region may affect its expression upregulation,

positively correlating with tumor metastasis, angiogenesis, and EMT. These could illustrate the heterogeneity of LIMA1 expression and the diversity of its functions, and more detailed studies of specific regulatory mechanisms are needed in the future to provide new insights for the development of new biomarkers and personalized cancer therapy.

8 Expression of *LIMA1* and its regulatory mechanisms in other tumors

8.1 *LIMA1* and osteosarcoma

Osteosarcoma is the most common primary malignancy among bone tumors, with peak incidence concentrated in children and adolescents (102). Osteosarcoma has a high propensity for local invasion and metastasis (103). Seong et al. (82) identified genes differentially regulated by special AT-rich-binding protein 2 (SATB2), including LIMA1, by microarray analysis. Silencing LIMA1 expression resulted in reduced cell adhesion and increased stress fibers in knockdown SATB2 cells compared with control cells, partially rescuing the reduced invasive phenotype of knockdown SATB2. It is evident that SATB2-mediated invasion may be due to interference with LIMA1 expression, which is a key mediator of SATB2-regulated osteosarcoma invasion. In addition, the novel finding indicated that LIMA1 regulated paxillin levels and phosphorylation (82) and phosphorylated paxillin was known to affect variations of adherent patches (30, 51). These suggest that LIMA1 may regulate osteosarcoma invasion by regulating cell adhesion and adherent patch changes.

In future work, there is a need to explore in depth the transcriptional regulatory mechanisms of SATB2 regulatory genes and signaling pathways, including LIMA1 that control the effect of the actin cytoskeleton on motility and invasion. This may help to discover targeting proteins for metastatic osteosarcoma and other cancers with high expression of SATB2.

8.2 *LIMA1* and mucosa-associated lymphoid tissue lymphomas

Mucosa-associated Lymphoid Tissue (MALT) lymphoma is a relatively inert non-hodgkin lymphoma (NHL) containing B cells (104). Its pathogenesis progresses in association with chronic inflammation (105). A gene fusion between apoptosisinhibitor-2 (API2) on chromosome 11 and the mucosa-associated lymphoid tissue translocation gene 1 (MALT1) on chromosome 18 formed the API2-MALT1 oncogenic chimera (106). This is the most common chromosomal translocation in MALT lymphomas and has disrupted the function of the MALT1 gene. Using an efficient strategy related to tandem mass spectrometry, Nie et al. (83) identified LIMA1 as a novel interactor and substrate for API2-MALT1 chimeric cystathionase. Interestingly, it was also shown that API2-MALT1-mediated protein hydrolysis produced a LIM domain-only containing oncogenic characteristic fragments both in vivo and in vitro (83), implying that API2-MALT1 converted LIMA1 into an oncogenic LIM domain-only-like protein in MALT lymphoma.

The oncogenicity of B cells was observed through LIMA1-α cleavage and RNA deletion that can be mediated by API2-MALT1 (107). This suggests that LIMA1-α functions as a putative tumor suppressor in B cells akin to its inhibitory function in epithelial cells. Overall, specific inhibition of the interaction between API2 and LIMA1 may facilitate the development of targeted therapies against API2-MALT1 positive lymphomas.

8.3 *LIMA1* and diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive lymphoma. DLBCL is frequently found in most cases of NHL that are aggressive or moderate to highly malignant (108). The pathology of DLBCL is characterized by a diffuse growth of large lymphocytes and a characteristic distribution of tumor cells in the perivascular space (109).

Based on miRNA analysis of DLBCL, Kwanhian et al. (110) identified microRNA-142 (miR-142) as the human microRNA gene that was consistently mutated in 20% of cases with primary DLBCL. Deletion of miR-142 in knockout mice has been reported to result in dysregulated lymphangiogenesis and immunodeficiency (111). Menegatti et al. (84) validated the effect of miR-142 inactivation on protein expression in DLBCL by CRISPR/Cas9 knockdown of miR-142 in DLBCL cell lines BJAB and SUDHL4. MiR-142 knockdown induced a consistent upregulation of genes or proteins that were oncogenic and a downregulation of genes or proteins associated with immunodeficiency responses required for MHC-I presentation. Among them, CCNB1, LIMA1, and TFRC were identified as potential targets and novel targets for miR-142 knockdown cell lines (84). The role of miRNAs to influence cellular transcriptional regulatory networks was further enhanced.

9 Conclusions and future prospects

Notably, using human tumor specimens as the "gold standard", the EPLIN expression was found to be negatively correlated with clinical lymph node metastasis in a variety of solid tumors (Table 3). The role of LIMA1 in malignancy progression has expanded from a tumor suppressor that acts primarily in early disease stages to a metastasis suppressor that may act in late stages to prevent and delay the invasion and spread of primary cancer cells.

With the deepening of the LIMA1 gene research, LIMA1 has been recognized as being actively involved in cancer cell signaling, possibly through multiple protein interactions associated with cancer progression, in addition to its function as a structural protein. Moreover, LIMA1 is also involved in apical elimination, cilia growth, cholesterol uptake, cellular metabolism, angiogenesis, and endothelial cell dynamics. This provides an additional avenue to explore the implications and mechanisms of LIMA1 in a broader

TABLE 3 Clinical pathological features and prognostic significance of LIMA1 in cancers.

Cancer types	Samples	LIMA1 expression	Related clinical pathological features	Prognostic significance	Ref.
Esophageal cancer	Tumor tissues, normal tissues adjacent to tumor and normal tissues for each patient (no specific quantity is mentioned)	Downregulated	Histological grade, survival status, nodal status, and TNM stage	A tumor suppressor with prognostic value	(79)
Gastric cancer	The first cohort contained 320 gastric cancer tissues and 175 paired normal tissues, and the second cohort contained 78 gastric cancer tissues and 80 normal tissue sample regarding patient responsiveness to NAC	Downregulated	TNM stage, T stage, nodal involvement, metastasis status, invasion, embolism and chemosensitivity	A prognostic factor associated with NAC chemosensitivity.	(80)
Prostate cancer	Human PCa tissue specimens (no specific quantity is mentioned)	Downregulated	Clinical lymph node metastasis	A negative regulator	(11)
	20 prostate tumor and 11 normal prostate tissue samples	Downregulated	/	A tumor suppressor	(42)
	69 primary PCa cases and 10 cases composed of benign prostatic glands and stroma	Downregulated	Histological grade	A predictor of tumor aggressiveness and poor prognosis	(81)
Breast cancer	120 tumor and 32 normal mammary tissues	Downregulated	Histological grade, TNM stage, nodal involvement, overall and disease-free survival	A potential tumor suppressor and had a prognostic value	(43)
Epithelial ovarian cancer	30 epithelial ovarian serous carcinomas, 15 samples were non-metastatic and 15 had lymph node or omentum metastases.	Downregulated	Metastasis status	A prognostic indicator and a protective factor	(44)
Head and neck squamous cell carcinoma	519 tissues of head and neck squamous cell carcinoma and 44 normal tissues from the TCGA cohort	Upregulated	TNM stage, clinical stage, radiation therapy, overall survival, disease specific survival	An independent prognostic predictor	(45)
Mucosa-associated lymphoid tissue lymphoma	API2–MALT1-positive and -negative MALT lymphoma tissues (no specific quantity is mentioned)	Downregulated	/	Aggressive clinical behavior with poor clinical outcome	(83)

"/" means that this aspect has not been studied out or or not covered in the relevant reference.

context. Expanding our exploration of multiple areas of this important molecule, LIMA1, in the future will increase its therapeutic potential and help design new metastatic disease prevention and treatment.

Author contributions

XW and CZ drafted and revised the original draft preparation. HS and JY revised the manuscript. XZ and YY collected relevant papers. LZ and JH reviewed the article. XW designed tables and charts. All authors contributed to the article and approved the submitted version.

Funding

This article was supported by the National Natural Science Foundation of China (Grant No. 82073090), Human Resources and Social Security Department System of Shanxi Province (Grant No. 20210001), Research Project Supported by Shanxi Scholarship Council of China (Grant No. 2021-116), Shanxi '136' Leading Clinical Key Specialty (Grant No. 2019XY002), and Shanxi Provincial Key Laboratory of Hepatobiliary and Pancreatic Diseases (under construction).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

References

1. Yin LM, Schnoor M, Jun CD. Structural characteristics, binding partners and related diseases of the calponin homology (CH) domain. *Front Cell Dev Biol* (2020) 8:342. doi: 10.3389/fcell.2020.00342

2. Davidson AJ, Wood W. Unravelling the actin cytoskeleton: a new competitive edge? *Trends Cell Biol* (2016) 26:569–76. doi: 10.1016/j.tcb.2016.04.001

3. Lappalainen P, Kotila T, Jegou A, Romet-Lemonne G. Biochemical and mechanical regulation of actin dynamics. *Nat Rev Mol Cell Biol* (2022) 23:836–52. doi: 10.1038/s41580-022-00508-4

4. Smith MA, Hoffman LM, Beckerle MC. LIM proteins in actin cytoskeleton mechanoresponse. *Trends Cell Biol* (2014) 24:575–83. doi: 10.1016/j.tcb.2014.04.009

5. Collins RJ, Jiang WG, Hargest R, Mason MD, Sanders AJ. EPLIN: a fundamental actin regulator in cancer metastasis? *Cancer Metastasis Rev* (2015) 34:753–64. doi: 10.1007/s10555-015-9595-8

6. Maul RS, Song Y, Amann KJ, Gerbin SC, Pollard TD, Chang DD. EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. *J Cell Biol* (2003) 160:399–407. doi: 10.1083/jcb.200212057

7. Han MY, Kosako H, Watanabe T, Hattori S. Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. *Mol Cell Biol* (2007) 27:8190–204. doi: 10.1128/MCB.00661-07

8. Chang DD, Park NH, Denny CT, Nelson SF, Pe M. Characterization of transformation related genes in oral cancer cells. *Oncogene* (1998) 16:1921–30. doi: 10.1038/sj.onc.1201715

9. Maul RS, Chang DD. EPLIN, epithelial protein lost in neoplasm. *Oncogene* (1999) 18:7838–41. doi: 10.1038/sj.onc.1203206

10. Chen S, Maul RS, Kim HR, Chang DD. Characterization of the human EPLIN (Epithelial protein lost in neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. *Gene* (2000) 248:69–76. doi: 10.1016/s0378-1119(00)00144-x

11. Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, et al. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. *Oncogene* (2011) 30:4941–52. doi: 10.1038/onc.2011.199

12. Abe K, Takeichi M. EPLIN mediates linkage of the cadherin catenin complex to f-actin and stabilizes the circumferential actin belt. *Proc Natl Acad Sci USA* (2008) 105:13–9. doi: 10.1073/pnas.0710504105

13. Wu D. Epithelial protein lost in neoplasm (EPLIN): beyond a tumor suppressor. *Genes Dis* (2017) 4:100–7. doi: 10.1016/j.gendis.2017.03.002

14. Zeng J, Jiang WG, Sanders AJ. Epithelial protein lost in neoplasm, EPLIN, the cellular and molecular prospects in cancers. *Biomolecules* (2021) 11(7):1038. doi: 10.3390/biom11071038

15. Huang Z, Yu C, Yu L, Shu H, Zhu X. The roles of FHL3 in cancer. *Front Oncol* (2022) 12:887828. doi: 10.3389/fonc.2022.887828

16. Wei X, Zhang H. Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression. *Cancer Biol Med* (2020) 17:270–81. doi: 10.20892/j.issn.2095-3941.2019.0420

17. Maul RS, Sachi GC, Chang DD. Characterization of mouse epithelial protein lost in neoplasm (EPLIN) and comparison of mammalian and zebrafish EPLIN. *Gene* (2001) 262:155–60. doi: 10.1016/s0378-1119(00)00540-0

18. Wang H, Wang H, Zhu Z, Yang S, Feng S, Li K. Characterization of porcine EPLIN gene revealed distinct expression patterns for the two isoforms. *Anim Biotechnol* (2007) 18:101–8. doi: 10.1080/10495390600864660

19. Miyazaki S, Funamoto T, Sekimoto T, Kurogi S, Ohta T, Nagai T, et al. EPLINbeta is involved in the assembly of cadherin-catenin complexes in osteoblasts and affects bone formation. *Acta Histochem Cytochem* (2022) 55:99–110. doi: 10.1267/ahc.22-00027

20. Song Y, Maul RS, Gerbin CS, Chang DD. Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. *Mol Biol Cell* (2002) 13:1408–16. doi: 10.1091/mbc.01-08-0414

21. Ohoka A, Kajita M, Ikenouchi J, Yako Y, Kitamoto S, Kon S, et al. EPLIN is a crucial regulator for extrusion of RasV12-transformed cells. *J Cell Sci* (2015) 128:781–9. doi: 10.1242/jcs.163113

22. Leitner L, Shaposhnikov D, Descot A, Hoffmann R, Posern G. Epithelial protein lost in neoplasm alpha (Eplin-alpha) is transcriptionally regulated by G-actin and MAL/MRTF coactivators. *Mol Cancer* (2010) 9:60. doi: 10.1186/1476-4598-9-60

23. Taguchi K, Ishiuchi T, Takeichi M. Mechanosensitive EPLIN-dependent remodeling of adherens junctions regulates epithelial reshaping. *J Cell Biol* (2011) 194:643–56. doi: 10.1083/jcb.201104124

24. Chen NP, Uddin B, Hardt R, Ding W, Panic M, Lucibello I, et al. Human phosphatase CDC14A regulates actin organization through dephosphorylation of epithelial protein lost in neoplasm. *Proc Natl Acad Sci U S A* (2017) 114:5201–6. doi: 10.1073/pnas.1619356114

25. Goncalves J. LUZP1: a new player in the actin-microtubule cross-talk. *Eur J Cell Biol* (2022) 101:151250. doi: 10.1016/j.ejcb.2022.151250

26. Goncalves J, Sharma A, Coyaud E, Laurent E, Raught B, Pelletier L. LUZP1 and the tumor suppressor EPLIN modulate actin stability to restrict primary cilia formation. *J Cell Biol* (2020) 219(7):e201908132. doi: 10.1083/jcb.201908132

27. Duraivelan K, Samanta D. Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways. *Biochim Biophys Acta Rev Cancer* (2021) 1876:188589. doi: 10.1016/j.bbcan.2021.188589

28. Honig B, Shapiro L. Adhesion protein structure, molecular affinities, and principles of cell-cell recognition. *Cell* (2020) 181:520–35. doi: 10.1016/j.cell.2020.04.010

29. Karakose E, Geiger T, Flynn K, Lorenz-Baath K, Zent R, Mann M, et al. The focal adhesion protein PINCH-1 associates with EPLIN at integrin adhesion sites. *J Cell Sci* (2015) 128:1023–33. doi: 10.1242/jcs.162545

30. Tsurumi H, Harita Y, Kurihara H, Kosako H, Hayashi K, Matsunaga A, et al. Epithelial protein lost in neoplasm modulates platelet-derived growth factor-mediated adhesion and motility of mesangial cells. *Kidney Int* (2014) 86:548–57. doi: 10.1038/ki.2014.85

31. Linklater ES, Duncan ED, Han KJ, Kaupinis A, Valius M, Lyons TR, et al. Rab40-Cullin5 complex regulates EPLIN and actin cytoskeleton dynamics during cell migration. *J Cell Biol* (2021) 220(7):e202008060. doi: 10.1083/jcb.202008060

32. Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, Chen Z, et al. Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. *J Biol Chem* (2013) 288:1469–79. doi: 10.1074/jbc.M112.438341

33. Ohashi T, Idogawa M, Sasaki Y, Tokino T. P53 mediates the suppression of cancer cell invasion by inducing LIMA1/EPLIN. *Cancer Lett* (2017) 390:58–66. doi: 10.1016/j.canlet.2016.12.034

34. Nguyen D, Yang K, Chiao L, Deng Y, Zhou X, Zhang Z, et al. Inhibition of tumor suppressor p73 by nerve growth factor receptor *via* chaperone-mediated autophagy. *J Mol Cell Biol* (2020) 12:700–12. doi: 10.1093/jmcb/mjaa017

35. Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Furst K, et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. *Cancer Cell* (2013) 24:512–27. doi: 10.1016/j.ccr.2013.08.023

36. Nowak E, Bednarek I. Aspects of the epigenetic regulation of EMT related to cancer metastasis. *Cells-Basel* (2021) 10(12):3435. doi: 10.3390/cells10123435

37. Bracken CP, Goodall GJ. The many regulators of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol* (2022) 23:89–90. doi: 10.1038/s41580-021-00442-x

38. Zhitnyak IY, Rubtsova SN, Litovka NI, Gloushankova NA. Early events in actin cytoskeleton dynamics and e-Cadherin-Mediated cell-cell adhesion during epithelial-mesenchymal transition. *Cells-Basel* (2020) 9(3):578. doi: 10.3390/cells9030578

39. Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, et al. Autophagy and EMT in cancer and metastasis: who controls whom? *Biochim Biophys Acta Mol Basis Dis* (2022) 1868:166431. doi: 10.1016/j.bbadis.2022.166431

40. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. *Trends Cell Biol* (2019) 29:212–26. doi: 10.1016/j.tcb.2018.12.001

41. Sanders AJ, Martin TA, Ye L, Mason MD, Jiang WG. EPLIN is a negative regulator of prostate cancer growth and invasion. *J Urol* (2011) 186:295–301. doi: 10.1016/j.juro.2011.03.038

42. Collins RJ, Morgan LD, Owen S, Ruge F, Jiang WG, Sanders AJ. Mechanistic insights of epithelial protein lost in neoplasm in prostate cancer metastasis. *Int J Cancer* (2018) 143:2537–50. doi: 10.1002/ijc.31786

43. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. *Mol Cancer* (2008) 7:71. doi: 10.1186/1476-4598-7-71

44. Liu R, Martin TA, Jordan NJ, Ruge F, Ye L, Jiang WG. Epithelial protein lost in neoplasm-alpha (EPLIN-alpha) is a potential prognostic marker for the progression of epithelial ovarian cancer. *Int J Oncol* (2016) 48:2488–96. doi: 10.3892/ijo.2016.3462

45. Ma W, Liao Y, Gao Z, Zhu W, Liu J, She W. Overexpression of LIMA1 indicates poor prognosis and promotes epithelial-mesenchymal transition in head and neck squamous cell carcinoma. *Clin Med Insights Oncol* (2022) 16:1363230453. doi: 10.1177/11795549221109493

46. Kon S, Fujita Y. Cell competition-induced apical elimination of transformed cells, EDAC, orchestrates the cellular homeostasis. *Dev Biol* (2021) 476:112–6. doi: 10.1016/j.ydbio.2021.03.015

47. Pothapragada SP, Gupta P, Mukherjee S, Das T. Matrix mechanics regulates epithelial defence against cancer by tuning dynamic localization of filamin. *Nat Commun* (2022) 13:218. doi: 10.1038/s41467-021-27896-z

48. Tanimura N, Fujita Y. Epithelial defense against cancer (EDAC). *Semin Cancer Biol* (2020) 63:44–8. doi: 10.1016/j.semcancer.2019.05.011

49. Saitoh S, Maruyama T, Yako Y, Kajita M, Fujioka Y, Ohba Y, et al. Rab5-regulated endocytosis plays a crucial role in apical extrusion of transformed cells. *Proc Natl Acad Sci USA* (2017) 114:E2327–36. doi: 10.1073/pnas.1602349114

50. Kadeer A, Maruyama T, Kajita M, Morita T, Sasaki A, Ohoka A, et al. Plectin is a novel regulator for apical extrusion of RasV12-transformed cells. *Sci Rep* (2017) 7:44328. doi: 10.1038/srep44328

51. Kasai N, Kadeer A, Kajita M, Saitoh S, Ishikawa S, Maruyama T, et al. The paxillin-plectin-EPLIN complex promotes apical elimination of RasV12-transformed cells by modulating HDAC6-regulated tubulin acetylation. *Sci Rep* (2018) 8:2097. doi: 10.1038/s41598-018-20146-1

52. Shi X, Dong X, Young S, Chen AM, Liu X, Zheng Z, et al. The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer. *Cancer Med* (2019) 8:5930–8. doi: 10.1002/cam4.2462

53. Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, et al. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. *Br J Cancer* (2017) 116:356–61. doi: 10.1038/bjc.2016.427

54. Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. *Semin Cancer Biol* (2022) 86:981–96. doi: 10.1016/j.semcancer.2022.02.009

55. Chervin-Petinot A, Courcon M, Almagro S, Nicolas A, Grichine A, Grunwald D, et al. Epithelial protein lost in neoplasm (EPLIN) interacts with alpha-catenin and actin filaments in endothelial cells and stabilizes vascular capillary network. *Vitro J Biol Chem* (2012) 287:7556–72. doi: 10.1074/jbc.M111.328682

56. Abu TA, Schnittler HJ. Dynamics between actin and the VE-cadherin/catenin complex: novel aspects of the ARP2/3 complex in regulation of endothelial junctions. *Cell Adh Migr* (2014) 8:125–35. doi: 10.4161/cam.28243

57. Hofer I, Schimp C, Taha M, Seebach J, Aldirawi M, Cao J, et al. Advanced methods for the investigation of cell contact dynamics in endothelial cells using florescence-based live cell imaging. *J Vasc Res* (2018) 55:350–64. doi: 10.1159/000494933

58. Taha M, Aldirawi M, Marz S, Seebach J, Odenthal-Schnittler M, Bondareva O, et al. EPLIN-alpha and -beta isoforms modulate endothelial cell dynamics through a spatiotemporally differentiated interaction with actin. *Cell Rep* (2019) 29:1010–26. doi: 10.1016/j.celrep.2019.09.043

59. Sanders AJ, Ye L, Mason MD, Jiang WG. The impact of EPLINalpha (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. *Angiogenesis* (2010) 13:317–26. doi: 10.1007/s10456-010-9188-7

60. Liang L, Zhao L, Zan Y, Zhu Q, Ren J, Zhao X. MiR-93-5p enhances growth and angiogenesis capacity of HUVECs by down-regulating EPLIN. *Oncotarget* (2017) 8:107033–43. doi: 10.18632/oncotarget.22300

61. Ghalehbandi S, Yuzugulen J, Pranjol M, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. *Eur J Pharmacol* (2023) 949:175586. doi: 10.1016/j.ejphar.2023.175586

62. Tubon I, Zannoni A, Bernardini C, Salaroli R, Bertocchi M, Mandrioli R, et al. *In vitro* anti-inflammatory effect of salvia sagittata ethanolic extract on primary cultures of porcine aortic endothelial cells. *Oxid Med Cell Longev* (2019) 2019:6829173. doi: 10.1155/2019/6829173

63. Maucher D, Schmidt B, Schumann J. Loss of endothelial barrier function in the inflammatory setting: indication for a cytokine-mediated post-transcriptional mechanism by virtue of upregulation of miRNAs miR-29a-3p, miR-29b-3p, and miR-155-5p. *Cells* (2021) 10(11):2843. doi: 10.3390/cells10112843

64. Rizzelli F, Malabarba MG, Sigismund S, Mapelli M. The crosstalk between microtubules, actin and membranes shapes cell division. *Open Biol* (2020) 10:190314. doi: 10.1098/rsob.190314

65. Gupta VK, Chaudhuri O. Mechanical regulation of cell-cycle progression and division. *Trends Cell Biol* (2022) 32:773–85. doi: 10.1016/j.tcb.2022.03.010

66. Chircop M, Oakes V, Graham ME, Ma MP, Smith CM, Robinson PJ, et al. The actin-binding and bundling protein, EPLIN, is required for cytokinesis. *Cell Cycle* (2009) 8:757–64. doi: 10.4161/cc.8.5.7878

67. Smith TC, Fang Z, Luna EJ. Novel interactors and a role for supervillin in early cytokinesis. *Cytoskeleton (Hoboken)* (2010) 67:346–64. doi: 10.1002/cm.20449

68. Sundvold H, Sundvold-Gjerstad V, Malerod-Fjeld H, Haglund K, Stenmark H, Malerod L. Arv1 promotes cell division by recruiting IQGAP1 and myosin to the cleavage furrow. *Cell Cycle* (2016) 15:628–43. doi: 10.1080/15384101.2016.1146834

69. McNiven MA, Ridley AJ. Focus on membrane dynamics. *Trends Cell Biol* (2006) 16:485–6. doi: 10.1016/j.tcb.2006.08.010

70. Carlton JG, Jones H, Eggert US. Membrane and organelle dynamics during cell division. *Nat Rev Mol Cell Biol* (2020) 21:151–66. doi: 10.1038/s41580-019-0208-1

71. Duethorn B, Groll F, Rieger B, Drexler H, Brinkmann H, Kremer L, et al. Lima1 mediates the pluripotency control of membrane dynamics and cellular metabolism. *Nat Commun* (2022) 13:610. doi: 10.1038/s41467-022-28139-5

72. Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. *J Clin Invest* (2019) 129:3006–17. doi: 10.1172/JCI127201

73. Matey-Hernandez ML, Williams F, Potter T, Valdes AM, Spector TD, Menni C. Genetic and microbiome influence on lipid metabolism and dyslipidemia. *Physiol Genomics* (2018) 50:117–26. doi: 10.1152/physiolgenomics.00053.2017

74. Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. *Clin Chem* (2021) 67:143–53. doi: 10.1093/clinchem/hvaa252

75. Zhang YY, Fu ZY, Wei J, Qi W, Baituola G, Luo J, et al. A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption. *Science* (2018) 360:1087–92. doi: 10.1126/science.aao6575

76. Donato LJ. LIMA1: a newly identified player in the field of cholesterol control. *Clin Chem* (2018) 64:1792–3. doi: 10.1373/clinchem.2018.294645

77. Lim GB. LIMA1 variant influences cholesterol absorption. *Nat Rev Cardiol* (2018) 15:502. doi: 10.1038/s41569-018-0054-4

78. Su MW, Chang CK, Lin CW, Ling SJ, Hsiung CN, Chu HW, et al. Blood multiomics reveal insights into population clusters with low prevalence of diabetes, dyslipidemia and hypertension. *PloS One* (2020) 15:e229922. doi: 10.1371/journal.pone.0229922

79. Liu Y, Sanders AJ, Zhang L, Jiang WG. EPLIN-alpha expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome. *Anticancer Res* (2012) 32:1283–9. doi: 10.1016/j.canlet.2016.12.034

80. Gong W, Zeng J, Ji J, Jia Y, Jia S, Sanders AJ, et al. EPLIN expression in gastric cancer and impact on prognosis and chemoresistance. *Biomolecules* (2021) 11(4):547. doi: 10.3390/biom11040547

81. Wu D, Osunkoya AO, Kucuk O. Epithelial protein lost in neoplasm (EPLIN) and prostate cancer: lessons learned from the ARCaP model. *Am J Clin Exp Urol* (2021) 9:264–76. doi: 10.1016/j.gendis.2017.03.002

82. Seong BK, Lau J, Adderley T, Kee L, Chaukos D, Pienkowska M, et al. SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. *Oncogene* (2015) 34:3582–92. doi: 10.1038/onc.2014.289

83. Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, et al. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. *Nat Commun* (2015) 6:5908. doi: 10.1038/ncomms6908

84. Menegatti J, Nakel J, Stepanov YK, Caban KM, Ludwig N, Nord R, et al. Changes of protein expression after CRISPR/Cas9 knockout of miRNA-142 in cell lines derived from diffuse Large b-cell lymphoma. *Cancers (Basel)* (2022) 14(20):5031. doi: 10.3390/cancers14205031

85. Wang J, Ma X, Ma Z, Ma Y, Wang J, Cao B. Research progress of biomarkers for immune checkpoint inhibitors on digestive system cancers. *Front Immunol* (2022) 13:810539. doi:10.3389/fimmu.2022.810539

86. Zhang Y, Huang S, Yang G, Zou L, Huang X, Liu S. The role of miRNAs during endoplasmic reticulum stress induced apoptosis in digestive cancer. *J Cancer* (2021) 12:6787–95. doi: 10.7150/jca.62352

87. Lopes N, Correia MP, Henrique R, Jeronimo C. Epigenetic alterations in oesophageal cancer: expression and role of the involved enzymes. *Int J Mol Sci* (2020) 21(10):3522. doi: 10.3390/ijms21103522

88. Xie J, Fu L, Jin L. Immunotherapy of gastric cancer: past, future perspective and challenges. *Pathol Res Pract* (2021) 218:153322. doi: 10.1016/j.prp.2020.153322

89. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. *Int J Mol Sci* (2020) 21(11):4012. doi: 10.3390/ijms21114012

90. Jiang L, Ma Z, Ye X, Kang W, Yu J. Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer. *World J Surg Oncol* (2021) 19:44. doi: 10.1186/s12957-021-02157-x

91. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. *J Hepatol* (2018) 68:526–49. doi: 10.1016/j.jhep.2017.09.016

92. Couri T, Pillai A. Goals and targets for personalized therapy for HCC. *Hepatol Int* (2019) 13:125–37. doi: 10.1007/s12072-018-9919-1

93. Lorenc T, Klimczyk K, Michalczewska I, Slomka M, Kubiak-Tomaszewska G, Olejarz W. Exosomes in prostate cancer diagnosis, prognosis and therapy. *Int J Mol Sci* (2020) 21(6):2118. doi: 10.3390/ijms21062118

94. Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. *Protein Cell* (2021) 12:29–38. doi: 10.1007/s13238-020-00786-8

95. Brill-Karniely Y, Dror D, Duanis-Assaf T, Goldstein Y, Schwob O, Millo T, et al. Triangular correlation (TrC) between cancer aggressiveness, cell uptake capability, and cell deformability. *Sci Adv* (2020) 6:x2861. doi: 10.1126/sciadv.aax2861

96. Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. *Semin Cancer Biol* (2020) 60:14–27. doi: 10.1016/j.semcancer.2019.08.012

97. Yang WH, Huang Z, Wu J, Ding CC, Murphy SK, Chi JT. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer. *Mol Cancer Res* (2020) 18:79–90. doi: 10.1158/1541-7786.MCR-19-0691

98. Chattopadhyay I, Verma M, Panda M. Role of oral microbiome signatures in diagnosis and prognosis of oral cancer. *Technol Cancer Res Treat* (2019) 18:1078135002. doi: 10.1177/1533033819867354

99. Warnakulasuriya S, Kerr AR. Oral cancer screening: past, present, and future. *J Dent Res* (2021) 100:1313–20. doi: 10.1177/00220345211014795

100. Wirsing AM, Bjerkli IH, Steigen SE, Rikardsen O, Magnussen SN, Hegge B, et al. Validation of selected head and neck cancer prognostic markers from the pathology atlas in an oral tongue cancer cohort. *Cancers (Basel)* (2021) 13(10):2387. doi: 10.3390/cancers13102387

101. Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. *J Hematol Oncol* (2021) 14:157. doi: 10.1186/s13045-021-01169-0

102. Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. The osteosarcoma microenvironment: a complex but targetable ecosystem. *Cells-Basel* (2020) 9(4):976. doi: 10.3390/cells9040976

103. Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. *Cancer Lett* (2021) 500:1–10. doi: 10.1016/j.canlet.2020.12.024

104. Marcelis L, Tousseyn T, Sagaert X. MALT lymphoma as a model of chronic inflammation-induced gastric tumor development. *Curr Top Microbiol Immunol* (2019) 421:77–106. doi: 10.1007/978-3-030-15138-6_4

105. Kiesewetter B, Raderer M. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). *Hematol Oncol* (2020) 38:417–24. doi: 10.1002/hon.2754

106. Izumi K, Nishikori M, Yuan H, Otsuka Y, Nakao K, Takaori-Kondo A. Establishment and characterization of a MALT lymphoma cell line carrying an API2-MALT1 translocation. *Genes Chromosomes Cancer* (2020) 59:517–24. doi: 10.1002/gcc.22855

107. Dotlic S, Gasparov S, Lovric E, Dominis M, Korac P. Is it possible to overcome antiapoptotic API2/MALT1 events in tumor b-cells by influencing tregs in MALT lymphoma? *Med Hypotheses* (2012) 79:500–3. doi: 10.1016/j.mehy.2012.07.001

108. Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. *Nat Rev Clin Oncol* (2019) 16:634–52. doi: 10.1038/s41571-019-0225-1

109. Modi D, Potugari B, Uberti J. Immunotherapy for diffuse large b-cell lymphoma: current landscape and future directions. *Cancers (Basel)* (2021) 13 (22):5827. doi: 10.3390/cancers13225827

110. Kwanhian W, Lenze D, Alles J, Motsch N, Barth S, Doll C, et al. MicroRNA-142 is mutated in about 20% of diffuse large b-cell lymphoma. *Cancer Med* (2012) 1:141–55. doi: 10.1002/cam4.29

111. Kramer NJ, Wang WL, Reyes EY, Kumar B, Chen CC, Ramakrishna C, et al. Altered lymphopoiesis and immunodeficiency in miR-142 null mice. *Blood* (2015) 125:3720–30. doi: 10.1182/blood-2014-10-603951

Glossary

LIM domain and actin-binding protein 1	LIMA1
epithelial protein lost in neoplasms	EPLIN
sterol regulatory element binding protein 3	SREBP3
Dual Specificity Phosphatase 5	DUSP5
Vinculin	VCL
Catenin Delta 1	CTNND1
Catenin Alpha 1	CTNNA1
Catenin Beta 1	CTNNB1
Signal Induced Proliferation Associated 1 Like 1	SIPA1L1
Cadherin 17	CDH17
Nexilin F-Actin Binding Protein	NEXN
Interferon Related Developmental Regulator 2	IFRD2
actin-related protein complex 2/3	Arp2/3
extracellular signal-regulated kinase	ERK
mitogen-activated protein kinase	MAPK
megakaryoblastic acute leukemia	MAL
myocardin related transcription factor	MRTF
cell division cycle 14A	CDC14A
leucine zipper protein 1	LUZP1
extracellular matrix	ECM
particularly interesting new cysteine-histidine rich protein 1	PINCH-1
platelet derived growth factor	PDGF
mitogen-activated protein kinase	MEK
epidermal growth factor	EGF
insulin like growth factor 1 receptor	IGF1R
Protein Kinase B	PKB
signal transducer and activator of transcription 3	STAT3
Epithelial mesenchymal transition	EMT
epithelial defense against cancer	EDAC
Caveolin-1	Cav-1
histone deacetylase 6	HDAC6
vascular endothelial cadherin	VE-cadherin
junction-associated intermittent lamellipodia	JAIL
human umbilical vein endothelial cells	HUVEC
ACAT-related protein required for viability 1	Arv1
low-density lipoprotein cholesterol	LDL-C
Niemann-Pick C1-like 1	NPC1L1
The Cancer Genome Atlas	TCGA

(Continued)

Continued

quantitative polymerase chain reaction	q-PCR
neoadjuvant chemotherapy	NAC
Hepatocellular carcinoma	HCC
focal adhesion kinase	FAK
Androgen-Repressed Prostate Cancer	ARCaP
Epithelial ovarian cancer	EOC
reverse transcription-polymerase chain reaction	RT-PCR
immune-histochemistry	IHC
head and neck squamous cell carcinoma	HNSC
special AT-rich-binding protein 2	SATB2
Mucosa-associated Lymphoid Tissue	MALT
non-hodgkin lymphoma	NHL
apoptosisinhibitor-2	API2
the mucosa-associated lymphoid tissue translocation gene 1	MALT1
Diffuse large B-cell lymphoma	DLBCL
microRNA-142	miR-142

Frontiers in Oncology

Advances knowledge of carcinogenesis and tumor progression for better treatment and management

The third most-cited oncology journal, which highlights research in carcinogenesis and tumor progression, bridging the gap between basic research and applications to imrpove diagnosis, therapeutics and management strategies.

Discover the latest Research Topics

See more →

Frontiers

Avenue du Tribunal-Fédéral 34
1005 Lausanne, Switzerland
frontiersin.org

Contact us

+41 (0)21 510 17 00
frontiersin.org/about/contact